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Management of semi-invasive aspergillosis and
Aspergillus empyema with combination of
systemic antifungals and intrapleural
amphotericin B in an immunocompetent patient
Y. Tezer, O. Memikoglu, H. Kur (Ankara, TR)
The spectrum of pulmonary aspergillosis varies, ranging from
allergic bronchopulmonary aspergillosis to invasive diseases
depending on the immune status of the patient and the under-
lying lung condition. Pleural invasion by Aspergillus species
occurs commonly as a late complication of thoracoplasty with
bronchopleural ﬁstula.Rarely the ruptureof cavitaryaspergillosis
into the pleural space can produce Aspergillus empyema.
Case report: A 39-year old man referred to tertiary hospital,
with a history of destroyed left lung and Aspergillus fungus ball
for a thoracotomy in thorax surgery department. He had no
known medical problems or smoking history. He suffered from
cough, hemptysis and weight loss for a month. He had been
operated for fungus ball. But after a week fever and leukocytosis
were predominant. Chest tube continually drained purulent
ﬂuid and air, indicative of bronchopleural ﬁstula. Control thorax
computarized tomography had been conﬁrmed that. Pleural
ﬂuid specimens examined biochemically, microscopically and
cultured for bacteria, mycobacteria and fungi. In exudative ﬂuid
Aspergillus fumigatus was grown. Then caspofungin theraphy
was started. After 14 days, due to culture positivity and allergic
reactions we changed to the liposomal Amphotericin B. After
14 days, purulant ﬂuid discharge were continue. On cultures
Aspergillus fumigatus were grown. Then we combined systemic
amfhotericin B with caspofungin. But purulant ﬂuid discharge
had not been diminished. So we decided to attempt intrapleural
antifungal treatment and systemic antifungals together. As
described in literature, liposomal amphotericin B was given
intrapleurally. During theraphy there were no complications
occur. After 3 weeks his fever and leukocyte were in normal
range and his galactomannan and CRP levels were dropped. His
chest tube drainage was diminished but not stopped in 66th day.
So he required radical surgery with thoracostomy. Then we
continued the treatment with oral voriconazole up to 6 months.
Result: After 1 year of follow-up, the patient is well. In our
experience we were able to control clinic progress of disease
when considered fever and status of the patient by using
intrapleural amphotericin B and combined systemic antifungals.
But we were unable to control aspergillosis totally.
Conclusion: A successful management with remarkable clinical
improvement was achieved by pleural drainage, combined
antifungal treatment and surgical approach.
P1199
Clinical presentation and epidemiology of
Mucorales infections in Geneva university
hospitals
I. Uc¸kay, M. Djordjevic, J. Garbino, C. Garzoni, Y. Chalandon,
V. Jacomo, P. Rohner, C. Van Delden (Geneva, CH; Nis, CS)
Objective: Fungal infections by Mucorales are rare, even in
highly immunocompromized patients. Unless diagnosis can be
made early, local invasive disease tends to progress with a poor
prognosis. Initial symptoms are unspeciﬁc and an early high
index of suspicion is crucial. We are interested in the epidemi-
ology, microbiology, therapy and outcome of mucormycosis in
our institution.
Methods: University of Geneva Hospitals is a tertiary hospital
with 1600 acute care beds and 40,000 admissions each year,
containing all disciplines including several intensive care units
and a transplantation centre. Retrospective analysis of all
electronical and clinical databases from 1989 till 2004. All results
containing Mucorales were analysed.
Results: We identiﬁed 7 cases of infection: 2 bone marrow
transplant patients, 1 liver transplantation patient, 1 renal
transplantation patient, 1 patient with AIDS and 2 patients
receiving high doses of steroids. Rhizopus and Absidia sp were
the causative fungus agent in 3 cases each. Survival (3 of 7
patients) could only be achieved during local disease such as the
involvement of the orbita, associated with early diagnosis, early
and aggressive surgical therapy and speciﬁc antifungal treat-
ment. Table 1 resumes the characteristics of the infection cases.
In 35 cases the presence of mucormycosis were considered as
colonisation since there was no invasive disease, no secondary
prophylaxis, no speciﬁc surgical or antifungal treatment and no
clinical importance reported in the records. The most prevalent
body sites for colonisation were nasal sinuses and tracheal
aspirates.
Conclusion: Mucormycosis is a rare disease even in a tertiary
hospital. Disseminated fungal infections have a poor prognosis
and may evolve into multiorgan failure within a short period of
time, whereas early recognized local infections can be success-
fully treated. In the presence of a severely immunocompromized
host, a high index of suspicion remains mandatory. Physicians
should be aware of the possibility of this fungal infection in
order to begin a rapid diagnostic workup including aggressive
surgical and antimycotic therapy with amphotericin B or
posaconazole.
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006
P1200
Caspofungin therapy in documented fungal
infections: Spanish experience before licencing of
the drug
C. Sanz-Rodriguez, J.M. Cisneros, J.M. Aguado, R. Martino on
behalf of the Spanish Caspofungin Clinical Study Group
Objective: Retrospective evaluation of clinical effectiveness and
safety of caspofungin in the compassionate treatment of invasive
or superﬁcial fungal infections before marketing of the drug in
Spain in August 2002.
Methods: Eighty-two patients received compassionate treat-
ment with caspofungin. All patients were considered evaluable
for safety, yet only those treated for ‡7 days for mould infections
or ‡5 days for yeast infections were considered evaluable for
clinical effectiveness. Response was graded as favourable
(complete or partial resolution of clinical, microbiological and/
or radiographic evidence of fungal disease) or unfavourable
(stable or progressive disease).
Results: The main underlying disorders were haematological
neoplasias (48 patients; 59%), COPD (9; 11%), and AIDS (8; 10%).
Seventeen patients (21%) underwent an allogeneic stem cell
transplant, while another 6 (7%) were solid organ transplant
recipients. Sixty-three patients (77%) were diagnosed of invasive
mould infection (16 proven, 24 probable, 23 possible per MSG/
EORTC criteria), 10 (12%) invasive yeast infection, 7 (9%)
esophageal candidiasis, and 2 (2%) tracheobronchial aspergil-
losis. The median length of therapy was 15 days (range, 2–154),
typically a 70-mg loading dose followed by 50 mg daily. Sixty-six
(80%) patients were evaluable for clinical effectiveness. Of them,
63 patients (95%) were refractory to other antifungals, including
35 (53%) treated with ‡2 drugs. Most patients (63/66; 95%)
progressed to ‡1 amphotericin B (amphB) formulations (median
total dose 3,778 mg, range 60–31, 920). Favourable response rates
were 66% (21/32) for proven or probable invasive aspergillosis
(caspofungin monotherapy, 62% [8/13] vs combination therapy,
68% [13/19]), 69% (11/16) for possible invasivemould infections,
67% (6/9) for invasive candidiasis, and 100% (7/7) for oesopha-
geal candidiasis. Onepatientwithdisseminated fusariosis did not
respond to caspofungin + liposomal amphB, while another
patient with an invasive yeast infection (species unknown)
responded fully to caspofungin + amphB lipid complex. Overall,
the safety and tolerability proﬁlewas favorable; no treatmentwas
discontinued due to caspofungin-related adverse events.
Conclusion: Caspofungin was efﬁcacious and generally well
tolerated in the treatment of invasive and superﬁcial Aspergillus
and Candida infections, and provided an alternative for those
who failed to respond or became intolerant to other available
antifungals.
P1201
Zygomycosis in a general hospital during a
17-year period. Is there an increase in incidence
after introducing voriconazole?
M. Torres-Narbona, J. Guinea, J. Martı´nez-Alarco´n, T. Pela´ez,
P. Mun˜oz, E. Bouza (Madrid, ES)
Objectives: The question of an increase in the number of cases
of zygomycosis (ZM) has been raised in American and Euro-
pean institutions. The use of voriconazole (Vori) as antifungal
prophylaxis may correlate with this increase but that may not be
the case in institutions in which Vori is not used prophylacti-
cally. We reviewed the evolution of ZM, before and after the
introduction of Vori in our hospital.
Methods: We retrospectively evaluated all cases of ZM in
Gregorio Maran˜o´n Hospital from 1987 to 2005. Proven or
probable diagnosis of ZM was performed according to estab-
lished criteria (Ascioglu, CID 2002). Vori was introduced for
therapeutic use in our hospital in 2002.
Results: During the study period, 10 patients had proven or
probable ZM (0.6 cases/year). The clinical forms and underlying
conditions of the patients were 1 rhino-cerebral (kidney trans-
plant), 2 sinuses (1 diabetes mellitus, 1 bone marrow aplasia), 3
cutaneous (1 diabetes mellitus under corticosteroid treatment, 1
heart transplant, 1 lymphoma), 3 pulmonary (1 COPD under
corticosteroid treatment, 1 heart transplant, 1 leukaemia) and 1
cerebral (HIV infection). The cases had a sporadic distribution.
Only one case of ZM occurred after the introduction of Vori. The
consumption of Vori in 2004 was 1110 DDDs. Mean consump-
tion per month was 88.6 DDDs (Standard deviation of 48.91
DDDs).
Conclusions: Since 2002, therapy with voriconazole in our
institution has not been associated with changes in the incidence
of ZM.
P1202
Candida colonization, colonization index and
invasive candidiasis in patients at a
multidisciplinary intensive care unit, Sweden
C. Agvald-Ohman, L. Klingspor, H. Hjelmqvist, C.
Edlund (Huddinge, SE)
Objectives: Intensive care units (ICU) have emerged as epicen-
tres for fungal infections such as candidaemia. The aim of the
study was to investigate candida colonization, colonization index
(CI) and its relation to invasive candidiasis in patients with a
length of ICU stay (LOS) ‡7 days.
Material and methods: ICU patients with a LOS ‡7 days were
consecutively included for sampling during Mars 2004–July
2005. The study was approved by the Ethical Committee in
Stockholm. A total of 59 patients, 38 men and 21 women, mean
age 59 years (range 19–81) were included. Mean LOS was
19.8 days (range 7–77) and mean days of ventilation was 16
(range 0–74). A majority of the 59 patients were exposed to
antimycotic drugs during their ICU stay, 35 received ﬂuconaz-
ole, 16 liposomal amphotericin 3 voriconazole and 3 caspofun-
gin. Samples were collected at day 7 and then weekly as long as
the patient was admitted to the ICU. Sampling sites were oral
cavity, lower airways, urine, blood and rectum from all included
patients and from drainage and wounds when this was an
option.
Results: Fourteen patients were not colonized by candida
(CI = 0). C. albicans was isolated from 35 patients, C. glabrata
from 10 and 12 had other non-albicans species. Seven patients
were colonized by ‡2 species of whom two by ‡3 species. At the
ﬁrst sampling occasion 42% of the patients (25/59) had a CI ‡0.5,
eight had CI 1.0, while 26% (8/31) had an index ‡0.5 and two
had CI 1.0 at day 14. Only 10 patients or fewer were sampled at
days 21, 28, 35, 42 and 49, range of mean CI were 0.4–0.7.Ten
patients developed invasive candidiasis, of whom six had
candidaemia. Mean CI for these 10 patients were 0.8 and all
invasive species were also colonizing species. Infections were
caused by C. albicans (6), C. glabrata (3), C. tropicalis (1) and C.
dubliniensis (1). Nine patients were treated with at least one
antimycotic drug, the majority with liposomal amphotericin.
The three months mortality among these patients was 70%
compared to 49% (29/59) among all included patients.
Conclusion: The ICU in the present study is a tertiary unit at
a university hospital and 66% of the patients were treated
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with immunosuppressive drugs (17/59) and/or cortisone (39/
59). Despite the fact that all patients were treated with
antimycotic drugs as soon as CI exceeded 0.5, invasive
candidiasis was diagnosed during the ICU stay in 17% of
included patients. A high CI was correlated to invasive
candidiasis and high mortality.
P1203
Treatment of invasive Pseudallescheria boydii
infections with voriconazole or voriconazole plus
caspofungin
A. Pan, A. Soresina, C. Cattaneo, S. Lorenzotti, S. Magri,
N. Manca, A. Plebani, G. Pinsi, G. Rossi, L. Soavi, L. Signorini,
R. Stellini, G. Carosi (Brescia, IT)
Objective: To report the efﬁcacy of new antifungal drugs in the
treatment of Pseudallescheria boydii infections, to date associated
with a very high mortality.
Methods: We report 4 cases of P. boydii infections successfully
treated with voriconazole at our Institution.
Results:
Case 1: A 26-year old male with chronic granulomatous
disease (CGD) was admitted to the Infectious Disease Depart-
ment (IDD) and pulmonary and mediastinic lesions identiﬁed
on thoracic CT scan. Hyphae were identiﬁed on histology and
biopsy yielded P. boydii. Oral voriconazole was started and an
initial reduction of the lesion observed on CT scan. Repeated
CT scans performed thereafter monthly showed mild further
improvement. The patient is now in fair conditions and still
on oral voriconazole.
Case 2: A 54-year old male, woodcrafter, in general good
conditions, was admitted to neurosurgery because of identiﬁca-
tion of cerebral mass on a brain CT scan. He was operated and
the surgical material showed the presence of hyphae and
yielded P. boydii. Intravenous (IV) voriconazole was started and
reduction of the lesion observed on CT scan. Voriconazole was
switched to oral formulation after 1 month and stopped after
3 months of therapy. One month after stopping voriconazole he
still is in ﬁne conditions.
Case 3: A 70-year old male affected by multiple mieloma, on
chronic corticosteroid therapy was admitted to the haematology
because of respiratory symptoms. No biopsy was performed.
The sputum culture yielded P. boydii. The patient was started on
oral voriconazole and an improvement of the pulmonary lesions
observed over the following months. Treatment with voricon-
azole was stopped after 3 months.
Case 4: A 28-year old male with CGD was admitted to the
IDD because of worsening of pulmonary and mediastinic
lesions on thoracic CT scan while on voriconazole therapy,
observed over a 6 months period. After P. boydii was isolated
form a biopsy and hyphae identiﬁed on histology, a surgical
de-bulking was performed. Caspofungin was associated to
voriconazole and improvement of the general conditions
observed. Combined IV therapy was continued for 4 months
with progressive reduction of the mycosis and improvement
of his general conditions.
Conclusions: Voriconazole is an effective and safe therapy for
invasive P. boydii infections either alone or combined with
surgery depending on the severity of the disease. Patients
who fail voriconazole may respond to salvage treatment with
caspofungin.
P1204
The emergence of caspofungin resistance during
treatment of recurrent Candida glabrata
candidaemia
N. Daneman, A.K. Chan, S.M. Poutanen, R. Rennie, C. Sand,
S. Porter (Toronto, Edmonton, Vancouver, CA)
Objective: The development of caspofungin resistance during
treatment has not been frequently described. This report
documents caspofungin resistance emerging during treatment
of recurrent Candida glabrata candidemia.
Methods: The patient’s clinical chart was reviewed. Suscepti-
bility testing of all saved C. glabrata isolates was completed
following the NCCLS M27-A2 standards. Electrokaryotyping
and restriction enzyme pulsed ﬁeld gel electrophoresis (RE-
PFGE) were performed to assess the relatedness of the isolates.
Results: A 45 yo female with Crohn’s disease with ﬁstulae and
dependent on TPN was admitted in April 2004 with C. glabrata
candidemia. Her central venous catheter was changed and she
was treated with 3 weeks of caspofungin at 70 mg od x 1, then
50 mg od with clinical response. Blood cultures and line tip
were negative. In January 2005, her C. glabrata candidemia
recurred. Her central line was changed and caspofungin at the
same dose was started. Follow-up blood cultures were negative.
Ophthalmologic examination and ECG were normal. Line tip
cultures were not completed. Her course was complicated by
septic shock. Abdominal CT scan revealed a small bowel ﬁstula
and intra-abdominal abscess. Broad-spectrum antibacterial ther-
apy was added with clinical response. Caspofungin therapy was
discontinued after 2.5 weeks. Nine days later in February 2005,
the patient developed recurrent C. glabrata candidemia. The
central catheter was changed and caspofungin was re-started at
the same doses. The line tip grew Candida spp, not albicans.
Repeat blood cultures were negative. Caspofungin was contin-
ued for a total of 1 month. Follow-up blood cultures off
caspofungin were negative. The patient was lost to follow up
until she returned to hospital in October 2005 with a lower
gastrointestinal bleed. She died 3 days after admission. Ante-
mortem blood cultures grew C. glabrata. Multiple C. glabrata
blood culture isolates from April 2004, January 2005, and
February 2005 were available for testing. Capsofungin MICs
were 0.5 mg/L, 8 mg/L, and >16 mg/L respectively. Molecular
testing indicated that the multiple isolates were probably
related.
Conclusion: This case demonstrates that caspofungin resistance
may emerge during treatment. An undetected nidus of infection
may contribute to fungal persistence with development of
antifungal resistance despite apparent adequate therapy and
documentation of negative blood cultures after treatment.
P1205
An open-label study of anidulafungin in invasive
candidiasis and candidaemia
R. Betts, D. Kett, K. Clark, H.T. Schlamm, D.S. Krause (Rochester,
Miami, New York, US)
Objectives: Candida species (spp.) are the leading cause of
invasive fungal infections in hospitalised patients (pts), and are
associated with excess morbidity and mortality, despite the
availability of several new agents. Anidulafungin (ANID) is a
novel echinocandin with potent in vitro and in vivo fungicidal
activity against Candida spp. ANID was superior to ﬂuconazole
(FLU) in a Phase 3 efﬁcacy study of invasive candidiasis and
candidaemia (IC/C) previously reported.
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Methods: We conducted an open-label trial of the efﬁcacy of
ANID. In contrast to the Phase 3 trial, pts on prior FLU were
allowed. Adult pts with IC/C received a loading dose of ANID
on Day 1 of 200 mg, then 100 mg IV daily for a total of 14–
42 days. Pts could be switched to oral FLU after at least 10 days
of IV ANID. Pts were assessed at the end of IV therapy (EIV),
and at 2 & 6 week follow-up (FU) after the end of all therapy. A
successful global response required clinical improvement and
microbiological eradication. The EIV was the primary time point
of interest. Safety evaluations included haematology and bio-
chemistry labs and recording of all adverse events (AEs),
regardless of attribution.
Results: Thirty three (33) pts were enrolled; 22 completed
through the 6-week FU visit. The mean APACHE II score was 14
(range 2–27); 20% had scores > 20. Presence of a central venous
catheter was the most common (84%) reported risk factor. Most
(91%) received at least one prior dose of FLU. Candidaemia was
present in 90% of pts; most had multiple positive cultures at
baseline. C. albicans and C. glabrata were isolated from 42% and
38% of pts, respectively. The median exposure to ANID was 14
doses. Most pts (26/33) did not switch to oral FLU. A successful
global response was observed in 21/31 (67.7%) culture positive
pts. Three pts (9.7%) had persistent infections. On a pathogen
level, success was similar for albicans and non-albicans isolates.
AEs were reported by all pts; 11 pts had AEs that were related
per investigator attribution. Only 2 pts experienced AEs that led
to discontinuation of study drug. At the 6 week FU 79% of pts
survived. Few pts experienced infusion reactions. Clinical
laboratory results did not suggest drug toxicity.
Conclusions: ANID was efﬁcacious and well tolerated. These
results conﬁrm and extend the phase 3 data previously reported.
P1206
Systemic fungal infection due to Trichosporon
beigelii in immunocompromized patient
I. Radonjic, S. Mitrovic, V. Arsic Arsenijevic, I. Kranjcic Zec,
A. Dzamic (Belgrade, CS)
Objectives: Invasive trichosporonosis caused by yeast Tricho-
sporon beigelii often results in rapid, widespread dissemination
and high mortality because diagnostic and therapeutic means
have not been established well. The authors report a case of fatal
T. beigelii fungemia in a 28-year old woman with acute leukemia
and neutropenia. The patient was not on antifungal therapy
before this episode of fungemia.
Methods: During ﬁve days seven blood samples were collected.
All samples were inoculated on Sabouraud dextrose broth and
agar and incubated at 37C for 10 days. Yeasts were identiﬁed
by morphologic criteria, germ tube test, chlamydospore forma-
tion test and assimilation test API 20 C AUX. Antifungal
susceptibility was evaluated by disk agar diffusion method to
amphotericin B, miconazole, ketoconazole, ﬂuconazole, itracon-
azole and ﬂucytosine (1 lg and 10 lg) and by broth macrodi-
lution method for amphotericin B (inoculum 104 CFU/ml, YNB
medium, incubation at 37C, 24 h and 48 h).
Results: All blood samples were positive and isolates identiﬁed
as T. beigelii. All isolates had the same pattern of susceptibility
in vitro. They were sensitive to miconazole, ketoconazole,
ﬂuconazole, itraconazole anf ﬂucytosine, but resistant to amph-
otericin B. The resistance to amphotericin B was conﬁrmed by
broth macrodilution test with MIC = 12.8 lg/ml.
Conclusion: We observed that the strain of T. beigelii was
primary resistant to amphotericin B. Amphotericin B is the most
important agent in therapy of disseminated fungal infections but
most of T. beigelii strains are resistant to this antifungal.
Therefore it is important to test susceptibility to antifungal
agents in vitro for any isolate from blood samples, especially in
immunocompromized patients.
P1207
Epidemiology of dermatophytosis in Khouzestan
province, southwest Iran, from 2002 to 2005
A. Raﬁei, M. Omidian, M. Radmanesh, M. Mapar, R. Yaghobi,
R. Rasaei, R. Taddaion (Ahwaz, IR)
Objectives: Cutaneous fungal infection especially dermatophy-
tosis are common in different parts of Iran. Dermatophyte
organisms are in constant competition for their particular
environmental niche. These data can be used for ascertain past
and present trends in incidence and the emergence of more
predominant dermatophytes. The aims of this study were to
identify the epidemiologic trends and causative organisms of
dermatophytosis in Khuzestan province.
Methods: A total of 2953 specimen were collected from patients
clinically suspected to have fungal infection from 2002 through
2005. Materials collected from hair, nail and skin and were
investigated by direct examination and cultured in Sabouraud
dextrose agar and mycobiotic Agar (Difco). Fungal colonies
were identiﬁed by macroscopic and microscopic examination
and supplementary tests.
Results: The prevalence of dermatophytosis among the suspec-
ted patients was 24.1%. The most predominant types of infection
of dermatophytosis were as follows: Tinea cruris (40.1%), Tinea
corporis (14.5%), Tinea pedis (14.5%), and Tinea capitis (10%) Tinea
pedis (6.7%), Tinea faciei (6.5%), Tinea ungium (6.0%) and Tinea
barbae (1.2%). The most frequent dermatophyte organisms were:
Epidermophyton ﬂoccosum, Trichophyton Verrucosum, Trichophyton
rubrum, Trichophyton mentagrophytes, Trichophyton Viollaceum,
Microsporum canis and Trichophyton schoenleinii. The frequency
rate of dermatophytosis was higher in males than females. The
duration of infection had a wide range from70 days to 20 years.
Age patients were from 4 months to 85 years old, but 21–
40 years age group was found to be the most common infected
group (45.2%).
Conclusion: Dermatophytosis is still one of the most infectious
diseases in Khozestan and probably in Iran. As the causal agent,
the anthropophilic (E. ﬂoccosum) and zoophilic (T. verrucosum)
species were the most common dermatophyte of tinea in
khozestan province, Iran.
P1208
Cutaneous infection by Absidia corymbifera and
Syncephalastrum racemosum treated with
amphotericin B and surgical debridement
R. Bandettini, E. Mantero, A.M. Tamisani, P. Tuo, R. Ceccarelli,
L. Pescetto, L. Ricagni, G. Melioli (Genoa, IT)
Objective: The infections by Absidia spp. and Syncephalastrum
spp. are opportunistic invasive diseases in immunocompro-
mized hosts, in patients with underlying disease or with skin
lesions. A high mortality is described even when aggressive
invasive antifungal therapy and surgical debridement are used.
We describe a clinical case of a paediatric patient with cutaneous
infection by Absidia corymbifera and Syncephalastrum racemosum.
Materials and Methods: A 1-year-old child was hospitalized in
February 2005 for Streptococcus pneumoniae septicemia and
purpura fulminans followed by severe reliquates like cutaneous
necrosis (hands, feet, legs and nose). For this reason in April the
patient was treated with multiple escarectomy and multiple
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grafts of skin and autologous keratinocytes but only the 50% of
the treated surface improved. In the half of May some pieces of
debrided tissue submitted for microbiological examination
resulted positive for Absidia corymbifera and Syncephalastrum
racemosum. In this period the patient presented an intermittent
fever >38.5C. The laboratory ﬁndings showed leukocytosis with
neutrophilia (WBC: 18,000/mmc and neutrophils 79%),
CRP > 10 mg/dl and negative blood cultures. In May 26 an
antifungal therapy with liposomal amphotericin B (10 mg/kg/
day) was started and the debridement of cutaneous infected
sites was performed. The antifungal treatment was completed
with topical amphotericin B and continued until June 13, 2005.
Results: In May 30 the microbiological examinations of the skin
biopsies were negative, the fever disappeared and haemato-
chemical tests turned to normal values. The side effects of
antifungal therapy were not observed. The cutaneous lesions
recovered and from July the patient had not signs and
symptoms of fungal infection.
Conclusions: Zygomycosis are very severe infections with high
mortality despite the use of in vitro effective antifungal therapy.
We present a clinical case of successful treatment of cutaneous
infection by Absidia corymbifera and Syncephalastrum racemosum
with liposomal amphotericin B and topic amphotericin B,
associated with surgical debridement. The therapy was well
tolerated and the patient recovered without any diffusion of the
infection to other sites. We think that the combination of two
different approaches, medical and surgical, offers the best
chance for survival.
P1209
The Janus head of histoplasma
E. Vlieghe, M. Ieven, H. Jansens, B. Hendriks, K. Van de Vyvere,
P. Fonteyne, E. Van den Enden, R. Colebunders (Antwerp,
Brussels, BE)
Objectives: To describe an unusual case of invasive infection
with H. capsulatum
Methods: A description of the clinical, pathological and micro-
biological ﬁndings.
Case study: A 33-year old African man was admitted to the
hospital with fever, night sweats and a tender mass in the left
fossa iliaca. He was recently diagnosed HIV-positive, with CD4-
count 2 ll (0.6%) and viral load 649,000 copies/ml. He appeared
in good clinical condition besides a generalised lymphadenop-
athy, a splenomegaly and a tender mass (7 · 5 cm) in the left
iliac fossa. The relevant lab analyses were: ESR 53 mm/h, CRP
5 mg/dl, Hb 12.5 g/dl, thrombocytes 172 · 109/l, WBC
2.5 · 109/l, LDH 870 U/l. Serology for syphilis and toxoplas-
mosis was negative and showed immunity for CMV and EBV.
Cryptococcus Ag and Histoplasma Ag were negative. Retinal
fundoscopy showed no abnormalities. Cultures of sputum and
blood remained initially sterile. CT scan of the thorax and
abdomen showed enlarged lymph nodes in the upper mediast-
inum, retroperitoneum, peripancreatic, para-aortic and along
the left a. iliaca externa and femoralis; the latter nodes appearing
with a necrotic centre. A CT-guided ﬁne-needle biopsy was
taken from the iliacal mass. Histology of the biopsy showed
yeast forms of Histoplasma capsulatum. The patient was started
on IV liposomal amphotericin-B 3 mg/kg and switched after
10 days to PO itraconazole 2 · 200 mg for 3 months. The
symptoms and the mass subsided soon thereafter. After four
weeks, growth of a ﬁlamentous fungus was observed in one of
the mycobacterial blood culture bottles. It was identiﬁed as H.
capsulatum through PCR carried out on a subculture on blood
agar at 37C. The test was positive after 2 different extractions
and with 2 different PCR-protocols. DNA sequencing of the ITS
locus, our reference method for molecular identiﬁcation con-
ﬁrmed these results. Twelve weeks later, the patient was doing
well and itraconazole was reduced tot 1 · 200 mg/d for secon-
dary prophylaxis.
Conclusion: Invasive histoplasmosis is a well-known oppor-
tunistic infection in AIDS-patients. The growth of a ﬁlamentous
fungus in the blood of this patient was surprising, since this
dimorphous organism normally converts to the yeast phase at
37C. Apparently this conversion did not take place, possibly
due to the culture medium or the environment.
P1210
Successful therapy of zygomycosis with
posaconazole in a patient intolerant of liposomal
amphotericin B
S. Savvanis, A. Papadopoulos, D. Kavvatha, H. Giamarellou
(Athens, GR)
Introduction: Zygomycosis is a rare invasive fungal infection,
but incidence is increasing. Infection typically occurs in patients
with immunodeﬁciency or diabetes mellitus and is associated
with high mortality rates. Treatment includes surgical debride-
ment and the use of antifungal agents, such as liposomal
amphotericin B and new and investigational azoles (eg, posac-
onazole).
Case presentation: A 33-year-old woman with an unremarka-
ble medical history was admitted to the hospital with signs of
diabetic ketoacidosis, intense pain in her left shoulder extending
to the left upper limb in an ulnary nerve distribution, and
Claude Bernard-Horner syndrome. A computed tomography
scan of the chest revealed a mass in the upper lobe of the left
lung. The patient underwent surgery, and a mass inﬁltrating the
cervical sympathetic chain, the stellate ganglion, the left subcl-
avian artery, and the brachial plexus was partially excised.
Biopsy specimens revealed aseptate hyphae with right-angle
branching compatible with zygomycosis. Liposomal amphoter-
icin B was initiated at a dose of 8–12 mg/kg/day. A postoper-
ative magnetic resonance image (MRI) revealed reoccurrence of
the mass inﬁltrating the left lung apex and the stellate ganglion
and extending to the C7-Th1 intervertebral foramen and the left
subclavian artery, causing focal occlusion, and an embolized
mycotic aneurysm. New lesions appeared in the glottis and the
right upper lobe. The patient received 48 g of liposomal
amphotericin B in a 5-month period; this therapy was stopped
owing to nephrotoxicity. The patient subsequently received
posaconazole 400 mg twice daily as an oral solution for
11 months. Posaconazole therapy resulted in almost complete
resolution of the pathologic ﬁndings and was well tolerated.
Three months after the end of the treatment, the patient remains
in excellent clinical condition, and the latest MRI shows no
evidence of relapse.
Conclusion: Radical surgery combined with control of immu-
nodeﬁciency or diabetes mellitus represents the gold standard of
treatment for zygomycosis. Antifungal agents may resolve
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remnant lesions as well as prevent relapse. Liposomal ampho-
tericin B may be given over the long term with strict surveillance
of toxicity. The investigational antifungal agent posaconazole
has shown high antifungal activity against Zygomycetes with
low toxicity, and may be administered orally.
P1211
Carbon assimilation proﬁles as a tool for
Zygomycetes species identiﬁcation
P. Schwarz, O. Lortholary, F. Dromer, E. Dannaoui (Paris, FR)
Objectives: Identiﬁcation of Zygomycetes to the genus and/or
species level remains difﬁcult by standard mycological proce-
dures. The aim of this study was to evaluate carbon assimilation
proﬁles as a tool for identiﬁcation of the most common
Zygomycetes responsible for infections in humans.
Methods: ID32C yeast identiﬁcation system was used. Strips
were inoculated by spore suspensions of 47 well-characterized
isolates belonging to 8 Zygomycetes species (15 Rhizopus oryzae, 8
Absidia corymbifera, 7 Mucor circinelloides, 7 Rhizomucor pusillus, 4
Rhizopus microsporus, 3 Syncephalastrum racemosum, 2 Mucor
indicus and 1 Cunninghamella bertholletiae). Strips were incubated
at 28C and were read visually after 72 hours of incubation.
Results: Overall seventeen carbon sources were useful for
discriminating among the examined Zygomycetes species. The
assimilation of the majority of carbon sources was homogeneous
within a given species and heterogeneous between species. Each
species showed a speciﬁc carbon assimilation proﬁle allowing
accurate identiﬁcation except for M. circinelloides and M. indicus
that shared similar proﬁles. Table 1. Percentage of positive
assimilation results for the most useful carbon sources
Conclusions: These results demonstrate that diagnosis of the
main pathogenic Zygomycetes to the genus and species level is
possible based on their carbon assimilation proﬁles. This
technique using a commercially available system provides a
fast and easy tool for identiﬁcation of the most common
Zygomycetes species.
P1212
Is posaconazole a new treatment option for brain
abscess?
L. Matkham, C. Garzoni, B. Hirschel, S. Harbarth,
K. Bouchuigui-Waf, J. Garbino (Geneva, CH)
Introduction: Cladophialophora bantiana is a dematiaceous
fungus, a rare cause of cerebral abscess. Its high mortality is
related to its poor response to currently available anti-fungal
therapy.
Case report: A 60-year old Egyptian woman with a systemic
sclerosis and long term corticoid therapy, pulmonary ﬁbrosis
chronic hepatitis C with cirrhosis, chronic thrombocytopenia
and arterial hypertension. The patient was hospitalised for
frequent falls and confusion. On admission, the patient was
febrile, sleepy and confused. A CT-scan showed an expansive
lesion compressing the left lateral ventricle. The magnetic
resonance image (MRI) suggested an image of glioblastoma
and a chemotherapy was started. The patient developed a
progressive right hemiparesis, aphasia and worsened in senso-
rium. Cerebral biopsy was performed on hospital day 12. Due to
its location resection was not possible and aspiration was done.
The microbiological cultures yielded a Cladophialophora bantiana.
A treatment was initiated with voriconazole 400 mg po/12 h
and liposomal amphotericin B 7 mg/kg/d. The MRI 5 days after
showed increased size lesion. Increased in liver tests suspected
hepatic toxicity and voriconazole was replaced by posaconazole
400 mg/12 h. A MRI done after 16 days of posaconazole
treatment showed a similar size of the lesion, but without
peri-lesional oedema. In addition to her neurological problems
the patient developed pneumonia with severe sepsis and
continued to deteriorate and died.
Discussion: Phaeohypomycosis is the infection caused by
dematiaceaous moulds which are unique owing to presence of
melanin pigments in their cell walls and spores. Melanin may be
a virulence factor in these fungi. Dematiaceous fungi are
widespread in the environment especially in the soil and
decaying vegetation One of them C. bantiana has a predilection
for brain tissue.Recommendation for therapy is based upon the
experience of published cases. Long-term survival is reported
only when complete surgical resection of the lesion is possible
accompanied by an anti-fungal treatment. The recommended
treatment is high dose of amphotericin B in combination with a
new triazole and if is it possible 5 ﬂuctocystosine. Posoconazole
could be a new drug option for its better tolerability and less
drug-drug interactions.
P1213
Clinical and epidemiological analysis of candida
bloodstream infection in a university hospital
M. Cuervo, M.A. Miguel, M. Lecuona, S. Campos, M.I.
Montesinos, A. Torres, T. Delgado, A. Sierra (La Laguna Sta Cruz
Tenerife, ES)
Objectives: Candida spp is emerging as an important pathogen
or coloniser in hospital settings. The aim of this study was to
determine demographic, clinical and microbiologic features in
Candida bloodstream infection in our hospital.
Methods: We have revised prospectively demographic, clinical
and microbiologic data from 125 patients with candidemia in a
period between 1/06/2002 to 1/06/2005. All the specimens were
performed with Bact/ALERT 3D (bioMe´rieux) initially during
ﬁve days either 30 days in special cases. The yeast identiﬁcation
was performed with ID-YST Vitek2 and/or api 20 C AUX
(bioMe´rieux).
Results: Of 33043 blood cultures processed in our laboratory,
9500 shown any kind of grown and 355 isolates (3.73%) proved
to be yeast strains which belong to 125 patients. The infection
rate of males and females was 56.8% and 43.2% respectively. The
highest rate was seen in persons >60 years old (47.25%) followed
by the group <10 years old (16.8%), most frequently related to
neonatal period, especially in premature newborn. Most strains
were recovered from patients attended to internal medicine
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departments (44%), 31.2% belong to surgical departments and
24.8% were in intensive care units. Of a total of 125 candidemias,
the most common origins were unknown (52.58% cases) and
37.11% were secondary to central venous catheter. The most
common species isolated was C. albicans (51.2%) followed by C.
parapsilosis (21.6%), C. tropicalis (14.4%) and C. glabrata (7.2%).
Conclusions: Comparing the distribution of the demographic
data to other Spanish hospitals similar results were found. In
our hospital, C. albicans was the yeasts most frequently isolated
followed by C. parapsilosis, C. tropicalis and C. glabrata. Most
candidemias were primary or secondary to intravascular cath-
eter related infections. It should be necessarily to remove the
catheter when it is no longer essential for medical management.
P1214
A prospective French national survey to evaluate
renal function in patients treated with
amphotericin B lipid formulations
S. Faouzi (Villejuif, FR)
Objective: To evaluate renal function in patients treated with
Amphotericin B lipid formulations (recommended for treating
patients with renal failure).
Methods: A prospective multicentre national survey to evaluate
the renal function in adult patients (pts) treated for fungal
infections with the two available lipid formulations Abelcet and
Ambisome. From April 2003 to December 2004, 99 pts were
treated with lipid formulations, 88 pts (43F; 45M) with mean age
of 49 + 13 years were evaluable from renal safety. 44% of pts
had neutropenia <500/mm3.
Results: 28 pts (32%) were treated for invasive candidosis, 29 pts
(33%) for aspergillosis and 8 pts (9%) for rare fungal infections. 23
pts (26%) had empirical treatment for febrile neutropenia. 68% of
the pts received 2 or more nephrotoxic drugs (72% for Abelcet;
61% for Ambisome).60 pts were treated with Abelcet (median
dose: 4.8 g/kg/day) and 38 pts with Ambisome (median dose:
3.3 g/kg/day). The mean duration of treatment was
13.5 ± 8 days for Abelcet and 15 ± 11 days for Ambisome. In
the group of 26 pts with renal failure, no signiﬁcant changement
occurred between mean serum creatinine level and creatinine
clearance at baseline (188 + 98 lmol/l; 47 + 24 ml/mn) and end
of the therapy (173 + 70 lmol/l; 45 + 20 ml/mn).
Conclusion: Amphotericin B lipid formulations have a good
renal safety proﬁle in patients with either altered or normal
renal function combined with nephrotoxic drugs.
P1215
Fungal peritonitis in continuous ambulatory
peritoneal dialysis patients
B. Arda, O. Sipahi, G. Asci, M. Ozkahya, S. Ulusoy (Izmir, TR)
Objective: The aim of this study was to evaluate the continuous
ambulatory peritoneal dialysis (CAPD) patients with culture
proven peritonitis between 1992–2004 in our center.
Method: We analysed the hospital charts of all patients that
received diagnosis of fungal peritonitis between 1992–2004,
retrospectively. Patients with either cloudy peritoneal efﬂuent
containing more than 100 white cells/mm3 or signs compatible
with peritonitis together with one or more isolations of fungal
pathogens were considered to have fungal peritonitis.
Results: During the study period a total of 9 (5 males, 4 females,
aged 49.0 ± 12.2) of 342 patients (overall fungal peritonitis rate
2.6%), who were started CAPD had fungal peritonitis. Four
patients had diabetes mellitus. The infecting pathogen was
Aspergillus spp. in three, Candida parapsilosis in two, Candida
trpopicalis in two and Candida albicans in two patients. All but
two patients had earlier bacterial peritonitis attacks (mean
bacterial peritonitis attack 2.2 ± 1.6, range 0–6). Leucocyte
number in peritoneal ﬂuid was 791 ± 504/mm3 (Range 300–
1400/mm3). Overall mortality rate was 22.2% (one with Asperg-
illus spp. one with C. parapsilosis). CAPD catheter was removed
in all patients. Mean duration of treatment was 27 ± 19 days,
range 14–70 days). Three patients were treated with amphoter-
icin b deoxycholate, ﬁve with ﬂucanazole and one with
amphterivcin b cholesterol dispersion. All patients received
conventional antibiotic treatment before the diagnosis of fungal
peritonitis.
Conclusion: Fungal peritonitis is a mortal and morbid compl-
ication of CAPD: Fungi especially non-albicans Candida spp.
should be taken into consideration in peritonitis patients not
responsive to conventional antibiotics.
P1216
Intra-abdominal fungal infection in surgical
patients
I. Gutie´rrez, N. Batista, A. Varona, O. Dı´ez (Santa Cruz de
Tenerife, ES)
Objective: Several surgical procedures into abdominal cavity
are associated with a high incidence of fungal infections. The
aim of the study is to analyse the clinical an microbiological
aspects of patients with abdominal fungal infections after
surgical procedures.
Material and methods: We investigated retrospectively forty-
ﬁve patients, admitted to the Surgical Digestive Service for
urgent selective surgery. Clinical investigation included: host
and risk factors, history of the disease, surgical procedures,
postoperative complications, intraocular ﬁndings. Microbiologi-
cal criterion included: positive cultures from intra-abdominal
liquids and tissues, intraocular and blood samples. Bacterio-
logical and mycological tests included cultures for aerobic and
anaerobic, yeast and fungi. Fungal isolates were identiﬁed using
standard mycologic laboratory methods and tested for suscep-
tibility to ﬂuconazol (FCZ), amphotericin B (AMB), itraconazol
(IT), 5-ﬂuorocytosine (5FC) and voriconazol (VOR).
Results: The most commonly identiﬁed yeast species were
Candida albicans (64%), followed by Candida glabrata (21%),
Candida tropicalis (6%), Candida parasilopsis (3%), Candida krusei
(2%), other species (4%). In 67% patients coexisted yeast and
bacteria, and in 33% pure yeast culture was found. The bacteria
most frequently associated were enterobacteria (26%), entero-
coccus (25%), non fermenting gram negative rods (18%), gram
positive cocci (20%), other (2%). The predominant fungal
association was C. albicans/C. glabrata (64%), C. albicans/C.
tropicalis (24%). All the yeast isolated showed susceptibility to
ﬂuconazol except 50% isolates of C. glabrata and one C. krusei
isolate. From the forty-ﬁve patients 45% showed post-surgical
complications, 33% perforation of hollow viscus, 11% pancrea-
titis, and 11% biliary pathology. Five patients showed invasive
fungal infection, one presented mediastinitis and three died.
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Conclusions: High percentage of C. glabrata isolated in intra-
abdominal infections precludes the election of ﬂuconazol as
empiric antifungal treatment in most severe cases.
P1217
Mucormycoses: a report of eleven cases
T. Turunc, Y.Z. Demiroglu, H. Uncu, S. Colakoglu,
H. Arslan (Baskent, TR)
Objectives: Mucormycoses are infections caused by fungi of the
order Mucorales. We reviewed the clinical features of 11 patients
who developed mucormycosis. The aim of this study is to
evaluate the clinical spectrum, diagnosis and treatment of
Mucormycosis.
Material-methods: This was a retrospective study conducted
over a 2-year period (2003–2005). The study included 10 patients
with hematologic malignancies, diabetes mellitus (DM), chronic
renal failure, an one patient was immunocompetent with proven
or probable mucormycosis.
Results: The research data base includes 8 men and 3 women
(age range: 30–80 years; median age: 53.5 years). Predisposing
conditions in decreasing order of frequency were diabetes
mellitus (DM) (4), DM and chronic renal failure (3), DM and
chronic myeloid leukemia (2), acute lymphoblastic leukemia (1),
and immunocompetent (1). Six patients presented with the
rhinocerebral form of the disease and ﬁve patients presented
with central nervaus system involvement. The Mucor spp. was
isolated from cultures in four cases while it was diagnosed by
histopathological examination along with clinical and radiolo-
gical ﬁndings in other cases. Seven patients underwent surgical
treatment. Liposomal amphotericin B (3 mg/kg/day) was
administered in the treatment of 11 patients. Five of the patients
responded well to the therapy. Six patients died within 1 month
of the diagnosis of fungal infection. Mucormycosis was the
cause of death in all of them.
Conclusions: Mucormycosis occurs most frequently in neu-
tropenic patients with haematological diseases. In our study,
DM and chronic renal failure were found to be more signiﬁ-
cantly related with mucormycosis than the hematological
malignities. These results suggest that mucormycosis should
be considered in the differential diagnosis of orbital cellulitis not
only in the patients with hematologic malignities but also in the
patients with DM and/or chronic renal failure.
P1218
Bipolaris spicifera isolation from the nasal polyps
of an allergic boy: a case report
A. Sergounioti, H. Kirikou, A. Velegraki, K. Chryssaki,
M. Choulakis, K. Stefanaki, A. Pangalis (Athens, GR)
Allergic fungal sinusitis (AFS) is a non-invasive form of
paranasal sinus mycosis caused by the dematiaceous fungi,
usually Bipolaris, Curvularia, Exserohilum, Alternaria, Drechslera,
and less often by Aspergillus. We present a case of a boy with a
massive paranasal polyp, from which Bipolaris spicifera was
isolated.
Case report: A 10-year-old immunocompetent boy, with a
history of allergic rhinitis, nasal congestion, postnasal purulent
discharge and restricted nasal breathing during last year, was
admitted to our hospital for investigation of his symptoms. The
clinical examination revealed the presence of a massive polyp
which obstructed the left nostril. Chest radiography was normal.
The eosinophils of the peripheral blood were not elevated. The
C/T showed an extended polyp which occupied the left
maxillary sinus and protruded from the maxillary sinus
ostium in the left nostril. Bony erosion of the sinus walls was
also apparent. Levels of fungal-speciﬁc IgE(RAST)for Cladospo-
rium herbarum and Alternaria alternata were elevated. The polyp
was surgically removed and full histological and microbiologi-
cal investigation followed. The histologic ﬁndings included
inﬂammation of a chronic inﬂammatory process, presence of
allergic mucin, eosinophils and lymphocytes inﬁltration of the
mucosa, whereas Grocott’s and PAS staining rendered fungal
hyphae. After 72 hours’ incubation, the histological specimen
culture yielded a dark olive to black fungus identiﬁed as
Bipolaris spicifera. Conventional identiﬁcation was conﬁrmed by
sequencing (Marcogen, Seoul, Korea) of the ampliﬁed ITS1 and
ITS2 regions showing 99% homology (Bioedit) with the pub-
lished rRNA sequences (GenBank Acc. No AY253918). The
patient, after the surgical removal of the polyp, received therapy
with budesonide and desloratadine and was regularly followed
up by the otolaryngology department of our hospital. Antifun-
gal therapy was not administered Eight months after his
admission to the hospital, recurrence of the disease was
observed.
Conclusions: Recent evidence supports the theory that AFS
represents an immunologic, rather than infectious, disease
process, similar to that of allergic bronchopulmonary fungal
disease. Although important, surgery alone does not lead to a
long-term disease-free state and plan incorporating medical,
surgical and immunologic care remains the most likely means of
providing long-term control of disease.
P1219
Mucormycosis: still a problem (a report of 4 cases)
L. Ammari, B. Kilani, H. Tiouiri ben Aissa, F. Kanoun,
E. Chaker, A. Goubontini, T. Ben Chaabane (Tunis, TN)
Mucormycosis is a rare and invasive fungal infection which is
frequently lethal. It affects commonly on immunocompromised
patients, especially diabetics. The rhinocerebral form is the most
frequent complication, but other localizations may occur.
Objective: The aim of this study is to analyse demographic
characteristics, clinical presentation, radiological ﬁndings, man-
agement and outcome of mucormycosis.
Methods: We conducted a retrospective study of patients who
developed a mucormycosis between January 1988 and Decem-
ber 2004 and admitted in the department of infectious diseases
of Rabta hospital in Tunis. Diagnosis of mucormycosis was
conﬁrmed by mycological and/or histological ﬁndings.
Results: 4 patients with mucormycosis were included in the
study, 3 male and one female. The mean age is 53 years. All
patients were diabetics, three of them had diabetic ketoacidosis
at the time of diagnosis. The sites of infection were: sinonasal (2
cases), rhinocerebral infection (2 cases). One patient with
rhinocerebral involvement had carotid artery thrombosis on
RMI. The direct detection of fungus in tissues and samples were
noted in all cases and Rhizopus oryzae grew in 3 cases. Our
patients were treated with amphotericin B associated to surgical
debridement of devitalized tissue in 3 cases. A fatal outcome
was observed in two patients, whereas two patients are still
alive with sequelae: facial paralysis and numbness (1 case) and
facial necrosis (1 case).
Conclusion: Mucormycosis remains a severe infection disease
in diabetics patients. Early diagnosis and treatment are manda-
tory to improve survival and prevent brain dissemination.
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P1220
Candida deep sternal wound infections: an
emerging problem?
T. Ejlertsen, I. Modrau, L. Lemming, B.S. Rasmussen (Aalborg,
DK)
Objectives: Deep sternal wound infection (DSWI)imposes seri-
ous consequences to the patient after open heart surgery in
terms of signiﬁcantly increased morbidity and mortality inclu-
ding prolonged hospital stay. Candida as a causative organism
for DSWI has only been reported in few cases in relation to
nosocomial outbreaks. The increasing number of DSWI with
Candida at our institution required systematic investigation.
Methods: The study was conducted for all open heart surgery
performed at the department of Cardiothoracic Surgery Aalborg
Hospital, Aarhus University Hospital, in the period of January
2001 through December 2004. All cases of DSWI were investi-
gated retrospectively. DSWI was deﬁned as clinical signs of
infection requiring open exploration of the sternum with
ﬁndings of bacteria or yeast from bone biopsy, deep tissue
biopsy, or aspiration of pericardiac ﬂuid.
Results: From year 2001 to 2004, a total of 2138 patients
underwent an operation involving median sternotomy. DSWI
was identiﬁed in 39 patients, 29 cases were early onset (0–
30 days), (incidence 1.4%); 10 caseswere late onset (32–165 days).
Twelvepatients experiencedmore thanone episodeof infection (a
total of 55 episodes). Candidawas a frequent agents (12 episodes),
only second to coagulase-negative staphylococci (36 episodes).
Re-operation, prolonged stay in ICU, and colonisation with
Candida prior to infection were risk-factors for Candida infections.
Longterm mortality (0–4 years) of patients with Candida DSWI
was 45%, whereas mortality of patients with DSWI of other
aetiology was 18%.
Conclusions: Candida infections in DSWI following median
sternotomy have become a problem of major concern in our
hospital. Spread over time together with presence of several risk
factors contradicteda clonal outbreak.Candida infections require a
prolonged course of antimycotic chemotherapy and have a poor
clinical outcome. Findings of Candida species from sternal wound
should prompt further investigations including bone or tissue
biopsies to verify a DSWI. Antimycotic chemotherapy should be
initiatedas soonas adiagnosisofCandida infectionhasbeenmade.
P1221
Survey on dermatophytosis in patients referred to
a dermatology hospital in Ghazvin, Iran
M.R. Aghamirian, D. Keshavarz, J.H. Hashemi (Ghazvin, IR)
Dermatophytosis has been considered to be a major public
health problem in many parts of the world. The aim of this study
was to identify aetiological agents of patients with dermatophy-
tosis infections in referred to the dermatology Hospital Boali
Sina, Ghazvin, Iran. A total of 341 patients suspected to have
dermatophytosis lesions were examined over a period of one
year (2004–2005).Material collected from skin, hair and nails was
submitted to direct microscopic examination using KOH,
cultured in sabouraud dextrose agar and microscopically exam-
ined for colony morphology, in order to the identify 116
dermatophytes isolated. Epidermophyton ﬂoccosum was the most
frequent dermatophyte isolated (32.8%) followed by Ttrichophy-
ton mentagrophytes (22.4%), T. rubrum (18.1%), T. verrucosum
(17.2%), T. violaceum (0.86%). Tinea cruris (31.9%) was the most
common type of infection, followed by Tinea corporis (20.7%),
Tinea pedis (19%), Tinea unguium (11.2%), Tinea faciei (7.7%), Tinea
manuum (5.2%), Tinea capitis (4.3%). The frequency rate of Tinea
was higher in males than in females. The anthropophilic species
E. ﬂoccosum was the most common dermatophyte causative
agent of tinea.
P1222
Caspofungin and G-CSF as ﬁrst-line therapy of
pulmonary invasive fungal infections in 32
neutropenic patients with haematologic
malignancies
A. Candoni (Udine, IT)
Caspofungin is a large lipopeptide molecule able to inhibit the
enzyme complex 1,3-D-glucan synthetase; this action speciﬁcally
damages the fungal cell wall. Caspofungin (CAS) is active, in
vitro and in vivo, against most Candida species and Aspergillus
species. Herein we report our experience with this drug as a
ﬁrst-line therapy for pulmonary proven or probable IFI in
neutropenic patients with hematologic malignances. Thirty-two
consecutive patients (pts) have been treated with CAS (27 acute
leukemias, 3 lymphomas, 1 chronic leukaemias and 1 myeloma):
20 males and 12 females with a median age of 52 yrs (range 22–
72). 16/32 (50%) pts had a relapsed or resistant haematologic
disease, while 12 pts were in complete remission and 4 pts were
at onset of disease; 8/32 (25%) developed IFI after a Transplant
(BMT) procedure. Out of 32 pts, 7(22%) had proven pulmonary
IFI (7/7 Aspergillosis) and 25(78%) had a probable IFI (deﬁned
according to international consensus), all 32 cases with pul-
monary localization. 31/32 (97%) pts had less than 1000 gra-
nulocytes/mLl at onset of infection. CAS was given at the dose
of 70 mg on day 1, followed by 50 mg/daily. Median duration
of CAS therapy was 20 days (range 8–72); 31/31 neutropenic pts
(100%) received G-CSF. The overall response rate was 56% (18/
32) with 12/18 complete responses and 6/18 partial responses;
2/32 pts had a stable disease. Twelve out of 32 pts (37.5%) did
not respond and six of them (50%) died for mycotic infection.
Univariate analysis showed that granulocytes recovery and
status of haematologic disease were signiﬁcantly associated to
favourable outcome. No adverse clinical effects were reported
and only a grade I-II transient increase of alkaline phosphatase
and/or transaminases occurred in 4/32 (12%) pts. After CAS
therapy six non-responders and 6 pts with a partial or stable
response were rescued with voriconazole. Two out of 6 pts
(33%) in the former group and 6/6 (100%) in the latter obtained
a complete resolution of IFI. Our experience suggests an efﬁcacy
of CAS in combination with G-CSF, as ﬁrst-line treatment of
proven or probable IFI with lung localization. The drug was well
tolerated and there were no signiﬁcant hepatic adverse events
even in pts receiving CAS with cyclosporin after a BMT. A
signiﬁcant proportion of non-responders or partial responders
to CAS can be rescued with a subsequent voriconazole-based
therapy.
P1223
Clinical analysis of cryptococcal meningitis (with
72 case reports)
G. Shi (Shanghai, CN)
Objectives: To analyse the clinical characteristics, prognosis
and its related factors of patients with cryptococcal meningitis.
Methods: Clinical information of 72 patients with cryptococcal
meningitis treated in Huashan Hospital from January 2000 to
December 2004 were retrospectively analysed.
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Results: Among the 72 patients (46 men and 26 women;
mean age, 38.7 years), 37 have a background disease: 22 with
connective tissue disease, 6 with renal insufﬁciency, 4 with
diabetes mellitus, 3 with tuberculosis, 2 with HIV/AIDS. 14
(19.4%) of them have a clear contact history with pigeons. 29
of them were diagnosed as tubercular meningitis at ﬁrst, 9 as
suppurative meningitis, 7 as lupus encephalopathy, 2 as viral
encephalitis and 3 as other diseases. And 39 (54.2%) patients
had recently used glucocorticosteroid and (or) immunosup-
pressor. Lab Findings: 57 patients (79.2%) were positive for
CSF India ink smear, 21 (29.2%) positive for Cryptococcus
culture, 66 (91.7%) positive for Latex agglutination test (LAT).
And 18 patients had markedly elevated intracranial pressure
(‡300 mmH2O). Treatment: 37 patients with cerebral ventricle
dilatation got lateral ventricle drainage, and 33 individuals
implanted Ommaya. 58 patients were treated with a combi-
nation of Amphotericin B (AmpB) or its lipid formulations
plus ﬂucytosine. 52 individuals received ﬂuconazole contem-
porarily in induction course. 43 were treated with intrathecal
AmpB injection. The average dose of AmpB is 3.06 g; length
of therapy is between 12 weeks and 20 months. 54 patients
(75%) were cured, 9 (12.5%) improved and 9 (12.5%) died.
Conclusion: High rate of misdiagnosis is common to crypto-
coccal meningitis. The application of immunosuppressor such
as glucocorticosteroid and diseases such as HIV/AIDS cause
immunocompromise, which is the major risk for cryptococcal
meningitis. Besides, a contact history with pigeons is another
main pathogenic factor. CSF LAT is still the most sensitive
test for diagnosis. The keys to reduce mortality and improve
prognosis include early diagnosis, combination antifungal
therapy of AmpB with 5-FC, aggressive management of
elevated intracranial pressure and intracerebral or intrathecal
AmpB. Implantation of Ommaya and intra-Ommaya or
intrathecal AmpB help to reduce the veinal dosage of
AmpB and to get improvement earlier, and accordingly
shorten the length of therapy evidently.
P1224
The prevalance of aetiologic agents of
dermatophytosis in wrestlers in Isfahan, Iran
S. Shadzi, A. Karbassian, N. Kassaian, M. Khademi,
Z. Nokhodian (Isfahan, IR)
Objectives: Due to special conditions of wrestleing sport, this
group of athletes are at high risk of dermatophytic infections.
These infections are easily transmitted to other populations
either in gymnasium or home. The prompt diagnosis of infection
and identiﬁcation of the aetiological agents of dermatophytoses
would help the prevention and treatment of this group of
athletes which was the aim of this study.
Methods: Fifty-six male wrestlers suspected of having cutane-
ous dermatophytoses were studied during 2002–2004. Direct
exam and culture were performed on the collected scraping
specimens. The identiﬁcation of fungal species were done by
standard procedures.
Results: The wrestlers in this study were in 17–23 years of
age and 80% of them stated in their medical history the lack
of shower after exercises was the major factor of infection. On
12 patients only direct exam was performed and 44 specimens
were cultured in which 38 (86%) Trichophyton rubrum, 4 (9%)
T. violaceum and 2 (4.5%) Epidermophyton ﬂoccosum isolated
and identiﬁed.
Conclusion: Regarding to resistance of Trichophyton rubrum to
antifungal agents, the necessity of culture and identiﬁcation of
species involved in wrestlers is emphasized. Also, personal
hygiene and shower after exercise are important. In addition, the
disinfectant of gymnasium and exercise equipments and sufﬁ-
cient ventilation of these places are recommended
P1225
Slowly progressing, and indolent pulmonary
mucormycosis (zigomycosis) in a patient with an
underlying multiple sclerosis, managed without
immunosuppressive therapy
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
Introduction: Mucormycosis (M) is a infrequent ﬁlamentous
fungal infection borne by a very elevated fatality rate despite
prompt diagnosis and adequate therapy especially in its
frequent rhinocerebral presentation and/or when decompen-
sated diabetes mellitus, neutropenia or immunosuppression are
of concern.
Case report: A 53-year-old female patient (p) with a multiple
sclerosis previously treated with steroids-azathioprine (but
controlled since 3 months without treatment), was hospitalized
owing to hemophtoe in absence of other respiratory symptoms
and fever. Laboratory testing did not disclose signiﬁcant
abnormalities (WBC, ESR and serum glucose were within
limits) and tumoral markers tested negative but the detection
of multiple lung inﬁltrates at chest X-ray and HRCT (predom-
inant at right lobes, with an appreciable air bronchogram),
prompted a bronchoscopy with biopsy-BAL involving the
medial right lobar bronchus area. After an uncertain microscopy
(with Aspergillus hyphae still suspected) and negative serum
Aspergillus antigen search, cultures led to the isolation of Mucor
spp., with tested in vitro susceptible to amphotericin B-posac-
onazole and resistant to itraconazole-voriconazole. Liposomal
amphotericin B (3 mg/kg/day) was delivered for 6 weeks
predominantly on Day-Hospital basis with favourable tolerab-
ility: no hematological, blood chemistry and urinalysis altera-
tions occurred. One month later our p completely recovered and
a repeated HRCT and bronchoscopy conﬁrmed a complete
clinical, radiological and mycological cure.
Discussion: M is a rare occurrence especially when neutropenia
and ketoacidosis are absent. However, anecdotal reports
occurred after trauma and during COPD. Although the usual
portal of entry of M is respiratory, however the rhinocerebral M
remains the most frequent and life-threatening presentation.
Clinicians should consider M even when obvious risk factors
and an apparently slow progression are found. Diagnosis
includes microscopic differentiation from Aspergilli, although
mixed infections are not so rare. In pulmonary forms, percuta-
neous biopsy becomes sometimes needed. Liposomal ampho-
tericin B remains the treatment of choice but surgery is
sometimes necessary to debride extensive necrotic areas due to
angioinvasion; some doubt remains about hperbaric O2 therapy.
In our p, a slowly progressive pulmonary M was identiﬁed and
cured in a reasonably short time, even in absence of underlying,
active risk factors and an overwhelming clinical progression.
P1226
AIDS-deﬁning fungal opportunism in the
HAART era. Trend of frequency and reduced
incidence when HIV protease inhibitors are
administered
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
Background: Nine years after the introduction of HAART,
opportunistic AIDS-related mycoses show a progressive drop of
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incidence. Aim of our work is to assess the temporal trend of
major AIDS-associated fungal infections during the last three-
year period, and to relate our ﬁgures with HAART administra-
tion, and the different combinations of administered antiretr-
ovirals, with attention focused on protease inhibitors (PI).
Methods: Through a retrospective analysis of clinical-microbio-
logical records, 118 episodes of AIDS-deﬁning mycoses were
identiﬁed from 2001 to June 30, 2005.
Results: The great majority of the 118 episodes of visceral
mycosis was represented by esophageal candidiasis (101 cases),
followed by CNS-disseminated cryptococcosis (15 episodes),
and candidemia (two episodes). The temporal trend demon-
strated a progressive tendency to a reduction of diagnosed
cases: 34 in the year 2001, 27 in the year 2002, 25 in the year 2003,
12 in the year 2004, and 20 in the ﬁrst 6 months of 2005. In even
63 patients (p) of 118 (53.4%), visceral mycoses occurred
concomitantly with the ﬁrst positive HIV serodiagnosis: the
so-called ‘‘AIDS presenters’’, who were never treated with
antiretrovirals. In the remaining 55 episodes, fungal infections
occured as the ﬁrst AIDS-related disorder in 31 cases, while in 24
p they represented a subsequent opportunistic complication
interesting p already diagnosed with AIDS. Although all p
suffered from an advanced HIV disease (as expressed by a CD4+
lymphocyte count of 127.3 ± 52.7 cells/lL), among the 55
patients who were taking antiretrovirals, PI were administered
in 11 p only, while other combinations excluding PI were used
in 44 p (p < 0.001).
Conclusions: Over 50% of episodes of visceral candidosis and
cryptococcosis occur in ‘‘AIDS presenters’’, while the lack of
adjunct of PI could contribute to explain the apparent increased
predisposition to these opportunism versus other AIDS-deﬁning
diseases. Pathogenetic hypotheses cannot exclude the demon-
strated direct in vitro antifungal effect exerted by PI.
P1227
Concurrent invasive cryptococcosis and
candidiasis in AIDS presenters. Clinical
epidemiology and features never observed also
during the pre-HAART era
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
Background: The HAART regimens changed the course of HIV
infection, ﬁrst leading to a drop of opportunism related to a
severe immunodeﬁciency, including visceral candidiasis-cryp-
tococcosis. However, the incidence of the so-called AIDS
presenters is increasing during HAART since patients (p) who
are unaware of or neglect HIV cannot take advantage from
HAART.
Methods: Two rare cases of concurrent visceral Candida-Cryp-
tococcus co-infection occurred in p with a undiagnosed HIV
disease are presented.
Results: Two pwhowere unaware of HIV disease, were referred
with a far compromised clinical situation, including prolonged
fever, dysphagia, pancytopenia and weight loss, Pneumocystis
carinii-Mycobacterium kansasii-Staphylococcus aureus pneu-
monia in the ﬁrst p, and persisting headache in the second p. A
candidiasis was conﬁrmed by esophageal biopsy in both cases,
while the ﬁrst p also had positive Candida albicans blood cultures.
Cryptococcosis was the result of fungemia in the ﬁrst p, and
meningeal localization in the second one, whose CSF proved
positive at culture-antigen search. The severe immunodeﬁciency
was expressed by a CD4+ lymphocyte count of 44 and 13 cells/
lL respectively. After the diagnosis of concomitant dual Can-
dida-Cryptococcus infection, ﬂuconazole, and concurrent AmB-
isome in the ﬁrst p, were administered, leading to mycological
and clinical cure. No relapses of yeast opportunism occurred
during the 16–48-mo follow-up, while immune reconstitution
took place thanks to HAART.
Conclusions: Multiple, concomitant-subsequent AIDS-deﬁning
illnesses were anecdotally described, but the concurrent detec-
tion of two different visceral and AIDS-related yeast diseases
has no equivalents until now. Preventive-educational efforts are
needed for each population target, since many p are at risk of
suffering from a missed-delayed HIV recognition, and have an
increased risk of advanced, life-threatening HIV disease inclu-
ding multiple AIDS-related disorders.
P1228
A 3-year study of resistance of Candida
pathogens obtained from patients with
fungaemia with emphasis on new antifungal
agents
A. Koutsoukou, A. Stylianakis, S. Tsiplakou, M. Tachtatzis,
E. Tsakona, A. Vourtsi, A. Sideri (Athens, GR)
Objective: The aim of the present study was to examine the
resistance of Candida species to amphotericin-B, ﬂuconazole,
itraconazole, 5-ﬂucytocine and to the new antifugal agents
voriconazole and caspofungin.
Methods: 152 non duplicated Candida species, isolated from
blood cultures (Bactec, Becton Dickinson) over a 3 year period
(2003–2005), were identiﬁed and MIC values were determined.
Identiﬁcation was performed by VITEK II automated system
(Biomerieux) and conﬁrmed by the API 20C AUX (Biomerieux).
MICs for amphotericin-B, ﬂuconazole, itraconazole and 5-
ﬂucytocine were determined by ATB fungus 2 (Biomerieux).
For the new agents voriconazole and caspofungin, MICs were
deﬁned by E-test (AB Biodisk, Solna, Sweden) and conﬁrmed by
broth microdilution method, according to NCCLS criteria
(document M 27-A).
Results: Candida parapsilosis was the predominant species (64%)
followed by Candida albicans (24%), Candida tropicalis (8%),
Candida glabrata (2%), Candida krusei (1%). 77 (50%) strains
were resistant to itraconazole 44 (33%) strains were resistant to
ﬂuconazole, 7 (5%) strains were resistant to 5-ﬂucytocine while
no strain was found resistant to amphotericin-B. The MICs of
caspofugin were between 0.25–2 lg/ml and the MICs of
voriconazole were less than 1 lg/ml. Only 2 strains of Candida
parapsilosis had MICs higher than 2 lg/ml to voriconazole and
would be classiﬁed as resistant to the drug.
Conclusions: Our ﬁndings show that fungemia in our hospital
is caused mainly by Candida parapsilosis. Moreover Candida
blood stream infections had high-rates of resistance to itracon-
azole and ﬂuconazole in contrast to voriconazole. All Candida
strains were susceptible to caspofungin. Also, no resistance was
observed to amphotericin-B which remains the more active
antifungal agent in common use.
P1229
Candida embolic stroke and secondary fungal
mycotic aneurysm
C. Garzoni, I. Uckay, L. Markham, R. Sztajzel, K. Bouchuigui-
Waf, P. Temperli, J. Garbino (Geneva, CH)
Introduction: Embolic events are known complications of
infective endocarditis but fungal secondary mycotic aneurysms
rarely result. C. parapsilosis endocarditis with intra-cerebral
embolism and secondary mycotic aneurysm formation was
never described before.
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Case report: A 37 year-old i.v. drug abuser was ﬁrst hospital-
ized on October 2004 with acute thromboembolic stroke and C.
parapsilosis candidemia. Exhaustive research for a primary
focus was negatives. The fungigram showed an intermediary
sensitivity to ﬂuconazole for the isolated strain and a treatment
with voriconazole was started. The patient had favourable
evolution and the treatment was discontinued after 3 months.
Six weeks after the treatment was stopped he was hospitalized
due to an acute hemiparesia. The MRI showed a cerebral artery
occlusion and an intra-arterial thrombolysis was performed. C.
parapsilosis yielded from the blood cultures with the same
resistance pattern to the previous strain. Voriconazole was
restarted. Due to an important aortic insufﬁciency with ﬂoating
vegetation the aortic valve was replaced by a porcine xenograft.
The neurological symptoms had an slight improvement. The
new MRI done showed the cerebral media artery occluded with
a fusiform aneurysm. Serial The stability of the lesion in the
following months was documented by MRI done for control.
After 9 months of voriconazole treatment the patient did not
experienced any recurrence.
Discussion: Acute stroke is a feared complication of infective
endocarditis. Up to 50% of patients with fungal endocarditis
show arterial thromboembolic events and nearly 20% of them
are intra-cranial. Interestingly, despite endocarditis is the major
cause of intra-cranial bacterial aneurysms, secondary intra-
cranial fungal aneurysm are very rare. A limited number of
reports describe fungal mycotic aneurysm, but most are due to
Aspergillus sp. To our knowledge there are only 2 reports of
candida intra-cranial aneurysms and none caused by Candida
non-albicans species. Given the limited number of experience,
therapeutic guidelines and experience with invasive therapeutic
interventions are lacking.
P1230
Monitoring of voriconazole blood levels for
prevention of serious neurological adverse events
A A. Pascual, S. Bolay, O. Marchetti (Lausanne, CH)
Background: Voriconazole (VRC) is a widely used broad-
spectrum antifungal agent. Non-linear pharmacokinetics, poly-
morphism of cytochrome CYP2C19, drug interactions and
hepatic dysfunction may result in inter- and intra-individual
variations of VRC blood levels. We reported Serious Neurolog-
ical Adverse Events (SNAE) probably associated with prolonged
VRC overdosing (trough blood levels > 5.5 mg/L during >7 d)
(ICAAC 2005, M-2164). This observation suggested that VRC
dose adjustment based on monitoring of blood levels may help
to prevent SNAE.
Objective: To prospectively evaluate the utility of monitoring
VRC blood levels for prevention of SNAE.
Methods: VRC trough blood levels were measured by HPLC
during the ﬁrst week of therapy in 25 consecutive treatment
courses during 2005. VRC dosing was adjusted if VRC trough
blood levels were >5.5 mg/L. Clinical follow-up included
surveillance for adverse events (NCI criteria). Occurrence of
SNAE during VRC therapy in 2004 (no prospective dose
adjustment based on VRC blood levels) and 2005 (prospective
dose adjustment) was compared.
Results: Indications for VRC therapy were aspergillosis (60%),
candidiasis (16%), and suspected mycosis (24%). Median VRC
dose was 4 mg/kg bid (range 1.3–5.7). Median number of VRC
trough blood levels measurements/treatment course was 2.5
(range 1–5). Median days to ﬁrst measurement after starting
VRC therapy were 2 (2–7). Nine pts (37%) presented transient
self-limiting visual disturbances/hallucinations. Two patients
(8%) presented severe hepatotoxicity. Occurrence of SNAE in
2004 and 2005 is compared in table 1.
Conclusions: These prospective data corroborate our prelimin-
ary report that rapid dose adjustment in patients with VRC
blood levels exceeding 5.5 mg/L may help to prevent serious
neurological adverse events. Further observations are needed to
conﬁrm this ﬁnding.
P1231
Inﬂuence of azoles on mixed long-term
continuous ﬂow cultures of Candida albicans and
Candida glabrata under aerobic and anaerobic
conditions
H. Bernhardt, M. Knoke, K. Zimmermann, G. Schwesinger,
J. Buﬂer, K. Ludwig, J. Bernhardt (Greifswald, Karlsruhe, Rostock,
DE)
Objectives: Around 3% of cultures obtained from candidaemia
patients and 13% of those from oesophageal candidiasis patients
grew both C. albicans and C. glabrata. A continuous ﬂow system
was used to investigate the effects of ﬂuconazole (FLU) and
voriconazole (VORI) on mixed Candida infections under aerobic
and anaerobic conditions. This allows the simulation of the in
vivo situation.
Methods: Candida strains were cultured at 37C in double-wall
vessels containing 110 ml medium. Anaerobic conditions were
obtained by ﬂushing with N2/CO2; aerobic conditions were
maintained with pressurized air. Media ﬂow rate was 6.0 ml/h.
The system was adjusted to a generation time of 15–20 h. Media
contained FLU (20 or 60 mg/l), VORI (20 mg/l) or no antifungal
(controls). For the detection of morphologic alterations of the
Candida cells half-size slides were kept in the culture vessels. At
the end of the trials the bioﬁlms on the slides were stained with
BLANKOPHOR (Bayer AG Leverkusen, Germany) and exam-
ined by ﬂuorescence microscopy.
Results: Growth of C. glabrata was particularly strong in co-
culture with C. albicans. C. glabrata consistently achieved higher
densities than C. albicans (7.5 vs. 6.6 log10 cfu/ml). In this
setting, C. albicanswas inhibited more effectively than C. glabrata
by 20 and 60 mg/l FLU. At 60 mg/l, FLU inhibited C. glabrata
more effectively under anaerobic conditions and after 96 h.
Clinical isolates and type strains of both C. albicans and C.
glabrata were inhibited more strongly by FLU and VORI under
anaerobic conditions. The decrease in germ counts after addition
of FLU or VORI to a C. albicansmonoculture was more rapid and
more profound under anaerobic (>99%; i.e. fungicidal) than
aerobic conditions (90–99%; i.e. fungistatic). Both FLU and VORI
strongly inhibited bioﬁlm formation: in the absence of antifun-
gals, a bioﬁlm of budding yeast, mycelia and pseudomycelia
developed on glass slides. In the presence of FLU or VORI, only
few yeast cells and germ tubes were observed, but no mycelia or
pseudomycelia.
Conclusion: In a long-term continuous ﬂow culture system, the
inhibition of various Candida strains by FLU or VORI was
strongly enhanced by anaerobic conditions. This ﬁnding may be
of relevance for the clinical setting, as mycotic abscesses and
sequestered areas of infected tissue are hypoxic.
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P1232
Investigation of synergistic effect of sertraline on
ﬂuconazole-resistant Candida spp. by
microbiological methods and electron microscopy
N. Nuhoglu, T. San, G. Soyletir (Istanbul, TR)
Objectives In neutropenic patients long-term antibiotic pro-
phylaxis or treatment creates a selective environment for fungal
growth and Candida spp. are the most frequently isolated agents.
Fluconazole administration during neutropenic attacks may
have the risk of selecting ﬂuconazole-resistant Candida spp.
which can further lead to serious infections. In order to
overcome this resistance, we investigated the synergistic activity
between ﬂuconazole and achievable levels of sertraline, an
antidepressant drug, which was previously shown to have
antifungal activity in higher concentrations than that of serum
levels.
Methods: Antifungal susceptibility testing (NCCLS M27-A) of
nonalbicans Candida isolates were performed and ﬁve ﬂuconaz-
ole resistant Candida (three C. krusei, two C. glabrata) strains
which have MICs for ﬂuconazole and sertraline in th ranges of
32–128 mcg/ml and 24–48 mcg/ml respectively, were tested for
synergy between these two drugs. To do this checkerboard
assay and electron microscopy were used.
Results: The MIC values of ﬂuconazole dropped to 4–32 mcg/
ml at sertraline’s plasma achieveable concentrations (0.09–
0.18 mcg/ml) and fractional inhibition concentration (FIC)
indices were found to be 0.06–0.5 indicating the presence of
synergy. We also observed irreversible changes of the cell
morphologies including disruption of the cell wall and dis-
charge of the cytoplasmic content, both at MIC levels of drugs
and their synergistic concentrations under electron microscope
(Fig 1).
Conclusion: In the case of candidiasis due to ﬂuconazole
resistant strains, routine dosages of sertraline can be added to
treatment protocol, provided that these in vitro results are
furtherly conﬁrmed with in vivo studies. Our ﬁndings also
suggest that, as a broad spectrum efﬂux inhibitor, sertraline may
also be tested for synergistic effect against other microorganisms
with efﬂux mediated resistance.
Antimicrobial resistance, permeability and ﬁtness
P1233
Fitness costs of antimicrobial resistance
associated with chromosomal mutations and
plasmid-borne resistance genes in Escherichia
coli: in vitro and in vivo studies
A. Petersen, F.M. Aarestrup, M. Bisgaard, J. Olsen (Frederiksberg,
Copenhagen, DK)
Objectives: A reduced ﬁtness, often measured by growth in
vitro, is associated with antimicrobial resistance phenotypes. The
ﬁtness of antimicrobial resistant bacteria may inﬂuence their
persistence and transmission. The question remains whether a
reduced ﬁtness in vitro can be conﬁrmed by in vivo experiments.
Methods: E. coli BJ4 with different mutation- and plasmid
mediated resistances were grown separately and in pair-wise
competitions to estimate ﬁtness cost in vitro. In vivo studies were
performed by oral inoculation of equal numbers of two test
strains in 4–5 weeks old chickens and colonization was followed
for one week. At each sampling point, 4 chickens were sacriﬁced
and content of the caecum was examined for the inoculated
bacteria.
Results: In vitro: A single chromosomal mutation conferring
resistance to streptomycin (str) did not impose a ﬁtness cost to E.
coli BJ4. An additional mutation leading to rifampicin (rif)
resistance reduced relative ﬁtness 19%. Introduction by conju-
gation of 53–60 kB plasmids with one or several resistance genes
did not signiﬁcantly reduce relative ﬁtness of E. coli BJ4. In vivo:
A co-introduction of a E. coli BJ4 harbouring a 53 kB plasmid
and a str rif resistant E. coli BJ4 (in vitro ﬁtness 1 and 0.82,
respectively) in chicken resulted in average higher number of
recoveries in the caecum of the former after 7 days but the
difference was not signiﬁcant. When a selection pressure in
favour of either of the two strains was introduced, the favou-
rised strain was recovered in signiﬁcantly higher numbers than
the other.
Conclusions: Fitness costs associated with antimicrobial resist-
ance was demonstrated under laboratory conditions. In vivo
experiments only conﬁrmed differences of in vitro relative ﬁtness
when a selective pressure was applied. The dynamics and
epidemiology of antimicrobial sensitive and resistant bacteria in
animals and in the environment may thus be difﬁcult to predict
based on in vitro studies.
P1234
The ﬁtness cost imposed by plasmid RP1 on
Escherichia coli differs from strain to strain
V.I. Enne, P.M. Bennett (Bristol, UK)
Objectives: Our previous studies have demonstrated a relat-
ively low, and sometimes non-existent ﬁtness cost imposed by
antibiotic resistance plasmids on the Escherichia coli strain 345-
2RifC. These results are in contrast to those found by other
researchers who, using laboratory strains of E. coli, have
reported much higher costs associated with plasmid carriage.
These conﬂicting results may be due to variations between the
strains used. We therefore investigated the overall ﬁtness of cost
incurred by carriage of the plasmid RP1 in ﬁve distinct E. coli
strains.
Methods: The ﬁtness impact of the IncP plasmid RP1 was
studied in ﬁve E. coli strains: the K12 laboratory strain JM109; 99-
24 and 99-40, two recent human clinical isolates and 345–8 and
343–9, two recent isolates from pig faeces. The study strains
were selected on the basis that they are fully antibiotic
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susceptible and have different biochemical proﬁles and are
therefore not related to each other. Plasmid RP1 was introduced
into the strains by conjugation. The ﬁtness cost of RP1 in each
strain was assessed in vitro by pairwise growth competition in
Davis minimal medium for six days, with six replicate experi-
ments performed.
Results: In the laboratory strain JM109 plasmid RP1 imposed a
ﬁtness cost of )5.8 ± 1.0% per generation. This was lower than
the -9.1 ± 4.1% cost it imposed on the clinical strain 99-24 and
signiﬁcantly lower than the -9.7 ± 1.4% cost imposed on clinical
strain 99-40 (t = -5.48, p = 0.0003). In contrast, there was little or
no cost to carriage of RP1 by the animal strains 345–8 and 343–9.
RP1 imposed a small ﬁtness cost of –1.8 ± 0.8% on 345–8, and
conferred a slight beneﬁt of +0.8 ± 0.9% on 343–9. The ﬁtness
impacts of RP1 on 343–9 and 345–8 were signiﬁcantly lower than
the costs imposed on JM109, 99-24 and 99-40 (p < 0.002 in all
cases).
Conclusion: The ﬁtness cost associated with carriage of antibi-
otic resistance plasmids can vary considerably depending on the
strain. It is therefore unwise to generalise results obtained with
any one particular strain. In the case of RP1 and our ﬁve strains,
the lowest costs were incurred by the strains of animal origin,
while strains of human clinical origin incurred the highest costs.
P1235
Long-term persistence of resistant strains in the
human intestinal microﬂora due to restored
ﬁtness
S. Lo¨fmark, H. Billstro¨m, C. Jernberg, C. Edlund (Stockholm, SE)
Objectives: Antibiotic therapy often leads emergence of resistant
intestinal bacteriamainly attributed tomutations or acquisition of
resistance genes. Resistance traits are generally considered to lead
to decreased ﬁtness due to a cost for the bacteria.However, ﬁtness
may be restored by compensatory events, thus the level of
resistance may not automatically revert to pre-antibiotic levels
when the antibiotic is removed. The aim of the present study was
to analyse ﬁtness in consecutive isolates of two clindamycin
resistant clones of Bacteroides spp, cultured from two clindamycin
exposed subjects.
Methods: The ﬁtness of serial isolates of two B. tetaiotaomicron
clones, A and B veriﬁed by Rep-PCR, originally susceptible to
clindamycin and lacking erm-genes was studied by an in vitro
competition method. The strains derived from faecal samples of
two healthy volunteers exposed for clindamycin (150 mg · 4 for
7 days). Isolates belonging to clone A were analysed pretreat-
ment (A:0-S), at the last day of administration (A:7d-R), after
two weeks (A:2w-R) and 18 months (A:18m-R). The three latter
isolates carried the ermG gene and expressed phenotypic
clindamycin resistance. Clone B was isolated at corresponding
intervals except for day 7 when the numbers of CFU were under
the detection limit (B:0-S; B2w-R; B18m-R), post exposure
isolates carried the ermF gene. Relative ﬁtness was analysed in
vitro by pair-wise competition experiments in triplicate, where R
isolates were challenged against the S isogenic parent isolate.
Results: The imposed cost of resistance during clindamycin
exposure was high for clone A, A:7d-R were competed out in
vitro by its parental A:0-S. After 2 weeks no growth disadvan-
tages was detected for the R isolates compared to the pre-
exposed S isolates in any of the two studied clones. This
regained ﬁtness remained 18 months after administration.
Conclusion: The results indicate that the biological cost to carry a
resistance gene can be compensated for and once the resistant
clone has gained its resistance determinant it is difﬁcult to
eliminate. Most studies have focused on the ﬁtness costs associ-
atedwith resistances due tomutational events.Herewe show that
the impact the acquired erm genes had on the ﬁtness of the
bacteria was low or non-existing, even though the initial cost was
high. The fact that the clones persisted for at least 18 months is
probable due to restored ﬁtness in spite of the presumed extra
burden of the resistance gene.
P1236
Mutators among UK CTX-M b-lactamase-
producing E. coli pose a risk for the emergence of
fosfomycin resistance
M.J. Ellington, D.M. Livermore, T.L. Pitt, L.M.C. Hall,
N. Woodford (London, UK)
Objectives: Fosfomycin (FOS) is a possible oral treatment for
lower urinary tract infections caused by the growing number of
E. coli with CTX-M extended-spectrum B-lactmases. However,
mutational resistance can occur and hypermutability among
natural E. coli populations might increase this risk. We examined
the prevalence of mutators amongst UK multi-resistant CTX-M
producing E. coli urinary isolates and the risk they pose to the
emergence of resistance.
Methods: Consecutive CTX-M positive E. coli clinical isolates
from urinary tract infections (n = 231) were screened for a
mutator phenotype by rifampicin (RIF) and FOS disc assays.
MICs were determined by BSAC methodology. Wild-type and
isogenic MutS- controls were also tested. Mutation frequencies
were determined on agar in triplicate with 4 x MIC or with
256 lg/ml FOS.
Results: Eleven of 231 isolates were highly resistant to FOS or
RIF and were not tested further. The MutS- strain and 10/231
(4.3%) CTX-M E. coli isolates yielded >70 and >10 colonies
within the zones around both 50 lg FOS and 30 lg RIF discs
indicating likely mutator phenotypes. The wild-type E. coli
control and 80 clinical isolates gave <30 and <10 colonies in the
zones around FOS and RIF discs, respectively, indicating non-
mutators. The remaining 130/231 isolates gave 30–70 and <10
colonies in the zones, implying weak-mutator status at most.
Mutation studies at 4 x MIC were done on 20 isolates (including
the hypermutator candidates). Mutation frequencies, for the
MutS- control were 2.74 · 10-4 for RIF and 286 · 10-6 for FOS.
Nine of 10 likely mutators from the screen had frequencies of
0.008–1.52 · 10-4 for FOS and 0.1–2.26 · 10-6 for RIF, and 2 of the
10 were conﬁrmed as strong mutators to both RIF and FOS. The
non-mutator control and 7 putative non-mutators selected from
the screen had mutation frequencies of 2.99–6.42 · 10-6 for FOS
and 0.8–3.73 · 10-8 for RIF, conﬁrming non-mutator status. Only
strong mutators (RIF frequencies >8.86 · 10-7) consistently gave
single-step mutants at 256 lg/ml FOS. No nitrofurantoin (NIT)
resistant mutants were raised from any isolate or strain, except
in only one of the three triplicated experiments with hypermut-
able MutS- control strain, (mutation frequency = 6.67 · 10-9).
Conclusion: Of 231 multi-resistant urinary isolates of CTX-M E.
coli, 4.3% were mutators with an enhanced risk for the
emergence of FOS resistance. Whilst NIT is a far from ideal
antibiotic it was less vulnerable to mutational resistance.
P1237
Ertapenem promoted the selection of totally
resistant pathogens
F. Walsh, S. Bracher, P. Turner, S.G.B. Amyes (Edinburgh, UK;
Cheshire, UK)
Objectives: The objective was to identify if ertapenem would
encourage or inhibit the selection of a carbapenem-resistant
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hospital-acquired pathogen from a mixed population. Thus, if a
resistant isolate emerged to dominate the population in vitro,
there would be a high possibility that this would happen within
hospital settings and select for totally resistant pathogens.
Methods: The bacteria tested in these experiments were Pseu-
domonas aeruginosa blaVIM and blaIMP isolates with P. aerugi-
nosa ATCC 27853, an ertapenem resistant and a susceptible
Klebsiella pneumoniae from Scotland, Acinetobacter baumannii
containing OXA-23, OXA-24 and OXA-58 competing with
A. baumannii ATCC 19606. In each case, the resistant isolate
and sensitive isolate were grown overnight in broth. The
resistant isolate was mixed with the sensitive isolate in a ratio
of 1:100. Ertapenem (8 mg/L) was added to the broth mixture at
the recommended dosing interval of T0, T24 and T48. The broth
was serially diluted and spread on plates containing imipenem,
meropenem or ertapenem (8 mg/L in each) as well as plates
with no antibiotic, at regular intervals. The colonies were
counted and the percentage resistance development calculated
for each strain and antibiotic. The competition studies were
performed at least twice and the percentage resistances were
averaged.
Results: The P. aeruginosa experiments identiﬁed that addition
of ertapenem to a mixed population selected the blaVIM
resistant isolate with cross-resistance to imipenem and merope-
nem but did not promote the emergence of the blaIMP isolate.
Addition of ertapenem to a mixed population of K. pneumoniae
promoted the growth of the resistant isolate over the susceptible
isolate after 48 hours. The 3 OXA carbapenemase-containing
A. baumannii were exposed to ertapenem using the same
methods. However, the OXA-24 positive isolate differed from
the OXA-23 and OXA-58 isolates. In both the OXA-23 and OXA-
58 competition studies only isolates resistant to ertapenem
emerged from the population. In the OXA-24 study, resistance to
all 3 carbapenems emerged at T24 and initially at higher levels
to imipenem and meropenem than ertapenem.
Conclusions: The results of this study indicated that exposure
to ertapenem at the recommended dosing intervals promoted
growth of strains resistant not only to ertapenem but also cross-
resistant to imipenem and meropenem.
P1238
Convergent selection of ceftazidime resistance
mutations at position 167 of CTX-M-3 beta-
lactamase in hypermutable Escherichia coli
strains
M. Stepanova, M. Edelstein (Smolensk, RU)
Objectives: In CTX-M beta-lactamases, mutations at position
167 confer increased ceftazidime (CAZ) hydrolyzing activity.
Recently, we reported in vivo acquisition of P167T mutation in
CTX-M-3 beta-lactamase rendering it into a ceftazidimase, CTX-
M-42. The consecutive clonal isolates that produced CTX-M-3
and CTX-M-42 were found to be hypermutable. In this study, we
used an in vitro selection with CAZ to simulate the evolution of
CTX-M-3 in the mutator E. coli hosts and to characterize
mutations increasing CAZ resistance.
Methods: The blaCTX-M-3 gene and its upstream promoter
region were PCR-ampliﬁed from the original clinical isolate
Irk1224, cloned in the pCC1 vector and introduced into the
laboratory mutator strain GM2995 (mutD5). Both the Irk1224
and GM2995 carrying the blaCTX-M-3 were used in selection
experiments. Mutants were obtained on agar plates containing
CAZ at concentrations of 2x the MICs. Thirty-two randomly
selected mutants of each strain were tested for their suscepti-
bilities to CAZ and cefotaxime (CTX) by agar dilution method
and for the presence of mutations in the promoter and blaCTX-
M ORF by sequencing. To conﬁrm the role of particular
mutations in CAZ resistance, wild type (WT) and mutant
blaCTX-Ms were then recloned in E. coli EPI300 and suscepti-
bilities of the resulting clones were determined.
Results: The total rates of mutations increasing CAZ resistance
were 2E-8 and 2E-6 for the Irk1224 and GM2995, respectively.
Both strains yielded two types of mutants. Those of the 1st type
had CTX MICs ‡ CAZ MICs, contained no changes in the
sequences of blaCTX-M-3 and its 5’ vicinity and comprised the
majority of clones obtained. Their increased resistance to CAZ
was apparently not related to the beta-lactamase and could have
resulted from alterations in outer membrane permeability.
Mutants of the 2nd type had CTX MICs < CAZ MICs. Out of
them, 1 and 8 clones derived, respectively, from Irk1224 and
GM2995 contained a single P167S substitution in the CTX-M.
Another derivative of Irk1224 carried previously unidentiﬁed
mutation, N136K. Comparison of CAZ MICs for isogenic strains
expressing WT and mutant CTX-Ms clearly supported the
involvement of S167 and K136 in CAZ resistance (Tab.1).
Conclusions: This study demonstrates the convergent in vitro
selection of CAZ resistance mutations at position 167 of the
CTX-M-3 which parallels its evolution in vivo. It also under-
scores the role mutator strains in the evolution of CTX-M beta-
lactamases.
P1239
Mechanisms of high-level ciproﬂoxacin
resistance in clinical isolates of Escherichia coli
collected in the British Isles
S. Mushtaq, M.J. Ellington, D.M. Livermore, N. Woodford
(London, UK)
Objectives: To investigate mechanisms and clonality in highly-
ciproﬂoxacin- resistant clinical isolates of E. coli collected as part
of a survey in 2001 – when this resistance was starting to expand
rapidly.
Methods: Twenty-ﬁve highly ciproﬂoxacin-resistant (MICs
32ﬁ256 mg/L) isolates from 16 different centres were investi-
gated. MICs were determined by the BSAC agar dilution
method. Isolates were examined for relatedness by PFGE of
XbaI digested DNA. The Quinolone Resistance Determining
Regions (QRDR) of gyrA, gyrB, parC and parE, and the marOR
regions of the mar operon were ampliﬁed by PCR and
sequenced directly or after cloning into pCR2.1. Isolates were
screened for qnrA by PCR. A fosfomycin/rifampicin disc
method was used to screen for hypermutator phenotypes.
Results: PFGE banding patterns were obtained for 21/25
isolates; 3 pairs had similarities, all others appeared distinct.
All 25 isolates had double mutations in gyrA resulting in Ser83
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to Leu and substitution of Asp87 by Asn (n = 22), Tyr (n = 2), or
Gly (n = 1); 24 also had known mutations at Ser80 in parC
leading to substitution with Ile (n = 20) or Arg (n = 4). Eleven
replaced Glu84 of ParC with Gly (n = 6), Val (n = 4) or Lys
(n = 1) and 1 had Ala81 to Pro. A new ParC substitution was
found -Gly78 to Cys (n = 2)- as was a mutation at novel site:
Ser57 to Thr (n = 3). Fourteen of 25 gyrB QRDRs were
sequenced, 13 had wild-type sequences, one had a novel
Lys455 to Ile substitution. Seven of 25 had substitutions in
ParE, 6 with Ser458 replaced by Thr (n = 3), Ala (n = 2) or Pro
(n = 1) and one at a new site, changing Ile464 to Met. Twenty
had Gly103 to Ser and Tyr137 to His substitutions in MarR, 4
also had a Lys62 to Arg substitution. No nucleotide mutations
were found in the MarR binding sites or in the marbox of marO,
but A1333C mutations (n = 19) were found in the accessory
MarA binding site, and a T1328C mutation (n = 3) in the soxbox,
of marO. All isolates were negative for qnrA; 5 had a hyper-
mutator phenotype.
Conclusions: These ciproﬂoxacin-resistant E. coli were clonally
diverse and their resistance was due to variable combinations of
mutations, some of them novel. We conclude that high-level
resistance emerged repeatedly and independently, and that
hypermutability may be a facilitating factor in some isolates.
P1240
Evaluation of the accumulation of 99mTc-
ciproﬂoxacin in S. aureus and P. aeruginosa
J.M. Sierra, D. Rodriguez-Puig, A. Soriano, J. Mensa, C. Piera,
J. Vila (Barcelona, ES)
Objective: Gammagraphy with 99mTc-ciproﬂoxacin has been
proposed as a useful test to diagnose infections. The objective of
this study was to evaluate the intracellular accumulation of
ciproﬂoxacin labelled with 99mTc in Staphylococcus aureus and
Pseudomonas aeruginosa.
Methods: The accumulation of free ciproﬂoxacin, 99mTc-ci-
proﬂoxacin, and 99mTcO4- was evaluated in two strains of S.
aureus, 1199B and 1199 (with and without overexpression of an
efﬂux system) and two strains of P. aeruginosa, PAOLC1-6 and
KG2239 (with and without overexpression of an efﬂux system).
Accumulation was measured at two different end- points, 5 and
30 minutes. Strains were cultured in LB overnight at 37C. Cells
were washed and resuspended in phosphate buffer to an
OD600 nm of 1.5. After that 490 ml were taken and 10 ml of
ciproﬂoxacin were added to obtain an extracellular concentra-
tion of 10 mg/l (99mTc-ciproﬂoxacin presented an activity of
about 555KBq/sample and free 99mTcO4- presented an activity
of about 555KBq/sample) and were incubated at 37C during 5
or 30 min. Finally, samples were washed 3 times with PBS.
Accumulation of ciproﬂoxacin (unlabelled) was measured by
ﬂuorimetry (previously, samples were lysed with glycine-HCl
buffer) and accumulation of 99mTc-ciproﬂoxacin, and
99mTcO4- was measured by a gamma counter.
Results: The accumulation of unlabeled ciproﬂoxacin in S.
aureus and P. aeruginosa showing overexpression of an efﬂux
pump was lower than for those without an efﬂux pump
overexpressed.The accumulation of 99mTc-ciproﬂoxacin was
not affected by the presence of an efﬂux system being the same
in both pairs of strains at each end-points studied.Finally,
99mTcO4- did not show accumulation in any of the strains.
Conclusion: The accumulation of 99mTc-ciproﬂoxacin was not
affected by the overexpression of efﬂux systems in either S.
aureus or P. aerugionosa. All the radioactivity detected in the cells
was due to the accumulation of 99mTc-ciproﬂoxacin. Finally,
99mTc-ciproﬂoxacin may be useful as a radiopharmaceutical to
detect infection, regardless of the presence of an efﬂux system
affecting quinolones.
P1242
Occurrence of MexCD-OprJ overexpressing efﬂux
mutants of Pseudomonas aeruginosa isolated from
hospitalised patients
K. Jeannot, D. Hocquet, P. Ple´siat (Besanc¸on, FR)
Objectives: Overexpression of the multidrug efﬂux system
MexCD-OprJ in P. aeruginosa provides moderate-level resistance
to ﬂuoroquinolones (FQ) and "fourth generation" cephems such
as cefepime and cefpirome in mutants defective in nfxB, a gene
that negatively controls the mexCD-oprJ operon. Since the ﬁrst
description of this resistance mechanism more than 10 years ago
in in vitro mutants, clinical strains overexpressing MexCD-OprJ
have only been reported in cystic ﬁbrosis (CF) patients (Jalal S.
Antimicrob. Agents Chemother. 2000, 44: 710–11). This study
investigates the expression of the efﬂux system in strains
exhibiting the nfxB susceptibility proﬁle and recovered from
non CF patients.
Methods: Forty four ciproﬂoxacin, cefepime resistant nfxB-like
isolates of P. aeruginosawere isolated at the Teaching Hospital of
Besanc¸on between 2000 and 2005 (France). MICs of selected
antibiotics were determined with the conventional agar dilution
method (NCCLS). Expression levels of mexC and genes of other
efﬂuxoperons (mexB,mexE,mexG,mexJ,mexY)wereassessedby
quantitative Real Time PCR after retro-transcription. Search for
nfxB mutations was performed after DNA sequencing by align-
ment analysis.
Results: Only 4 strains (9%) were identiﬁed as MexCD-OprJ
overexpressing mutants. These clonally unrelated isolates which
exhibited baseline expression levels of the other known efﬂux
systems (MexAB-OprM, MexEF-OprN, MexGH-OmpD, MexJK,
MexXY) were resistant to ciproﬂoxacin (4 lg/mL) and cefepime
(4–8 lg/mL), but hypersusceptible to most of the other b-lactams
(e.g., aztreonam0.5 lg/mL; imipenem0.12 lg/mL), and to all the
aminoglycosides tested (e.g., amikacin 0.5–1 lg/mL). The four
strains harboured different deletions (from 2 to 17-pb) in the nfxB
repressor gene.
Conclusion: Our results support the notion that MexCD-OprJ
overproducing mutants are rather infrequent among non CF
clinical strains of P. aeruginosa. Their high susceptibility to
widely used antipseudomonal agents as well as their reduced
virulence might explain such a low occurrence in the hospital
setting. In agreement with this, the 4 nfxB mutants identiﬁed in
this study were involved in patient colonisations.
P1243
Eight non-antimicrobial medicaments induce
multidrug-resistance in Escherichia coli Ag100
strain
M.M. Tavı´o, V. Aquili, M. Perilli, L. Macia`, C. Balague´,
Z. Gonza´lez-Lama, G. Amicosante (Las Palmas de Gran Canaria,
ES; L´Aquila, IT; Rosario, AR)
Objectives: Multidrug resistance induced in Escherichia coli by
diazepam (a drug used in surgery) was described as equivalent
to Mar phenotype resulting from marAB operon activation by
salicylate (characterized by OmpF loss and enhanced active
efﬂux). This work studied whether another eight non-antimi-
crobial medicaments used in surgery could also induce Mar
phenotype in the susceptible E. coli Ag100 strain.
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Methods: The effect of concentrations 1/512, 1/256, 1/128, 1/
64, 1/32, 1/16, 1/8, 1/4 MICs of Chlorpromazine, Clonazepam,
Dexamethosone, Diclofenac, Haloperidol, Ketoroloac, Methim-
azol and Propacetamol in Ag100 was evaluated on antibiotic
MICs, OmpF expression and norﬂoxacin intracellular accumu-
lation. Results were compared with those of induction by
salicylate. OmpF expression was analysed in SDS-PAGE. Active
efﬂux was evidenced by carbonyl cyanide m-chlorophenylhy-
drazone (CCCP). Non-induced Ag100 and Ag112 (a marR
mutant) were control strains. The inducing concentrations of
medicaments were compared with their own levels in plasma in
adult humans.
Results: Only those concentrations higher than or equal to 1/
132 MICs of Clonazepam, Chlorpromazine, Haloperidol, Prop-
acetamol, Ketorolac and Diclofenac, and concentrations higher
than or equal to 1/128 MICs of Dexamethasone and Methimazol
in the Ag100 strain, induced OmpF loss, increased 2–32 fold
cefoxitin, nalidixic acid, norﬂoxacin, tetracycline and chloram-
phenicol MICs and decreased norﬂoxacin uptake in the Ag100
strain. 1/64–1/4 MIC of salicylate in the Ag100 strain led to
equivalent results. Norﬂoxacin accumulation in Ag100 induced
by salicylate or any of the eight medicaments was increased 2–4
fold by adding CCCP.
Conclusion: i) The tested medicaments like salicylate induced
Mar phenotype only with concentration ranges between 1/128–
1/4 of their MICs in the Ag100 strain.ii) Inducing concentrations
of Mar phenotype of Clonazepam, Dexamethosone, Diclofenac,
Haloperidol, Methimazol and Propacetamol might be found in
plasma of patients in the course of treatments with them.
P1244
The role of the multi-drug efﬂux systems of
Pseudomonas aeruginosa in tea tree oil tolerance
C.J. Papadopoulos, C.F. Carson, B.J. Chang, T.V. Riley (Perth,
AU)
Objectives: Melaleuca alternifolia (tea tree) oil is an established
topical antimicrobial agent with a broad spectrum of activity.
Pseudomonas aeruginosa is substantially less susceptible than
most bacterial species to the oil, with MICs ranging from 1 to
8%, compared with <0.5% for other Gram negative bacteria. The
mechanisms by which P. aeruginosa attains resistance often
involve efﬂux systems spanning the cytoplasmic membrane,
periplasm and outer membrane. One pump commonly involved
is MexAB-OprM, which has a diverse substrate proﬁle including
antibiotics and disinfectants. Previous work in our laboratory
has indicated that an energy-dependant process, such as efﬂux,
is involved in tolerance to tea tree oil in P. aeruginosa. The aim of
this work was to establish the relationship between multi-drug
efﬂux pumps and tea tree oil tolerance in P. aeruginosa.
Methods: The susceptibility of several types of efﬂux pump
mutants of P. aeruginosa to tea tree oil and terpinen-4-ol, its
major active component, was examined using time-kill assays
and by determining MICs and MBCs. Complementation of
mutants deﬁcient in MexAB-OprM was achieved by transform-
ing with pRSP17 (pRK415:mexAB-oprM).
Results: The tea tree oil MICs of MexAB-OprM deletion
mutants were from 4 to 8 greater than times lower than their
respective parental strains. MICs for the tea tree oil components
terpinen-4-ol, cineole and alpha-terpineol were also decreased in
these mutants. Mutants deﬁcient in other pumps such as
MexCD-OprJ, MexJK and MexXY did not show any increase
in susceptibility. Time-kill assays demonstrated substantially
increased killing rates in some efﬂux deﬁcient mutants com-
pared to isogenic parental strains. Sub-MIC concentrations of
the oil killed 90% of MexAB-OprM mutant cells after 30 min-
utes, compared with negligible death in the parent cells.
Complementation studies showed that addition of the MexAB-
OprM operon was able to successfully restore the tea tree oil and
terpinen-4-ol susceptibility to that of parental strains.
Conclusion: The use of efﬂux mutants in susceptibility, time-
kill and complementation assays indicates that the MexAB-
OprM efﬂux operon is involved in the reduced susceptibility of
P. aeruginosa to tea tree oil and some components.
P1245
Comparative analysis of Salmonella typhimurium
proteomes from MAR mutants and following
treatment with salicylate
N.G. Coldham, L.P. Randall, L.J.V. Piddock, M.J. Woodward
(Surrey, UK; Birmingham, UK)
Objectives: The chromosomal multiple antibiotic resistance
(mar) locus of Salmonella enterica and Escherichia coli, in cooper-
ation with other stress response regulatory loci, play a key role
in multiple antibiotic resistance (MAR). Mutations in these may
give rise to MAR and are biologically important as they enable
survival following exposure to sub-optimal concentrations of
antibiotic. Microarray analyses of mutants that over express
MarA have indicated differential expression of proteins which
modulate molecular ﬂux. The objective of the present study was
to determine the role of the mar locus in MAR by comparison of
proteomes following treatment with salicylate (a mar locus
inducer) and from MAR mutants.
Methods: S. typhimurium (SL1344) was exposed to salicylate
(5 mM) for 90 mins. Isogenic MAR mutants (n = 4) were
selected after exposure to tetracycline (5 mg/ml). These mutants
were also cyclohexane tolerant. All strains were grown to late
logarithmic phase in LB - glucose media, cell envelope proteo-
mes were extracted and digested with trypsin. The tryptic
peptides were analysed by 2-dimensional HPLC-mass spectr-
ometry.
Results: Relative to controls (100%), the expression of the efﬂux
pump proteins AcrA, AcrB and TolC were increased in MAR
mutants by 197% + 51, 182% + 30 & 216% + 31 (P < 0.0.1)
respectively and following treatment with salicylate by
127% + 2.4, 139% + 12.4 & 199% + 12.3 (P < 0.05). Similarly,
the outer membrane protein OmpF was signiﬁcantly reduced
(P < 0.01) in MAR mutants and with salicylate by 83.3% + 9.5
and 76.2% + 20 respectively compared to the parent. In contrast,
OmpX was increased with salicylate by 2037% + 697 but
reduced in MAR mutants 88.5% + 9.2. The putative omp
COG3203 (16764875) was only expressed after treatment with
salicylate.
Conclusion: Novel proteomic data was obtained that supports
and extends published microarray data and reveals that other
stress response loci, in addition to mar, also contribute to MAR.
P1246
Emergence of Enterobacter aerogenes strains
resistant to imipenem mediated by the
coexistence of metallo-beta-lactamase production
and outer membrane permeability
M. Biendo, G. Laurans, B. Canarelli, D. Thomas,
F. Hamdad Daoudi, F. Rousseau, C. Adjide, F. Eb (Amiens, FR)
Objective: We documented the emergence of imipenem resist-
ant (IPM-R) strains after prolonged antibiotic therapy.
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Methods: 22 cases of E. aerogenes colonization or infection were
monitored retrospectively (July 2003–May 2005). 62 strains were
found in 22 patients consisted of 12 men (54.5%) and 10 women
(45.5%) with a mean age of 67.1%. The antibiotic susceptibilities,
envelope permeabilities, and molecular typing of all the clinical
strains were studied.
Results: Of 62 strains, 22 (35.5%) were imipenem-susceptible
(IPM-S) and 40 (64.5%) IPM-R. The following Beta-lactam
resistance phenotype [FOX (R) CTX (R + I) FEP (R + I) CPO
(R + I) ATM (R + I) IPM (R + I) CAZ (R)] 40/62 (64.5%) was
found among the 40 IPM-R strains: The MBL production
screened by Etest imipenem + EDTA (IPE) among the 40 IPM-
R strains showed that 24 were producers [MICs IP: 16–64 lg/
mL versus MICs IPE 4–24 lg/mL] (ratio *IP/IPE > 8 lg/mL).
The AmpC enzyme production was investigated in the 40 IPM-R
strains in Mueller-Hinton (M.H) + 500 lg of cloxacillin contain-
ing Cefotaxime (CTX), Ceftazidime (CAZ), Moxalactam (MOX)
and Aztreonam (ATM) disks. Two strains were AmpC produc-
ers, 10 were ESBLs producers and 28 were AmpC + ESBL
producers (mean diameter inhibition between M.H + cloxacillin
and MH >5 mm). SDS-PAGE analysis showed 2 major proteins:
42 and 39 kDa presumed to be OmpC and OmpF like respect-
ively. 25 IPM-R strains (IPM-MICs of 8-32 lg/mL) produced
both Omps with the level of 42-kDa thinner than IPM-S strains
and E. coli HB101. 15 IPM-R strains (IPM-MICs > 32 lg/mL)
produced only a 39-kDa Omp. Pulsed-Field Gel Electrophoresis
using XbaI, revealed 6 pulsotypes (A-F). The prevalent epide-
miological pulsotype A included 77.4% of strains genetically
related; 28 (58.4%) of them were IPM-R and 20 (41.6%) IPM-S.
Conclusion: The emergence of multidrug-resistant E. aerogenes
strains involving the coexistence of ESBLs; AmpC Beta-lacta-
mase; alteration of Omps and MBL-production is very disqui-
eting in our hospital.*IP = imipenem
P1247
Resistance to cefoxitin and susceptibility to
amoxicillin-clavulanate in clinical isolates of
Escherichia coli not hyperproducing AmpC and
lacking the OmpF porin
F. Ferna´ndez Cuenca, G. Amblar, L. Martı´nez-Martı´nez,
A. Pascual (Seville, ES)
Objectives: To evaluate the role of AmpC hyperproduction and
porin loss in the resistance to cephamycins in clinical isolates of
Escherichia coli (Ec).
Methods: 13 Ec isolated from urine samples of outpatients
attended in 2000 were submitted to the Clinical Microbiology
Department, Univ Hosp Virgen Macarena, Seville, Spain. Gen-
otyping was performed by REP-PCR. MICs of cefoxitin (FOX),
cefotetan (CTT), cefotaxime (CTX), ceftazidime (CAZ), cefepime
(FEP), amoxicillin (AMX) and amoxicillin-clavulanate (AC) were
determined by microdilution (CLSI guidelines). The MICs of
FOX were also determined in combination with BRL42715 (BRL)
or clavulanic acid (CV). The isoelectric point (pI) and the
inhibition proﬁle of b-lactamases (BLs) with CV or cloxacillin
(CX) were determined by isoelectric focusing. Hydrolysis of
FOX was determined by spectrophotometry and by the clover-
leaf assay. Mutations in the promoter and attenuator region of
ampC were identiﬁed by DNA sequencing. Analysis of outer
membrane proteins (OMPs) was performed by using the
10%SDS-PAGE system with 6 M urea.
Results: Seven REP-PCR patterns were observed. Isolates were
resistant to FOX (MIC range: 32–128 mg/L) but susceptible to
AC (4–16 mg/L) and CTT (1-8 mg/L), suggesting an AmpC
non-hyperproducing phenotype. Seven isolates were resistant to
AMX (512ﬁ1024 mg/L) and 6 were susceptible to AMX (8–
16 mg/L). All isolates were also susceptible to CTX, (<0.5–
1 mg/L), CAZ (0.5–2 mg/L) and FEP (<0.125–0.5 mg/L). The
MICs of FOX were not affected or were reduced 1 dilution by
BRL or CV. A band of pI d9 (inhibited by CX but not by CV) was
observed in all Ec. A band of pI 5.4 (inhibited by CV but not by
CX) was also observed in AMX resistant isolates. Hydrolysis of
FOX was not detected. Three point mutation proﬁles not
associated with the hyperproduction of AmpC were observed
in the regulatory region of ampC: -76, -56, +22, +26, +27, +32,
+70, +80 (5 isolates); -88, -82, -18, -1, +58, +80 (5 isolates); and -56,
+80 (3 isolates). Six different OMP proﬁles were observed. All
these proﬁles where characterised by the expression of OmpC
and OmpA, and the absence of Omp F.
Conclusion: Resistance to FOX in the Ec isolates of this study is
not associated with resistance to CTT and AC. Resistance to
cefoxitin is related to the absence of porin OmpF but not with b-
lactamase production, including AmpC hyperproduction.
P1248
Are target gene mutations the major mechanisms
of ﬂuoroquinolone-resistance in salmonellae?
Y. Jin, J.M. Ling (Hong Kong, HK)
Objectives: 1. To study mechanisms of ﬂuoroquinolone-resist-
ance (FqR) in Salmonella sp. 2. To elucidate the importance of
different mechanisms in contributing to FqR in these strains.
Methods: Fifty-nine single patient isolates of Salmonella sp. (out
of 280)with ciproﬂoxacin (CIP)MICs>0.03 mg/l obtainedduring
2002 in New Territories East cluster hospitals of Hong Kongwere
tested for their susceptibilities to ﬁve other ﬂuoroquinolones (Fqs)
by determining the MICs using an agar dilution method recom-
mended by the Clinical Laboratory Standards Institute. The
quinolone resistance-determining region of gyrA, gyrB, parC and
parE in these strains were ampliﬁed and mutations detected by
single-stranded conformational polymorphism analysis and
DNA sequence determination. Seven of these strains and 5 FqR
mutants of S. Typhimurium (with or without target gene muta-
tions) obtained after selection by Fqs (unpublished data), and a
standard Salmonella enterica serotype Typhimurium strain (ATCC
13311)were tested forCIPaccumulation andefﬂux in thepresence
and absence of CCCP (carbonyl cyanide m-chlorophenyl-hydra-
zone) spectroﬂuorometrically at excitation and emission wave-
lengths of 279 and 447 nm, respectively, acrB gene expression by
real time RT-PCR and analysis of outer membrane proteins by
SDS-PAGE.
Results: Of the 59 isolates tested, 10% did not harbour any
detectable target gene mutations. However, 68% harboured 1
mutation (61% in gyrA [Asp87Asn/Gly or Ser83Phe/Tyr] and
7% in parC [Thr57Ser]), 15% harboured 2 mutations (8% with 2
gyrA [Ser83Phe + Asp87Asn] and 7% with 1 gyrA and 1 parC
mutations [Ser83Phe + Ser80Arg or Asp87Asn/Tyr/
Gly + Thr57Ser]), and 5% with 2 gyrA and 1 parC mutations
[Ser83Phe + Asp87Asn + Thr57Ser/Ser80Arg]. There was 1 iso-
late with 4 mutations (2 in gyrA [Ser83Phe + Asp87Gly], and 1
each in parC [Ser80Arg] and parE [Ser458Pro]). Although CCCP
enhanced accumulation of CIP in the tested strains, the amount
accumulated was less than that in the control strain. Production
of OmpA was decreased and acrB gene was overexpressed,
indicating decreased permeability and overexpression of
AcrAB-TolC efﬂux system, respectively in these strains.
Conclusions: The effects of efﬂux pump and decreased mem-
brane permeability were probably as important as target gene
mutations in contributing towards decreased Fq susceptibility or
FqR in salmonellae.
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Emergence of plasmid-mediated Ambler class A
beta-lactamase in association with the plasmid-
mediated quinolone resistance QnrS determinant
in Enterobacter cloacae
L. Poirel, C. Leviandier, A. Soares, P. Nordmann (Le Kremlin
Bicetre, FR)
Objectives: The plasmid-mediated quinolone-resistance deter-
minant QnrS had been identiﬁed ﬁrst in a Shigella ﬂexneri isolate
in Japan, then in Enterobacter cloacae from Vietnam (personal
data) and is now identiﬁed in several enterobacterial isolates in
hospital Biceˆtre, France. Analysis of the genetic background of
the qnrS gene in these latter isolates identiﬁed different self-
transferable plasmids. Several QnrS-positive plasmids from
clonally-unrelated E. cloacae isolates brought ampicillin resist-
ance to Escherichia coli recipient strains that was not related to
any known beta-lactamase.
Methods: PCR were performed using speciﬁc primers for
known beta-lactamase genes (those encoding derivatives of
TEM, SHV, and CARB enzymes). Then, cloning was performed
to identify any novel beta-lactamase gene from a QnrS-positive
E. cloacae clinical isolate. Pulsed-ﬁeld gel electrophoresis (PFGE)
allowed comparison of the E. cloacae isolates.
Results: A novel beta-lactamase gene was identiﬁed from a
single QnrS-positive E. cloacae isolate. This beta-lactamase
named LAP-1 (pI value of 6.7) shared low amino acid sequence
identity with other known enzymes, being 60% identical with
the most closely related TEM-1 penicilinase. Once expressed in
E. coli, LAP-1 conferred resistance to penicillins that was
inhibited by clavulanic acid and tazobactam. Its hydrolytic
activity spared expanded-spectrum cephalosporins and carbap-
enems. PCR screening with bla (LAP-1)-speciﬁc primers using
DNA of the six other QnrS-positive E. cloacae isolates (corres-
ponding to four different clones by PFGE) showed that ﬁve
isolates possessed this novel plasmid-borne beta-lactamase gene
on the qnrS-positive plasmid. These plasmids differed in size
and structures. A retrospective analysis showed that the QnrS-
positive E. cloacae isolate we had identiﬁed from a Vietnamese
isolate expressed also LAP-1, whereas a QnrA-positive E. cloacae,
a QnrS-positive E. coli, a QnrS-positive Serratia marcescens and
ten different Qnr-negative E. cloacae isolates from our hospital
were negative for bla (LAP-1).
Conclusion: This works identiﬁed a novel Ambler class A beta-
lactamase which gene is plasmid-mediated. This penicillinase
gene was identiﬁed associated with the QnrS determinant.
P1250
Detection of plasmid-mediated low-level
resistance to ﬂuoroquinolones in Enterobacter
cloacae
P. Higgins, H. Seifert, H. Wisplinghoff (Cologne, DE)
Background: Low-level resistance to ﬂuoroquinolones encoded
by the qnr gene and mediated by plasmid pMG252 has recently
been observed in clinical Enterobacteriaceae isolates, mainly E. coli
and K. pneumoniae.
Methods: To determine the prevalence of pMG252 carrying the
qnr, 110 clinical isolates from hospitals and private practices in
the Cologne Metropolitan area were screened using a PCR based
assay.
Results: Among 58 isolates from hospitalized patients with
urinary tract infection (UTI) and 52 isolates from patients with
community-acquired UTI, pMG252 was detected in one Ente-
robacter cloacae isolate from a hospitalized patient. The isolate
displayed an intermediate susceptibility to ciproﬂoxacin (MIC,
2 lg/mL) and was susceptible to levoloxacin. Presence of
pMG252 and the qnr gene was conﬁrmed by DNA sequencing.
Conclusion: This is one of the ﬁrst reports of pMG252 in a
clinical E. cloacae isolate. Even though the prevalence of
plasmid mediated resistance to ﬂuoroquinolones in clinical
isolates is low, pMG252 carrying the qnr gene has now been
reported in most clinically relevant Enterobacteriaceae. Further
studies monitoring the potential emergence of pMG252 posit-
ive strains may be warranted.
P1251
First characterisation of ﬂuoroquinolone
resistance in Streptococcus suis
J.A. Escudero, A. San Millan, A.M. Catalan, A.G. De la Campa,
M.A. Moreno, L. Dominguez, B. Gonzalez-Zorn (Madrid, ES)
Objectives: Streptococcus suis is a worldwide distributed gram
positive bacterium that causes meningitis, endocarditis, septi-
cemia, septic arthritis, pneumonia, and abortion both in humans
and pigs. During the summer of 2005, 215 people were infected
by S. suis in China, of which 39 (18%) ended fatally.Second
generation quinolones (ﬂuoroquinolones), such as enroﬂoxacin
or ciproﬂoxacin, are one of the main families of antimicrobial
compounds used for the treatment of S. suis infections. The use
of ﬂuoroquinolones against S. suis is causing the emergence of
quinolone-resistant strains, with unpredictable consequences for
pig production and Public Health. Here we present the
molecular basis of ﬂuoroquinolone resistance in S. suis.
Methods: Identiﬁcation of S. suis isolates was performed using
a species speciﬁc PCR of the gld (glutamate dehydrogenase)
gene. All isolates were subjected to PFGE to assess phylogenetic
relatedness. MICs were determined following the guidelines of
the NCCLS. gyrA and parC genes were ampliﬁed using primers
designed on the basis of conserved regions of other Streptococ-
cus species.
Results: We have ﬁrst identiﬁed the gyrA and parC genes in six
unrelated ﬂuoroquinolone sensitive S. suis isolates, including
type strain ATCC 43765, a clinical isolate from Chile and four
Spanish isolates. The QRDR of these genes was undistinguish-
ible. Further, we ampliﬁed and sequenced the QRDR of eleven
high-level resistant S. suis strains from different geographical
origins. The parC gene of these bacteria possessed a S79Y
mutation, known to confer resistance to ﬂuoroquinolones in
other bacteria. Sequence comparison of the gyrA gene revealed
the E85D mutation conferring ﬂuoroquinolone resistance, as
well as novel mutations at S81K not yet described in other
bacterial species.
Conclusions: We have identiﬁed and characterised the gyrA
and parC genes of S. suis. Sequence analysis revealed mutations
in these genes responsible for ﬂuoroquinolone resistance in S.
suis.
P1252
Step-wise parC and gyrA mutations in
Streptococcus pneumoniae: the role of the Lys137
to Asn mutation in ﬂuoroquinolone resistance
V. Allen, K. Green, D.J. Bast, J. Azavedo, C. Duncan, D.E. Low
(Toronto, CA)
Objectives: Recent US data comparing 1994–1995 to 2002–2003
has found the emergence of parC mutations in Streptococcus
pneumoniae (SP) isolates concurrent with a doubling of ﬂuoro-
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quinolone resistance (Doern et al). The most commonly identi-
ﬁed mutation in this series was Lys-137-Asp. The aim of this
study is to determine the association between ciproﬂoxacin (C)
and levoﬂoxacin (L) prescription patterns and the development
of the Lys-137-Asp parC mutation as a potential contributor to
the step –wise ﬂuoroquinolone resistance mechanisms in SP.
Methods: A total of 17,978 clinical isolates of SP were collected
between 1993–2002 as part of a surveillance program through-
out Canada. Specimens were stratiﬁed by C MIC and by year
according to the ﬂuoroquinolone (FQ) available and most
commonly used in Canada; prior to 1998 C was the sole
ﬂuoroquinolone available, whereas L was the respiratory
ﬂuoroquinolone most commonly used during 2000–2002. The
parC and gyrA genes were ampliﬁed by polymerase chain
reaction for random isolates from each MIC stratiﬁcation
during each of these periods. C and L prescription patterns
in Canada over time were also collected.
Results: C prescription rates peaked in 1999 at 1,536,402/yr but
has remained stable since then. In contrast L prescription
continued to increase from 16, 627 outpatient prescriptions in
1998 to 315, 467 in 2001. The rate of the Lys-137-Asn mutation in
SP isolates was found in all MIC groups at a combined rate of
23.6%. There was a linear increase in the frequency of the Lys-
137-Asn mutation as a function of the MIC in the 2000–2002
cohort. There was no such linear trend seen in the 1993–98
group. An increased frequency of combination parC and gyrA
mutations was identiﬁed with MICs >4 lg/ml. 52% of isolates
with an MIC >4 lg/ml demonstrated mutations in both of these
genes, compared to 94% of isolates with an MIC >16 lg/ml.
Conclusion: The Lys-137-Asn parC mutation may be a harbin-
ger of future resistance in SP as a ﬁrst of a series of step-wise
mutations. Unlike the previous US series, the overall rates of this
mutation in our series did not increase as a function of F
prescription patterns, and evidence of a linear increase in Lys-
137-Asn as a function of higher MICs was only seen after 2000.
Further details need to be elucidated regarding the clinical
signiﬁcance of the Lys-137-Asn mutation and whether the
frequency and role of this mutation is altered by antimicrobial
selection pressures created by newer ﬂuoroquinolones.
P1253
Molecular characterisation of antibiotic resistance
mechanisms in Salmonella enterica isolates in
Ireland
D. Lee, S. Fanning, A. Coffey (Cork, Dublin, IE)
The primary objective of this study was to determine the level
and range of antibiotic resistance among a broad collection of
Salmonella enterica isolates from both human and animal sources
in Ireland. The emergence of antibiotic resistance in Salmonella
was highlighted over a decade ago. Many cases of Salmonella
infection now involve multi-drug resistant strains. Quinolones,
including Fluoroquinolones, are broad-spectrum antibiotics and
are often the treatment of choice in cases of life-threatening
Salmonellosis caused by multi-drug resistant strains. Resistance
to the quinolones is mainly attributed to alterations of the target
sites, caused by speciﬁc mutations within the chromosomal
genes encoding DNA gyrase (gyr A, B) and topoisomerase IV
(par C, E). These mutations are generally located within an area
known as the Quinolone Resistance Determining Region
(QRDR). The antibiotic resistance proﬁle was determined for
167 Salmonella isolates, against a panel of 17 antibiotics repre-
senting those regularly used for clinical treatment of Salmonella
infections. Isolates with reduced susceptibility to quinolones
were selected for further study with the aim of determining the
correlation between speciﬁc mutations and resistance. The
QRDR’s of gyr A, B and par C, E were ampliﬁed by the
Polymerase Chain Reaction (PCR) and the products sequenced.
The minimum inhibitory concentrations for Nalidixic acid (Nal),
Ciproﬂoxacin (Cip), and Norﬂoxacin (Nx) was determined using
the E-test. Within the gyrA gene, two different mutations were
identiﬁed. 9 isolates harboured a nucleotide substitution at
codon 87 (GAC-TAC), all of animal origin. One isolate had a
nucleotide substitution at codon 83 (TCC-TTC), of human origin.
Both mutations correlated with observed high level resistance of
>256 lg/ml to Nal, a reduced susceptibility to Cip and Nx was
also observed. Two isolates harboured a single mutation located
within the QRDR of par C at codon 57 (ACC-AGC) which was
linked to intermediate resistance to Nal. All mutations resulted
in amino acid substitutions. While treatment failure with
quinolones has been reported in Asia and the United States, to
date resistance to the quinolones in Ireland is rare, however
constant screening for quinolone resistance among Salmonella
isolates is vital.
P1254
Multidrug-resistant tuberculosis in Lisbon in
2003
I. Portugal, R. Macedo, E. Fernandes, J. Perdiga˜o, I. Joa˜o,
E. Pereira, L. Brum (Lisbon, PT)
Objectives: Portugal remains the country with the highest rate
of notiﬁed cases due to Mycobacterium tuberculosis in the
Western E.U. In 2003, the Portuguese Health Authorities
reported a tuberculosis (TB) incidence of 41.1/100 000 popula-
tion nation wide, and 1.7% of multidrug resistant cases of
tuberculosis (MDR-TB). Although strains isolated in hospital
and public health laboratories are currently notiﬁed to Portu-
guese authorities, the true magnitude of the problem is
unknown. In fact, even though only 17 MDR-TB cases were
notiﬁed in 2003, we have collected more than 100 MDR-TB
isolates in the Lisbon Health region. Our objectives were to
evaluate the prevalence and clustering of MDR-TB strains
isolated in Lisbon laboratories and hospitals, in particular a
previous described family of strains, family Lisboa, and to
investigate the mutations in genes associated with drug resist-
ance to ﬁrst line drugs.
Methods: MDR-TB strains were collected in several hospital
and public health laboratories in Lisbon area. We performed
mycobacterial interspersed repetitive units typing (MIRU) to all
the isolated strains. Mutations in genes associated to rifampicin,
isoniazid, streptomycine and pyrazinamide resistance were
analysed.
Results: MIRU analysis revealed that family Lisboa strains are
still responsible for 36% of all the MDR-TB strains analysed in
this study. Nevertheless we could not ﬁnd any relevant outbreak
due to these strains. In fact, we did not found more than three
strains in one particular hospital or public health laboratory.
These results were in agreement with mutation analysis of some
of the genes involved in resistance.
Conclusion: In view of the above ﬁndings, we can conclude
that family Lisboa strains are still spread at least in Lisbon area
and probably all over the country and continues to be respon-
sible for the main resistant tuberculosis, although no signiﬁcant
outbreak was detected.
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Genotypic assessment of rifampin resistance in
Mycobacterium tuberculosis isolated in Belarus
V. Slizen, S. Zaker, L. Surkova, A. Bahrmand, M. Taghikhani,
L. Titov (Minsk, BY; Tehran, IR)
Objectives: The mechanism of resistance to rifampin involves
missense mutations in 81-bp fragment of rpo B gene with the
majority of mutations occurring at codons 531, 526, 516, 511.
Proﬁle of mutations in rpo B gene depends on geographical
region. The aim of the study was to identify mutations
associated with rifampin resistance in strains isolated in Belarus.
Methods: Susceptibility to RMP and INH in 44 clinical isolates
of Mycobacterium tuberculosis was determined by internationally
accepted reference technique, their rpo B gene (305 bp region)
was ampliﬁed and autosequenced.
Results: All 44 tested strains displaying resistance to isoniazid
(0.1 lg/mL) and rifampin (2 lg/mL) had point mutations in 1–4
separate codons with the prevalence of double mutations. l, 2, 3
and 4 mutations carried 11 (25%), 22(50%), 8 (18%), 4 (7%)
strains respectively. Most of the mutations (80%) were located in
510, 526, 523, 531 codons accounted for resistance in 50, 45.5,
40.9, 29.5% of isolates correspondingly. The rpoB codons 531,
526, 516, 511 were reported to be the most frequently mutated
codons worldwide. In Belarus, in contrast to other studies, most
common codons affected by point mutations were 510 and 523.
Point mutations in codons 508, 507, 512, 516, 520, 522, 521, 525
occurred in 2.3–9.1% of isolates. Most of the detected mutations
led to alterations of coding aminoacids and only 7 mutations
were silent. Mutations occurred in codon 510 resulted in
replacement of Gln to Glu (59%) or Lys (13.6%) or generated
stop codon. Mutations in codon 526 led to substitution
His > Asp (85%) or His > Leu, in codon 523 there were revealed
substitution Gly > Ala (78%) or silent mutations, in codon 531 –
Ser > Leu (one strain displayed Ser > Lys).
Conclusion: It was revealed geographical variation in rpo B gene
mutations proﬁle in Mycobacterium tuberculosis isolates from
Belarus, characterised by high frequency of double, triple, quad-
ruple mutations and mutations localised in 510 and 523 codons.
P1256
Metronidazole heteroresistant C. difﬁcile strains:
morphotypes with cell-wall thickening
J. Martı´nez-Alarco´n, T. Pela´ez, J. Garcı´a-Bordas, P. Sandoval,
L. Alcala´, E. Cercenado, E. Bouza (Madrid, ES)
Objectives: We previously reported a high prevalence of
metronidazole-resistant (MTZ-R) Clostridium difﬁcile strains in
our institution. Resistance to MTZ seemed to be heterogeneous
and unstable. We observed that strains which were heterore-
sistant to metronidazole suffered morphological changes
depending on the presence or absence of metronidazole. We
characterized the different morphotypes with and without MTZ.
Methods: We studied 18 MTZ-R isolates (MICs: 64–16 mg/L)
and a control strain (C. difﬁcile ATCC 9689). Brain Heart Infusion
broth tubes (BHI) with 4 and 8 mg/L of MTZ were inoculated
with 100 ll of a 0.5 McFarland suspension of each isolate and
incubated anaerobically at 37C for 10 days. The cultures were
later seeded onto Brucella agar without MTZ and examined.
Plates were further incubated under the same conditions and
observed for 10 days. Bacterial morphology was examined
macroscopically (colonies) and by optical and electronic micr-
oscopy. Susceptibility testing of the different morphotypes was
performed against vancomycin and teicoplanin using the E-test
method.
Results: Subcultures from BHI with MTZ produced colonies
with an atypical white appearance and round shape. These
colonies seeded onto the Brucellawithout MTZ reverted progres-
sively to characteristic C. difﬁcile morphotypes (pleomorphic,
yellow-green, ground-glass appearance). Macroscopic, optical
and electronic microscopy demonstrated a heterogeneous mor-
phology, consisting of a mixed population of small (cocci),
medium (cocobacilli) and large (bacilli) colonies. The cocci and
cocobacilli morphotypes showed signiﬁcant cell-wall thickening
that correlated with an increase in vancomycin and teicoplanin
MICs. The control strain did not grow in the presence of MTZ.
Conclusions: We observed a mixed population of different
morphotypes in heteroresistant C. difﬁcile strains in the pres-
ence of MTZ,. Two of the morphotypes presented cell-wall
thickening that was associated with an increase in vancomycin
and teicoplanin MICs.
P1257
Incidence and antimicrobial resistance pattern of
anaerobic bacteria isolated from clinical cases
P. Giannopoulou, E. Kontekaki, A. Kyratsa, Z. Kyriazi,
E. Trikka-Graphakos (Athens, GR)
Objectives: To evaluate the frequency of anaerobic bacteria
from clinical specimens and their in-vitro activity to antimicro-
bials.
Methods: 95 isolates were collected from documented infec-
tions during a three year period (2002–2005). Processing of
specimens was performed with conventional methods. Anaer-
obic culture media were as follow: Bactec bottles (Becton
Dickinson), Brucella Blood agar enriched with vitamin K1&
hemin, Neomycin-Vancomycin Laked Blood agar, Bacteroides
Bile-Esculin agar and Cooked Meat Broth. Preliminary, bacteria
were identiﬁed by Gram stain, colony morphology and
susceptibility to high-potency disks (colistin, kanamycin, vanco-
mycin, SPS). Species identiﬁcation was performed by rapid ID
32A (Biomerieux) and B-Lactamase production by nitrocephin
discs (Becton Dickinson). Antibiotic susceptibility was
performed by Etest method (ABBiodisk, Sweden) in National
Reference Center.
Results: From 95 isolates 66 (69.4%) were Gram negative (52
Bacteroides fragilis group, 6 Prevotella spp., 3 non-fragilis Bacter-
oides spp., 2 Fusobacterium sop, 2 Veillonella spp and 1 Porphy-
romonas spp.) and 29 (30.5%) Gram positive (10 Clostridium spp,
8 Peptostreptococcus spp, 8 Propionobacterium spp and 3 Eubacte-
rium spp). Forty one strains were isolated from wounds and
abscesses, 22 from blood cultures, 19 intra-abdominal infections,
8 pelvic infections and 5 diabetic foot ulcers. The most common
isolate from blood cultures was Bacteroides fragilis group 13.9%,
followed by Clostridium spp 12.6%. Bacteroides fragilis group was
also the most frequent isolate from all the other specimens.
Antimicrobial susceptibility testing was performed to penicillin,
cefoxitin, clindamycin, metronidazole, piperacillin/tazobactam,
and imipenem. Bacteroides fragilis group was resistant to
penicillin 96.1% and clindamycin25%, Prevotella spp to penicillin
83.3% and clindamycin 16.6%, Clostridium spp 13.2% and
Peptostreptococcus spp 12.4% to clindamycin. Non- susceptible
strains of gram-negative to cefoxitin was 25%. 3 isolates were
resistant to metronidazole. Piperacillin/tazobactam and imipe-
nem were highly effective to all isolates.
Conclusions: (a) Bacteroides fragilis group, the most common
anaerobe, was highly resistant to penicillin followed by clinda-
mycin (b) Clostridium and Peptostreptococcus spp showed low
resistance to clindamycin (c) the evidence that metronidazole
resistance may be emerging as well as high rates of resistance to
cefoxitin and clindamycin, require closer surveillance.
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Analysis of the mechanism of Acinetobacter
baumannii resistance to carbapenems in Jinan
D. Wu, Z. Geng, X. Yu, J. Hong (Jinan, Shandong, CN)
Objectives: Acinetobacter are important opportunistic pathogens
causing a wide range of clinical complications. There is a
growing on carbapenem-resistance Acinetobacter with the exten-
ded usage of carbapenems, and antimicrobial treatment of these
clinical infections may be compromised. This study was con-
ducted to analyse carbapenemase and out membrane proteins of
Acinetobacter baumannii isolates to investigate the mechanism of
Acinetobacter resistance to carbapenems in Jinan, China.
Methods: Extracted chromosome DNA of 5 Acinetobacter bau-
mannii isolates resistance to carbapenems determined by E-test
was subjected to polymerase chain reaction (PCR) with the
speciﬁc primers of blaOXA-23 blaOXA-24 blaIMP and blaVIM,
the PCR products were ligated with PMD18-T, transformed into
DH5’ and then sequenced. Out membrane proteins were
prepared by supersound collected by ultra-centrifugation and
separated by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis SDS-PAGEª of which the concentrations of separ-
ation gel and stacking gel were 15% and 5.1% respectively.
Results: PCR with the presence of blaOXA-23-speciﬁc primers
ampliﬁed a circa 1083-bp fragment with three isolates (11, 66
and 67), their DNA sequences were identical with blaOXA-23.
One isolate (40) obtained a circa 1043 bp PCR product with the
presence of blaOXA-24-speciﬁc primers, the DNA sequence was
identical with blaOXA-72. A protein of 29 kDa decreased in one
carbapenem-resistance isolate (66) and a protein of 24 kDa
overexpressed in two carbapenem-resistance isolates (66 and
67).
Conclusion: Producing class D b-lactamase OXA C23 and OXA
C72 was one of the mechanism of Acinetobacter baumannii
resistance to carbapenems in Jinan. The decrease of a 29 kDa out
membrane protein and the overexpression of the 24 kDa
penicillin-binding protein were related to the resistance to
carbapenems in Acinetobacter baumannii.
P1259
Grouping of CTX-M extended-spectrum beta-
lactamases by pyrosequencingTM
S.D. Nyberg, K. Rantakokko-Jalava, P. Huovinen, J. Jalava
(Turku, FI)
Introduction: During the last years the extended-spectrum
beta-lactamases, especially the CTX-M producing strains, have
increased in several countries in Europe (1). The CTX-M was
ﬁrst described in the early 1990s and since then over 40 different
types has been found (http://www.lahey.org/studies/
webt.htm). Enzymes of type CTX-M are typical ESBLs (2) and
showing 40% identity with TEM and SHV-beta-lactamases. A
rapid detection of the CTX-M enzymes enables faster identiﬁ-
cation of ESBL producers.
Methods: A large amount of CTX-M enzymes (K. Bush and
G.A. Jacoby, 2005, http://www.lahey.org/studies/webt.htm)
representing the four main groups; CTX-M-1, CTX-M-2, CTX-
M-8 and CTX-M-9 were aligned and a speciﬁc part in the
gene sequence was chosen in order to be able to separate the
main groups from each other. A speciﬁc biotinylated reverse
primer was designed for PCR. A speciﬁc sequencing primer
was designed for the pyrosequencing reaction to be able to
distinguish the different groups of CTX-M. A total amount of
81 E. coli and Klebsiella spp. strains collected at Turku
University Hospital were analysed. All strains were screened
for ESBL according to CLSI standard with cefotaxime and
ceftazidime alone and with clavulanic acid. All strains were
sequenced by pyrosequencing according to the instructions by
the manufacturer (Biotage Ab, Uppsala, Sweden).
Results: All strains had classical ESBL phenotypes according to
CLSI breakpoints. Of all strains 50% belonged to the CTX-M-1
and 50% to the CTX-M-9 groups.
Conclusion: With pyrosequencing it is possible to separate the
CTX-M subgroups with a short DNA sequence. The grouping of
CTX-M by pyrosequencing TM is a simple and rapid method. It
is also possible to recognize K1/OXY producing strains.
References
1. Bradford, P. A. 2001. Clin. Microbiol. Rev. 14:933–51.
2. Tzouvelekis, L. S., E. et al. 2000. Int. J. Antimicrob. Agents
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P1260
Phenotypic antimicrobial resistance patterns of
Enterobacteriaceae, Pseudomonas aeruginosa, and
Acinetobacter spp. Multicentre Intensive Care
Unit Surveillance Survey (ISS), 1996–2003
M.A. Abramson, G. Gallagher, S. Rawlins, H. Wilson (West
Point, US)
Objectives: ISS is an ongoing surveillance study of antimicro-
bial susceptibility of nosocomial Gram-negative bacilli. A
primary objective of ISS is to assess changes in resistance rates
of these organisms over time.
Methods: 36 110 initial isolates of Enterobacteriaceae, 12 471 of
Pseudomonas aeruginosa, and 3441 of Acinetobacter spp. from ICU
patients were tested at 60–99 centres in the United States
between 1996 and 2003. Cumulative susceptibility results for
imipenem, ceftazidime, piperacillin/tazobactam, amikacin, to-
bramycin, and ciproﬂoxacin were recorded.
Results: Results for Enterobacteriaceae are graphed below. Sus-
ceptibility trends of P. aeruginosa and Acinetobacter spp. were
similar to the Enterobacteriaceae, with decreases noted for all
agents, and more pronounced for Acinetobacter spp. to ciproﬂ-
oxacin (57.4–33.1%), ceftazidime (62.6–37.3%), and piperacillin/
tazobactam (64.1–44.8%); and P. aeruginosa to ciproﬂoxacin
(79.6–64.7%), imipenem (85.8–76.9%), and ceftazidime
(82.2–81.2%).
Conclusion: In all years, imipenem and amikacin were consis-
tently the most active agents against all isolates tested (main-
taining greater than 85% susceptibility) with the exception of P.
aeruginosa. Overall, susceptibility of all isolates to all agents
trended downward over the 8-year time frame.
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P1261
Antimicrobial activity of daptomycin tested
against Gram-positive strains collected from
European medical centres in 2005: results of the
Daptomycin Surveillance Programme
H. Sader, J. Streit, T. Fritsche, R. Jones (North Liberty, US)
Objective: To evaluate the in vitro activity of daptomycin (DAP)
tested against recent clinical isolates collected in Europe in 2005.
DAP is a cyclic lipopeptide with activity against Gram-positive
cocci (GPC) that displays no cross-resistance to other agents,
making it ideal for treatment of multi-drug resistant (MDR)
strains.
Methods: A total of 3,192 consecutive strains were collected in
21 medical centres located in 13 European countries. The main
pathogens evaluated were: S. aureus [SA; 31% oxacillin (OXA)-
resistant (R)]; coagulase-negative Staphylococci (CoNS; 76%
OXA-R), E. faecalis [EF; 1% vancomycin (VAN)-R], E. faecium
(EFM; 21% VAN-R), beta-haemolytic Streptococcus spp. (BHS;
228), and viridans group Streptococcus spp. (VGS; 102). The
strains were susceptibility (S) tested by broth microdilution
methods in Mueller-Hinton broth supplemented to 50 mg/L of
calcium. Numerous comparators were also tested.
Results: DAP activity is summarized in the table: All Enterococci
and Staphylococci were inhibited at DAP S breakpoint (BKP)
established by the Clinical and Laboratory Standards Institute
(formerly NCCLS; £4 and £1 mg/L, respectively). DAP and
linezolid were the only compounds active against all Enterococci
at the S BKP, and R to VAN did not adversely affect DAP
activity. DAP was highly active against SA and CoNS (MIC90,
0.5 mg/L) and independent of their S to OXA. BHS was highly S
to DAP (MIC90, 0.25 mg/L) and most comparison agents tested.
DAP was also active against all VGS strains at the S breakpoint.
Conclusions: All GPC tested were S to DAP. R to other com-
pounds did not inﬂuence the high DAP activity against Staphy-
lococci,EnterococciorStreptococci. DAPshowedsigniﬁcantpotency
andbroad spectrumactivity against recent clinical isolates ofGPC
isolated in European medical centres, including MDR subsets.
P1262
Antimicrobial activity of cefepime tested against
ceftazidime-resistant Gram-negative clinical
strains from North American hospitals: report
from the SENTRY Antimicrobial Surveillance
Program, 1998–2004
H. Sader, T. Fritsche, R. Jones (North Liberty, US)
Objectives: To evaluate antimicrobial spectrum and potency of
cefepime (CPM) and selected comparators against ceftazidime
(CAZ)-resistant (R; MIC ‡ 16 mg/L) Gram-negative bacilli
(GNB) collected in North America (NA) medical centres over
a 7-year period (1998–2004).
Methods: Isolates were consecutively collected mainly from
bloodstream (47%), respiratory tract (33%), urinary tract (9%)
and skin/soft tissue (5%) infections in 48 major hospitals.
Isolates were susceptibility (S) tested by reference CLSI broth
microdilution methods in a central laboratory.
Results: A total of 42,061 GNB were collected during the study
period. The most frequently isolated pathogens were E. coli
(28.0%) > P. aeruginosa (PSA; 14.9%) > Klebsiella spp. (KSP;
14.0%) > H. inﬂuenzae (11.2%) > Enterobacter spp. (ESP; 7.8%) >
Serratia spp. (4.0%). CAZ-R was observed in 8.5% of GNB and
5.6% of Enterobacteriaceae (ENT). The highest rates of CAZ-R
were observed among Acinetobacter spp. (ASP; 40.3%) > ESP
(20.9%) > PSA (16.9%) > Citrobacter spp. (CIT; 15.3%) > indol-
pos. Proteae (10.0%). The activity of CPM against the most
frequent CAZ-R organisms is summarized in the Table. Overall,
90% of CAZ-R ENT and 30% of CAZ-R PSA remained S to CPM.
The activities (%S) of other antimicrobials tested against CAZ-R
ENT and PSA were: amikacin 90 and 88%, ciproﬂoxacin 63 and
46%, ertapenem 93 and 6%, gentamicin 59 and 67%, imipenem
99 and 65%, levoﬂoxacin 69 and 44% and piperacillin/tazobac-
tam only 40 and 41%.
Conclusions: CAZ-R GNB exhibited high rates of R to other
antimicrobials. CPM was very active against CAZ-R ENT,
especially (‡90% S) ESP, CIT and indol-pos. Proteae, and
showed activity similar to that of CAZ against all PSA and
ASP isolated in NA medical centres. Continued R surveillance
monitoring will be necessary to assess the effectiveness of
widely used broad-spectrum antimicrobials.
P1263
Frequency of occurrence and antimicrobial
susceptibility of bacterial isolates causing
bloodstream infections in European medical
centres: report from 9 years of the SENTRY
Antimicrobial Surveillance Program in Europe
(1997–2005)
H. Sader, D. Biedenbach, T. Fritsche, R. Jones (North Liberty, US)
Background: To evaluate the frequency of occurrence and
antimicrobial susceptibility (S) of pathogens causing blood-
stream infection (BSI) in Europe.
Methods: The ﬁrst 20 unique and clinical relevant BSI isolates
from 42 medical centres (10–31 years) were sent to a monitor
each month. The isolates were tested for S (>30 antimicrobials)
by broth microdilution methods and results interpreted accord-
ing to the 2006 CLSI M100-S16 document. Selected resistance (R)
mechanisms were characterized.
Results: 42,411 isolates 51.6% [Gram-negative bacilli (GNB)]
were processed. The rank order for all years was (no. of isolates/
%of total): E. coli (9,586/22.7%) > S. aureus (8,254/19.7%) >
coagulase-negative Staphylococci (5,638/13.3%) > Enterococcus
spp. (3,203/7.6%) > Klebsiella spp. (3,099/7.3%) > P. aeruginosa
(PSA; 2,642/6.2%). This rank order and the frequencies were
very stable through the years. The antimicrobial S rates of the
key GNB are summarized in the table. ESBL phenotypes were
observed in 4.8% of E. coli, 24.2% of K. pneumoniae and 9.1% of P.
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mirabilis. Metallo-beta-lactamase (MBL) production was detec-
ted among Enterobacteriaceae (ENT) from Greece, Italy, Spain and
Turkey. S rates for key antimicrobials against S. aureus were:
71.9% for oxacillin (OXA), 68.9% for ciproﬂoxacin, 47.7% for
erythromycin, 81.3% for clindamycin, 98.1% for TMP/SMX,
>99% for quinupristin/dalfpristin, teicoplanin, vancomycin
(VAN), linezolid (LNZ) and daptomycin (DAP). VAN R was
observed in 1.3% of E. faecalis and 10.7% of E. faecium with
escalating rates in recent years, and no R to DAP or LNZ was
detected among Enterococci. Among S. pneumoniae, S and R to
penicillin were 74.5 and 12.4%, respectively, while 99.6% of
strains were S to levoﬂoxacin and gatiﬂoxacin.
Conclusions: The main R problems detected among BSI strains
collected in Europe by the SENTRY Program were: OXA R S.
aureus, ESBL-producing ENT, multi-drug resistant PSA and
ACB, and MBL-producing ENT and PSA.
P1264
Inﬂuence of serum-resistance properties and
multidrug-resistance of Pseudomonas aeruginosa
on mortality and duration of mechanical
ventilation in patients with Pseudomonas
aeruginosa pneumonia
A. Vitkauskiene, V. Dudzevicius, D. Adukauskiene,
J. Braziulyte, R. Sabaniauskaite, R. Sakalauskas, H. Sahly
(Kaunas, LT; Kiel, DE)
Aim: To evaluate the association between serum- and antibi-
otic-resistance of P. aeruginosa and the duration of mechanical
ventilation (MV) and mortality of ICU patients with pseudo-
monal pneumonia.
Materials and methods: Data of 149 ICU patients (mean age
54.8 ± 1.5 years) suffering from pneumonia caused by P. aeru-
ginosa were analysed at the onset, after 5–7 and 21–30 days after
the start of treatment. P. aeruginosa was isolated from patients’
bronchoalveolar lavage ﬂuid or bronchial secretions. The ability
of the P. aeruginosa isolates to resist killing by human serum was
tested and the strains were classiﬁed as serum-sensitive,
intermediately resistant, or highly resistant to serum. Resistance
to antibiotics was tested using the disc diffusion method (discs
BBL) according to the NCCLS standards. Strains showing
resistance to 3 or more antibiotics were considered as multi-
drug-resistant (MDR). Initial treatment effectiveness, pneu-
monia type, and pathogen resistance patterns were assessed.
Logistic regression was performed to detect factors associated
with mortality 21–30 days after pneumonia onset. T-test and
ANOVA were used for evaluation of difference in MV duration.
Results: After 5–7 days of treatment the early mortality was
20.9% (n = 31) and none of the analysed factors had signiﬁcant
inﬂuence on it. Mean MV duration was longer in patients
infected with serum-resistant strains (16.9±4.3 days, and
6.8±1.1 days, respectively) (p < 0.05). Antibacterial resistance
had no effect on the duration of MV. 21–30 days after the
pneumonia onset overall mortality was 45.3% (n = 67), outcome
was not evaluated in 12.8% (n = 19) of cases. Isolation of
intermediately serum-resistant or highly serum-resistant strains
was signiﬁcantly associated with increased late mortality 21–
30 days after initiation of treatment (OR 9.00; CI 1.94–41.65 and
OR 7.50; CI 0.93–60.42, p < 0.05). Mean duration of MV was
longer in patients with MDR strains (13.5 ± 3.0 and
7.6 ± 1.5 days, respectively) (p < 0.05). Analysing all cases at
all time-points showed that the MV duration was signiﬁcantly
longer in patients infected with MDR strains (15.1 ± 2.9 days
and 8.1 ± 1.2 days, respectively) (p < 0.05).
Conclusions: 1. Serum-resistance property of P. aeruginosa
increases patients’ late mortality 21–30 days after the treatment
initiation. 2. Serum-resistance property and multi-resistance of
P. aeruginosa strains prolong the duration of mechanical venti-
lation in ICU patients
P1265
Antimicrobial potency and spectrum of activity
for meropenem: report from the USA MYSTIC
Programme (2005)
P. Rhomberg, T. Fritsche, H. Sader, R. Jones (North Liberty, US)
Objective: To monitor the activity of meropenem (MEM) and
10 broad-spectrum comparison agents against pathogens col-
lected from hospitalized patients within United States (USA)
medical centres participating in the Meropenem Yearly Suscep-
tibility Test Information Collection (MYSTIC) Programme, a
global longitudinal surveillance network of >100 medical centres
actively using carbapenems worldwide. In the USA, 15 sites
participated by submitting up to 200 consecutive, non-duplicate
clinical isolates from serious infections.
Methods: A total of 2910 isolates (97% compliance) including
1657 Enterobacteriaceae (ENT), 836 Non-fermentative Gram-neg-
ative bacilli (NFGB), and 417 oxacillin-susceptible Staphylococci
were tested at a central monitoring laboratory using CLSI
reference broth microdilution susceptibility (S) methods with
interpretative criteria. Ribotyping (RT) and pulsed-ﬁeld gel
electrophoresis (PFGE) were performed on multi-drug resistant
(R) strains to determine possible clonal dissemination contribu-
tion to R patterns.
Results: Against the ENT isolates, the carbapenems demon-
strated the greatest susceptibility (S; >98.7%) and all other
agents, except the ﬂuoroquinolones (FQ; 83.9–84.9% S) showed
>90% S. Sixty-six E. coli (EC) and Klebsiella spp. isolates
producing ESBLs (7.0%) were submitted from 12 sites, and 24
clonally related (RT 105.497.1) K. pneumoniae strains were
identiﬁed that produced a KPC carbapenemase, and 2 addi-
tional strains with a SME type carbapenemase were detected
from two sites. FQ-R was most prevalent in indole-positive
Proteae and EC strains with six epidemic/endemic clusters
identiﬁed. Piperacillin/tazobactam, tobramycin and MEM were
the most active agents (>87.6% S) against the 589 P. aeruginosa
(PSA) isolates. Against the 125 Acinetobacter spp. isolates only
tobramycin, imipenem and MEM demonstrated >85.6% S, all
other agents were less than 72.0% S.
Conclusions: These 2005 MYSTIC Program results demonstrate
the continued high activity of MEM against ENT, PSA, and
oxacillin-susceptible Staphylococci (MIC90, 0.12 lg/ml), but the
rising incidence of clonally-related carbapenemases (KPC-2 and
-3) among ENT is a concern. Continued surveillance within
these USA participant sites appears warranted to monitor the
residual activity of the important carbapenem class as well as
other broad-spectrum agents against key nosocomial pathogens
compared to the 6 prior years, only FQ-R rates continued to
signiﬁcantly progress.
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P1266
Difference in quinolone resistance in
Pseudomonas aeruginosa from cystic ﬁbrosis and
non-cystic ﬁbrosis patients
B. Henrichfreise, I. Wiegand, I. Noll, W. Pﬁster,
B. Wiedemann (Bonn, Berlin, Jena, DE)
Objectives: German Network for Antimicrobial Resistance
Surveillance (GENARS) data reveal for P. aeruginosa strains
from cystic ﬁbrosis patients (CFP) a higher rate but lower level
of resistance to quinolones compared to strains from non-CF
patients (nCFP). The aim of our study was to investigate this
phenomenon on a molecular level.
Methods: 76 CFP and 207 nCFP GENARS strains from Jan 2002
to Jun 2004 with reduced susceptibility to ciproﬂoxacin (CIP)
were included. For 12 CFP and 10 nCFP strains the QRDR of
gyrA and parC, mexR and nfxB were sequenced. Clonal
relationship among those strains was precluded by PFGE and
a PCR screening for qnr was carried out.
Results: In Table 1 the MIC distributions of CIP for CFP and
nCFP strains are shown. In CFP strains MICs £ 4 mg/L were the
most frequent, single mutations in gyrA predominated and no
mutation in parC was found. Multiple mutations and a 4-fold
higher rate of MICs ‡ 16 mg/L was found in nCFP strains. Qnr
was not detected.
Conclusion: In several strains other mechanisms than the
tested seem to contribute to CIP resistance. In CFP strains
resistance to CIP was characterized by low-level resistance
mostly due to single mutations in gyrA. In contrast, high-level
resistance and multiple mutations were typically found in
nCFP strains. Lower concentrations of quinolones in the mucus
of the CF lung or bioﬁlm formation may reduce the need for
multiple mutations in CFP strains.
P1267
Molecular typing and alterations analysis of
penicillin-binding proteins 1A, 2X and 2B and
MurM protein and in 33 isolates of Streptococcus
pneumoniae with vary penicillin and amoxicillin
MICs
K. Kosowska-Shick, P.C. Appelbaum (Hershey, US)
Subject: Alterations in one or more of the conserved motifs of
penicillin-binding proteins (PBPs) 1A (370STMK373,
428SRN430, 557KTG559), PBP 2X (337STMK340, 394HSSN397,
546LKSG549), and PBP 2B (385SVVK388, 442SSNT445,
614KTG616) as well as changes in murein (MurM) play an
important part in resistance of pneumococci to b-lactams.
Methods: 33 strains from 10 countries with varying penicillin
(PEN), amoxicillin (AMOX) and carbapenem MICs were selec-
ted from surveillance studies and PFGE analyses. b-Lactam
resistance mechanisms, sequencing analysis of pbp 1a, 2x and 2b
regions encoding the 3 conserved motifs within the active
penicillin-binding sites, and regions encoding the transpepti-
dase active site were performed in all strains. All strains with
carbapenem MICs of 1 lg/ml were subjected to MLST.
Results: PEN, AMOX and carbapenems MICs and changes in
the transpeptidase active site and ﬂanking the conserved PBP
motifs were as follows: The 14 strains with AMOX MICs higher
than PEN all showed changes in 10 amino acid sequences in the
PBP2B 590–640 region (group 3), which surrounds the
614KTG616 motif. The remaining 17 strains belonging to
PBP2B groups 1 and 2 with AMOX £ PEN MICs had up to 4
of these changes, but none had a change at position 618, which
may be the critical alteration resulting in the MIC changes seen
in group 3. Altered MurM protein was present in all but two
strains with elevated sulopenem MICs (1 lg/ml) and had the
same set of alterations in PBP2B and PBP1B.
Conclusions: Alterations in MurM seemed to be associated
with elevated sulopenem MICs. The 10 amino acid changes in
the 590–640 region of PBP2B surrounding the KTG motif were
associated with strains with higher AMOX than PENMICs, with
618AﬁG likely to be the key substitution.
P1268
Molecular epidemiology of extended-spectrum
beta-lactamase-producing Klebsiella pneumoniae
and Serratia marcescens in a neonatal intensive
care unit
V. Crivaro, M. Bagattini, A. Di Popolo, F. Gentile, M.F. Salza,
F. Rossano, P. Villari, M. Triassi, R. Zarrilli (Naples, Campobasso,
Rome, IT)
Objectives: To investigate the molecular epidemiology of
extended-spectrum beta-lactamase (ESBL)-producing Klebsiella
pneumoniae and Serratia marcescens in the neonatal intensive care
unit (NICU) of a university hospital in Italy.
Methods: Antibiotic susceptibility was evaluated by disc diffu-
sion and E-test. ESBLs were identiﬁed by isoelectric focusing,
PCR and DNA sequencing analysis. Genotyping was performed
by pulsed- ﬁeld gel electrophoresis (PFGE) and dendrogram
analysis. Beta-lactamase gene transfer was performed by broth
mating.
Results: The molecular epidemiology of ESBL-producing K.
pneumoniae and S. marcescens was studied in the neonatal
intensive care unit of University ‘‘Federico II’’ of Naples, Italy
from September 2002 to September 2005. During the study
period, ESBL-producing K. pneumoniae and ESBL-producing S.
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marcescens were responsible for 23 infections (15.6%) and 290
colonizations (37.4%), and 6 infections (4.1%) and 60 (7.7%)
colonizations, respectively. The outbreak period began in
September 2002 for ESBL-producing K. pneumoniae and in May
2004 for ESBL-producing S. marcescens. Molecular typing iden-
tiﬁed two distinct PFGE patterns for ESBL-producing K. pneu-
moniae isolates, one major PFGE pattern and two subtypes for
ESBL-producing S. marcescens. The two K. pneumoniae epidemic
clones showed an identical antibiotype, characterized by resist-
ance to penicillins, monobactams, third generation cephems,
kanamicin, netilmicin and gentamicin. S. marcescens strains of
the major PFGE type and of the two subtypes were all resistant
to penicillins, monobactams, third and fourth generation cep-
hems, kanamicin, netilmicin and gentamicin. Molecular analysis
of beta-lactamase genes identiﬁed blaTEM-1 in chromosomal
and plasmid DNA and blaSHV-12 in plasmid DNA from K.
pneumoniae strains of both PFGE types. All S. marcescens
epidemic strains showed ampC in chromosomal DNA,
blaTEM-1 in chromosomal and plasmid DNA and blaSHV-12
in plasmid DNA. Conjugation experiments demonstrated that
resistance to third generation cephems, along with blaTEM-1
and blaSHV-12, was transferred from all K. pneumoniae and S.
marcescens epidemic strains to a susceptible E. coli host at a
frequency of about 1 · 10)6 CFU/recipient cells.
Conclusions: The conjugal transfer of blaSHV-12 ESBL genewas
responsible for the selectionofESBL-producingK. pneumoniae and
S. marcescens epidemic clones in the NICU of our university
hospital.
P1269
Epidemiology of Haemophilus inﬂuenzae strains
collected in 2004 in France and in vitro
assessment of their susceptibility to beta-lactams
H. Dabernat, G. Faucon, M. Seguy, C. Delmas (Toulouse, FR)
Objectives: The objective of this study was to describe the
epidemiology of H. inﬂuenzae strains collected in 2004 at the
National Reference Center and to evaluate the activity of
b-lactam antibiotics
Methods: Demographic characteristics and clinical specimens,
capsular serotyping by slide agglutination with speciﬁc antisera,
b-lactamase (Bla+) by a chromogenic cephalosporin test (Nitr-
oceﬁn) and MICs of amoxicillin (AMX), co-amoxiclav (AMC),
cefpodoxime (CPD), cefaclor (CEC), cefuroxime (CXM), and
ce´fotaxime (CTX) by agar dilution method on Haemophilus Test
Medium were determined for each strain.
Results: 808 strains of H. inﬂuenzae were isolated: 41.8% from
bronchial secretions (BS), 16.2% from conjunctivitis, 6.6% from
otitis media (OM), 4.2% from CSF and 8.6% from blood cultures.
95.6% of strains were not capsulated and 4.4%were of serotype b,
e or f. 26.3% of strainswere bla+producers (TEM-1 type), 31.4% of
them being isolated from OM and 24.7% from BS. 185 isolates
(22.8% of total strains) had reduced susceptibility to b-lactams
due to modiﬁcation of PBP 3A/3B (low BLNAR) associated or
not with bla+. The MICs 50/90 (mg/L) were as follow: overall
strains (n = 808): AMX 0.5/16 mg/L; AMC 0.25/2 mg/L; CEC
2/4 mg/L; CXM 1/2 mg/L; CPD 0.06/0.25 mg/L; CTX 0.015/
0.06 mg/L. Susceptible (n = 471): AMX 0.25/0.5 mg/L; AMC
0.25/0.5 mg/L; CEC 2/4 mg/L; CXM 0.5/1 mg/L; CPD 0.06/
0.12 mg/L; CTX 0.015/0.03 mg/L. Bla+ (n = 152): AMX 8/
16 mg/L; AMC 0.25/0.50 mg/L; CEC 2/4 mg/L; CXM 1/
2 mg/L; CPD 0.06/0.12 mg/L; CTX 0.015/0.03 mg/L. Low
BLNAR Bla+ n = 62): AMX 16/>16 mg/L; AMC 1/2 mg/L;
CEC 4/8 mg/L; CXM 2/4 mg/L; CPD 0.25/0.25 mg/L; CTX
0.03/0.06 mg/L. Low BLNAR (n = 123): AMX 1/2 mg/L; AMC
1/2 mg/L; CEC 4/8 mg/L; CXM 2/4 mg/L; 1CPD 0.25/
0.25 mg/L; CTX 0.03/0.06 mg/L.
Conclusions: Theses results show that both bla+ and modiﬁca-
tions of PBP are widespread among H. inﬂuenzae strains isolated
in France. CTX, and CPD remain the most active compounds
against H. inﬂuenzae, whatever the resistance mechanisms.
P1270
Overdetection of imipenem resistance by VITEK
2 in blaVIM 12 producing Klebsiella pneumoniae
with E-test low level carbapenem MICs
D. Tokatlidou, Z. Afkou, C. Papadopoulou, S. Pournaras, D.
Soﬁanou (Thessaloniki, Larissa, GR)
The clinical signiﬁcance of the carbapenem-hydrolysing metallo-
b-lactamases (MBLs) is increasing. VIM-type MBLs are more
common in non-fermenting gram negative bacteria. We describe
8 blaVIM-carrying Klebsiella pneumoniae isolates referred to as
resistant to imipenem by Vitek 2 automated system (bioMerieux,
france), and characterized as susceptible to carbapenems by E-
test, according to the NCCLS breakpoints.
Methods: A total of 8 K. pneumoniae isolates recovered from
blood cultures (2), from urine (1), from wound (1), from
bronchial secretions (2), from sputum (1) and from drainage
ﬂuid (1). All isolates were identiﬁed and characterized as
imipenem resistant by Vitek 2 automated system (bioMerieux,
france). MICs of imipenem (IMP) and meropenem (MER) were
determined by E-test. Susceptibility testing to other antimicro-
bial agents was conﬁrmed by disk diffusion method. The
isolates were tested for production of metallo-beta-lactamase
(MBL) by the IMP-EDTA double disk synergy test. MBL genes
were detected by PCR, using VIM primers, and conﬁrmed by
DNA sequencing.
Results: The MICs of IMP and MER ranged from 1 lg/ml to
4 lg/ml and from 0.5 lg/ml to 2 lg/ml respectively by E-test
and determine susceptibility to imipenem and meropenem. By
Vitek 2 six isolates were characterized as intermediate to
imipenem with MICs 8 lg/ml. The remaining two isolates
were characterized as resistant with MICs > 16 lg/ml. The
strains were resistant or intermediate to aztreonam and resistant
to cefepime, ciproﬂoxacin, 3rd generation cephalosporins, ami-
kacin and gentamicin. All strains exhibited synergy with EDTA
in the IMP-EDTA double disk synergy test. The PCR for blaVIM
was repeatedly positive using VIM primers and DNA sequen-
cing conﬁrmed blaVIM-12 carriage by all isolates.
Conclusions: These results conﬁrm the overdetection of carbape-
nemresistancebyanautomatedsystem.Thediscrepanciesbetween
testing methods pose difﬁculties in the characterization of the
isolates as susceptible or resistant to carbapenems and may have
implications for the management of infections caused by them.
P1271
Viridans group streptococci in blood culture
isolates, antibiotic susceptibility and
identiﬁcation of resistance genes
K. Westling, I. Julander, P. Ljungman, S. Jalal, C.E. Nord,
B. Wretlind (Stockholm, SE)
Objectives: Viridans group streptococci (VGS) cause severe
infections, in immunocompromised patients antibiotic resistance
is reported.
Methods: Patients with VGS isolated in blood cultures from
four clinics 1998–2003, Karolinska University Hospital were
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included in this study. Clinical data as septicaemia, haemato-
logical diseases, infective endocarditis (using Dukes criteria)
were registered. Identiﬁcation of the VGS species by using
RNase P RNA gene (rnpB). Antibiotic susceptibility testing
against ciproﬂoxacin, clindamycin, dalbavancin, erythromycin,
linezolid, penicillin, tigecycline, TMP-SMX, vancomycin and
daptomycin was performed using agar dilution method, refer-
ence values according to NCCLS 2003. Identiﬁcation of ermB
and mefA genes was performed in strains with a reduced
susceptibility to erythromycin (MIC ‡ 0.5 lg/ml).
Results: Antibiotic susceptibility testing results from 129 VGS
blood cultures isolates (except for daptomycin). A reduced
susceptibility to penicillin was documented in 18%
(MIC ‡ 0.25 lg/ml) of the isolates while resistance to penicillin
(MIC ‡ 4.0 lg/ml) was found in 4%, all patients with haema-
tological diseases. 6% of the strains from patients with deﬁnite
or possible endocarditis had a reduced susceptibility to penicil-
lin. A reduced susceptibility to erythromycin was found in 25/
129 (19%) of the isolates, nearly all patients with haematological
diseases. ErmB and mef A gene were identiﬁed in 48% (12/25)
and 80% (20/25) of the isolates respectively. The strains
sequenced as Streptococcus mitis had a higher degree of non-
susceptibility to penicillin and erythromycin. All the isolates
were susceptible to vancomycin and linezolid.
Conclusion: Penicillin and erythromycin resistance in VGS is
primarily a problem in neutropenic haematological patients but
a reduced susceptibility to penicillin exists in immunocompetent
patients.
P1272
Evidence of an efﬂux pump mediating a mar
phenotype in two ciproﬂoxacin-resistant marR-
mutant Escherichia coli isolates
F. Fendukly, G. Kronvall, K. Dornbusch (Stockholm, SE)
Objectives: The marR gene of the multiple antibiotic resistance
(mar) locus was sequenced for the detection of mutations in 25
ciproﬂoxacin-resistant Escherichia coli isolates from septicaemia
patients admitted to the Karolinska University Hospital, Stock-
holm, Sweden. All isolates were previously shown to harbour at
least one mutation involving the quinolone resistance-determin-
ing region (QRDR) of the gyrA gene, while the more resistant
isolates harboured additional mutations involving the parC
gene. The marR mutants detected were further analysed to
assess a possible role of such mutations in the enhancement of
quinolone resistance.
Methods: DNA ampliﬁcation and nucleotide sequencing of the
complete marR gene was performed using oligonucleotide
primers designed according to the published E. coli K12
genome (accession number NC 000913). Testing for organic
solvent tolerance was a modiﬁcation of the agar overlay method
described by Oethinger M, Kern WV, Goldman JD, Levy SB.
Association of organic solvent tolerance and ﬂuoroquinolone
resistance in clinical isolates of Escherichia coli. J Antimicrob
Chemother 1998; 41(1):111–114. Time-concentration studies of
the two marR mutants and three other non-mutant controls in
ciproﬂoxacin with and without the efﬂux pump inhibitor
carbonyl cyanide m-chlorophenyl-hydrazone (CCCP) were
then carried out to determine the possible involvement of an
efﬂux pump in the quinolone resistance phenotype of the marR
mutant isolates.
Results: A single point mutation involving the marR gene was
detected in each of two isolates, namely a Val96ﬁIle and a
Lys43ﬁArg. These two isolates were shown to be resistant to
tetracycline and chloramphenicol in addition to ciproﬂoxacin
and were also tolerant to the organic solvents hexane and
cyclohexane. They lost their tolerance to cyclohexane when
treated with the CCCP. Time concentration curve analysis of
these two isolates demonstrated a more than 2 log reduction of
bacterial counts after 8 hours of growth in ciproﬂoxacin and
CCCP as compared to their growth in ciproﬂoxacin alone. This
ﬁnding could not be conﬁrmed in the reference strain E. coli
ATCC 25922, or in three other non-marR mutant isolates
exhibiting tolerance to cyclohexane which was not reversible
by pretreatment with CCCP.
Conclusion: We propose that the two marR mutations observed
in the two E. coli isolates may play a role in the enhancement of
quinolone resistance.
P1273
First report of a linkage between tet(M) and
erm(B) genes in Clostridium difﬁcile clinical
isolates
P. Spigaglia, F. Barbanti, P. Mastrantonio (Rome, IT)
Objectives: To investigate the possible linkage of tetracycline
and erythromycin resistance determinants in a large number of
C. difﬁcile clinical isolates positive for both tet(M) and erm(B)
genes
Methods: A sample of 100 C. difﬁcile strains isolated from 1986
to 2002 was analysed by PCR assays to detect tet(M) and erm(B)
genes. Forty-four isolates, positive for these genes, were exam-
ined for int and tndX, markers for the Tn916 and the Tn5397-like
elements, respectively. Tetracycline, erythromycin and clinda-
mycin MIC values were determined by the E-test method and
the isolates were typed by PCR-ribotyping. Molecular analysis
of the tetracycline and erythromycin resistance elements was
performed by hybridization, PCR, PFGE assays and sequencing.
Tetracycline and erythromycin resistance transfer was evaluated
by ﬁlter mating experiments using C. difﬁcile strain p881R as
recipient.
Results: Nineteen isolates were positive for int and 25 for tndX.
An increasing presence of Tn916-like elements was observed in
recent C. difﬁcile isolates. Forty-two per cent of the isolates
positive for int were isolated in the early 2000s and belonged to
PCR-ribotype R, predominant during the last decade in our
Country. The erm(B) gene was detected in two isolates positive
for int and in all those positive for tndX. All strains were
naturally resistant to tetracycline, erythromycin and clindamy-
cin, except one int positive isolate that resulted inducibly
resistant to tetracycline. Both the int/erm(B) positive isolates
showed two Tn916-like elements, whereas all the tndX positive
showed only one Tn5397-like element. erm(B) and tet(M) were
located in proximity only in one of the two Tn916-like elements
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harboured by the ﬁrst two isolates, in the other isolates the genes
were located in different elements. Sequence analysis indicate
that the element carrying tet(M) and erm(B) has presumably
arisen from a complex series of genetic events that combined
DNA fragments from plasmids and transposons of different
origin. This element seems to be not conjugative, as observed for
other composite elements.
Conclusion: A genetic linkage between a tet(M) and a erm(B)
gene was demonstrated for the ﬁrst time in C. difﬁcile, indicating
that this bacterium has acquired the ability to cluster antibiotic
resistance genes and that Tn916-like elements are probably
implicated in this mechanism.
P1274
Dissemination of 16S rRNA methylase in AmpC
producing Enterobacter cloacae, Citrobacter
freundii and Serratia marcescens in Korea
S. Lee, Y-J. Park, J-K. Yu, K. Lee, Y. Arakawa (Seoul, KR; Tokyo,
JP)
Objectives: A new type of mechanisms, methylation of 16S
rRNA, conferred by plasmid, has been reported in a few clinical
isolates of gram-negative bacteria and it can confer high-level
broad-range resistance to aminoglycosides except neomycin and
streptomycin in gram-negative human pathogens. In this study,
we investigated (1) the prevalence of high-level aminoglycoside
resistance and plasmid-mediated 16S rRNA methylase in Ente-
robacter cloacae, Citrobacter freundii and Serratia marcescens in
Korea, and (2) its association with ESBLs.
Methods: A total of 413 consecutive, non-duplicate isolates,
including E. cloacae (158), C. freundii (126), and S. marcescens
(129), collected from clinical specimens at 11 clinical laborator-
ies, were used in this study. For isolates showing high-level
resistance (MICs of 512 lg/ml) to amikacin or arbekacin, a
search for the 16S rRNA methylase genes (armA, rmtA, and
rmtB) was performed by PCR ampliﬁcation with the following
sets of primers: rmtA, rmtB, armA. For detection of extended-
spectrum b-lactamase genes, the pairs of primers speciﬁc for
blaTEM, blaSHV, bla CTX-M-1, M-2, M-9, and blaPER-1 were
used.
Results: Of the total of 413 isolates, 49 were highly resistant to
both amikacin and arbekacin. One E. cloacae isolate was highly
resistant to arbekacin but susceptible to amikacin (MIC of
16 lg/ml). The prevalence of the high level resistance to
amikacin or arbekacin was 9.5% (15/158), 10.3% (13/126), and
17.1% (22/129) in E. cloacae, C. freundii and S. marcescens,
respectively and almost all of them (14 E. cloacae, 12 C. freundii
and 21 S. marcescens isolates) harboured armA. In E. cloacae and
C. freundii, all but one of the armA producers also harboured
ESBLs (13 out of 14 E. cloacae, 11 out of 12 C. freundii) but in S.
marcescens, 14 out of 21 armA-producing S. marcescens harboured
ESBLs. The most common type of ESBL was CTX-M (Table 1).
One C. freundii isolate harboured rmtB gene and it also
harboured CTX-M type ESBL. None harboured rmtA gene.
Conclusion: The prevalence of high-level aminoglycoside
resistance was quite high (12.1%), and it was highest in S.
marcescens and followed by C. freundii and E. cloacae. Co-
existence of ESBL was higher in E. cloacae (92.9%) and C. freundii
(81.8%) than in S. marcescens (71.4%). CTX-M type was the most
common. One C. freundii harboured rmtB gene and it also
harboured CTX-M gene.
P1275
Resistance mechanisms in S. pneumoniae in the
Netherlands
J.W. Mouton, D. Klomberg, S. Meijers, C. Klaassen (Nijmegen,
NL)
Background: In 1999, 2001–2002 and 2003 we performed sur-
veys in The Netherlands (NL) to monitor antimicrobial resist-
ance in S. pneumoniae (SP). We found increasing prevalence of
macrolide resistance but virtually no resistance to quinolones.
We here report the survey in 2005; we also determined the
resistance mechanisms to macrolide and quinolone resistance, if
present. In particular, we looked at the number of non-wild-type
at the right tail of the MIC distribution of levoﬂoxacin (Le).
Methods: 34 laboratories equally distributed throughout NL
participated in the study. Each lab was asked to collect up to 25
strains of consecutive samples. Only blood or sputum (including
lavage) was allowed. Strains were identiﬁed by participating
laboratories using their own standard identiﬁcation technique.
MIC’s were determined using the E-test on site for (Le),
Moxiﬂoxacin (Mo), Penicillin (Pe), Amoxicillin, Clarithromycin
(Cl), Azithromycin, Cefotaxim (Ce), Cotrimozazole and Doxyc-
yclin; control ATCC strains were included. Afterwards, strains
were collected by the central lab for further analysis. Identiﬁ-
cation conﬁrmation of SP was performed by bile solubility
testing and also by LytA PCR for resistant strains. Resistance
genes were identiﬁed using validated PCR-based methods for
all strains with a MIC of >1 mg/L for Le, >0.5 mg/L for Cl and
>0.06 for Pe.
Results: Overall, 12.7% of strains were Cl R, 0.5% Le R and 5.9%
Pe I or R. 5.2% of strains had a MIC of 1.5 or 2 mg/L for Le. Of
these, 32% were non SP (LytA-), comparable to results from
earlier surveys in NL. Of the remaining strains, 25% had a
known ParC or GyrA mutation, no mutations of ParE or GyrB
were found. Of the Cl R strains, 41% was LytA-. Of the LytA +
strains, 43% possessed the ErmB gene, 30% MefA, 5% MefE, 5%
a 23S mutation, one strain a L4 mutation and no strains with
ErmTR or L22 mutation. No mechanism was found for 6 strains.
Interestingly, one Pe I strain was ErmB positive but susceptible
to Cl. All strains were Ce susceptible.
Conclusions: Routine identiﬁcation of true Sp remains prob-
lematic. Macrolide resistance in Pneumococci is still increasing
in The Netherlands and approaches values that may prohibit
blind prescribing. Analysis of less susceptible Le strains
indicate that a ParC or GyrA mutation is present in a
signiﬁcant portion at the tail of the wildtype distribution.
Given the PkPd characteristics, Le treatment may pose a risk
for selection of double mutants.
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P1276
Fluoroquinolone resistance in Streptococcus
pneumoniae: screening for ﬁrst-step mutations
C. Ardanuy, L. Balsalobre, A.G. de la Campa, L. Calatayud,
E. Bouza, R. Martı´n, R. Pallares, J. Lin˜ares for the Spanish
Pneumococcal Infection Study Network
Objective: Fluoroquinolone resistance (FQ-R) in S. pneumoniae
(Spn) occurs mainly by mutations at the QRDRs of the DNA
gyrase (gyrA and gyrB), and DNA topoisomerase IV (parC and
parE) target enzymes. The aims of this study were: (1) To
characterize 14 (3.9%) ciproﬂoxacin-R strains (CipR,
MIC ‡ 4 lg/ml) obtained among 360 strains consecutively
isolated in 2004 in a Spanish Multicenter Study. (2) To analyse
the presence of ﬁrst-step mutations among 157 Spn strains with
Cip MICs of 1–2 lg/ml.
Methods: Using a PCR-RFLP method, 157 Spn strains (all 107
strains with Cip MIC of 2 lg/ml and 50 selected strains with
Cip MIC of 1 lg/ml) were screened for mutations known to
confer resistance to FQ: ParC (S79, D83), ParE (D435) and GyrA
(S81, E85). The QRDRs of 14 the CipR strains and of 8 strains
with Cip MICs of 1–2 lg/ml with presumed mutations as
deduced by the PCR-RFLP method were sequenced. PFGE
(SmaI) were performed in all CipR strains.
Results: No ParC or ParE mutations involved in CipR were
found by the PCR-RFLP method among the 50 strains with Cip
MIC of 1 lg/ml. Although the PCR-RFLP method predicted that
seven (7.5%) of 93 strains with Cip MIC of 2 lg/ml had ParC
D83 mutation QRDR sequencing revealed a GAT to GAC
polymorphism at D83. Only 1 of 93 strains (1%) with Cip MIC of
2 lg/ml had a ParC mutation (S79F) involved in FQ-R. None of
these 93 strains had ParE D435 mutations. The 14 CipR strains (6
with MIC of 4–8 lg/ml and 8 with MIC of 16–64 lg/ml) were
isolated from adult patients, and showed 14 different PFGE
patterns. Among the 6 strains with low level of CipR, 3 had a
single ParC mutation (S79F) and 3 had not mutations (suggest-
ing an efﬂux mechanism). The 8 strains with high-level R
showed double mutations at ParC (S79 or D83) and at GyrA
(S81).
Conclusions: The prevalence of FQ-R in Spn in Spain was 3.9%
and no clonal dissemination of these strains was observed. No
mutations were found among strains with Cip MIC of 1 lg/ml.
The frequency of ﬁrst-step mutations among Spn with Cip MIC
of 2 lg/ml was low (1%). The PCR-RFLP method could be
useful for screening of ﬁrst step mutations, but the QRDRs
sequencing of positive strains is necessary in order to discharge
the presence of polymorphisms.
P1277
Telithromycin resistance in pneumococci
M. Rantala, P. Huovinen, J. Jalava and Finnish Study Group for
Antimicrobial Resistance
Objective of this study was to test the telithromycin (TEL)
susceptibility of pneumococci with known macrolide resistance
determinant by disk diffusion method. Susceptibility testing to
TEL of 196 erythromycin resistant (ERY MIC ‡ 0.5 mcg/ml)
pneumococci with known macrolide resistance determinant [88
erm(B), 4 erm(B)+mef(E), 104 with mef(A/E)] and 47 ERY
susceptible pneumococci was performed by disk diffusion
technique according to CLSI guidelines. If growth was detected
inside the inhibition zone, one colony was picked and suscep-
tibility testing for zone isolate (N = 26) was performed. Whole
erm(B) gene with its leader peptide, and genes coding L4 and
L22 ribosomal proteins were sequenced, and mutations confer-
ring macrolide resistance were screened by pyrosequencing at
the positions of 2058–2059 and 2611 of domain V, and loop 35 of
domain II of 23S rRNA of 3 TEL resistant isolates and their
respective zone isolates. In addition, whole 23S rRNA gene was
sequenced from one TEL R isolate and its respective zone
isolate. Twenty four erm(B) isolates, and two erm(B)+mef(E)
isolates showed heterogenous resistance to TEL that means that
one to several colonies grew inside the inhibition zone. In
addition, two mef(A/E) positive isolates were grouped to
intermediate category. The rest of the isolates carrying macro-
lide resistance determinant were susceptible to TEL, as well as
47 macrolide susceptible isolates. Of 26 zone isolates 23 were
resistant to TEL (<15 mm), 2 were intermediate (16–18 mm) and
1 was susceptible (19 mm). Majority of the zone isolates showed
high level resistance to TEL without any detectable inhibition
zones. Nucleotide sequences of genes of TEL R isolates and their
respective zone isolates were identical. No mutations known to
confer macrolide resistance were detected in these isolates. 23S
rRNA gene was identical between TEL R and zone isolate and
was correspondent with wild type sequence. In conclusion, 14%
of macrolide resistant pneumococci showed resistance to TEL,
and most often the resistance was manifested as heterogenous
growth pattern around the TEL disk. The results indicate that
TEL resistance may be more frequent than previously reported.
Thus, we suggest that susceptibility testing to TEL should
routinely be performed with pneumococci known to be resistant
to macrolides. TEL resistance is associated to erm(B), but the
exact mechanism behind high level TEL resistance is not known.
P1278
Theoretical framework on the uses of
standardised antibiotic phenotype and pattern
indexes
I.C. Acuner (Samsun, TR)
Objectives: Acuner et al. have deﬁned standard antibiotic
phenotype and pattern indexes that are suitable for phenotype
and pattern cataloguing using information derivable from prob-
ability distributions in event space. Here, I explore the theoretical
framework of the indexes, compare their advantages to the
possible alternatives in numerical taxonomy, and discuss the
potential uses, especially in antimicrobial resistance surveillance.
Methods: The standard antibiotic phenotype index (SAPI) has
been deﬁned as: I = cv/p where; c = observed value of the
different categorical case probabilities, v = total number of
tested variables, p = speciﬁc position (location) of the tested
variable in event space. I ¼Pvi¼1ðcv  piÞ. The index is aimed at
including and representing the information derivable from all of
these deﬁned dimensions that forms the event space, such that
none of the index values obtained would match with other
values. Wherever the derivable information is categorical, it has
been digitized for use in the index. To deﬁne the dimensions
that constructs the event space and use the index for the
purposes of standardized antibiotic susceptibility phenotype
(pattern) surveillance of bacteria; a. probable categorical case
results; resistant, intermediate and susceptible have been digit-
ized as 1, 2 and 3, respectively, and used as probable c values, b.
total number of the tested antibiotics has been used as v, c.
speciﬁc positions (locations) of the tested antibiotics have been
digitized as 1, 2,…, N in order. An example of a theoretical
bacterial taxon at a speciﬁc taxon level (genus, species, subspe-
cies) has been considered to be tested against 21 different
antibiotics, and the index values have been calculated. The index
values obtained for each of the sequential observable pattern
probabilities are digitized as standard pattern index (SPI) values
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in the same order as 1, 2,…., n. The numerical taxonomy
alternative on the base-3 system has been compared.
Results: The index value for the theoretically most sensitive
phenotype (i.e. susceptibility results of all tested antibiotics are
sensitive) is I = 3.645358705; SPI = 1. The index value for the
theoretically most resistant phenotype is I = 38131739603;
SPI = n.
Conclusion: It has been concluded that SAPI and SPI may be
useful in phenotype (including MIC) and pattern cataloguing for
the purposes of resistance surveillance besides being a potential
tool for the investigation of population dynamics of bacteria.
P1279
Trends in antibacterial resistance of Streptococcus
pneumoniae: PROTEKT Global Years 1–5
D.J. Farrell, R. Canton, W. Hryniewicz (London, UK; Madrid, ES;
Warsaw, PL)
Objectives: Data from Year (Y) 1–5 of PROTEKT (1999–2000 to
2003–2004) were analysed to compare the in vitro activity of
telithromycin with that of other antibacterials against isolates of
Streptococcus pneumoniae (SP) from patients with community-
acquired respiratory tract infections.
Methods: In vitro antibacterial activity and susceptibilities of SP
isolates from patients with CAP, AECB, sinusitis, otitis media
and pharyngitis were determined at a central laboratory using
CLSI methodology and interpretive criteria. Macrolide resist-
ance genotypes were determined by PCR.
Results: For Years 1–5 a total of 3435, 4256, 6320, 6739, 7083 (Y1,
Y2, Y3, Y4, Y5) SP isolates were collected from 166 centres in 42
countries. Resistance rates (%) by year were: erythromycin
(ERY), 31.4, 32.7, 36.9, 36.4, 37.2; penicillin (PEN), 21.7, 18.0, 24.0,
22.3, 23.9. The prevalence of multidrug resistance (MDR;
resistance to ‡2 antibacterial classes) by year was 36.0%,
34.9%, 41.4%, 39.7%, 40.0% of isolates. Most ERY-resistant SP
(ERSP) exhibited the erm(B) genotype (57.0, 63.5, 57.9, 56.9,
55.0% of isolates). The prevalence of the mef(A) genotype
decreased slightly over the ﬁrst two study years (34.3%, 30.1%,
30.4%, 30.3%, 30.6%), while the proportion of erm(B)+mef(A)
isolates (MIC90 > 256 mg/L) almost doubled (6.7, 5.0, 10.2, 10.5,
12.0%) over the ﬁve study years. The vast majority of
erm(B)+mef(A) isolates were MDR [99.4% (955/961)]. Telithro-
mycin retained potent in vitro activity against MDRSP, with
99.5% of such isolates fully susceptible to this antibacterial.
Telithromycin in vitro activity and susceptibility data are shown
below.
Conclusions: PEN and ERY resistance remained high in isolates
of SP over the 5 study years. Telithromycin demonstrated potent
in vitro activity against SP, including MDRSP isolates with the
increasingly prevalent erm(B)+mef(A) genotype.
P1280
Activity of telithromycin against Streptococcus
pneumoniae isolates resistant to other
antibacterials: PROTEKT Year 5
G.C. Schito, D.J. Farrell, J.A. Ramirez (Genoa, IT; London, UK;
Louisville, US)
Objectives: Continual monitoring of antibacterial resistance in
common respiratory pathogens such as Streptococcus pneumoniae
(SP) is essential to guide optimal antibacterial therapy for
community-acquired respiratory tract infections (CARTIs).
PROTEKT is a global, longitudinal surveillance study of anti-
bacterial resistance among key respiratory tract pathogens,
which was initiated in 1999. Data from PROTEKT Year 5
(2003–2004) were analysed to assess the susceptibility of SP
isolates to the ketolide telithromycin and a range of other
antibacterials.
Methods: Isolates were collected at 123 centres in 39 countries
from patients with CARTIs. Antibacterial minimum inhibitory
concentrations (MICs) were determined centrally using CLSI
methodology. CLSI interpretive breakpoints were used to
determine susceptibility (S).
Results: A total of 7083 SP isolates were collected in Year 5.
Antibacterial activities [MIC50 (mg/L)/MIC90 (mg/L)/S (%)]
were: amoxicillin-clavulanate (AMC), 0.03/2/92.6; azithromycin
(AZI), 0.12/>128/62.7; cefuroxime (CEF), 0.06/8/68.1; clarith-
romycin (CLA), 0.06/>64/62.4; penicillin (PEN), 0.03/4/62.6;
those for telithromycin are shown below. Susceptibility rates
varied markedly between countries [e.g. AZI: 2.4% (Taiwan) to
100% (Colombia); PEN: 18.3% (Taiwan) to 96.6% (Netherlands)].
Of the 1696 (23.9%) PEN-resistant SP (PRSP) isolates, 1174
(69.2%), 1317 (77.7%), 1318 (77.7%) and 1695 (99.9%) were
resistant to AMC, AZI, CLA and CEF, respectively. Of the 2638
(37.2%) erythromycin (ERY)-resistant SP (ERSP) isolates, 1325
(50.2%) were resistant and 549 (20.8%) were intermediately
susceptible to PEN, 222 (8.4%) were resistant to AMC and 1587
(60.2%) were resistant to CEF. Overall, 18.7% (1325/7083) of
isolates were co-resistant to PEN and ERY (PRSP + ERSP).
Conclusions: Reduced susceptibility to beta-lactams and/or
macrolides remains common worldwide among SP isolates
collected from CARTI patients. Telithromycin continues to
demonstrate strong in vitro activity against this common
respiratory pathogen, including strains resistant to other anti-
bacterials.
P1281
Evaluation of the VITEK 2 AST-N 041 card for
detection of extended-spectrum beta-lactamase
producing E. coli and Klebsiella pneumoniae
S.H. Koo, J.S. Goh, J.U. Kang, K.C. Kwon, J.W. Park (Daejeon,
KR)
Objective: Increasing incidence of ESBL producing Gram-neg-
ative pathogens requires proper and rapid detection of resist-
ance phenotype. The VITEK 2 AST-N 041 card (bioMerieux) is
new and automated test for ESBL detection. The aim of this trial
was to evaluate and compare equivalency between the bio-
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Merieux VITEK 2 AST-N 041 card and conﬁrmatory NCCLs
methods for detection of ESBL producing E coli and Klebsiella
pneumoniae.
Methods: A total of 178 clinically signiﬁcant Gram negative
bacterial pathogens (69 Klebsiella and 118 E coli), which were
isolated from various material (blood, urine, stool, wounds)
were included in this study. Detection for ESBL-producing
strains was performed by VITEK 2 AST-N 041 card and a
modiﬁed double disk diffusion test (MDDT) according to the
latest NCCLs documents. For the quality control, ATCC 700603
for K pneumoniae and ATCC 25922 for E coli were used as
reference strains.
Results: A high correlation was found between the results
obtained by the VITEK 2 AST-N 041 card and by the NCCLS
reference methods. The overall concordant rate between the two
tests was 98.4%, the sensitivity was 96.6%, and the speciﬁcity
was 98.7%. For E coli, the concordant rate of detection was
98.3%, sensitivity was 100% and speciﬁcity was 98.1%. The
results for K. pneumoniae were 98.6%, 93.3% and 100% respect-
ively.
Conclusions: The bioMerieux VITEK 2 AST-N 041 card repre-
sent an accurate and acceptable means for detection of ESBL
producing gram-negative pathogens. It is very simple and fast
for detection of ESBL and can be used as an alternative to disk
diffusion test which is time consuming and labour-intensive.
P1282
Antibiotic susceptibility among invasive and
non-invasive Streptococcus pyogenes isolates in
Sweden; 2002–2004
B. Luca, J. Darenberg, B. Henriques Normark,
A. Norrby-Teglund, C. Schalen, A. Jasir (Lund, Stockholm, Solna,
SE)
Objectives: Since Streptococcus pyogenes is still susceptible to
betalactams, but for other antibiotics highly variable resistance
A major objective was to study antibiotic susceptibility of
invasive and none invasive isolates and type distribution of
resistant strains in Sweden.
Methods: During active surveillance (2002–04) of invasive
group A streptococcal infections in Sweden, 746 invasive isolates
were collected from all microbiological laboratories (36) in the
country. During the same period, 774 non-invasive skin- or throat
control isolates were collected at 6 of the laboratories. In vitro
susceptibility to antibiotics, MICs of resistant strains, T and emm
typing and resistance gene detection were performed according
to previously established methods.
Results: Erythromycin resistance was uncommon (0.2%),
whereas an overall high rate of tetracycline resistance was
found (25–30%). MIC for tetracycline resistant strains varied
between 8 and 64 mg/L with a clustering at 24 mg/L. The
tetracycline resistant strains belonged to more than 10 different
T types, the majority being of T-type 3/13/B3264, 28, and 13/28
sub-divided into two large clusters of emm types 81 and 77. All
tetracycline resistant isolates of emm type 81 carried tetM but
among emm 77 both tetM and tetO were detected. Clonal
relationships within sub-groups of isolates were investigated
with pulse ﬁeld gel electrophoresis (PFGE) and multi locus
sequence typing (MLST).
Conclusion: Tetracycline is used in the treatment of chlamydial
and mycoplasmal infections rather than streptococcal infections
in Sweden; hence the level of tetracycline resistance among S.
pyogenes clinical isolates, 25–30%, appeared comparatively high.
To account for resistance development, the role of commensals
bacteria, horizontal gene transfer from other Streptococci espe-
cially with regard to increasing veterinary usage of tetracycline
have to be considered.
P1283
Evaluation of cefoxitin disk test in the detection
of methicillin-resistant blood CoNS clinical
isolates in a tertiary university department
R. Vorou, E. Giannitsioti, I. Galani, E. Koratzanis,
H. Giamarellou (Athens, GR)
Objectives: Accurate phenotypical detection of methicillin-
resistant (MR) in Staphylococci is difﬁcult using standard media
due to heterogeneous expression of MR in many strains.
Detection of mecA gene is the gold standard for that purpose,
however an equally reliable routine test has not been currently
available especially for coagulase negative Staphylococci (CoNS)
which usually are involved in serious infections like endocar-
ditis and device associated infections. The present study was
conducted to evaluate the role of cefoxitin diffusion test in the
detection of MR CoNS.
Methods: All CoNs blood isolates that were collected during
the last 1 year in our tertiary hospital were evaluated by 3
methods in order to assess MR. (1) Cefoxitin disc diffusion test
(30 lg) was applied in Muller-Hinton agar and incubation lasted
for 24–36 hours in 37C. A cefoxitin zone <24 mm was
interpreted as MR for CoNS. MecA gene was detected by PCR
in all isolates. MecA1 (¢AAAATCGATGGTAAAGGTTGGC3¢)
and mecA2 (5¢AGTTCTGCAGTACCGGATTTGC3¢) primers
were used. Minimal inhibitory concentration (MIC) for oxacillin
was also performed according to the NCCLS standards
(Oxacillin MIC > 2 lg/l indicates MR).
Results: In 63 blood isolates (44 S. epidermidis and 19 CoNS,
non-epidermidis), MIC > 2 was found in 54 cases (85.7%). Both
cefoxitin disk and mec A gene assessed MR in 100% of strains.
Among the 17 isolates with MIC < 2 lg/l, only in one case of
oxacillin MIC = 0.5 lg/l, cefoxitin disk revealed resistance.
Conclusions: Cefoxitin disk could be a good alternative to
MIC oxacillin test for the detection of MR in clinical CoNS
isolates as it is also easier, faster and cheaper. However, a
larger number of observations could better conﬁrm this
statement for CoNs strains.
P1284
Quantitative antibiotic susceptibility of
Staphylococcus aureus strains isolated from blood
of septic patients with special attention to MRSA
F. Rozgonyi, N. Pesti, K. Kristo´f, H. Lagler, G. Kotola´csi,
E. Presterl, W. Graninger (Budapest, HU; Vienna, AT)
Objectives: Manifest bacteraemia and sepsis caused by S.
aureus are life threatening infections particularly if the pathogen
is MRSA. Their adequate treatment is of outmost importance.
The aims of this study were to determine quantitatively the
antibiotic sensitivity of 179 blood culture S. aureus strains and
compare the results according to MRSA vs MSSA.
Methods: S. aureus strains were isolated from patients admitted
to the Vienna University hospitals and identiﬁed by conven-
tional tests including rapid slide agglutination. The presence of
nucA gene was shown by PCR. Methicillin resistance was ﬁrst
detected with 1 lg oxacillin disc then conﬁrmed by amplifying
the mecA gene with PCR. Susceptibility to 10 antimicrobials was
determined with the broth microdilution method using
NCCLS/ICLS guidelines.
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Results: The mecA gene was present in 49 strains (27.4%). The
wast majority of MRSA expressed high level oxacillin resistance
(‡1024 mg/L), however a few strains was inhibited by as low as
2 mg/L oxacillin. Contrary, MBC for these strains proved to be
high indicating oxacillin tolerance. Both clindamycin and
clarithromycin were ineffective against MRSA (MIC ‡ 256 mg/
L). MSSA strains were highly sensitive to clarithromycin but not
to clindamycin. Most MRSA strains needed ‡16 mg/L ciproﬂ-
oxacin, ‡8 mg/L levoﬂoxacin and 4 mg/L moxiﬂoxacin to
inhibit growth, while MICs of them for most MSSA strains
were 0.5 mg/L. MICs of gentamicin were over 32 mg/L for
MRSA, while £2 mg/L inhibited the growth of most MSSA
strains. Amikacin was equally effective against MRSA and
MSSA ranging MICs 2–32 mg/L. Both MRSA and MSSA strains
were equally sensitive to vancomycin. MRSA needed teicopla-
nin MICs of 1–8 mg/L, while MSSA did only 0.5–2 mg/L to
inhibit growth.
Conclusions: Oxacillin tolerant S. aureus strains with low MIC
high MBC have appeared in the Vienna patients with bacteri-
aemia. For the treatment of MRSA sepsis, beside the glycopep-
tides, the new ﬂuoroquinolons and amikacin or their
combination should be considered.
Acknowledgement: Supported by O¨AAD-Te´T, grant no.: A-19/
02.
P1285
Antimicrobial resistance trends in invasive
strains of S. aureus, E. coli, Streptococcus
pneumoniae, and Enterococcus spp. in
Romania – a 4-year participation in the EARSS
I. Codita, M.C. Balotescu, A. Israil, M. Popa, D. Tatu-Chitoiu,
V. Ungureanu, M. Pana, M. Ghita (Bucharest, RO)
Objectives: (i) To collect comparable andvalidated antimicrobial
resistance data in Romania, following the EARSS protocols; (ii) to
analyse trends in Romania during the 2002–2005 interval; (iii) to
provide ofﬁcial national AMR data for policy decisions; (iv) to
provide information on relevant antimicrobial resistance; (v) to
encourage the implementation,maintenance and improvement of
national antimicrobial resistance surveillance programmes; and
(vi) to prepare and provide basic information for the Romanian
national laboratories to be used for participating in scientiﬁc
research programmes in Europe in the ﬁeld of antimicrobial
resistance.
Methods: 12–35 hospitals involved in the surveillance system
(2002–2005, respectively; 58% population coverage in 2005).
EARSS protocols used for collecting data and for laboratory
testing strategy. Disc diffusion testing performed following the
CLSI/NCCLS standards and MIC’s determined using E-test or
agar dilution methods. Since 2004, PCR for mecA introduced in
the National Antimicrobial Resistance Reference Laboratory.
Results: The total numbers of invasive strains completely
investigated were: 296 S. aureus (80/2002, 85/2003, 92/2004,
39/2005), 160 E. coli (25/2002, 46/2003, 41/2004, 48/2005), 55 S.
pneumoniae (10/2002, 22/2003, 11/2004, 12/2005), 37 E. faecalis/
faecium. The proportions of resistant strains were generally
increasing for MRSA (36.3/2002, 45.9/2003, 71.7/2004 and 61.5
for 2005), aminopenicillies resistant E. coli (50/2002, 69.6/2003,
78.6/2004, 76.9/2005), but showed irregular variations for
ﬂuoroquinolone resistant E. coli (20/2002, 14/2003, 17.1/2004,
4.2/2005) and PNSP (10/2002, 22.7/2003, 11.1/2004, 16.7/2005).
ESBL production varied between 21.7 (2004) and 15.1 (2005).
Rechecking MRSA strains using the cefoxitin disc and the PCR
for the mecA gene resulted in ﬁnding only 1 strain resistant
formerly reported as susceptible. Few strains of VRE were
reported.
Conclusions: Though the total number of strains is generally
low by comparison with other European countries participating
in the project, partially due to the comparatively low number of
blood cultures prescribed and analysed, we could conclude on
the general trends for the majority of important pathogenes.
There are generally high rates of resistance and the ESBL
production in E. coli strains is also high when compared to the
European median. For Enterococcus species the total number of
strains is very low and it is difﬁcult to predict the actual
resistance rate.
P1286
In vitro susceptibility of methicillin-resistant
Staphylococcus aureus and vancomycin-resistant
Enterococcus faecium to vancomycin, daptomycin,
linezolid, pristinomycin and other antibiotics
Z. Samra, O. Oﬁr, H. Shmuely (Petach-Tiqua, IL)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA)
is becoming increasingly prevalent as both a nozocomial and
community acquired pathogen in addition to an ever-growing
concern over development of vancomycin (VA) resistant. Simi-
larly VA resistant Enterococcus faecium (VREF) is becoming a
signiﬁcant pathogen in the immunocompromised patients. The
increasing prevalence of multi-drug resistant gram-positive
pathogens highlights a critical need for newer antimicrobial
agents. In this study we tested the in-vitro susceptibility of
MRSA and VREF clinical isolates to VA, daptomycin (DA),
linezolid (LI), pristinomycin (PR) and other antibiotics.
Methods: Susceptibility of 200 MRSA of 200 MRSA isolates (32-
blood, 168-wounds and body ﬂuids) and 90 VREF isolates (15-
blood, 31-wounds and body ﬂuids, 15-sputum and 29-stool). All
isolates were recovered from hospitalized patients, one isolate
from each patient. The minimal inhibitory concentration (MIC)
of VA, DA, LI and PR was tested by E-test (Biodisc). Suscep-
tibility to other antibiotics was tested by disc diffusion on
Mueller-Hinton agar according to the NCCLS criteria. S. aureus
ATCC 25923 and E. fecalis ATCC 29212 and 19433 were used for
quality control.
Results: The MICs results are summarized in the Table. All the
MRSA isolates were sensitive to VA, DA and LI. 0.5% were
resistant to PR. All the VREF isolates were sensitive to DA and
resistant to VA.14% were resistant to PR and 1% to LI. The
sensitivity of the MRSA isolates to other antibiotics was: fusidic
acid – 97.9%; trimethoprim/sulfametohoxazole – 96.9%; tetra-
cycline – 91.7%; rifampicin – 86.6%; chloramphenicol – 46.9%;
gentamicin – 37.6%; clindamycin – 22.2% and erythromycin –
20.6%. The sensitivity of the VREF isolates was: cholramphenicol
– 96.7%; gentamicin – 66.7%; fusidic acid – 41%; tetracycline –
13%; ampicillin, penicillin and erythromycin – 4%.
Conclusion: This study has shown that daptomycin, a new
antibiotic agent with rapid in-vitro bactericidal activity given
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once daily, have good in-vitro activity against a diverse collec-
tion of MRSA and VREF clinical isolates. Daptomycin can be
considered as an alternative treatment for patients with VA
resistant MRSA strains or those who cannot tolerate VA. It may
be useful in the management of infections caused by multi-
resistant VREF isolates.
Antibacterial susceptibility studies – II
P1287
MBL mediated carbapenem resistance in
P. aeruginosa and A. baumannii in cancer patients
E. Chinou, M. Georgouli, P. Giannakakos, M. Alexiou,
H. Skouteli, P. Golemati (Athens, GR)
The use of carbapenem has increased over the last 3 years in our
oncologic wards due to increased prevalence of ESBL producing
strains.
Objective: This study was performed to determine the preval-
ence of metallo beta lactamase mediated (MBL) carbapenem
resistance in clinical isolates of P. aeruginosa and A. baumannii
from oncologic patients.
Methods: We examined ﬁfty four strains of P. aeruginosa and 17
strains of A. baumannii isolated from urine, sputum and blood
culture of patients with solid tumours hospitalized in one
oncologic ward during the last year. The E-test metallo-beta
lactamase strip method was used as a reference method. The
MIC, was determined by Microscan semi automated method.
The procedure and interpretation of E-test MBL results was
carried out according to the manufacturer’s recommendation
(AB Biodisk).
Results: Twenty-two isolates (40%) of P. aeruginosa and nine
isolates of A. baumannii (53%) were resistant to imipenem. All
imipenem resistant A. baumannii isolates were also resistant to
meropenem and gentamicin. 13 strains (60%) of the imipenem
resistant P. aeruginosa isolates were resistant to meropenem and
cefotaxime and 10 strains (45%) resistant to aztreonam. Seven
carbapenem resistant P. aeruginosa isolates and ﬁve A. baumannii
isolates were shown to produce an MBL activity by the E-test
MBL,while the rest isolates hadhighMICvalues to imipenembut
were not MBL producer reﬂecting other mechanisms of resist-
ance. The seven MBL producers P. aeruginosa strains were
sensitive only to aztreonam.
P1288
Efﬁciency of cefoperazone, sulbactam alone and
in two combinations against multidrug-resistant
Acinetobacter baumannii strains isolated from
nosocomial infections in seven different
intensive care units in Turkey
A. Karadenizli, S. Akhan, S. Gundes, F. Kolayli,
H. Vahaboglu (Kocaeli, TR)
Objectives: Multiresistance A. baumannii is an important ther-
apeutical problem. Sulbactam is a beta-lactamase inhibitor
which can be used in combination with beta lactams. In this
study, the activity of cefoperazone, sulbactam alone and
combined with two concentrations of sulbactam against sixty-
nine isolates of multidrug-resistant Acinetobacter baumannii
from Turkey were compared.
Methods: Sixty-nine multidrug-resistant A. baumannii strains
isolated from clinical materials in seven different ICUs in
Turkey. Strains were identiﬁed using colony morphology, Gram
stain, oxidase reaction, aerobic growth and use of commercial
identiﬁcation panel (API 20 NE, BioMerieux, France). Minimal
inhibitory concentrations (MICs) using agar dilution method
were determined according to NCCLS. Cefoperazone was
accepted as susceptible if MIC level was £16 mg/l. Cefopera-
zone (cfp) and sulbactam (sul) combinations were investigated
at two ratios as follows: cfp-sul (1:1), and cfp-sul (2:1).
Results: MICs were determined with each compound on its
own and in combination with sulbactam. The table shows
MIC50 and MIC90 values for sixty-nine isolates of A. baumannii
(mg/L).
Conclusion: MIC50 and MIC90 to cefoperazone were found
high. The addition of sulbactam did not enhance the activity of
sefoperazone in both concentrations against multidrug-resistant
Acinetobacter baumannii strains isolated from ICUs in Turkey.
P1289
High incidence of moxiﬂoxacin resistance among
Bacteroides spp. isolates in Greece. Results from
the Hellenic Study Group on Gram-Negative
Anaerobic Bacteria
A. Katsandri, D.P. Houhoula, G.L. Petrikkos, N.J. Legakis,
J. Papaparaskevas, A. Pantazatou, A. Avlamis (Athens, GR)
Objectives: The evaluation of the in vitro activity of moxiﬂoxa-
cin in comparison to penicillin, piperacillin + tazobactam,
cefoxitin, clindamycin, metronidazole and imipenem against
Bacteroides spp. isolates collected from 8 general hospitals, in
Athens, Greece
Materials and methods: A total of 190 Bacteroides spp. clinical
strains (162 Bacteroides fragilis group and 28 other Bacteroides spp.
non-fragilis) isolated during the period 11/2002–10/2005 were
tested using the E-test and the agar dilution methods, on
brucella agar plates supplemented with 5% horse blood, vitamin
K1 and haemin. All plates were incubated in a Bactron ChelLab
Anaerobic Chamber for 48 hours. Interpretation of the results
was according to CLSI guidelines M11-A6. For quality control
the strains B. fragilis ATCC25285 and B. thetaiotaomicron
ATCC29741 were used.
Results: Overall MIC90 to moxiﬂoxacin, penicillin, piperacil-
lin+tazobactam, cefoxitin, clindamycin, metronidazole and im-
ipenem were >32, >32, 8, 64, >256, 1 and 0.5 mg/L, respectively,
whereas MIC50 were 2, >32, 0.25, 16, 1, 0.5 and 0.064 mg/L,
respectively. Overall non-susceptible to moxiﬂoxacin (using a
tentative MIC breakpoint of ‡4 mg/L, as no breakpoint has been
established yet by CLSI or any other organization) were 44% of
the isolates. Bacteroides fragilis group MIC90 were >32, >32, 4, 64,
>256, 1 and 0.5 mg/L, respectively, whereas MIC50 were 2, >32,
0.25, 16, 1, 0.5 and 0.064 mg/L, respectively. Bacteroides non
fragilis MIC90 were >32, >32, 16, 32, 32, 1 and 0.5 mg/L,
respectively, while MIC50 were 4, >32, 0.25, 8, 1, 0.5, and
0.125 mg/L, respectively.
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Conclusions: Moxiﬂoxacin exhibited high rates of resistance
among the isolates tested, whereas piperacillin + tazobactam,
imipenem and metronidazole were highly active. In that respect,
it is recommended that the use of this newer ﬂuoroquinolone in
antimicrobial chemotherapy of anaerobic infections due to
Bacteroides spp. isolates requires prior susceptibility testing.
Acknowledgement: Members of the Hellenic Study Group on
Gram-Negative Anaerobic Bacteria are: Dr A. Avlami, Dr E.
Papafrangas, Dr C. Koutsia-Karouzou, Dr C. Trikka-Graphakos,
Dr C. H. Kontou-Castellanou, Dr H. Malamou-Ladas, Dr A.
Pangalis, Dr M. Foustoukou, and Dr A. Vogiatzi.
P1290
Laboratory investigation of the combination
effect of imipenem/colistin and sulbactam/
colistin on clinical isolates of multidrug-resistant
Acinetobacter baumannii
H-S. Leu, L-H. Su, J-W. Wang (Taoyuan, TW)
Objectives: Infections with multidrug-resistant Acinetobacter
baumannii (MDRAB) has become a global problem. Carbapenem
is usually the drug of choice in treating such infections.
However, a rapid increase in the proportion of imipenem-
resistant MDRAB (IR-MDRAB) isolates from 4% in 2002 to 22%
in 2004 was observed in our hospital. The shortage of newer
effective antibiotics has further deteriorated the problem. To
provide an alternative therapeutic strategy, the in-vitro combi-
nation effect of imipenem (IPM)/colistin methanesulfonate
(CM) and sulbactam (SB)/CM was evaluated.
Methods: By using a chequerboard method, 10 representative
isolates of MDRAB/IR-MDRAB were used in the preliminary
experiment to conﬁrm whether any synergistic effect could be
obtained by the proposed combinations. The effect of various
combination ratios was determined by calculating the fractional
inhibitory concentration index (FICI). The most frequent com-
bination ratios showing a synergistic effect (FICI not greater
than 0.5) were used in the subsequent screening of 90 isolates of
MDRAB/IR-MDRAB using a standard agar dilution method.
Results: Synergistic effects were observed for both proposed
drug combinations. For IPM/CM, when CM reached a concen-
tration of 0.5 ug/ml, the associated MICs of imipenem reduced
sharply no matter what the actual combination ratios of IPM/
CM were. Thus a ﬁxed concentration of CM at 0.5 lg/ml was
added to a serial 2-fold dilutions of IPM for the subsequent
screening. The proportion of IPM-non-susceptible isolates
reduced signiﬁcantly from 72.2% to 24.4% at the presence of
0.5 lg/ml CM (P < 0.00000005). For SB/CM, the best combina-
tion ratio of 1:4 (SB:CM) was used for the screening and the
MICs reduced by 1–3 folds were observed in 34.8% of the
isolates tested. However, the rate of CM-non-susceptible (MIC
not less than 4 lg/ml) isolates reduced only slightly from 4.5%
to 3.4% when SB was added at the ﬁxed ratio.
Conclusion: Both drug combinations produced synergistic
effects compared to when either drug was used alone. CM at
a low level of 0.5 lg/ml appeared to increase greatly the in-vitro
antibacterial effect of IPM in the IR-MDRAB/MDRAB isolates
tested. However, the addition of SB to CM did not produce as
promising results probably due to the low-level resistance to
CM observed in the test population. For both drug combina-
tions, no antagonism was found among the 90 isolates analysed.
P1291
Current state of antimicrobial resistance of S.
pneumoniae isolated from children in Russia:
results of multicentre study PEHASus
O. Sivaja, R. Kozlov (Smolensk, RU)
Objective: S. pneumoniae is one of the most common bacterial
pathogens casing respiratory tract infections in children. There-
fore it is of extreme importance to determine the antimicrobial
resistance of that microorganism in order to optimize empirical
therapy of pneumococcal infections.
Methods: This study was conducted in 1999–2005 in 25 cities of
different regions of Russia. Identiﬁcation of the strains was done
on the basis of colony morphology, Gram stain, optochin
susceptibility and bile solubility tests. Susceptibility to 15
antimicrobials was performed using cation-adjusted Mueller-
Hinton broth (BBL, USA) with 2–5% lysed horse blood.
Breakpoints were those of NCCLS/CLSI except for midecamy-
cin (<1; >4 mg/L, SFM, 1996).
Results: A total of 840 non-duplicate clinical S. pneumoniae
isolated from children of 1–18 years old were included in this
study. The susceptibility testing results are presented in the
Table.
Conclusions: Generally, non-susceptibility (I+R) to b-lactams
remains to be comparatively low, varying from 0.2% to amino-
penicillins to 8.3% to penicillin G. Resistance to all macrolides is
not exceeding 6% with 16-membered maclolides and lincosa-
mides being the most active with resistance less than 3%.
Tetracycline and co-trimoxazole should not be used for empir-
ical therapy of pneumococcal infections because of high resist-
ance.
P1292
In vitro bacteriostatic and bactericidal activity of
pristinamycin against Streptococcus pyogenes:
inﬂuence of macrolide resistance mechanism
H.B. Drugeon, M.E. Juvin, C. Dib-Smahi (Nantes, Paris, FR)
Objectives: The objective of this study was to evaluate the in
vitro bacteriostatic activity of pristinamycin (PRI) against 173 S.
pyogenes isolated in 42 French hospital (year 2003) and the in
vitro bactericidal activity of PRI against S. pyogenes isolates with
different macrolides resistance phenotypes: erythromycin (ERY)
susceptible, ERY-R mefA, ERY-R ermB, ERY-R ermA subtype
ermTR (2 strains by each phenotype).
Methods: PRI and ERY MICs were determined by agar and
broth dilution methods. The bactericidal activity was studied by
using a killing curve method. PRI concentrations were used
from 0.002 mg/L to 2 mg/L by following a two fold dilution.
Survival bacteria were counted at T0, T15 minutes, T30 minutes,
T1, T2, T4, T6, and T24 hours.
Results: 143 strains (82.7%) were erythromycin susceptible, 30
strains (17.3%) were erythromycin resistant with ERY-R ermB
(n = 26), ERY-R ermA subtype ermTR (n = 2), ERY-R mefA
(n = 3) and 1 isolate was ERY-R with no mechanism determined.
All the isolates (ERY S and ERY R) had PRI MIC £0.06 mg/L.
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PRI had a very rapid, concentration dependent bactericidal
activity against wild-type strains and ERY-R mefA. After
15 minutes of contact with PRI concentrations ‡0.5 mg/L, the
decrease of bacterial population was >2 log10 cfu/ml; after
2 hours, a decrease >3 log10 cfu/ml was observed with PRI
concentrations ‡0.25 mg/L. With 0.06 mg/L, 24 hours of contact
was necessary. With ERY-R ermA subtype ermTR and, with
ERY-R ermB strains, the bactericidal activity of PRI was slower
and time dependant. A 6 h-contact was needed with the ﬁrst
mechanism to obtain a bacterial population decrease of >2
log10 cfu/ml with PRI concentrations ‡0.25 mg/L. With ERY-R
ermB, a contact of 24 hours was necessary to reach a bacterial
population of >2 log10 cfu/ml with PRI concentrations
‡0.125 mg/L.
Conclusion: 100% of Streptococcus pyogenes isolates were sus-
ceptible to Pristinamycin. The mechanism of macrolide resist-
ance didn’t inﬂuence the bacteriostatic activity (MIC) of PRI.
Pristinamycin had a very rapid concentration dependent bacte-
ricidal activity against wild-type and ERY-R mefA isolates.
Pristinamycin had a time dependent bactericidal activity against
ERY-R ermA subtype ermTR and ERY-R ermB genotype.
Pristinamycin may an alternative to beta-lactams in the treat-
ment of S. pyogenes ERY-R.
P1293
In vitro activity of antimicrobial agent
combinations against Brucella melitensis isolates
by E test
S. Kaya Firat, B. Oral, F.S. Erdinc, M.A. Yetkin, N. Tulek,
A.P. Demiro¨z (Ankara, Samsun, TR)
Objectives: Brucellosis is a zoonotic disease seen world-wide
including Turkey. The management of the disease is difﬁcult
sometimes because of the intracellular localization of the Brucella
species. Antibiotics that penetrates into the macrophages should
be used in combination. In our study in vitro activities of
streptomycin, tetracycline and rifampicin were investigated.
Methods: In vitro activities of antimicrobial agent combinations
were tested against Brucella melitensis strains isolated from 30
patients treated at Infectious Diseases and Clinical Microbiology
Department of Ankara Research and Training Hospital between
1999 and 2002. In vitro effectiveness of streptomycin-tetracycline,
rifampicin-tetracycline and streptomycin-rifampicin combina-
tions were tested by E test method. The interactivity of in vitro
combinations were evaluated as synergism, indifference and
antagonism depending on the conclusions of FIK index calcu-
lated for each strain.
Results: Synergism was found in 20 strains (66.7%) with
streptomycin-tetracycline combination, in 26 strains (86.7%)
with rifampicin-tetracycline combination and in 18 strains
(60%) with rifampicin-streptomycin combination. Antagonism
was found with rifampicin-streptomycin combination in only
one strain. The rate of synergy of rifampicin-tetracycline
combination was found higher compared to other combinations
and this difference was statistically signiﬁcant. We found that
the rifampicin-tetracycline combination was the most effective
combination in vitro.
Conclusion: Although routine antimicrobial susceptibility test-
ing for Brucella isolates is not recommended, in case of
treatment failure, relapses and reinfection synergy test with E
test may be helpful for treatment approach.
P1294
Incidence and resistance patterns of pathogens
from lower respiratory tract infections
O. Dorobat, A. Moisoiu, D. Talapan (Bucharest, RO)
Objectives: To evaluate the incidence and antibiotic suscepti-
bility of pathogens in chronic LRTI and nosocomial infections in
a clinical hospital of respiratory diseases.
Methods: A number of 938 strains isolated between September
1st 2004 and September 1st 2005 were identiﬁed by standard
procedures and antimicrobial resistance was determined fol-
lowing CLSI approved standard. The majority of Gram-negative
and Gram-positive bacteria were tested against 14 and 9 or 6
antimicrobials, respectively. Imipenem-EDTA Double Disk Syn-
ergy test and Etest were used for detection of metallo-beta-
lactamase producing isolates of P. aeruginosa.
Results: There were isolated 744 Gram-negative strains: H.
inﬂuenzae 34.6%, P. aeruginosa 17.7%, H. parainﬂuenzae 15.9%, K.
pneumoniae 8.6% and another spp. and 194 Gram-positive strains:
54.1% S. aureus and 45.9% S. pneumoniae. AmongH. inﬂuenzae and
H. parainﬂuenzae isolates, the highest resistance rate was to
trimethoprim/sulfametoxazole (SXT 30.9% and 31.1%), followed
by ampicillin (AMP 11.6% and 13.4%), chloramphenicol (CHL
4.5%and 5.1%) and clarithromycin (1.6%and 13.6%).P. aeruginosa
strains showed a resistance rate between 7.9% to amikacin and
38.3% to cefoperazone. The resistance to imipenem (IPM) and
meropenem (MEM) was close: 28.2% and 26.0%. From 36 P.
aeruginosa IPM and multidrug resistant strains tested, 8 were
probably producing of metallo-beta-lactamase. For S. aureus the
highest resistance rate was to penicillin 93.3% followed by
erythromycin (ERY 45.7%), oxacillin (OXA 41.9%) and CIP
(33.3%); all strains were susceptible to vancomycin (VAN),
teicoplanin and linezolid. From S. pneumoniae strains 13.4%
were high resistant to penicillin and 39.3% were intermediate
resistant. The resistance ratewas 64.0% to SXT, 18.8% toERY, 8.3%
to CHL and all strains were susceptible to oﬂoxacin and VAN. K.
pneumoniae strains were resistant to cefepime (11.3%), CIP (7.8%)
and there was no resistant strain to IPM and MEM.
Conclusion: Our study indicate that: (1) H. inﬂuenzae and H.
parainﬂuenzae the most common cause of chronic LRTI were most
resistant to SXT, AMP,CHL. (2) P. aeruginosa, the second pathogen,
was mostly resistant to cephalosporins; a higher resistance to IPM
was observed in nosocomial infections. (3) From P. aeruginosa IPM
resistant strains, 22.2% probably producedmetallo-beta-lactamase.
(4) S. aureus resistance rate toOXAwas high. (5) From S. pneumoniae
strains, 52.7% were resistant to penicillin.
P1295
Comparative study of some antibacterial agents
in patients with shigellosis
M. Stoycheva-Vartigova, P. Koroljova (Plovdiv, BG)
Objectives: Treatment of shigellosis has been confounded by
the increasing bacterial resistance to some antibacterial agents.
The aim of this study was to outline a comparison between the
effect of several antibacterial agents on the clinical course and
early clearance of bacteria from faeces in patients with shigel-
losis and to suggest timely recommendations for empiric
antibiotic therapy.
Methods: The study comprised 194 adult patients with culture
proven shigellosis at the Clinics of Infectious Diseases, Univer-
sity Hospital-Plovdiv, Bulgaria. The antimicrobial susceptibility
of Shigella isolates was tested by Kirby-Bauer disk diffusion
method to gentamicin, amikacin, ciproﬂoxacin, ceftazidim and
ceftriaxone. Antibacterial therapy was assumed as adequate or
inadequate according to the in vitro susceptibility patterns.
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Results: Adequate antibacterial therapy resulted in clinical cure
in most of the treated patients (83%) whereas only 41% of
patients were with clinical improvement after inadequate
antibacterial treatment. Similarly good clinical effect was
observed in 46% of patients without antibacterial therapy
proving that in some patients shigellosis is a self-limiting
infection. Elimination of Shigella from faeces was most frequent
in patients (nearly 80%) with adequate therapy by amikacin,
ciproﬂoxacin and ceftriaxone compared to those with inad-
equate or lacking antibacterial treatment.
Conclusion: These agents may be recommended for initial
empiric antibacterial treatment in shigellosis.
P1296
Preliminary report on a speciﬁc anti-Helicobacter
pylori microbicidal peptides produced by clinical
strain of Candida albicans
E. Karczewska, P. Mak, A. Targosz, D. Trojanowska, M. Wcislo,
A. Budak (Cracow, PL)
Objectives: The presented abstract demonstrate preliminary
results of chromatographic fractionation of Candida albicans cells
homogenate. The homogenate was obtained from a special
clinical yeast-like fungus strain isolated from the stomach ulcer
patient that simultaneously does not suffer from Helicobacter
pylori infection. The results of fractionation prove, that the
isolated C. albicans strain produce a proteinaceous factor that is
able to selectively kill H. pylori cells.
Methods: C. albicans clinical isolatewas grown on the Sabouraud
medium, the cells were spun down, washed twice in the
phosphate buffered saline and homogenized in the glass bead
homogenizer. The homogenate was centrifuged, obtained clear
supernatant was acidiﬁed, desalted on a solid-phase extraction
cartridge and then fractionated on a C-18 reversed-phase column
using high-performance liquid chromatography (HPLC) system
and elutionwith a linear gradient of buffers containingmixture of
water, acetonitrile and triﬂuoroacetic acid. Fourteen collected
fractions were vacuum-dried, redissolved in water and subjected
to SDS-PAGE electrophoresis as well as to H. pylori killing assay.
Results: Chromatographic separation of whole C. albicans cell
lysate demonstrate that this material is especially rich in small
proteins and peptides having molecular weights in range of 5 to
20 kDa. Two last fractions, containing most hydrophobic com-
ponents, had pronounced killing activity toward H. pylori.
Conclusions: Obtained results prove that some strains of C.
albicans produce a variety of proteinaceous factors that inhibit
the growth and kill H. pylori cells. This observation explain a
clinical phenomenon that many patients suffering from stomach
ulcers and simultaneously from C. albicans infection simulta-
neously do not exhibit symptoms of H. pylori infection. We are
conducting intensive research to purify these speciﬁc anti-H.
pylori peptides in a homogenous form.
P1297
In vitro demonstration of synergy with two
bacteriophage lytic enzymes (Cpl-1 and Pal),
autolysin (LytA), and cefotaxime against
Streptococcus pneumoniae
M. Gracia, V. Rodriguez-Cerrato, E. Garcia, P. Garcia, R. Lopez,
G. del Prado, C. Martinez-Marin, L. Huelves, C. Ponte, F.
Soriano on behalf of the Spanish Pneumococcal Infection Study
Network G03/103
Objective: New therapeutic alternatives are currently explored
to combat multi-drug resistant pneumococcal infections. We
perform an in vitro study to determine the activity of Cpl-1, Pal,
LytA, and cefotaxime alone and in combination against two
pneumococcal strains.
Methods: Cpl-1, Pal, and LytA were overproduced in Escheri-
chia coli (strains HB101 [pCIP100], DH5alpha [pMSP11], and
RB791 [pGL100], respectively) and puriﬁed by afﬁnity chroma-
tography in DEAE-cellulose columns. Two pneumococcal clin-
ical isolates, one involved in meningitis (strain 3693, serotype
19F), and one in lower respiratory tract infection (strain AR-
33118, serotype 3) were used. MIC determinations and synergy
testing were performed by the checkerboard method in micro-
titre trays with cation-supplemented Mueller Hinton broth
containing 4% lysed horse blood. Inocula were prepared by
suspension of colonies to produce ﬁnal inocula of approximately
5 · 10(5) cfu/mL and trays were incubated overnight at 35C.
MIC and Fractional Inhibitory Concentration (FIC) values were
determined by standard methods and FIC results were inter-
preted as follows: £0.5 (synergy), >0.5 to 4.0 (indifferent), and >4
(antagonism).
Results: the MIC values of Cpl-1, Pal, LytA, and cefotaxime
were 16, 128, 16, and 4 mg/L for strain 3693, and 16, 32, 8, and
£0.015 for strain AR-33118, respectively. Cpl-1 and Pal combi-
nation showed synergism against both strains. LytA combined
with Cpl-1 or with Pal showed indifference for both strains.
Synergy was demonstrated with Cpl-1 or LytA combined with
cefotaxime, but indifference was shown with Pal combined with
cefotaxime when the highly-cephalosporin resistant isolate 3693
was tested. FIC indices indicating antagonism were not found.
Conclusions: The synergistic effect showed between Cpl-1 and
Pal, and between Cpl-1 or LytA with cefotaxime in this study
warrants the evaluation in in vivo infection models using
antibiotic-resistant pneumococcal strains.
P1298
Activity of moxiﬂoxacin and comparators against
isolates of Chlamydia trachomatis from the UK
L. Williams, J. Northwood, I. Morrissey (London, UK)
Background: Chlamydia trachomatis (serovars A–K) is by far the
most common sexually transmitted infection worldwide, espe-
cially amongst adolescents, and is a major cause of acute pelvic
inﬂammatory disease (PID). Tetracyclines have been the basis of
antichlamydial therapy for over 20 years, with quinolones
becoming an important alternative. Moxiﬂoxacin (MXF) is a
fourth-generation ﬂuoroquinolone with enhanced broad spec-
trum in vitro antimicrobial activity. In this study we compared
the activity of MXF with levoﬂoxacin (LFX), erythromycin
(ERY), azithromycin (AZI) and doxycycline (DOX), against 51
Chlamydia trachomatis (CT) isolates.
Methods: Isolates collected between 1999 and 2004 from UK
laboratories were included in the analysis. MICs of MXF and the
4 comparators were determined by a broth microdilution
method, using McCoy cells in a supplemented McCoy Growth
Medium.
Results:
Conclusions: The data show that MXF produced lower MICs
against all C. trachomatis isolates. MXF showed greater activity
than LFX against this species with improved activity compared
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with the macrolides ERY and AZI. This antimicrobial activity
compliments the activity already shown against other bacteria,
for the empirical treatment of genital tract infections and acute
PID.
P1299
The antimicrobial susceptibility of bacteraemia
isolates of Gram-negative pathogens in seven
haematological centres in Russia
G. Kliasova, A. Mironova, L. Speranskaya, S. Ptitcin,
A. Maschan, N. Yuritcina, S. Vereschagina, T. Kaporskaya,
L. Krainova, T. Pospelova, O. Markina (Moscow, Samara, Irkutsk,
Novosibirsk, Ekaterinburg, RU)
Objectives: To evaluate the antimicrobial susceptibility of GNP
from blood in haematological centres (HC) of Russia.
Methods: Minimal inhibitory concentrations of antimicrobial
agents were determined by the broth microdilution (NCCLS
2003).
Results: 288 GNP were isolated between January 2003 and
October 2005. The predominant isolates were: E. coli (38%),
Klebsiella spp. (16%), P. aeruginosa (16%), Acinetobacter spp. (9%),
E. cloaceae (7%). 42% enterobacteria strains were conﬁrmed as
ESBL producers. The susceptibility data (%) were for main
species are summarized in Table:
Conclusion: P. aeruginosa indicated high levels of resistance to
antimicrobial agents. The most active antibiotics against Entero-
bacteriaceae were carbapenems, cefoperazone/sulbactam, cefep-
ime. Acinetobacter spp. showed the highest susceptibility rate to
cefoperazone/sulbactam and high resistance to meropenem.
P1300
Extending observed susceptibilities with
predicted susceptibilities based on a retrospective
statistical analysis
A.D. Nielsen, S. Andreassen, M. Paul, L. Leibovici on behalf of the
TREAT Study group
Objectives: In vitro testing of bacterial susceptibility is usually
performed on a limited set of antibiotics, which may not
necessarily include all relevant antibiotics. Clinically, coverage
of untested antibiotics can sometimes be predicted from the in
vitro results, using known cross-resistance properties for the
antibiotics. The objective is to establish a statistically validmethod
for extending in vitro results to a larger set of untested antibiotics.
Methods: For each of several Gram negative bacteria the a
priori coverage for 19 antibiotics, P(antibiotic1 = covering), and
the conditional coverage given that another antibiotic was
covering, P(antibiotic1 = covering | antibiotic2 = covering) or
non-covering P(antibiotic1 = covering | antibiotic2 = non-cov-
ering), was calculated. Fisher’s test (p s = 0.05) was used to test
establish signiﬁcant increases or decreases in susceptibility,
given prior knowledge of susceptibility to the in vitro results.
Results: The susceptibilities of Acinetobacter sp., Campylobacter
sp., Citrobacter sp., Enterobacter sp., Escherichia coli, Haemophilus
sp., Klebsiella sp., Pseudomonas sp., and Salmonella sp. were
evaluated using this method on a bacteraemia database (con-
taining 11000 positive blood culture cases) from Rabin Medical
Center, Israel. For example, for Escherichia coli, the observation of
susceptibility to cefotaxime (a priori susceptibility: 89%) signi-
ﬁcantly increases the belief in susceptibility for an additional 4
antibiotics (ceftriaxone, aztreonam, ceftazidime, amikacin) to
more than 95% (see table line 2). The observation of resistance to
cefotaxime reduced the belief in susceptibility for an additional
5 antibiotics (ampicillin, cefazolin, piperacillin, cefuroxime,
ceftriaxone) to below 5%.
Conclusions: The use of statistically veriﬁed cross-resistance
can be used to extend the predictions of coverage or non-
coverage to a substantial set of antibiotics not included in the in
vitro test. This typically expands the number of clinically
acceptable choices by several appropriate antibiotic therapies,
as well as eliminating several others as inappropriate.
P1301
Moxiﬂoxacin in vitro activity against
non-pneumococcal streptococci isolated from
six recent clinical studies
J.E. Ambler, S. Choudhri, D. Haverstock, J. Song, P. Reimnitz
(West Haven, US; Leverkusen, DE)
Objectives: To determine clinically relevant susceptibility
breakpoints for moxiﬂoxacin against non-pneumococcal strep-
tococci based on MIC frequency distributions.
Methods: Moxiﬂoxacin MIC distributions were pooled for
streptococci group A, B, C and D for four controlled, double-
blinded, randomised, parallel group, phase III studies and two
open-label studies. Indications were in uncomplicated and
complicated skin and skin-structure infection and complicated
intra-abdominal infection (2 of each indication).
Results: For moxiﬂoxacin-treated patients (n = 217), and all
patients (n = 530) the moxiﬂoxacin MIC90 against all strepto-
cocci was 0.25 mg/L, the MIC50 0.12 mg/L and MIC range
0.008–32 mg/L. For beta- streptococci, for moxiﬂoxacin-treated
patients (n = 73), the moxiﬂoxacin MIC90 was 0.25 mg/L,
MIC50 0.12 mg/L and MIC range 0.03–2 mg/L; results were
similar for all patients (n = 160), though the MIC range was
0.016–2 mg/L. For viridans streptococci, for both moxiﬂoxacin-
treated (n = 144) and all patients (n = 370), the moxiﬂoxacin
MIC90 was 0.25 mg/L, MIC50 0.12 mg/L and MIC range 0.008–
32 mg/L. Using interpretative criteria of £1 mg/L for suscept-
ible, 2 mg/L intermediate and >2 mg/L for resistant, the
moxiﬂoxacin MIC frequency distribution for all streptococci
(see ﬁgure) shows 99.1% of strains susceptible, 0.6% intermedi-
ate and 0.4% resistant. Results were similar for moxiﬂoxacin-
treated patients only and for beta- and viridans streptococci
separately. These results are similar to those of 5,160 non-
pneumococcal streptococci pooled from published in vitro
activity studies (MIC90 0.25 mg/L, MIC50 0.12 mg/L).
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Conclusion: The moxiﬂoxacin MIC frequency distribution of
both clinical and in vitro isolates of streptococci groups A, B, C
and D support a clinical breakpoint of susceptible £1 mg/L,
intermediate 2 mg/L and resistant >2 mg/L.
P1302
In vitro combination of rifampin with other
antimicrobial agents against clinical isolates of
Stenotrophomonas maltophilia
S. Gandotra, M. El-Azizi, A. Adamski, J. Koirala, N. Khardori
(Springﬁeld, US)
Objectives: Stenotrophomonas maltophilia, often multi drug
resistant, is a nosocomial pathogen of increasing importance
especially in immunocompromised patients. We evaluated the
effectiveness of double antibiotic combinations against MDR
clinical isolates of S. maltophilia.
Methods: We tested the in vitro activity of Trimethoprim/
Sulfamethoxazole (TMP/SMX), Ticarcillin/Clavulanic acid
(TIC/CLV), Ciproﬂoxacin (CIP), Ceftazidime (CFZ) and Doxy-
cycline (DOX) alone and in combination with Rifampin (RIF)
against 37 clinical isolates of S. maltophilia recovered from blood,
urine, wound and sputum. The MICs were determined by using
the broth microdilution technique according to the Clinical
Laboratory Standards Institute. Drug combinations were tested
by using checkerboard and time kill assays.
Results: Synergistic effects were observed in combination of
RIF with DOX (49%), CFZ (41%), CIP (31%), TIC/CLV (30%) and
TMP/SMX (11%). Antagonism was observed in combination of
RIF with CIP (10%), TMP/SMX (8%), and TIC/CLV (3%). No
antagonism was observed in combination of RIF with either
DOX or CFZ.
Conclusion: Our data show that combination of RIF with any of
the tested antibiotics was more effective than using single drug
alone against MDR S. maltophilia.
P1303
Activity of Thymus vulgaris L. essential oil
against potential causative agents of premature
delivery
L. Suvajdzic, M. Bogavac, B. Bozin, N. Mimica-Dukic, M. Mikov,
N. Simin (Novi Sad, CS; Otago, NZ)
Objective: Reducing the number of preterm deliveries presents
the main obstetric goal, especially in the area of Vojvodina,
where we have been facing a negative rate of natural population
growth since few decades. A number of organisms, which
normally colonize vagina (Escherichia coli, Klebsiella, Enterococcus,
Streptococcus group B) were identiﬁed as causative agents of
preterm premature rupture of amniotic membrane (PPROM)
and premature delivery. Negative effects of most antibiotics and
vaginal tablets/suppositories in the ﬁrst trimester of pregnancy
are well known. In that respect, there is a growing tendency
towards developing new natural antibacterial substances and
generating innovative pharmaceutical preparations on natural
basis. In the present study, the results of biological activity of
thyme (Thymus vulgaris L.) essential oil were presented.
Methods: The essential oil was isolated from dried aerial parts
of thyme (cultivated in Vojvodina) by hydrodistillation. The
composition of essential oil was evaluated by GC-MS. RSC was
assessed using DPPH (2,2-diphenyl-1picrylhydrazyl)-method
(Kirby and Schmidt, 1997) and measuring OH - radical induced
degradation of 2-deoxyribose. Inhibition on LP in both systems
of induction was evaluated by TBA-test (Afanasev et al.1989)
Antibacterial activity of essential oil was tested against cited
bacterial strains, by standard antibiogram test.
Results: The examined essential oil strongly reduced free
radical formation of DPPH (IC50 = 0.19 lg/ml). The inhibition
2-deoxyribose degradation was 34.38% (2.13 lg/ml). In both
examined systems of induction, essential oil (2.13 lg/ml)
expressed signiﬁcant inhibitory effects on LP (54.10% in Fe2+/
H2O2 system). The most effective antibacterial activity was
observed against Pasteurella sp., E. coli, Klebsiella. Moderate
activity was observed against Enterococcus, Streptococcus group B
and Staphylococcus aureus.
Discussion and conclusion: Besides the well known use of
aromatic plants and their essential oils as ﬂavouring agents in a
wide range of food, beverage and confectionery products, they
have been known to support various biological activities such as
antimicrobial (Mimica-Dukic et al., 2003) and hepatoprotective
(Kuresh and Deans, 1999). The obtained results suggest that
thyme could serve in prevention, treatment or supplement-
therapy of vaginosis induced by the speciﬁed bacterial species.
Its possible clinical application still requires further investiga-
tion.
P1304
Sensitivity testing and empirical treatment of
pneumonia and acute exacerbations of COPD
S. Marinkovic, I. Marekovic, B. Balabanic-Kamauf, F. Pavicic,
M. Jakopovic, M. Korsic (Zagreb, HR)
Objectives: Start of antimicrobial treatment of acute lower
respiratory tract infections (pneumonia, acute exacerbations of
COPD) is usually empirical. Most of the guidelines in patients
with no co-morbidity or risk factors recommend per os macro-
lide or doxiciclyn, and in patients with risk factors with
combination of b-lactam and macrolide or quinolone. The
most important parameters for choosing appropriate antimicro-
bial agent is possible bacteria and it has sensitivity to antimi-
crobial agents at speciﬁc area. The aim is to estimate sensitivity
of the most common respiratory pathogens to antimicrobial
agents empirically used according to current guidelines in
University Hospital for Lung Diseases Jordanovac.
Methods: Sensitivity to antimicrobial agents was followed
during years 2003 and 2004 for isolates of: S. pneumoniae
(N = 128), H. inﬂuenzae (N = 76), K. pneumoniae (N = 128) and
P. aeruginosa (N = 198). Sensitivity was tested with diffusion
method according to NCCLS standards. E-test was used to
determine MIC, thus, S. pneumoniae isolates could be separated
to moderately and highly resistant.
Results: In 2004 percentage of decreased sensitivity to penicillin
S. pneumoniae slightly increased, although, this increase was due
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to increase in moderately resistant S. pneumoniae. In the follow
up period no highly resistant isolates were recorded. Resistance
of S. pneumoniae to macrolides slightly decreased. During follow
up period we found no resistant isolates to moxiﬂoxacin,
though, we recorded some isolates resistant to ciproﬂoxacin.
K. pneumoniae resistance to co-amoxiclav and ciproﬂoxacin
increase slightly. Resistance of K. pneumoniae to cephalosporines
of 2nd and 3rd generation was less than 10%. H. inﬂuenzae
resistance to amoxicillin was 14%, and all of the isolates are
sensitive to co-amoxiclav and 2nd and 3rd generation of
cephalosporines. During the follow up period resistance of P.
aeruginosa to ceftazidime increased slightly an at the same time
resistance decreased to carbapenems and ciproﬂoxacin.
Conclusion: Sensitivity of most common respiratory bacterial
pathogens tested in University hospital for lung diseases is
according to current guidelines for empirical treatment of
respiratory infections. Future continuous follow up is obligatory
because change in sensitivity dictate choice of empirical anti-
microbial agent.
P1305
Comparative in vitro activity of levoﬂoxacin
against enterobacteria isolated from intra-
abdominal infections
M. Mohseni Zadeh, S. Kopp, F. Jehl (Strasbourg, FR)
Objectives: Newer ﬂuoroquinolons have seen their ﬁelds of
action increased, especially with their recent use in intra-
abdominal infections. In this study, conducted at the University
Hospital of Strasbourg (France) we evaluated the sensitivity to
levoﬂoxacin of Enterobacteria isolated from abdominal infec-
tions, as well as other frequently used antibiotics, between June
and October 2005.
Materials and methods: We prospectively collected 69 strains
of Enterobacteria isolated from intra-abdominal infections and 1
strain of Bacteroides sp. All strains were obtained either from
blood cultures or intra-abdominal specimens. Minimal inhibi-
tory concentrations (MICs) of levoﬂoxacin (LVX), oﬂoxacin
(OFX), ciproﬂoxacin (CIP), amoxicillin-clavulanic acid (AMC),
piperacillin-tazobactam (TAZ), imipenem (IMI), ceftriaxon
(CRO), amikacin (AKN) and gentamicin (GN) for each strain
were obtained by the agar dilution method and MIC50 and
MIC90 were calculated.
Results: Enterobacteria collected were mostly Escherichia coli
(n = 42; 60%) followed by Klebsiella sp. (n = 9), Enterobacter sp.
(n = 8), Proteus mirabilis (n = 3), Serratia sp. (n = 3), Salmonella
sp. (n = 2), Citrobacter sp. (n = 2) and Bacteroides sp. (n = 1).
MIC50 and MIC90 of each antibiotic tested for all 70 strains and
those for E. coli strains are summarized in table 1. 63 strains
(90%) were sensitive to LVX and other ﬂuoroquinolons (FQ).
Only 4 strains of E. coli (5.7% of all strains collected), 2
Enterobacter cloacae strains and 1 Serratia sp. strain were resistant
to FQ.
Conclusions: This study conﬁrms the good activity of LVX
against strains encountered in intra-abdominal infections.
P1306
Activity of beta-lactam/beta-lactamase inhibitor
combinations against ESBL producing
Enterobacteriaceae
B. Rybak, L. Naumiuk, M. Bronk, A. Samet (Gdansk, PL)
Objectives: Beta-lactam/beta-lactamase inhibitor are some-
times considered an useful alternative to carbapenems in
treating infections caused by ESBL producing organisms. The
aim of the study was to compare in vitro activity of amoxicillin-
clavulanate (AMC), piperacilline-tazobactam (TZP) and cefop-
erazone-sulbactam (CSL) against ESBL (extended-spectrum
beta-lactamase) producing E. coli, Klebsiella spp., Enterobacter
spp., Citrobacter freundii and Serratia marcescens.
Methods: Over twenty-one month study (January 2004–Sep-
tember 2005) we isolated 464 nonreplicate ESBL positive isolates
of above mentioned species from patients hospitalized in Public
Hospital No.1. All isolates exhibited ESBL phenotype in routine
double-disk synergy test (DDS) with cefotaxime, amoxicillin-
clavulanate and ceftazidime disks. Antimicrobial susceptibility
testing was done according to disk diffusion CLSI guidelines.
Bacteria were divided to 2 groups EK with E. coli and Klebsiella
spp. and SEC with S. marcescens Enterobacter spp. and C. freundii.
Results: The most active in vitro antibiotic in 372 EK isolates
was TZP (56% susceptible) followed by CSL (53%) and AMC
(16%). In much smaller SEC group (92 isolates) 35% were
susceptible to TZP, 30% to CSL and 2% to AMC. Isolates were
recovered from urine (34%), stools and rectal swabs (30%),
respiratory tract (14%), blood culture (3.4%) and other (18.6%).
Conclusions: TZP and CSL were found active against half to
one third of isolates depending of the species involved (EK and
SCE respectively). AMC was active in vitro against a smaller
fraction of EK group and inactive against SEC group due to
AmpC enzyme production. TZP was only slightly more active
against all isolates than CLS. Since they both contain different
beta-lactam and beta-lactamase inhibitor it is difﬁcult to point
the factor which is responsible for their comparable activity.
P1307
Dynamic bactericidal activity of ceftazidime in
combination with glycopeptides and
azithromycin against Pseudomonas aeruginosa
B. Repetto, A. Palenzona, A. Marchese, E.A. Debbia (Genoa, IT)
Objectives: Pseudomonas aeruginosa is an opportunistic patho-
gen. It is intrinsically resistant to many antibiotics and evolution
toward resistance is very frequently. The low permeability of the
outer membrane, due to the presence of lipopolisaccaride (LPS),
is considered in part responsible of this resistance. It is assumed
that some agents might disorganize the structure of LPS and
allow the passage of other drugs into bacteria cell. In order to
verify this hypothesis, ceftazidime (CAZ) has been tested in
association with glycopeptides (GLYs) and azithromycin (AZI),
which is a non anti-pseudomonal agents but has been shown to
interfere with some virulence factors.
Methods: A bacterial suspension of about 109 CFU/ml was
seeded on plates containing increasing doses of CAZ and a ﬁxed
concentration of GLYs (300 mg/l) and AZI (16 mg/l) Results
were interpreted as synergism (99%), additivity (90%), and
indifference (10%) of the CFU/ml reduction found in the drugs
combination in comparison to the drug alone. Time-kill experi-
ments were performed by adding the drugs to log-phase
bacterial cultures diluted to 106–107 CFU/mL growing in
100 mL ﬂasks at 37C. Just before the compounds were added
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and at 2, 4, 6 and 24 hr thereafter, bacterial counts were carried
out. Survivors were evaluated by determining CFU on agar
plates.
Results: CAZ in combination with GLYs reacted synergically in
35% of cases, additivity was found 52% of cases and indifference
was noted in 13% of tests; the addition of AZI increased the
incidence of synergisms to 42%, additivities to 49% and
indifferences to 9%. The combinations that were tested through
the dynamic bactericidal tests are CAZ (2xMIC)+GLYs (300 mg/
l)+AZI (16 mg/l), CAZ (2xMIC)+GLYs (200 mg/l)+AZI
(16 mg/l) and CAZ (2xMIC)+GLYs (300 mg/l)+AZI (32 mg/l).
Preliminary results indicated that antimicrobical effect is always
signiﬁcant 6 hr thereafter, in particular at the presence of AZI;
instead the letal effect is reduced when GLYs is used at
concentration of 200 mg/l and it is increased when AZI is used
at concentration of 32 mg/l (ﬁg.1).
Conclusion: The present ﬁndings demonstrated that CAZ
favourably reacted with GLIs at the presence of AZI. Further
studies to determine the best combinations among the drugs to
achieve highest rate of synergism are under way.
P1308
Comparative antimicrobial susceptibilities of
Streptococcus pneumoniae and Haemophilus
inﬂuenzae in a university hospital in Turkey
A. Ilki, P. Sagiroglu, N. Elgormus, U. Over-Hasdemir,
G. Soyletir (Istanbul, TR)
Objective: Increasing rates of resistance in both Streptococcus
pneumoniae and Haemophilus inﬂuenzae to clinically useful anti-
microbials are major concern worldwide. In this study we aimed
to investigate the comparative susceptibility patterns of these
pathogens to antimicrobials (Table 1.).
Materials and Methods: Clinical strains of S. pneumoniae and H.
inﬂuenzae isolated between 2002 and 2005 were included. In
pneumococci, E-test was used for determination of MIC of
penicillin, and susceptibility to other antimicrobials were per-
formed by disk diffusion test (CLSI, M2-A8). Nevertheless,
ampicillin MIC determinations were also studied in H. inﬂuenzae
strains showing resistance to ampicillin in disk diffusion test.
Nitroceﬁn was used for detection of beta-lactamase activity in H.
inﬂuenzae.
Results: S. pneumoniae; Overall resistance to penicillin was
36.0%. Intermediate and full resistance to penicillin were
25.3% and 10.7%, respectively. Percentages of fully penicillin
resistant pneumococci gradually decreased by year: 14.3% in
2003; 10.7% in 2004; 6.3% in 2005. There were no marked
changes in MIC50 and MIC90 values over 3 years. Penicillin
resistant pneumococci were also highly resistant to erythromy-
cin, tetracycline and trimethoprim-sulfamethoxazole. No resist-
ance was detected against oﬂoxacin and vancomycin (Table 1.).
H. inﬂuenzae; Overall incidence of beta lactamase production
was 2.8%. Ampicillin resistance was only determined in beta
lactamase producers; except one beta lactamase negative isolate
presenting increased MIC (2.0 lg/ml) of ampicillin. There was
considerable resistance to chloramphenicol and trimethoprim-
sulfamethoxazole in ampicillin resistant strains. None of the
strains was found resistant to ampicillin sulbactam, azithromy-
cin, and cefotaxime.
Conclusion: When compared with older studies in our hospital,
full penicillin resistance in pneumococci reached to alarming
levels with cross resistance to erythromycin, a commonly used
alternative drug in respiratory tract pneumococcal infections. It
is pleasant to observe no resistance to other alternative drugs
including oﬂoxacin and vancomycin in pneumococci. Fortu-
nately, ampicillin resistance in H. inﬂuenzae is still in its initiative
levels and seems to be totally due to beta-lactamase production.
P1309
Reliability of daptomycin E-test strips for
susceptibility testing
R. Canto´n, J. Bille, A. MacGowan, C.E. Nord, G. Schito, H.
Seifert, C. Soussy, M. Struelens, J. Verhoef, I. Morrissey (Madrid,
ES; Lausanne, CH; Bristol, UK; Stockholm, SE; Genoa, IT; Cologne,
DE; reteil, FR; Brussels, BE; Utrecht, NL; London, UK)
Objectives: Daptomycin (DAP) is a new cyclic lipopeptide
antibiotic active against Gram-positive bacteria. Approval is
being sought in Europe for the treatment of complicated skin
and skin-structure infections. This study compared local labor-
atory DAP susceptibility testing by E-test (ET) with central
reference broth microdilution methodology (BM).
Methods: Staphylococcus aureus (SA) and coagulase-negative
Staphylococci (CNS), including methicillin resistant strains, En-
terococcus faecalis (Efc) and E. faecium (Efm), including vanco-
mycin (VAN) resistant strains, Streptococci (Str) and
corynebacteria (Cor) were collected by 81 centres in Austria,
Belgium, France, Germany, Ireland, Italy, Netherlands, Portugal,
Spain, Sweden, Switzerland and UK (October 2004–March 2005).
ET MIC for DAP (ET strip supplemented with Ca2+), teicopl-
anin (TEI) and VAN was determined using local methods. MIC
was repeated in a central lab using CLSI BM. CLSI breakpoints
were used but TEI EUCAST and SA CLSI breakpoints were
applied for Str and Cor, respectively.
Results: Complete categorical agreement for DAP, TEI and
VANwas 94.7%, 95.2% and 98.7% respectively. False susceptible
(S) (DAP, TEI or VAN BM non-susceptible but ET susceptible)
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and false resistant (R) (BM susceptible but ET non-susceptible)
results are shown in the table. False-S results were low and less
common for DAP than TEI or VAN. False-R was higher for DAP
but most SA, CNS or Str had ET MIC of 1.5 or 2 mg/L (just
above the DAP breakpoint of 1 mg/L). Efm was the most
problematical for all agents, especially TEI.
Conclusion: ET can be relied upon to accurately ascertain
susceptibility to DAP with high categorical agreement (>94%)
and a very low false-S rate, this being a bigger problem than
false-R.
P1310
In vitro antimicrobial activity of gatiﬂoxacin
against staphylococci
C. Tuchilus, A. Poiata, A. Vornicu, O. Gacea, D. Buiuc (Iasi, RO)
Gatiﬂoxacin is in a class of drug called ﬂuoroquinolone
antibiotics. It eliminates bacteria that cause many infections,
such as pneumonia and bronchitis, sinus, respiratory tract and
urinary tract infections and sexually transmitted diseases.
Gatiﬂoxacin ophtalmic solution is used to treat bacterial con-
junctivitis.
Objective: To assess trends in the susceptibility to oﬂoxacin and
gatiﬂoxacin of 634 staphylococci, communitary isolates.
Material and methods:
Microorganisms: A total of 634 staphylococci: 254 coagulase-
positive staphylococci (CPS) and coagulase-negative staphylo-
cocci (CNS), colonising skin and nasal mucous, obtained from
medical personal in 2005 year. Isolates were identiﬁed as CPS by
demonstrating a positive coagulase test. Antimicrobial agents.
Powders of oﬂoxacin and gatiﬂoxacin, obtained from commer-
cial sources were tested in concentration range from 0.125 to
128 mg/l. Sensitivity study:Minimum inhibitory concentrations
(MICs) were determined by the agar dilution method estabi-
lished by NCCLS guidelines.
Results: The in vitro antibacterial activity of gatiﬂoxacin and
oﬂoxacin is shown in Table. In conclusion, gatiﬂoxacin was more
active than oﬂoxacin against coagulase-positive and coagulase-
negative staphylococci.
Tigecycline In vitro studies - II
P1311
Sampling of Staphylococcus aureus and
Enterococcus species isolates resistant to other
drugs evaluated against tigecycline – T.E.S.T.
Program Global Data
J. Johnson, D. Hoban, B. Johnson, S. Bouchillon, T. Stevens,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
activity against community and hospital acquired staphylococ-
cal and enterococcal pathogens. The T.E.S.T. program deter-
mined the in vitro activity of TIG against strains resistant to 10
commonly prescribed antimicrobials for serious gram-positive
infections: amoxicillin-clavulanic acid (AUG), piperacillin-tazo-
bactam (PT), levoﬂoxacin (LVX), ceftriaxone (CAX), linezolid
(LZD), minocycline (MIN), vancomycin (VAN), ampicillin
(AMP), penicillin (P) and imipenem (IMP). Study strains were
collected from 80 laboratories globally throughout 2004–2006.
Methods: A total of 4440 clinical isolates (1735 Enterococci, 2705
S. aureus) were identiﬁed to the species level at each participa-
ting site and conﬁrmed by a central laboratory. Minimum
Inhibitory Concentrations (MICs) were determined by the local
laboratory using broth microdilution panels. Antimicrobial
resistance was interpreted according to CLSI breakpoints with
TIG susceptible breakpoints deﬁned as <0.25 mcg/ml for
Enterococci and <0.5 mcg/ml for S. aureus.
Results: 231/1735 (13%) Enterococci and 379/2705 (14%) S.
aureus (including MR + MS strains) were resistant to two or
more drug classes. The multi-drug resistant (MDR) Enterococci,
resistance rates were LVX 97%, P 82%, AMP 75%, VAN 55%,
MIN 21%, and LZD 1.3% rates for MDR S. aureus were P 100%,
AMP 100%, AUG 72%, LVX 92%, PT 67%, CAX 58%, IMP 31%,
LZD 0%, MIN 0.8% and VAN 0% TIG inhibited 98.3% of the
MDR enterococci and 100% of the MDR S. aureus. TIGMICs were
0.06 and 0.12 mcg/ml for enterococci and S. aureus, respectively,
against strains with or without resistant determinants.
Conclusions: TIG retained potent activity against MDR
S. aureus and enterococci, inhibiting >99% of strains at the
respective breakpoints. TIG should prove to be a useful empiric
agent against these gram-positive pathogens whether they are
determined to be resistant to other drugs or not.
P1312
Tigecycline in vitro activity against
Staphylococcus aureus and Enterococcus strains
resistant to other drugs in United States, 2004 –
2006
J. Johnson, D. Hoban, B. Johnson, S. Bouchillon, T. Stevens,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
activity against many Gram-positive and –negative organisms.
T.E.S.T. program determined the in vitro activity of TIG against
S. aureus and enterococci resistant to 10 commonly prescribed
antimicrobials: amoxicillin-clavulanic acid (AUG), piperacillin-
tazobactam (PT), levoﬂoxacin (LVX), ceftriaxone (CAX), linezo-
lid (LZD), minocycline (MIN), vancomycin (VAN), ampicillin
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(AMP), penicillin (P) and imipenem (IMP). Study strains were
collected from hospitals in the United States throughout 2004–
2006.
Methods: A total of 2776 clinical isolates (1081Enterococci, 1695 S.
aureus) from 77 labs in the United States were identiﬁed to the
species level at each participating site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentrations (MICs)
were determined by the local laboratory using broth microdilu-
tionpanels.Antimicrobial resistancewas interpreted according to
CLSI breakpoints with TIG susceptible breakpoints deﬁned as
<0.25 mcg/ml for Enterococci and <0.5 mcg/ml for S. aureus.
Results: 156/1081 (14%) Enterococci and 256/1695 (15%) S.
aureus (including MR + MS strains) were resistant to two or
more drug classes. The multi-drug resistant (MDR) Enterococci,
resistance rates were LVX 99%, P 85%, AMP 82%, VAN 72%,
MIN 14%, and LZD 1.3% rates for MDR S. aureus were P 100%,
AMP 100%, AUG 71%, LVX 98%, PT 64%, CAX 51%, IMP 20%,
LZD 0%, MIN 0.4% and VAN 0% TIG inhibited 99.4% of the
MDR Enterococci and 100% of the MDR S. aureus. TIG MICs were
0.06 and 0.12 mcg/ml for Enterococci and S. aureus, respectively,
against strains with or without resistant determinants.
Conclusions: TIG retained potent activity against MDR S.
aureus and Enterococci, inhibiting >99% of strains at the respect-
ive breakpoints should prove to be a useful empiric agent
against these gram-positive pathogens whether they are deter-
mined to be resistant to other drugs or not.
P1313
In vitro activity of multidrug-resistant
Acinetobacter against tigecycline from the
T.E.S.T. Program in Europe
J. Johnson, D. Hoban, B. Johnson, S. Bouchillon, T. Stevens,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: The global increase in the emergence of multi-
drug resistant (MDR) bacteria has created a dire need for new
effective antimicrobial agents. Tigecycline (TIG) is a new ﬁrst-in-
class antimicrobial agent with expanded broad-spectrum activ-
ity against Gram-negative and -positive aerobes and anaerobes
responsible for community and hospital acquired infections. The
T.E.S.T. program determined the in vitro activity of TIG
compared to piperacillin-tazobactam (PT), levoﬂoxacin (LVX),
ceftriaxone (CAX), cefepime (CPE), amikacin (AK), minocycline
(MIN), ceftazidime (CAZ), and imipenem (IMP) against multi-
drug resistant Acinetobacter strains collected from 33 investiga-
tional sites in 15 European countries throughout 2004–2006.
Methods: A total of 435 clinical Acinetobacter were identiﬁed to
the species level at each participating site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentrations (MICs)
were determined by the local laboratory using broth microdi-
lution panels. Antimicrobial resistance was interpreted accord-
ing to CLSI breakpoints with TIG susceptible and resistant
breakpoints deﬁned as <2 mcg/ml and >8 mcg/ml, respec-
tively.
Results: Resistance rates to the comparator drugs were CAX
35%, CAZ 35%. LVX 29%, CPE 23%, PT 28%, AK 18%, IMP 12%,
and MIN 3.2% were grouped by presence of resistance to 0, 1, 2,
3, 4, or 5 drug classes. The percentage of strains falling into
Groups 0 through 5 were 59%, 9%, 14%, 9%, 8%, and 1%,
respectively. TIG inhibited >98% of strains in each Group, and
99.3% of all strains overall, with 0.7% intermediate to TIG and
no resistant strains. MIC50/90 for Groups 0–5 were 0.12/0.25,
0.5/1, 0.5/1, 0.5/1, 1/1 and 1/2 mcg/ml, respectively.
Conclusions: It has been seen in some species that existing
multi-drug efﬂux pumps may also pump TIG. In spite of this,
TIG remained effective although resistance to one or three drug
classes increased the TIG MIC90 by 4-fold, and resistance to 4 or
more drug classes increased it by 8-fold, TIG remained active
against the great majority of the multi-drug resistant strains, and
99.3% of all Acinetobacter isolates. In vitro activity against multi-
drug resistant Acinetobacter should prove useful in therapy of
infections caused by such strains.
P1314
Tigecycline in vitro activity against multidrug-
resistant Acinetobacter from global population in
the T.E.S.T. Program 2006
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: The global increase in the emergence of multi-
drug resistant (MDR) bacteria has created a dire need for new
effective antimicrobial agents. Tigecycline (TIG) is a new ﬁrst-in-
class antimicrobial agent with expanded broad-spectrum activ-
ity against Gram-negative and -positive aerobes and anaerobes
responsible for community and hospital acquired infections. The
T.E.S.T. program determined the in vitro activity of TIG
compared to piperacillin-tazobactam (PT), levoﬂoxacin (LVX),
ceftriaxone (CAX), cefepime (CPE), amikacin (AK), minocycline
(MIN), ceftazidime (CAZ), and imipenem (IMP) against multi-
drug resistant Acinetobacter strains collected from 120 investiga-
tional sites globally throughout 2004–2005.
Methods: A total of 1491 clinical Acinetobacter were identiﬁed to
the species level at each participating site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentrations (MICs)
were determined by the local laboratory using broth microdi-
lution panels. Antimicrobial resistance was interpreted accord-
ing to CLSI breakpoints with TIG susceptible and resistant
breakpoints deﬁned as <2 mcg/ml and >8 mcg/ml, respec-
tively.
Results: Resistance rates to the comparator drugs were CAX 43%,
CAZ44%.LVX40%,CPE34%,PT27%,AK14%, IMP10%, andMIN
2.3%.Strainsweregroupedbypresenceof resistance to0,1, 2, 3, 4, or
‡ 5 drug classes. The percentage of strains falling into Groups 0
through 5 were 50%, 7.8%, 25.8%, 11.7%, 4.3%, and 0.3%, respect-
ively. TIG inhibited >95% of strains in eachGroup, and 98.5% of all
strains overall, with 1.1% intermediate to TIG and only 1 isolate
with a resistant MIC of 8 mcg/ml. MIC50/90 for Groups 0–5 were
0.12/0.25, 0.5/1, 1/2, 1/2, 1/2 and 1/2 mcg/ml, respectively.
Conclusions: It has been seen in some species that existing
multi-drug efﬂux pumps may also pump TIG. In spite of this,
TIG remained effective although resistance to one or two drug
classes increased the TIG MIC90 by 4-fold, and resistance to 3 or
more drug classes increased it by 8-fold, TIG remained active
against the great majority (98.0%) of the multi-drug resistant
strains, and 98.9% of all Acinetobacter isolates. In vitro activity
against multi-drug resistant Acinetobacter should prove useful in
therapy of infections caused by such strains.
P1315
Multidrug-resistant Acinetobacter in the United
States evaluated against tigecycline - T.E.S.T.
Program 2006
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
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expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections. The T.E.S.T. program determined the in
vitro activity of TIG compared to piperacillin-tazobactam (PT),
levoﬂoxacin (LVX), ceftriaxone (CAX), cefepime (CPE), amika-
cin (AK), minocycline (MIN), ceftazidime (CAZ), and imipenem
(IMP) against multi-drug resistant Acinetobacter strains collected
from 77 investigational sites in the United States throughout
2004–2006.
Methods: A total of 921 clinical Acinetobacter were identiﬁed to
the species level at each participating site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentrations (MICs)
were determined by the local laboratory using broth microdilu-
tionpanels.Antimicrobial resistancewas interpreted according to
CLSI breakpoints with TIG susceptible and resistant breakpoints
deﬁned as <2 mcg/ml and >8 mcg/ml, respectively.
Results: Resistance rates to the comparator drugs were CAX
45%, CAZ 45%. LVX 45%, CPE 37%, PT 24%, AK 8%, IMP 6%,
and MIN 2%. Strains were grouped by presence of resistance to
0, 1, 2, 3 and 4 or more drug classes. The percentage of strains
falling into Groups 0 through 4 were 48%, 7.7%, 33%, 10%, and
1.4%, respectively. TIG inhibited ‡85% of strains in each group,
and 98.4% of all strains, with 1.5% intermediate to TIG and one
resistant strain with an MIC of 8 mcg/ml. TIG MIC50/90 for
Groups 0–4 were 0.12/0.25, 0.5/1, 1/2, 1/2 and 2/4 mcg/ml,
respectively.
Conclusions: It has been seen in some species that existing
multi-drug efﬂux pumps may also pump TIG. In spite of this,
TIG remained effective although resistance to one drug class
increased the TIG MIC90 by 4-fold, resistance to two or more
drug classes increased TIG MICs by 8–16 fold but MICs still
remain 1 doubling dilution below the conservative proposed
resistant breakpoint of 8 mcg/ml. TIG remained active against
the great majority of these resistant strains, and 98.4% of all
Acinetobacter isolates in the United States. TIG’s in vitro activity
should prove a useful adjuvant in the armamentarium against
infections secondary to multiply-resistant Acinetobacter.
P1316
Determining tigecycline’s in vitro activity
multidrug-resistant Enterobacteriaceae from the
T.E.S.T. Program – Global Data
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline, a member of a new class of anti-
microbials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections including GN, GP, Anaerobic and resistant
strains. The T.E.S.T. program determined the in vitro activity of
tigecycline compared to amoxicillin-clavulanic acid, piperacil-
lin-tazobactam, levoﬂoxacin, ceftriaxone, cefepime, ampicillin,
amikacin, minocycline, ceftazidime and imipenem against
Enterobacteriaceae species collected from hospitals globally
throughout 2004–2006. The objective of this study was to
evaluate the activity of tigecycline against multi-resistant micro-
organisms, commonly associate with nosocomial infections.
Methods: A total of 9231 clinical Enterobacteriaceae were iden-
tiﬁed to the species level at each site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentration (MICs)
were determined by each site using supplied broth microdilu-
tion panels and interpreted according to CLSI guidelines.
Tigecycline breakpoint (FDA, 2005) is deﬁned as susceptible
MICs £2 mcg/ml.
Results: As expected, different resistance patterns were detec-
ted among Enterobacteriaceae sampled in this study. As shown in
the table below, tigecycline presented excellent inhibitory
activity against all resistance phenotypes encountered.
Conclusion: Multi-drug resistance is often seen in health care
acquired pathogens. The presented data suggest that tigecycline
is highly potent against nosocomial or community pathogens
regardless to the resistance patterns in these selected strains of
Enterobacteriaceae.
P1317
Cross-resistance in clinical isolates of
Enterobacteriaceae from the United States
evaluated against tigecycline and 10 comparator
antimicrobial agents
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
broad spectrum activity against most commonly encountered
species responsible for hospital acquired infections. Cross-
resistance to several classes of antimicrobials is often seen in
nosocomial pathogens. The T.E.S.T. program determined the in
vitro activity of tigecycline against strains of Enterobacteriaceae
cross-resistant to two or more drug classes that included the
following antimicrobials:amoxicillin-clavulanic acid (AC), pip-
eracillin-tazobactam (PT), levoﬂoxacin (LV), ceftriaxone (CX),
cefepime (CP), ampicillin (AMP), amikacin (AK), minocycline
(MN), ceftazidime (CZ) and imipenem (IMP). The isolates were
collected from 77 investigational sties in the United States
during 2004–2006.
Methods: A total of 5760 clinical isolates were identiﬁed to the
species level at each site and conﬁrmed by the central laborat-
ory. Minimum Inhibitory Concentrations (MICs) were deter-
mined by the local laboratory using broth microdilution panels.
Antimicrobial resistance was interpreted according to CLSI
breakpoints with TIG’s FDA approved susceptible and resistant
breakpoints deﬁned as <2 mcg/ml and >8 mcg/ml, respec-
tively.
Results: 392/5760 Enterobacteriaceae were multi-resistant to two
or more drug classes. Of these resistant strains, 4.3% were
resistant to TIG (MIC >8) compared to AMP 99%, AC 54%, CZ
37%, LV 72%, MN 44%, CX 23%, PT 23%, CP 13%, IMP 4.8% and
AK 0.3%. the 2,239 Enterobacter spp. and S. marcescens collected,
106 presented resistance against CX and CZ but susceptible to
CP suggestive of AmpC phenotype. 85/106 (80%) of these
isolates demonstrated MICs <2 mcg/ml against TIG. TIG
showed excellent inhibitory activity against members of Enter-
obacteriaceae that were resistant to AK (n = 1), LV (n = 630), and
IMP (n = 59) inhibiting 100%, 90.8%, 93.2% of isolates, respec-
tively, at <2 mcg/ml.
Conclusion: The presented data suggest that TIG is little
affected by cross-resistance mechanisms present in these selec-
ted strains of Enterobacteriaceae. TIG may be an effective
therapeutic option against Enterobacteriaceae regardless of the
resistance patterns to commonly used antimicrobial agents.
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P1318
In vitro activity of tigecycline and comparators
against community and hospital-acquired
infections in the United States – T.E.S.T. Program
2006
D. Hoban, B. Johnson, S. Bouchillon, T. Stevens, J. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline, a member of a new class of anti-
microbials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections. The T.E.S.T. program determined the in
vitro activity of tigecycline compared to most commonly
prescribed broad spectrum antimicrobials against gram negative
and gram positive species collected from hospitals across United
States throughout 2004–2006.
Methods: A total of 12,442 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentration (MICs)
were determined by the local laboratory using supplied broth
microdilution panels and interpreted according to CLSI guide-
lines.
Results: Results are in the table as follows*: *Tigecycline
susceptibility deﬁned according to FDA package insert (Tygacil
, 2005) where available. Tigecycline Acinetobacter susceptibility
breakpoint are deﬁned as £2 mcg/ml for comparative purposes
only.
Conclusions: Tigecycline’s in vitro activity was comparable to
or greater than most the commonly antimicrobials for both
hospital and community acquired infections. The presented data
suggest that tigecycline may be an effective and reliable
therapeutic option against nosocomial or community pathogens.
P1319
In vitro activity tigecycline and 10 broad
spectrum comparators against multidrug-resistant
Staphylococcus aureus: a multi-nation evaluation
D. Hoban, B. Johnson, S. Bouchillon, T. Stevens, J. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: S. aureus are increasingly displaying resistance to
multiple drug classes (MDR). Therapeutic options to MDR S.
aureus phenotypes are limited. Tigecycline, a new glycylcycline
offers the potential of enhanced activity against MDR S. aureus.
The tigecycline evaluation surveillance trial (T.E.S.T.) evaluated
the activity of tigecycline and comparators to MDR S. aureus
isolated worldwide.
Methods: 116 hospital sites in 25 countries between 2004–2006
collected 2705 clinically signiﬁcant S. aureus. MICs were deter-
mined at each site using broth microdilution panels and results
interpreted as speciﬁed by CLSI at each site.
Results: MIC90 of tigecycline and comparators to MDR groups
0–4 are shown in the table. 1. Resistant to 0, 1, 2, 3 or 4 drug
classes.
Conclusions: Tigecycline exhibited the lowest MIC90 of all
study agents against S. aureus strains worldwide without regard
to multiple drug class resistance. Tigecycline MIC values
remained at or below its susceptible breakpoint of 0.5 mcg/ml
for S. aureus.
P1320
Continuity of mutant prevention concentration
values for gatiﬂoxacin, gemiﬂoxacin and
moxiﬂoxacin against clinical isolates of
Streptococcus pneumoniae (1994–2004)
J. Blondeau, S. Borsos (Saskatoon, CA)
Objectives: Mutant prevention concentration (MPC) deﬁnes the
antimicrobial drug concentration threshold that would require
an organism to simultaneously possess 2 resistance mutations
for growth in the presence of the drug. We have previously
shown that MPC testing identiﬁed differences between newer
and older quinolones for their propensity to select for resistant
subpopulations with clinical isolates of Sp. In order to assess
potential changes to MPC values over time, we compared MPC
measurements for gatiﬂoxacin (GAT), gemiﬂoxacin GEM),
levoﬂoxacin (LFX) and moxiﬂoxacin (MFX) against >550 clinical
Sp isolates collected from 1994–2004.
Methods: For MPC testing, isolates were inoculated to blood
agar plates, incubated overnight in ambient air and temperature
and the next day transferred to 500 ml of Todd Hewitt Broth
(THB) and incubated as described. The next day, the cultures
were concentrated by centrifugation and then resuspended in
3 ml of THB. A total of 200 ll of THB containing >1 billion
organism were inoculated to drug containing agar plates and
incubated for 24–48 hours. The lowest drug concentration
preventing growth was the MPC.
Results: A total of 488–559 clinical isolates were tested to all
compounds. For GAT, GEM and MFX, MPC 50/90 values (lg/
ml) remained constant over time at 1/2, 0.125/0.25, 0.5/1
respectively. For LFX, MPC 50/90 values (lg/ml) ranged from
2/2 to 2/4 being higher for more recently collected strains. The
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number of strains with MPCs of 4 lg/ml or greater was as
follows: GAT 19, GEM 1, LFX 108, MFX 6. GEM and MFX had
the lowest overall MPC values. There were 12 Sp strains with
MPC values of 16 lg/ml or greater to LFX as compared to 4 for
GAT and none for GEM and MFX.
Conclusion: GAT, GEM and MFX had lower MPC values than
did LFX. MPC90 values have not increased for the newer drugs.
The number of strains with MPC values to LFX of 4 (lg/ml) or
greater have increased over time as have the number of strains
withMPCmeasurements greater than 16 lg/ml. Preferential use
of more active compounds may slow the rate of quinolone
resistance in Sp.
P1321
In vitro activity of tigecycline against tetracycline-
resistant Gram-positive cocci isolated from
patients with bacteraemia
S. Forsthuber, H. Lagler, K. Stich, S. Reichmann,
A. Georgopoulos, W. Graninger, E. Presterl (Vienna, AT)
Objectives: The aim of this study was (i) to evaluate the in vitro
activity of tigecycline against tetracycline-resistant Streptococcus
pneumoniae (SPN), Staphylococcus aureus (SA) and viridans group
streptococci (VGS) isolated from patients with bloodstream
infections in Austria and (ii) to detect the genetic mechanism of
tetracycline resistance.
Methods: A total of 153 tetracycline-resistant (TetR) gram-
positive cocci (51 SPN, 54 SA, 48 VGS) were isolated from
patients with bacteraemia. Isolates were collected between 2001
and 2004. MICs (minimal inhibitory concentrations) of tetracyc-
line (TET), penicillin (PEN), erythromycin (ERY), clarithromycin
(CLR), azithromycin (AZM), clindamycin (CLI), telithromycin
(TEL), ciproﬂoxacin (CIP), levoﬂoxacin (LVX), moxiﬂoxacin
(MXF), linezolid (LZD), gentamicin (GEN), fusidic acid (FUS)
and vancomycin (VAN) were determined by the microdilution
method according to the Clinical and Laboratory Standards
Institute (CLSI). MIC of tigecycline (TIG) was tested by the Etest
method (AB Biodisk). Tigecycline susceptible breakpoint was
deﬁned as £2. The presence of tetracycline resistance genes
(tetM, tetO, tetK) was determined by PCR.
Results: The MICs of tigecycline ranged from 0.125 to
0.25 mcg/ml (MIC50 = 0.25, MIC90 = 0.5) for all isolates of
TetR S. pneumoniae, including 34 tet(M) positive strains. Similar
ﬁndings were observed for tetracycline-resistant VGS. The range
of MICs was 0.125–1 mcg/ml, including 28 tet(M) and 1 tet(O)
positive VGS. 30 S. aureus isolates contained tet(K) and two
tet(M). The tigecycline MICs for tet(M/O) positive strains were
higher (range, 0.25–1 mcg/ml) than for isolates which lacked tet
determinants (range, 0.25–0.5 mcg/ml). All tested pathogens
were sensitive to vancomycin and linezolid.
Conclusions: (i) The present study suggest that tigecycline may
be an effective alternative to commonly prescribed antimicrobials
in the treatment of gram-positive cocci. (ii) There was no relation
between the presence or absence of tetracycline resistance
determinants and the MICs of tigecycline in TetR VGS and
SPN, whereas tet (K/M) positive S. aureus isolates showed higher
MICs.
P1322
Benchmarking tigecycline activity against Gram-
positive and Gram-negative pathogens with
multidrug-resistance phenotypes derived from
patient specimens from USA and Europe
D. Draghi, M. Jones, D. Sahm, C. Thornsberry (Herndon, US;
Plaisir, FR)
Objectives: Staphylococcus aureus (SA), Enterobacteriaceae (EB)
and Acinetobacter spp (AC) are frequently associated with
infections in hospital-based patients. New agents, such as
tigecycline (TIG), a glycylcycline with potent activity against
both gram-positive and gram-negative agents, are essential to
combat organisms with specialized resistance mechanisms. The
activity of TIG was proﬁled against a recent, geographically
diverse collection of organisms that exhibited resistance pheno-
types to commonly used antibacterial agents.
Methods: EB [n = 1656; included E. coli (EC; n = 550), K.
pneumoniae (KP; n = 551), Citrobacter spp (CT; n = 222), Enterob-
acter spp (ET; n = 222), S. marcescens (SM; n = 111)] AC
(n = 265), and SA (n = 2,210) collected during 2000–2005 from
US and Europe were tested by broth microdilution against TIG
and several comparators according to CLSI guidelines. Baseline
TIG activity was analysed according to multi-drug resistance
(MDR), deﬁned as resistance to ‡2 key comparator agents. MIC
interpretative breakpoints were based on CLSI (M100–S15) for
all agents, where applicable and FDA breakpoints for TIG.
Results: TIG MIC range/MIC90 (mg/L) for all SA was 0.015–1/
0.12. The TIG activity based on MIC90, for MDR (0.25 mg/L)
isolates was comparable to the non-MDR isolates (0.12 mg/L).
TIG MIC90s (mg/L) for MDR/non-MDR, respectively were as
follows: 1/1 EC; 4/1 ET; 1/1 KP; 2/2 SM; and 0.5/0.25 EC. TIG
susceptibility was >90% for all EB, regardless of resistance
phenotype. Among AC, for ciproﬂoxacin non-susceptible (NS;
n = 138), imipenem NS (n = 30), and cefepime NS (78) isolates,
TIG maintained an MIC90 of 2 mg/L.
Conclusions: TIG exhibited potent in vitro activity against SA,
EB, and AC, including MDR phenotypes from US and EU. These
data serve as a benchmark to monitor the activity of TIG in both
the US and EU.
P1323
A Nordic study exploring the activity of
tigecycline against tetracycline-resistant Gram-
positive and Gram-negative bacteria
L.E. Nilsson, T. Koernig, N. Frimodt Møller, G. Skov Simonsen,
M. Vaara (Linko¨ping, Solna, SE; Copenhagen, DK; Tromsø, NO;
Helsinki, FI)
Objectives: Tigecycline is a glycylcycline developed as a par-
enteral extended-spectrum agent. This study shows the activity
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of tigecycline against tetracycline resistant isolates of Gram-
positive and Gram-negative bacteria isolated in four Nordic
countries.
Methods: A total of 1641 Gram-positive isolates and 1660 gram-
negative isolates were collected from hospital laboratories in
Denmark (n = 9), Finland (n = 11), Norway (n = 12) and
Sweden (n = 24) during 2005. Susceptibility testing was per-
formed with Etest using FDA breakpoints for tigecycline
(Staphylococci S £ 0.5 mg/l, Streptococci except S. pneumoniae
S £ 0.25, E. faecalis S £ 0.25, enterobacteriacae S £ 2 mg/l) and
the Swedish Reference Group for Antibiotics (SRGA) break-
points for tetracycline (R > 2 mg/l). A total of 457 tetracycline
resistant Gram-positive isolates and 821 tetracycline resistant
gram-negative isolates were evaluated.
Results: Activity of tigecycline is summarized in the table. The
susceptibility was high against all species with FDA-breakpoints
except for P. mirabilis andM. morganii. The other species showed
a high tigecycline susceptibility ‡90% for tetracycline resistant
isolates. For tetracycline resistant isolates tigecycline MIC50
increased 2-fold for CoNS, Acinetobacter spp and H. inﬂuenzae
and MIC90 increased 2-fold for S. aureus, S. pyogenes, K.
pneumoniae, M. morganii and Acinetobacter spp
Conclusion: Tigecycline remained highly active against most
tetracycline resistant isolates, probably due to stability to the
commonly occurring tetracycline resistant mechanisms in Gram-
positive and Gram-negative bacteria.
P1324
Antimicrobial activity of tigecycline against CTX-
M extended-spectrum betalactamase-producing
Enterobacteriaceae isolated from Austrian
patients
A. Eisner, G. Feierl, L. Masoud, A. Grisold, E. Marth (Graz, AT)
Objectives: To evaluate the antimicrobial activity of tigecycline
against Enterobacteriaceae that were found to be CTX-M produc-
ers isolated from Austrian patients in the period from 1999 to
2004. Tigecycline is a novel glycylcycline that inhibits protein
translation in bacteria by binding to the 30S ribosomal subunit
and blocking the entry of amino-acyl tRNA molecules into the A
site of the bacterial ribosome.
Methods: A total of 49 non-related clinical isolates (38 E. coli, 11
Klebsiella spp.) that had previously been identiﬁed as CTX-M
producers were tested for antibiotic susceptibility against
tigecycline and tetracycline as a comparator agent. Isolates
were tested using Etest. MIC results for tetracycline were
interpreted using the criteria recommended by the National
Committee for Clinical Laboratory Standards, results for tige-
cycline were interpreted using FDA interpretative criteria
(£2 mg/ml susceptible, 4 mg/ml intermediate, and ‡8 mg/ml
resistant).
Results: Among the tested isolates, 76% (29 of 38) of E. coli and
54% (6 of 11) of Klebsiella spp. were found resistant to tetracyline.
Tigecycline was highly active against E. coli (MIC50 and 90,
0.125 mg/ml and 0.25 mg/ml, respectively) and Klebsiella spp.
(MIC50 and 90, 0.75 mg/ml and 1 mg/ml, respectively). All
CTX-M-producing isolates were inhibited at £1 mg/ml of
tigecycline, no intermediate or resistant isolates were detected.
Conclusion: Tigecycline demonstrated a high activity against
CTX-M extended-spectrum betalactamase-producing isolates in
vitro. Moreover, tigecycline was highly stable to resistance
mechanisms responsible for resistance against tetracycline. Our
data indicate that tigecycline may represent a reliable option for
the treatment of infections due to multiresistant CTX-M-produ-
cing Enterobacteriaceae.
P1325
In vitro efﬁcacy of tigecycline tested against
community-associated methicillin-resistant S.
aureus including analyses of 72 co-resistance
patterns
R. Jones, M. Stillwell, H. Sader, T. Fritsche (North Liberty, US)
Objective: To determine if the activity of tigecycline (TIG)
varies among prevalent susceptibility (S) patterns of CA-MRSA
(1989 strains) isolated in North America between 2000–2004. The
S patterns were deﬁned by S and resistant (R; includes
intermediate) criteria recommended by the CLSI (2005) for 10
drugs: chloramphenicol (CH), ciproﬂoxacin (CI), clindamycin
(CL), erythromycin (ER), gentamicin (GT) rifampin (RF), tetra-
cycline (TC), TMP/SMX, Synercid, and vancomycin (VA).
Methods: CA-MRSA isolates were deﬁned as S. aureus infec-
tions acquired in the non-healthcare setting or appearing in
hospitalized patients during the initial 48 hours as determined
by the demographic records of the laboratory and hospital
infection control services. A total of 1989 MRSA met inclusion
criteria and were categorized by S patterns and the S testing
used the CLSI both microdilution method with fresh Mueller-
Hinton medium for TIG. Patterns ranged from 1 to 8 drugs
being R; the 7 most common patterns accounting for 81.6% of
CA-MRSA isolates (72 total patterns). ER-R (94.2%) was highest
followed by ﬂuoroquinolones (CI-R, 84.4%)
Results: TIG-S rates varied from 89.7–100.0% among the most
frequently isolated S patterns (see table). Across all CA-MRSA,
TIG inhibited 98.2 and 100.0% of strains at £1 and £2 mg/L,
respectively. All non-S TIG MIC results were at 1 mg/L only 2-
fold greater than the US-FDA breakpoint for staphylococci.
However, 1 mg/L was 2-fold lower than the TIG breakpoint
applied to Enterobacteriaceae. The overall comparison agent S
rates (%) were: CH (82.6), GT (86.6), linezolid (>99.9), Synercid
(>99.9), RF (93.7), TC (90.4), TMP/SMX (91.1), and VA (100.0).
TIG activity versus nosocomial MRSA isolates (98.7% S) was
comparable to that observed for CA-MRSA.
Conclusion: TIG demonstrates high potency (MIC90, 0.25–
0.5 mg/L) and breadth of coverage (98.2–98.7%) against CA-
MRSA as well as nosocomial isolates. MDR patterns (72) did not
adversely inﬂuence TIG activity and high-level R was not
observed among nearly 4000 S. aureus isolates (all non-S MICs at
1 mg/L).
P1326
In vitro activity of tigecycline tested against an
international collection of minocycline-resistant
bacterial pathogens (2000–2004)
T. Fritsche, H. Sader, R. Jones (North Liberty, US)
Objective: To characterize the activity of tigecycline (TIG)
against an international collection of minocycline (MINO)-
susceptible (S) and -resistant (R) gram-positive and -negative
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pathogens. TIG, a novel glycylcycline, is the 9-butylglycylamido
derivative of MINO and has recently been approved by the US-
FDA as a parenteral agent for use in treatment of skin and skin
structure infections, and intra-abdominal sepsis. Glycylcyclines
are inherently stable to most tetracycline-class resistance mech-
anisms.
Methods: Bacterial strains were acquired from recent (2000–
2004) worldwide surveillance collections, and tested against
TIG, MINO and other comparator agents using the NCCLS
(2003) reference broth microdilution method. Interpretive cri-
teria were from the TIG package insert or CLSI (2005).
Results: Activity of TIG is summarized in the table. TIG was
highly active against all strains tested with deﬁned resistance
only being seen among the Proteae and SM (3.3–9.0%). Despite
close structural similarities between the two molecules, TIG
remained generally active against most MINO-S and -R organ-
isms with MIC50 values being 0.06–2 mg/L, and 0.06–4 mg/L
(exception, PSA, MIC50, 16 mg/L), respectively. Among MINO-
R subsets, >93% of such critical pathogens as EC, SA, EF and
EFM remained S to TIG. Decreases in TIG susceptibilities were
noted among MINO-R SM (29.2%), PM (43.3%), IPP (64.3%) and
ESP (63.6%), indicative of over-lapping binding sites.
Conclusions: TIG offers advantages to existing agents including
an enhanced spectrum of activity and stability to the commonly
occurring tetracycline class R mechanisms (tetA or B and tetM or
O). Although a derivative of MINO, TIG retains activity against
manyMINO-R isolates, making this ﬁrst-in-class glycylcycline an
attractive candidate for expanded clinical development.
P1327
Antimicrobial activity of tigecycline, a
glycylcycline, tested against carbapenemase-
producing Enterobacteriaceae
H. Sader, T. Fritsche, L. Deshpande, R. Jones (North Liberty, US)
Objectives: To evaluate the in vitro activity of tigecycline (TIG)
and comparator agents tested against a well-characterized
collection of carbapenemase (CPase)-producing Enterobacteria-
ceae (ENT) collected worldwide.
Methods: ENT strains collected through many surveillance
programs from 2000–2005 were tested for susceptibility (S)
against imipenem (IMI) and meropenem (MER). Isolates with
MIC, d 2 mg/L for IMP and MER (except indole+ Proteae and P.
mirabilis) were screened for production of metallo-b-lactamase
(MBL) and Bush group 2f b-lactamases (2f BL) by disk
approximation (DA) tests. Isolates with positive DA tests were
evaluated by PCR using generic primers for IMP, VIM and SPM
when DA-positive for MBL; and for KPC, SME, IMI and NmcA
when DA positive for 2f BL. CPase gene sequencing and
molecular typing were additionally performed to conﬁrm CPase
production and to evaluate clonality. All CPase-producers were
S tested against TIG and >25 comparators by CLSI broth
microdilution methods using fresh Mueller-Hinton broth.
Results: CPase production was characterized on 104 ENT
isolates among >45 000 tested during the 2000–2005 period.
The collection included K. pneumoniae (KPN; 52), K. oxytoca
(KOX; 8), Enterobacter spp. (ESP; 24), C. freundii (CF; 9), S.
marcescens (SM; 7) and E. coli (4) from the USA (79 strains, 11
medical centres (MC), 8 cities), Italy (2 strains, 2 MC, 2 cities),
Turkey (11 strains, 2 MC, 2 cities), Greece (10 strains, 1 MC) and
Spain (2 strains, 1 MC). The most frequent CPase was KPC)2/3
(73 strains), followed by VIM-1 (14), IMP-1 (11), SME-2 (5) and
IMI-1 (1). All 2f BLs were detected in the USA while all MBLs
were detected in Europe. The majority of KPC-2/3 isolates were
observed among KPN from the New York City area (43 strains;
‡9 clones). However, KPC)2/3 were also observed in CF, ESP,
E. coli and KOX from 7 MC in 5 USA cities. The antimicrobial S
of the CPase-producers are summarized in the table: (See table)
Conclusions: CPase-producing ENT showed high rates of R to
all antimicrobials tested except TIG, which was very active
against this signiﬁcant, contemporary collection of well charac-
terized strains (MIC90, 1 mg/L; 100% S). TIG appears to be an
excellent option to polymyxins for treatment of infections
caused by CPase-producing ENT.
P1328
Activity of tigecycline tested against an
international collection (2000–2004) of AmpC-
producing Enterobacteriaceae
T. Fritsche, H. Sader, R. Jones (North Liberty, US)
Objective: To evaluate the activity and potency of tigecycline
(TIG) when tested against an international collection of
Enterobacteriaceae (ENT) with chromosomal AmpC enzymes,
including subsets predictive of extended-spectrum b-lactamase
(ESBL) production. TIG is the ﬁrst-in-class glycylcycline to be
approved (US-FDA) as a parenteral agent indicated for intra-
abdominal and skin and skin structure infections, and has
demonstrated activity against a variety of Gram-positive and –
negative pathogens, including anaerobes.
Methods: Non-duplicate clinically-signiﬁcant bacterial isolates
(2413) were collected from 2000 to 2004 in >60 medical centres
participating in the global TIG surveillance program. Isolates
included Citrobacter freundii (CF), Enterobacter aerogenes (EA), E.
cloacae (EC) and Serratia marcescens (SM). All isolates were tested
using NCCLS (2003) broth microdilution methods against TIG
and representative comparator agents. Ceftazidime (CTZ) resist-
ance (R) was used as a marker for stably derepressed AmpC
production, and cefepime (CPM) elevated MIC values (‡4 mg/
L) as a predictive marker for concomitant ESBL-production.
Results: TIG results for the R organism subsets are in the Table:
Stably-derepressed AmpC- and ESBL-production were evident
in, respectively: 22.2 and 3.1% of EC; 24.7 and 0.6% of EA; 17.2
and 2.7% of CF; and 2.0 and 0.2% of SM. Slightly decreased
potency (MIC90 values) of TIG among the CTZ-R subsets was
noted and varied from 0- (SM) to 4-fold (EC and CF). Overall,
97.4 and 90.8% of CTZ-S and -R isolates, respectively, were
inhibited by £2 mg/L of TIG. The presence of additional ESBL
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phenotypes among these isolates did not affect the potency of
TIG, and >95% of CTZ- and CPM-R isolates remained S,
indicative of the broad-spectrum of activity retained by this
agent against highly-R ENT.
Conclusions: Among EC, EA, CF and SM, including those
strains that express AmpC and ESBL- enzymes, 96% were
inhibited by £2 mg/L of TIG (the current USFDA breakpoint)
and >99% were inhibited by 4 mg/L. TIG is highly stable to
most R determinants affecting multiple drug classes, and may
represent a signiﬁcant choice among parenteral agents for
broad-spectrum coverage, including the most commonly occur-
ring - and problematic - resistance phenotypes.
P1329
Evaluation of the in vitro activity of tigecycline
against multidrug-resistant Gram-negative and
Gram-positive isolates
F. Kontopidou, E. Koratzanis, A. Antoniadou, E. Giannitsioti,
P. Evangelopoulou, S. Kanavaki, S. Karambela, L. Zerva,
H. Giamarellou (Athens, GR)
Background: In order to evaluate the potent antibacterial
activity of tigecycline (TGC) which is a new compound evolving
from the tetracycline family, we conducted the study of the in
vitro activity of TGC against 400 multi-drug resistant (MDR)
Gram-negative and gram positive pathogens.
Methods: Four hundred MDR clinical isolates provided by
different ICUs Departments and our Department were collected
from 2003 to 2005 and were tested both for their in vitro activity
against TGC. This activity was compared to the in vitro activity
of 12 and 11 drugs against gram (-) and gram (+) respectively.
For these comparators drugs, MIC determination by broth
microdilution method according to the NCCLs standards and E-
test methodology for colistin, ampicillin/sulbactam and Quin-
opristin/Dalfopristin were applied.
Results: 1) Among 100 Acinetobacter baummanii strains provi-
ded by different ICUs, 95% were resistant to imipenem and 85%
of them to ampicillin/sulbactam too. TGC MIC <1 lg/ml and
<2 lg/ml accounted for 96% and 99% of all strains respec-
tively.2) All Klebsiella pneumoniae strains were MDR (producing
in 32% ESBL, 15% VIM and 35% both ESBL and VIM, while 12%
were resistant to colistin and 8% Pan-Drug resistant). MIC for
TGC <1 lg/ml and <2 lg/ml were detected in 82% and 97% of
strains, respectively. The lowest MICs (0.25 and 0.5 lg/ml) were
exhibited by the most resistant strains, those producing ESBL
and/or VIM). 3) Among E. coli strains tested, 90% ESBL
producing) 96% and 100% presented MICs levels <0.5 lg/ml
and <1 lg/ml. 4) 70% of MRSA strains tested were also resistant
to levoﬂoxacin while 99% of them had TGCMICs of <0.5 lg/ml;
in all, TGC MICs were <1 lg/ml. 5) Among VRE strains, 7%
were also resistant to linezolid and 8% resistant to Quinopristin/
Dalfopristin. TGC MICs against VRE strains were in 100% of
strains <0.12 lg/ml.
Conclusions: In vitro activity of TGC expressed by low MIC
levels against MDR K. pneumoniae, A. baummanii, E. coli as well
as MRSA and VRE probably makes this new drug a good
treatment option for MDR bacteria (with the exception of
Pseudomonas aeruginosa) taking also into account the PK/PD
properties that reinforce in vivo the excellent in vitro activity of
this new drug.
Nosocomial infection control: MRSA and VRE
P1330
Importance of premorbid and ICU-acquired nasal
colonisation
A. Molnar, E. Hajdu, Z. Peto, R. Benko, A. Hortobagyi (Szeged,
HU)
Objectives: Critically ill patients are at high risk to acquire
nosocomial infections of which at least one-third could be
prevented by infection control measures. Properly timed micro-
biological samplings are important in the early detection and
treatment of these infections. As more than 50% of critically ill
patients have already been colonised nasaly at the time of
intensive care unit (ICU) admission [1], the obtainance of
nasopharyngeal samples could be of extreme importance. In
the present study we aimed to screen nasal colonisation and
determine development rate of severe infections (pneumonia,
sepsis) caused by identical bacteria.
Methods: We performed a prospective study between 2001–
2004 at our 6-bed surgical ICU. All patients who were expected
to stay over 48 hours at our ICU were routinely screened for
nasal carriage of micro-organisms at admission and afterwards
on every third day of stay. We obtained quantitative endotra-
cheal aspirates on every third day from intubated patients and
blood cultures in the presence of fever. Positive endotracheal
aspirates and positive blood cultures were retrieved for those
patients who had proven nasal colonisation and were on
antibiotic course due to clinically evident nosocomial infections.
Microbiologically positive endotracheal aspirates and blood
cultures were analysed for the presence of identical bacteria
previously found by nasal swabbing.
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Results: Our results are summarized in the following table:
Conclusion: Our survey shows that the premorbid and the ICU
acquired nasal colonisation led to development of severe infections
caused by identical bacteria and required antibiotic therapy in
almost every second case (average: 47.3 ± 13.2). Nasal swabbing
can be of help in the early start of targeted antibiotic therapy and
therefore shorten length of stay and lower healthcare expenses.
Further investigations are needed to determine the proper indica-
tion, frequency and predictive value of nasal screening.
Reference: Eggimann P, Pittet D. Infection control in the ICU.
Chest 2001; 120(6):2059–93.
P1331
Management of an outbreak of vancomycin-
resistant enterococci in a German university
hospital hemato-oncology department
D. Mlangeni, H. Bertz, M. Bussmann, A. Conrad, J. Huebner,
D. Jonas, M. Kist, A. Serr, M. Dettenkofer for the VRE Task Force,
University Hospital Freiburg, DE
Objective: To investigate which infection control measures are
efﬁcient in controlling an outbreak of vancomycin-resistant
enterococci (VRE).
Methods: At the peak of the outbreak in October 2004 in which 6
VRE-infected patients were identiﬁed, a VRE Task Force was
formed and a multifaceted infection control policy was imple-
mented. Empiric antibiotics for neutropenic patients with fever of
unknown origin were changed by replacing ceftazidim with
piperacillin/tazobactam. Use of vancomycin was restricted. All
new admissions to the Hemato-Oncology Department were
screened using rectal swabs and rapid identiﬁcation of the van
A and van B genes using PCR was established. Isolation of
carriers (special ward) and cohorting of contacts was enforced.
Environmental screening and intensiﬁed cleaning of the patient
rooms was performed. Finally, sampling of health care workers
hands (bag broth technique) on wards mainly affected was done.
Results: Between November 2004 and September 2005, 131
patients were VRE-positive (mainly van A genotype). Of these,
30 (23%) suffered from a VRE infection and 101 (77%) were VRE
carriers as identiﬁed by screening. A total of 2549 screening tests
were performed between November 2004 and September 2005.
Of these, 309 (12%) were positive for VRE. Since the introduction
of the measures of the VRE-Task Force the number of infected
patients decreased signiﬁcantly from 6 in October 2004 to 2 in
January 2005. After April 2005 (1 patient infected), no additional
primary infections occurred. The number of patients colonized
with VRE was highest in December 2004 with 23 patients but
subsequently decreased with 10 patients colonized in January
2005. Since then the number of colonized patients has further
declined reaching an average of 6 (range 5–8) patients per
month. Of the 236 environmental specimens, 16 (7%) were
positive for VRE which was isolated from ultrasound equip-
ment, infusion equipment, ventilators, tracheal suction equip-
ment, cardiac monitor, bedrails, curtains and bedside table. The
hands of 68 health care workers were studied and ﬁve (7.4%)
were positive for VRE. Educational seminars on hand hygiene
were then held by the Infection Control staff on the wards
affected by the outbreak.
Conclusion: The infection control measures initiated by the
VRE -Task Force reduced the number of patients infected with
VRE signiﬁcantly. However, further screening is necessary to
ensure timely detection of colonized patients.
P1332
The Uro-Quick system for detecting vancomycin
resistance in enterococci
S. Roveta, C. Cassanelli, A. Marchese, E.A. Debbia (Genoa, IT)
Objectives: The automated Uro-Quick system has been
employed to detect vancomycin-resistance in enterococci
(VRE): in order to achieve full agreement between the antibiotic
susceptibility results obtained by the reference method (CLSI)
and the Uro-Quick system, the optimal experimental conditions
(inoculum size, time of incubation, antibiotic concentration)
were determined.
Materials and methods: A total of 71 clinical isolates of
Enterococcus that belong to our Institute collection was tested:
all microorganisms were identiﬁed by standard procedures with
the API 20 STREP system (Bio-Merieux). The strains were
chosen for the presence of VanA and VanB genes determined by
PCR. E. faecalis ATCC 29212 and other 10 strains of Enterococcus
spp. vancomycin-susceptible (MIC £2 mg/l) were used as
glycopeptide-susceptible controls. Vancomycin susceptiblity
testing was performed by Mueller-Hinton broth microdilution
method according to the procedures of the CLSI. The results
obtained with the reference method were compared to those
obtained using the Uro-Quick automated system. Two vanco-
mycin concentrations (4 and 10 mg/l) were tested with the Uro-
Quick system: the antibiotic was added in a vial containig 2 ml
of broth suspension strain (standard inoculum: 0.1 ml, 106 cell/
ml) and a drug-free vial was used as control. Broths employed in
this study were Mueller-Hinton (MH) and Brain-Heart (BH)
alone or supplemented with NaCl 2%. After incubation (5, 8 or
18 hours) the instrument printed the results: no growth and a
growth curve like the control are representative of a susceptible
and resistant strain respectively.
Results: Vancomycin resistance was correctly detected by the
Uro-Quick system in all the VRE strains within 8 hours
employing BH and vancomycin 4 mg/l. NaCl did not affect
the results. The instrument printed the corrected results on
susceptible strains under all the experimental conditions.
Conclusions: This study assessed the ability of the Uro-Quick
system to detect VRE enterococciwith the important advantage of
a signiﬁcant reduction of test-time. On the basis of the present
ﬁndings the system appears to be useful in severe nosocomial
infections due to Enterococcus spp.: the rapid evaluation of
vancomycin-susceptibility allows a more direct treatment redu-
cing the empiric therapy and the diffusion of resistant pathogens.
P1333
Impact of infection control interventions on
hospital MRSA: a time-series analysis
A. Mahamat, F.M. MacKenzie, K. Brooker, D.L. Monnet,
I.M. Gould (Nıˆmes, FR; Aberdeen, Elgin, UK; Copenhagen, DK)
Objectives: Hospitals in the North-east of Scotland have
experienced MRSA outbreaks since 1997. Several infection
Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
control measures and a new antimicrobial policy were intro-
duced to control the incidence of MRSA. We evaluated the
effects of these interventions on MRSA rates.
Methods: From January 1997 to December 2004, monthly
percentage, non-duplicate S. aureus infections caused by
MRSA and monthly antimicrobial drug use (deﬁned daily
doses/100 occupied bed-days) were collated from Dr Gray’s
hospital and a control hospital. Both hospitals introduced a
common, new antimicrobial policy in January 2000 and the use
of alcohol hand gel in November 2002. Furthermore, Dr Gray’s
introduced an environmental-hygiene audit in March 2001,
chlorine disinfection of the environment in September 2001,
discharge screening in December 2001 and admission screening
in November 2003. Dynamic regression analysis with linear
transfer functions and interrupted times-series analyses were
used to estimate the effects of the interventions.
Results: At Dr Gray’s hospital, % MRSA increased between
January 1998 and January 2001 and then decreased. In the
control hospital, % MRSA increased from January 1997 to
December 2004. By multivariate analysis, introduction of the
new antibiotic policy and the use of alcohol hand gel were
associated with a decrease in %MRSA of 35% and 23%
respectively for Dr Gray’s and 23% and 26% respectively for
the control hospital. At Dr Gray’s, the environmental hygiene
audit and admission screening were associated with decreases
of 35% and 26% in %MRSA respectively, one month and
4 months later. The use of chlorine disinfection was associated
with an increase in MRSA rates of 28% (but only for one month).
Discharge screening did not signiﬁcantly affect the MRSA rates.
Conclusion: Four infection control interventions were associ-
ated with a reduction in %MRSA, one was associated with a
temporary increase in %MRSA and one had no impact
P1334
Reservoirs and transmission routes of
methicillin-resistant Staphylococcus aureus and
methicillin-susceptible Staphylococcus aureus in
a tertiary hospital: one-year surveillance
N.A. Faria, D.C. Oliveira, M.L. Amorim, E. Calado, C.
Vasconcelos, A.P. Castro, J.M. Amorim, H. de Lencastre (Oeiras,
Porto, PT; New York, US)
Objectives: To decrease the burden of nosocomial S. aureus
infections and prevalence of methicillin-resistant Staphylococcus
aureus (MRSA) in Hospital Geral de Santo Antonio, character-
ized by a high frequency of S. aureus infections and a MRSA
prevalence of 40%. A systematic study was designed in order to:
(i) identify the reservoirs of S. aureus; (ii) to characterize the
transmission routes of S. aureus; (iii) to evaluate the prevalence
of S. aureus colonization among outpatients; (iv) to make the
monitorization of S. aureus clones.
Methods: To identify the S. aureus reservoirs, patients and
healthcare personnel from the units with the highest risk of S.
aureus infection, as well as diabetic foot outpatients, were
screened for nasal colonization. To clarify the transmission
routes, nasal swabs and infection samples were taken from
patients with S. aureus infection. All strains were clustered in
clonal types by pulsed-ﬁeld gel electrophoresis. Clonal clusters
were further characterized by spa typing and multilocus
sequence typing (MLST). Staphylococcal chromosomal cassette
(SCCmec) typing was also performed for all MRSA strains.
Results: In the vascular surgery and endocrinology units, active
surveillance showed MRSA carriage rates of 11% and 9% among
patients, and 8% and 0% among healthcare personnel, respect-
ively. In the paediatric intensive care unit no MRSA carriers
were found. Among diabetic foot outpatients, 9% were MRSA
carriers. The percentage of methicillin-susceptible Staphylococcus
aureus (MSSA) carriers was always higher than the MRSA
carriers and was particularly high among health care personnel
in the paediatrics intensive care and vascular surgery units (36%
and 25%, respectively). Comparative analysis between infection
and colonization isolates in the few available samples showed
that the same strain was in both sites in 38% of the cases studied.
Longitudinal analysis of carriage showed that most (72%)
patients carried the same strain for long periods of time
(£6 months). Concerning the monitoring of MRSA clones, the
previously dominant ST239-IIIA clone decrease its incidence to
16%, and clone ST22-IV has emerged with an incidence of 79%.
Conclusions: The vascular surgery and endocrinology units
were shown to be the major reservoirs of MRSA among the
hospital units studied. The infection control measures adopted
by the paediatric intensive care unit were effective to curtail the
MRSA transmission. Diabetic foot outpatients are important
reservoirs of MRSA and may be vectors for MRSA dissemin-
ation between the community and the hospital.
P1335
A patient-centred approach to a clinical audit of
the clinical practice in MRSA control
A. Guleri, J. Roberts (Liverpool, UK)
Introduction: This audit was conducted to assess the clinical
practice in management of new and previously known hospi-
talised patients with Methicillin resistant Staphylococcus aureus
(MRSA). The hospital MRSA control policy is based on national
guidelines for control of MRSA. As a novel initiative, this audit
essentially took on board the views of the patient on different
aspects of their management and understanding of MRSA
acquisition. The initial audit was conducted in June/July 2004
and this re-audit in June 2005.
Method: Over 1-week, 25 new and previously known MRSA
patients in 13 wards of the hospital were assessed. Each
questionnaire comprised of 3-sections, each to be completed
by the staff nurse in-charge of the patient, the patient (or care
nurse if patient unresponsive) and the assessor respectively.
Results: There was 100% compliance with easy availability and
use of alcohol hand rubs/hand washing, aprons and gloves,
documentation in case notes and awareness in nurses, doctors
and domestic staff about MRSA status of patient. 24% patients
were either unresponsive or confused from primary illness/
treatment. 72% patients were nursed in isolation rooms, while
the rest were cohort nursed and on decolonization procedure.
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All of the 76% patients had been counselled about their MRSA
status, had a positive attitude about its management and
observed doctors, nursing and domestic staff taking care with
hand hygiene and using aprons/gloves. 50% of doors of
isolation rooms were found open. There was considerable
improvement on all assessed parameters from the earlier audit
(to be presented)
Conclusions: There is a range of improvement in compliance to
the hospital MRSA control policy. However, some areas need
further attention such as isolation rooms with closed doors,
quality surveillance, a tiered system of education and training
on infection control for all health care workers and ensuring that
infection control and health hygiene is everyone’s business.
P1336
Patient decontamination to control MRSA in an
intensive care unit
I.M. Gould, F.M. MacKenzie, G. MacLennan (Aberdeen, UK)
Objectives: To assess the effect of a change in patient decon-
tamination policy on MRSA rates in a 16-bed, teaching/tertiary
referral hospital ICU.
Methods: This cohort study used segmented regression analy-
sis of time series data applied to monthly MRSA data from May
1999 to August 2005, split into 3 phases. In phase 1 (24 months)
retrospective MRSA data were analysed. In phase 2 (28 months)
all patients were screened on admission for MRSA and those
found positive after 48–72 hours were barrier nursed. All
patients underwent daily decontamination using 4% chlorhex-
idine body and hair washes and six hourly nasal application of
neomycin/chlorhexidine or fucidin cream from admission to
discharge. (Phase 2 was presented at ECCMID 2003, abstract
O336). In phase 3 (24 months) the only difference from phase 2
was that body decontamination was discontinued in patients
when MRSA screen-negative results were conﬁrmed by the
laboratory.
Results: Figure 1 details monthly % ICU patients identiﬁed as
MRSA positive at any point during their stay. Phase 1: 1232
admissions and 192 new MRSA cases. Phase 2: 1675 admissions
and 105 new MRSA cases. Phase 3: 1550 admissions and 123
new MRSA cases. Mean (SD) % MRSA per month are phase 1;
15.7 (8.23), phase 2; 6.6 (4.5) and phases 2 and 3 combined; 7.1
(4.0). Comparing phases 1 and 2, the change in slope was –0.08
(p = 0.769) and the change in levels (%MRSA) was –11.3
(p = 0.006). Comparing phases 2 and 3, the change in slope
was –0.01 (p = 0.952) and the change in levels (%MRSA) was 2
(p = 0.378). Thus, during the individual phases, the% MRSA
rates were constant. Between phases 1 and 2 there was a
signiﬁcant change in %MRSA and between phases 2 and 3 there
was no signiﬁcant change in %MRSA. Introduction of the
interventions signiﬁcantly reduced MRSA rates in the ICU.
Despite stepping down the intervention between phases 2 and 3,
there was no signiﬁcant difference in rates of MRSA acquisition.
Conclusions: After 24 months of the modiﬁed intervention
(phase 3), there continues to be no erosion of the efﬁcacy of
the intervention (phases 2 and 3). This suggests that the effect is
due to decontamination of MRSA patients rather than prophy-
laxis against acquisition of MRSA.
P1337
Usefulness of axillar swab in the detection of
methicillin-resistant Staphylococcus aureus
colonisation
J. de Otero, C. Capo, M.A. Rada, E. Padilla, A. Serra (Manacor,
ES)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA)
control policies in Spain usually recommend nasal, axillary and
inguinal swabs for colonisation screening. Our aim was to
analyse the efﬁciency of performing the axillar swab in the
screening of MRSA for colonised patients and contacts.
Methods: From January-2004 to October-2005 we examined
patients positive for MRSA in any site and contacts assisted in
our 207-beds regional Hospital in Manacor (Mallorca, Spain).
Cultures were taken from nares, axillae, groins and other sites
under suspicion to be colonised or infected. Patients with any
positive culture for MRSA were considered colonised. Cultures
were repeatedly performed after elimination treatment and
during follow-up until 3 consecutive negative sets in 1-week
intervals. Every complete set of nasal-axillar-inguinal swabs was
considered as a case for analysis. Any uncomplete set was then
excluded. Sensibility, speciﬁcity and positive and negative
predictive values of axillar swab were calculated. Efﬁciency
was evaluated considering every patient follow-up.
Results: A total of 214 triple sets corresponding to 86 patients
were analysed. Of the 78 MRSA-colonised cases, 16 (20.51%) had
a positive axillar swab culture (real positive) and 62 (79.48%) a
negative one (false negative). All 136 negative axillar swab
cultures corresponded to non-colonised cases (real negative).
Sensitivity, speciﬁcity, positive predictive value and negative
predictive value were 20.51%, 100%, 100% and 68,68, respect-
ively. Only in 2 out of 78 (0.93%) MRSA-colonised cases, axillar
swab culture was the only positive of the triple set. In one case,
MRSA was simultaneously yielded from a skin ulcer culture.
The second case was the screening set of a MRSA diabetic-foot
infection and the following 3 consecutive sets in 1-week
intervals remained negative after elimination treatment.
Conclusion: The ﬁnding of a positive axillar swab did not
improve the identiﬁcation of MRSA colonisation under our
policy. Due to a very low sensitivity and negative predictive
value it seems not to be an efﬁcient technique. We conclude that
axillar swabs should not be a part of routine MRSA screening.
P1338
A prospective study comparing IDI-MRSA real-
time PCR assay (SmartCycler) versus
chromogenic culture method for detection of
methicillin-resistant Staphylococcus aureus
B. Ghebremedhin, W. Ko¨nig, B. Ko¨nig (Magdeburg, DE)
Objective: Nosocomial infections caused by Methicillin resist-
ant Staphylococcus aureus (MRSA) increase the length of hospital
stay, are responsible for rising health care costs and have a high
attribution to mortality. Reliable and rapid detection of MRSA
carriage is essential as part of epidemiologic investigation but is
also necessary for the prompt implementation of barrier isola-
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tion of colonized patients. Real-time PCR allows an early
detection of MRSA colonization, 2 hours compared to 1 or
2 days for culture and represents a rapid and powerful tool
which can be used for the prevention of the spread of MRSA in
healthcare setting.
Methods: We evaluated the feasibility of the IDI-MRSA ampli-
ﬁcation assay on the SmartCycler and compared the assay with
in-house chromogenic culture plates. IDI-MRSA assay was
performed according to the manufacturer’s instructions This
study has been initiated in routine since March 2005. Specimen
swabs from different sites of hospitalized patients and outpa-
tients at high risk for MRSA carriage (medical and surgical ICU,
general surgery, haemato-oncology, diabetology, dermatology
and geriatry) from the University Clinic in Magdeburg and
rehabilitation centre Flechtingen were examined.
Results: Over 2789 swabs of different sites were examined. IDI-
MRSA assay revealed 2488 negative, 269 positive and 32
unresolved results. Culture procedure detected less MRSA
positive swabs (n = 230) and in consequence more MRSA
negative swabs (n = 2559). SmartCycler procedure (4–6 h
depending on collection time of samples and transport logistic)
was indeed shorter than that for routine culture diagnostic
which took up to 60 h.
Conclusion: We conclude that careful consideration of IDI-
MRSA method is more useful than routine-culture diagnostic
method. These preliminary results obtained by SmartCycler for
MRSA detection are promising. Despite 1,3% (32/2786) ampli-
ﬁcation failure or unresolved results, we consider that IDI-
MRSA real-time PCR assay with an excellent sensitivity repre-
sents at our clinic a signiﬁcant breakthrough in the detection of
MRSA colonization and infection.
P1339
Molecular MRSA screening: ﬁnding negatives
a.s.a.p.
E.J. van Hannen, P. Foppen, B.M. de Jongh (Nieuwegein, NL)
Objectives: To contain the development and spread of MRSA
in the Netherlands there is agreement among health-care
professionals to follow the policy of ‘‘Search and Destroy’’.
This policy implies the need for screening for MRSA. With
increasing prevalence of MRSA there is a rise in demand for
screening with associated rise in number of isolation episodes.
Especially in an outbreak setting there is a need for a sensitive
and rapid MRSA assay with high volume capacity.
Methods: Traditional MRSA screening in our hospital consisted
of overnight culturing of samples in oxacillin broth and
subsequently incubation of these enrichments on CNA agar
plates for 48 hours. This procedure generated negative out-
comes in 3 to 5 days. During this time, patients with a history of
contact with the MRSA index are kept in strict isolation. In
addition of the extra costs of isolation, long isolation of patients
is undesirable. To reduce the time to generate a negative
outcome, we developed a multiplex real time PCR that detects
Staphylococcus aureus and the mecA gene in overnight oxacillin
enrichments after Magna Pure DNA isolation.
Results: In total, 1217 clinical samples were analysed by real
time PCR and compared to culture. The assay had a negative
predictive value of 99.1%. This assay reduced the time to
produce a negative outcome with 3 days and subsequently the
total time of isolation of patients.
Conclusion: We developed a rapid and high throughput MRSA
assay that gave a reduction of a total of 30 isolation days in an
outbreak setting.
P1340
Effect of nose carrier screening in liver transplant
candidates for preventing Staphylococcus aureus
infections after transplantation: a retrospective
study
V. Lamonaca, R. Di Stefano, G. Caruana, R. Volpes,
M. Campanella, G. Vizzini, P. Grossi, B. Gridelli (Palermo, IT)
Background: Several studies suggest nasal colonization is an
important risk factor for Staphylococcus aureus (Staph. aureus)
infection.
Aims of the study: Evaluate efﬁcacy of mupirocin topical
therapy and impact of nasal carrier screening in preventing
Staph. aureus infections after liver transplantation (OLTx).
Patients and methods: Review of 5-year follow-up in patients
(pts) listed for OLTx and 6-month follow-up after OLTx, from
July 1999 to November 2004. Rate of Staph. aureus colonization
by nasal swab at listing, eradication after mupirocin therapy,
rate and time of re-colonization, rate of colonization at the time
of OLTx, and Staph. aureus infections after OLTx were evalu-
ated.
Results: 377 listed pts were reviewed. At listing 237 pts (63%)
had negative swab; 140 pts (37%) had Staph. aureus: 119 (31%)
MSSA, 21 (6%) MRSA. After therapy, eradication rate was 98%:
122 pts (87.3%) after a single treatment, 15 pts (10.7%) after two.
Failure was 2% (3 pts). Total re-colonization rate was 23% (32
pts): 0% by 6 months; 1.4% (2 pts) after 7–9 months; 8.6% (12
pts) after 10–14 months; 13% (18 pts) between 16 and
38 months.162 patients underwent OLTx and received 183
grafts: 142 cadaveric, 7 split, 16 living-related, 18 re-OLTx. At
the time of transplantation 127 pts (78%) had negative nasal
swab, 35 pts (22%) were colonized: 30 (18.5%) with MSSA, 5
(3.0%) with MRSA. After mupirocin, eradication rate was 100%;
31 pts (88.5%) with a single treatment; 4 pts (11.5%) after two.
Re-colonization was 5.7% (2 pts, MSSA) after 6 ± 2 months. De-
novo nasal colonization was 2.1% (2 pts). After OLTx 8 pts (5%)
developed Staph. aureus infections: 7 (4.4%) by MSSA, 1 (0.6%)
by MRSA. 6 of them were colonized at admission and developed
infection within 2 days after starting mupirocin. They had CVL
infections (2 pts), CVL-sepsis (2 pts), pneumonia (1 pt), wound
infection (3 pts), ascites infection (1 pt). The remaining 2 pts,
though with negative nasal swab, had wound infections: 1
MSSA and 1 MRSA (probable personnel handling cross-colon-
ization). All infections solved after speciﬁc therapy.
Conclusions: In our experience nose carrier screening and
topical mupirocin therapy result very effective in eradicating
Staph. aureus carriers and in preventing infections after OLTx. In
the 34 re-colonized patients, in 97% of cases re-colonization
occurred not earlier than 6 months post eradication.
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Regional spread and outbreaks caused by nosocomial pathogens
P1341
European intercountry dissemination of a
glycopeptide resistant E. faecalis clone
C. Novais, T.M. Coque, J.C. Sousa, M. Del Grosso, L. Peixe
(Porto, PT; Madrid, ES; Rome, IT)
Objectives: To establish the diversity of PFGE types, genes
coding for antibiotic resistance and virulence and Tn1546
structure among representative vancomycin resistant E. faecalis
(VREﬂs) isolates from Portugal (PT) and Italy (IT). These are two
of the six European countries with highest VRE prevalence rates
in Europe (http//:www. earss.rivm).
Methods: Thirty-two clinical and environmental isolates that
belong to a widespread clone (29 resistant and 3 susceptible to
vancomycin) recovered from 3 different Portuguese regions
between 1996–2002, and a bloodstream isolate from a hospital in
the Center of Italy (2002) were studied. Clonal relatedness was
established by PFGE. Antibiotic susceptibility was evaluated by
agar dilution and microdilution methods (NCCLS). Character-
ization of antibiotic resistance genes (glycopeptides, macrolide,
aminoglicosides), putative virulence factors and the backbone
structure of Tn1546 were performed by PCR as previously
described.
Results: Similar PFGE proﬁles were detected between PT and
IT VREﬂs. The same PFGE type was also detected among clinical
vancomycin susceptible E. faecalis (VSEﬂs) obtained from a PT
hospital. Most of the isolates were resistant to erythromycin
[erm(B), gentamicin [aac(6’)-aph(2’’)], streptomycin, kanamycin
(aph-III), tetracycline, ciproﬂoxacin and all were susceptible to
ampicillin and linezolid. All VRE isolates harboured vanA but
located in a high diversity of Tn1546 (types PP2, PP4, PP5, PP15,
PP17 among PT strains and the prototype Tn1546 in the IT one).
Insertion of ISEf1 between vanX and vanY, was frequently and,
exclusively observed in PT Enterococci. Variable presence of
putative virulence traits was detected asa1 (PT+IT), gel (PT), cyl
(PT) and esp (PT).
Conclusion: We reported the European intercountry dissemin-
ation of a VREﬂs clone causing severe clinical infections. The
recovery of some isolates susceptible to glycopeptides and the
diversity of Tn1546 and putative virulence traits harboured by
different isolates belonging to this clone suggest spread of
speciﬁc E. faecalis strains harbouring different genetic elements
(as Tn1546 and putative virulence factors) probably selected
among those available in local metagenomes.
P1342
Genomic diversity of vancomycin-resistant
Enterococcus faecium isolated in France
L. Mihaila-Amrouche, J. Loubinoux, A. Doloy, G. Collobert,
N. Gaitch, A. Bouvet (Paris, FR)
Objective: Vancomycin-resistant Enterococcus faecium (VREF)
has emerged as a nosocomial pathogen in the USA but remains
rare in Europe. An increase of VREF incidence was observed in
France (0.4% in 2003 to 2.9% in 2004). Thus, we compared 78
VREF strains isolated from 2004 to 2005 in different regions of
France.
Methods: Clinical data from the colonised or infected patients
were collected. Identiﬁcation of VREF isolates was ﬁrst per-
formed with the rapid ID32 STREP commercialized systems
(bioMe´rieux, Marcy l’Etoile, France) and then conﬁrmed by
species-speciﬁc PCR ampliﬁcation of the D alanine-D alanine
ligase genes. Antimicrobial susceptibility to 11 antibiotics was
determined by the agar diffusion method according to the
guidelines of the ‘Comite´ de l’Antibiogramme de la Socie´te´
Franc¸aise de Microbiologie’ (http://www.sfm.asso.fr). For beta-
lactams and glycopeptides, the minimal inhibitory concentra-
tions (MICs) were also determined. The genes vanA, vanB,
vanC1 and vanC2/3 responsible for resistance to glycopeptides
were identiﬁed by multiplex PCR. Clonality of isolates was
studied by pulsed-ﬁeld gel electrophoresis (PFGE) after diges-
tion of DNA with SmaI.
Results: VREF isolates were more often responsible for coloni-
sation than infection. Most of the isolates (74/78) were resistant
to penicillin G, amoxicillin, and piperacillin (MICs>256 mg/L).
Intermediate susceptibility to amoxicillin was observed for 4
strains. Most of the strains (76/78) were resistant to macrolides.
Resistance to aminoglycosides and tetracycline was variable. All
strains were resistant to vancomycin (MICs 24–256 mg/L), and
intermediate or resistant to teicoplanine (MICs 6–256 mg/L). All
strains but one had the gene vanA. PFGE identiﬁed fourteen
different clones.
Conclusions: Resistance to glycopeptides in VREF isolates was
mainly due to the presence of the gene vanA. More than 10
different clones were identiﬁed by PFGE. These results demon-
strate the genomic diversity of VREF isolated in France. A single
clone was present in some hospitals. Thus, the transmission of
VREF isolates between patients must be taken into account for
the prevention of these nosocomial infections.
P1343
Molecular epidemiology of vanA-containing
Enterococcus faecium in a university general
hospital in Greece
M. Souli, I. Galani, L. Galani, A. Antoniadou, M. Pantelaki,
N. Siafakas, V. Sakka, F. Kontopidou, S. Athanasia, V. Veloni,
S. Tsiodras, L. Zerva, H. Giamarellou (Chaidari, GR)
Objective: The aim of this study was to determine the clonal
relationship and the involved genotype of vancomycin-resistant
E. faecium (VRE) isolates colonizing the gastrointestinal track of
hospitalized patients in our hospital.
Methods: Prospective, point-prevalence surveys of faecal car-
riage of VRE in all hospitalized patients were performed with
10-day intervals during the 20 April-30 May period. Identiﬁca-
tion was performed by standard methodology and susceptibil-
ities by E-test. Multiplex PCR for identiﬁcation of the
vancomycin resistance genes and the species was performed
in 69 VRE isolated in various patients and in one isolated from
the environment (light switch), using crude extracts as target
DNA. E. faecalis ATCC 51299 (vanB) and E. faecalis (vanA) were
included as control strains. All isolates were typed by PFGE
using SmaI. PCR-RFLP analysis, of the 634 bp PCR amplicons
corresponding to V domain region, with NheI was used to
detect the G2576T mutation in 6 linezolid resistant isolates.
Results: From the 3 surveys 460 samples were evaluated from
367 patients. Total mean VRE carriage was 19.7% initially to
decline gradually to 14.4% and 9.5%, subsequently, as strict
multidisciplinary infection control measures were implemented.
All isolates were identiﬁed as E. faecium, with vanA genotype.
Six VRE strains had linezolid MIC of 12 lg/ml. Based on PFGE,
8 unique restrictional proﬁles were identiﬁed. Two frequently
presented clonal types (A and B) with 29 and 25 strains
respectively were identiﬁed among these proﬁles. Based on
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PFGE ﬁve of the six linezolid resistant isolates were identical
(clone type C), including the isolate from the light switch. The
sixth isolate belonged to one of the predominant clone types (A).
PCR-RFLP analysis of the 634bp amplicon from puriﬁed DNA of
linezolid resistant isolates revealed the existence of at least one
mutated copy of 23S rRNA gene.
Conclusions: This study revealed high VRE colonization rates
among hospitalized patients in our hospital but we successfully
managed to contain the VRE outbreak by applying the recom-
mended infection control measures. This is the ﬁrst outbreak
due to a linezolid-resistant VRE strain in a tertiary care hospital.
Of note, this multiresistant clone was identiﬁed during the ﬁrst
survey and completely disappeared thereafter as a result of
infection control measures.
P1344
Establishment of polyclonal endemicity with
hospital-adapted ampicillin-resistant
Enterococcus faecium in a Dutch hospital
J. Top, R.J.L. Willems, H. Blok, A. Troelstra, M.J.M. Bonten
(Utrecht, NL)
Objectives: A retrospective study on the occurrence of entero-
coccal infections in the University medical center Utrecht
(UMCU) between 1994-2003 revealed an increase in ampicillin
resistant E. faecium (ARE). The objective of current study was a)
to determine whether this increase was due to complex-17
isolates, a hospital-adapted genetic subpopulation characterized
by ampicillin resistance, and associated with clinical infections
and hospital outbreaks world-wide. b) to determine the colon-
ization prevalence on 2 wards (haematology and nephrology/
gastroenterology) and an outpatient group and c) to determine
risk factors for colonization with ARE.
Methods: Multiple locus variable number of tandem repeat
analysis (MLVA) was used to genotype the ARE in the UMCU.
Rectal swabs of 193 hospitalized patients and 650 outpatients
were screened for ARE in the period March-October 2004.
Twenty-two different variables were included in a risk factor
analysis for rectal colonization with ARE among nephrology
and gastroenterology patients.
Results: Genotyping of 130 clinical and 59 screening ARE
isolates showed clonal spread of ARE and revealed that 31 of 38
different genotypes (189 isolates) belonged to complex-17.
Colonization prevalence among nephrology patients (45.6%)
was signiﬁcantly higher than among gastroenterology patients
(17.6%, p < 0.001), although patients were treated in the same
ward, and was 28.1% among haematology patients. The preval-
ence in the outpatient group was signiﬁcant lower compared to
the two hospital wards (2.9% p < 0.001). Analysis of E. faecalis to
E. faecium ratios in the ﬁrst 20 enterococcal blood isolates per
year (1994–2004) showed a relative increase of blood stream
infections caused by E. faecium (p = 0.001). In multivariate
analysis, diabetes mellitus (OR 8.59, 95% CI 2.08–35.44), three or
more admissions (OR 14.84, 95% CI 3.44–64.10), beta-lactam
antibiotics (OR 2.97, 95% CI 1.09–8.09) and quinolone use (OR
5.23, 95% CI 1.22–22.48) were associated with colonization with
ARE.
Conclusions: Our ﬁndings demonstrate ecological replacement
of E. faecalis by E. faecium and clonal spread of ARE belonging to
the hospital-adapted complex-17. Antibiotic use, especially
quinolones, appeared to be an important risk factor. Emergence
of ARE in European hospitals will have important consequences
for empirical antimicrobial treatment of immunocompromised
patients.
P1345
Colonisation of vancomycin-resistant Enterococci
in paediatric unit of a teaching hospital in Turkey
H. Guducuoglu, E. Aktas, F. Begendik Comert, K. Aygul, N.
Ozlu, S. Baykal (Van, Zonguldak, TR)
Objectives: Upon a ﬁrst time isolation of VRE from a urine
sample of a 8 month-baby followed by another sample of a
5 month-baby, we decided to perform a VRE screening in our
paediatric unit. After screening, isolated VRE strains were
investigated by molecular methods to detect the resistance
genotypes and possible clonal relatedness.
Methods: For this reason 88 samples (rectal swabs, skin of
patients, surroundings of beds, hands of patients’ mothers, staff,
washbowl, stethoscope, and different environmental samples)
were collected from Paediatric Unit of our hospital. The
identiﬁcation was performed by conventional methods and
conﬁrmed by PhoenixTM NMIC/ID, Becton Dickinson, USA
kits. Vancomycin resistance genotypes were determined by PCR
using VanA and VanB primers. Pulsed-ﬁeld gel electrophoresis
(PFGE) was used to evaluate the molecular relatedness of VRE
isolates.
Results: 12 VRE strains were isolated from screening samples (8
of them were from rectal swabs, 3 of them were from
surroundings of the beds and one of them was from skin of a
patient). All of the isolates were identiﬁed as Enterococcus
faecium. The isolated VRE strains were tested against vancomy-
cin, teicoplanin, ampicillin, linezolid by disc diffusion method
and also with PhoenixTM NMIC/ID panels. All of the strains
were resistant to vancomycin, teicoplanin, ampicillin and were
susceptible to linezolid by both methods. All the strains were
found to be VanA genotype by PCR. According to PFGE band
proﬁles, 2 different major PFGE band patterns (A, B) were
detected. Five of the 14 isolates belonged to PFGE pattern A
while 7 belonged to PFGE pattern B. There was one isolate
closely related with PFGE pattern A (A1) and one isolate closely
related with PFGE pattern B (B1).
Conclusion: After a ﬁrst time isolation of VRE in our laborat-
ory, the isolated VRE strains from the screening were important
because of being the ﬁrst isolation in our hospital and rarely
reported incidence in our country. The detection of two major
clones of VRE showed a nosocomial transmission according to
contamination. Early detection of patients colonized or infected
with VRE by performing survelliance cultures is an essential
component of any hospital programme designed to prevent
nosocomial transmission of VRE. We gave advices for the
eradication of VRE to the paediatric unit like the rational use of
antibiotics, education of the employees and taking serious
preventions on controlling VRE colonisation.
P1346
A nosocomial VRE outbreak in the context of
regional changes in VRE prevalence
D. Jonas, K. Biehler, A. Serr, M. Kist, A.-M. Fahr, M. Dettenkofer,
J. Hu¨bner, H. Bertz, F. Daschner (Freiburg, Heidelberg, DE)
Objective: A nosocomial outbreak of vancomycin-resistant
Enterococcus faecium (VRE) and reports on an increasing preval-
ence of VRE in the South-West of Germany led to this
investigation on the origin and the phylogenetic relation
between strains from different health care facilities throughout
Germany.
Methods: 188 VRE strains from a nosocomial outbreak and 82
VRE strains from 32 different health care facilities were assigned
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to genotypes primarily by use of ‘Multiple Locus Variant
Number of Tandem Repeats’ (MLVA). In addition, in esp+
strains the number of type A-repeats was determined. Results
were conﬁrmed by typing of selected strains by use of MLST
and PFGE. Finally, the structure of the vanA encoding Tn1546
was investigated by RFLP in regionally predominating geno-
types from different institutions.
Results: The outbreak investigation revealed one predominant
MLVA genotypeMT-159, which however could be distinguished
in two PFGE types. Combining the numbers of type A-repeats in
the esp gene with the MLVA types resulted in a concordant
discrimination of the two predominating outbreak strains with
three and four A-repeats, Accordingly, they are named 159_3 and
159_4 and corresponded to the MLST genotypes ST-203 and ST-
194, respectively. Both ST were single locus variants of ST-74, a
previous outbreak strain from the same hospital in the year 2002,
which also belonged to the lineage of purK-1 epidemic Entero-
coccus faecium strains. The strains of both recent genotypes were
detectable in different health care facilities in the South West of
Germany, including hospitals more than 200 km apart. More-
over, strains of MT-159_4 are present as vanA+, vanB+ and
vancomycin susceptible isolates, indicating that VRE of this MT
have been independently arisen at least twice. The analysis of the
Tn1546 by means of RFLP did not reveal any further differences
in the structure of vanA+ MT-159 strains from different regions.
Conclusions: Determination of the number of esp A-repeats
improves the discrimination of MLVA results. The close phy-
logenetic relation between the VRE outbreak strains in different
surrounding regions supports the assumption that resistance
can be regional problem rather than just a local problem in a
single hospital.
P1347
Epidemiology and control of a cluster of USA300
methicillin-resistant Staphylococcus aureus
(USA300-MRSA) skin/soft tissue infections in an
inner-city haemodialysis unit
C. Manierski, K. Obeid, K. Reyes, S. Davis, M. Ajluni, A. Singh,
M. Perri, S. Donabedian, D. Vager, M. Zervos (Detroit, US)
Background: The purpose of this study was to evaluate epi-
demiology, outcome and control measures for a cluster of
USA300 infections in an outpatient dialysis unit. USA300 strains
have been known to cause outbreaks of CA-MRSA, little
information is available on outcome of infection and dissemin-
ation in the health care setting.
Methods: The outpatient haemodialysis has 42 stations with a
capacity for 252 thrice weekly ESRD patients. The unit is
geographically located on an acute care hospital campus. Rates
of MRSA infection were 1.65/ 1000 patient dialysis days in 2005.
A cluster of USA300 skin/soft tissue infections was identiﬁed
and contact precautions were implemented. Anterior nares
surveillance cultures of a sample of patients and cultures of
environmental surfaces were obtained.
Results: Over a 22 week period, isolates were collected from all
MRSA skin/soft tissue infections, patient nares and environ-
mental surfaces. There were four patients and one health care
worker with USA300, PVL positive isolates. Patients with
USA300-MRSA (n 5) vs those with non USA300-MRSA (n 4) or
which were negative for MRSA (n 21) had a mean age of 43, 68
and 61 years, respectively. Sites of culture were skin/soft tissue
(80, 75, 0%) and nares (20, 25, 0%). 40, 50 and 29% had antibiotic
use or hospitalization (60, 75, 48%) within 3 months prior to
infection. HIV was present in 20, 0 and 0%. Duration of dialysis
was 1.8, 3.6 and 4.8 years. USA300 isolates were susceptible in-
vitro to multiple agents with the exception of beta-lactams,
clindamycin and erythromycin. USA300 infections were associ-
ated with recurrent disease (n 2), necrotizing pyomyositis (n 1)
and death (n 1). Non USA300 infections were associated with
panniculitis (n 1) and osteomyelitis (n 1). Patients with USA300
isolates were temporally and geographically clustered, environ-
mental surface cultures (n 23) were negative for USA-300, two
environmental surfaces yielded non-USA 300 MRSA. Further
spread was controlled by contact isolation precautions. Follow-
up surveillance cultures showed no further cases at 2 months.
Conclusion: USA300 isolates are increasingly common causes
of CA-MRSA infection. Prompt identiﬁcation and control are
needed to prevent dissemination of isolates in the health care
setting. Prolonged therapy may be needed for patients with
recurrent disease.
P1348
Outbreak of surgical site infections in a cardiac
surgical unit caused by an epidemic methicillin-
susceptible Staphylococcus aureus clone
M. Pujol, A. Hornero, O. Arch, A. Manzur, M.A. Dominguez,
A. Garcia, C. Pe&ntilde;a, F. Gudiol, J. Ariza (Hospitalet
Llobregat, ES)
Background: The ability of methicillin-sensitive Staphylococcus
aureus (MSSA) for causing nosocomial infection outbreaks
related to a single clone is poorly recognised. The aim of the
study was to describe a surgical site infection outbreak caused
by an epidemic MSSA strain.
Methods: Prospective surveillance and molecular typing.
Results: From July to September 2005, 6 patients who under-
went cardiac surgery developed severe post surgical cardio-
thoracic infections caused by MSSA: 5 patients had mediastinitis
and 1 a deﬁbrillator infection, all of them had bacteraemia.
Pulsed ﬁeld gel electrophoresis showed that all isolates
belonged to the same MSSA clone, resistant to penicillin and
susceptible to the other anti-staphylococcal agents. The detec-
tion of Panton Valentin Leucocidine was negative. Screening for
nasal carriage among the surgical team and ward personnel
(n = 63 persons), revealed carriage of the same MSSA clone
among 3 anaesthetists, 1 surgeon, and 5 ward nurses. Rein-
forcement of barrier measures during surgery and nasal decon-
tamination with mupirocin of carriers of the epidemic strain
stopped the outbreak.
Conclusions: We identiﬁed an epidemic MSSA clone as respon-
sible for an outbreak of surgical infections among surgical
cardiac patients. The identiﬁcation of this strain among patients
and sanitary personnel shows that invasive MSSA clones may
cause nosocomial outbreaks as has been widely recognised for
MRSA.
P1349
Food-borne nosocomial outbreak of Salmonella
enterica serotype Enteritidis in a teaching
hospital in Greece
A. Gikas, S. Maraki, E.I. Kritsotakis, D. Babalis, M. Roumbelaki,
E. Scoulica, C. Panoulis, E. Saloustros, E. Kontopodis,
G. Samonis, Y. Tselentis Heraklion, GR
Objectives: To report a nosocomial outbreak of salmonella
food-poisoning in a tertiary-care hospital in Crete, Greece.
Methods: Epidemiological (case-control study), microbiological
(stool, blood cultures), environmental (food, water cultures) and
molecular (PFGE, ribotyping of isolates) examinations were
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employed in order to investigate and control the outbreak. A 2-
month clinical follow-up study was also carried out in order to
identify complications.
Results: In total, 133 enteritis cases were detected: 86 inpatients,
16 staff members and 31 visitors. Cases were scattered in 20/32
wards and all developed symptoms from 19 to 22 July 2005. The
epidemic curve suggested a point source (ﬁgures 1, 2). Statis-
tically associated with illness were: roasted chicken (OR 23.9;
p < 0.001), spaghetti (OR 13.4; p < 0.001) and crumbled cheese
(OR 4.5; p < 0.001). Roasted chicken was considered as the
probable transmission vehicle, since (a) 63% of cases did not eat
cheese, 90% of whom had consumed chicken; (b) all 18 cases in
the cardiology ward had consumed chicken, but not cheese. No
leftovers from implicated foods were available and environ-
mental sampling did not yield salmonella. S. enterica serotype
enteritidis was cultured from 64 stool and 6 blood patient
specimens. The strain was also cultured from 3 food-handlers (2
were asymptomatic) and sliced cheese stored in kitchen refrig-
erators, indicating cross-contamination of the roasted chicken
due to inappropriate food handling. PFGE and ribotyping
patterns of all isolates were identical, verifying the common
source. Macroscopic inspection of catering facilities guided the
interventions to food hygiene issues. Particular emphasis was
given to improving the existing Hazard Analysis and Critical
Control Point (HACCP) system. Quinolones were administrated
to all patients. Eleven patients presented serious complications:
7 suffered acute renal failure; 1 had a mild pancreatic reaction; 1
immunocompromised patient presented nosocomial pneu-
monia; whereas 2 presented decompensation of serious under-
lying diseases and subsequently died. The remaining patients
were discharged from the hospital.
Conclusion: This outbreak serves as a reminder of the impact of
Salmonella spp. food-poisoning in hospitals and underscores the
importance of establishing and systematically reviewing
HACCP systems in health-care institutions.
P1350
A Chryseobacterium meningosepticum
colonisation outbreak in a neonatal intensive care
unit
E. Galanakis, S. Maraki, E. Scoulica, A. Manoura,
C. Giannacopoulou, Y. Tselentis (Heraklion, Crete, GR)
Objective: The aim of this study was to report epidemiologic,
bacteriologic, and clinical features of a Chryseobacterium men-
ingosepticum outbreak in a neonatal intensive care unit (NICU) of
a referral teaching hospital.
Outbreak investigation: From April to October 2002, a strain of
C. meningosepticumwas isolated from four neonates in the NICU.
All neonates were colonized in the endotracheal tubes and
respiratory secretions but none of them progressed to clinical
infection. C. meningosepticum was multiresistant. None of the
neonates received speciﬁc antibiotic treatment. Pulse-ﬁeld gel
electrophoresis of isolates showed them to be representatives of
a single strain. Environmental surveillance did not reveal the C.
meningosepticum source. The outbreak was only controlled by
reinforcing of the usual measures, giving increased emphasis on
routine hand hygiene among healthcare workers, without a
need of restriction of further neonatal admissions or of thorough
disinfection of the NICU. No additional colonization/infection
was conﬁrmed for more than a year after the last case.
Conclusion: This study suggests that C. meningosepticum colon-
ization in neonates does not necessarily lead to clinical infection
and that such colonization outbreaks may be controlled with
emphasis on the standard precautions.
P1351
Spreading of beta-lactamase genes among
nosocomial isolates collected from Moscow
clinics
N.K. Fursova, A.N. Kruglov, I.V. Abaev, Y.N. Kovalev,
E.I. Pecherskikh, E.I. Astashkin, D.M. Pachkunov, S. Pryamchuk,
V.A. Anisimova, M.E. Mitzevich (Obolensk, Moscow, RU)
Objectives: Characterization of the Enterobacteriaceae nosocomi-
al strain collection on the presence of Extended Spectrum Beta-
Lactamase (ESBL) genes belonged to TEM, SHV, and CTX-M
groups.
Methods: Identiﬁcation of the strains was done using commer-
cial panels for the automatical identiﬁcation system MicroScan
DadeBehring. Strain resistance proﬁles was determined using
disc diffusion method. ESBL-test was done using Double-disc
method. Minimal inhibition concentrations (MICs) of antibiotics
were determined using microdilution method in Muller-Chin-
ton media on the plates. ESBL genes have been studied to
present by PCR.
Results: Collection of ESBL-producing Enterobacteriaceae strains
from 12 inspected Moscow clinics have been collected during
January-September, 2005. It contains: Klebsiella strains - 35.9%
(including Klebsiella pneumonia 34%), E. coli-29%, Enterobacter -
15%, Citrobacter - 10%, Proteus - 4.9%,Morganella - 3.5%, Serratia -
2%, Hafnia alvei - 1%. PCR analysis of 94 bacterial strains has
shownpresence of ESBLgenes alone and in several combinations:
TEM – 6.4%, CTX-M – 26.6%, SHV- 1%, CTX-M+SHV -26.6%,
CTX-M+TEM – 16%, TEM+SHV – 8.5%, CTX-M+TEM+SHV –
8.5%, and without any ESBL genes – 6.4% strains.
Conclusion: Epidemiology situation in some Moscow clinics
was estimated using PCR screening. ESBL phenotypes of
nosocomial strains under study are provided by different
compositions of beta-lactamase genes depending on bacterial
genus. Most E. coli have CTX-M or CTX-M+TEM (84%); Klebsiella
pneumonia - CTX-M or CTX-M+SHV (85%); Morganella - CTX-M
(80%); Proteus mirabilis – CTX-M+TEM (100%); Citrobacter
freundii – TEM (57%); Enterobacter cloacae – TEM+SHV (45.5%).
Following studies will be concentrated on regulatory mecha-
nisms of bacterial resistance in isolates collection under inves-
tigation.
P1352
An epidemic of hospital-acquired bacteraemia
due to Alcaligenes denitriﬁcans: true threat or
ﬁghting windmills?
H. Moraitou, M. Makarona, A. Gioga, I. Kousseris, E. Galani,
N. Makrygiannis, S. Triantafyllou, A. Pefanis, S. Kanavaki
(Athens, GR)
Objectives: We encountered 18 cases of bacteraemia, in differ-
ent wards throughout our hospital, during a 10-month period
(09/2004 – 07/2005), caused by a Gram(-), non-fermenting,
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oxidase(+) bacterium, identiﬁed ﬁrstly as Comamonas testosteroni,
by the Api NE system (Biomerieux, France). The unusual high
frequency of bacteremias prompted us to ensure the accurate
identiﬁcation of the strains and the epidemiology of the clinical
cases.
Methods: The strains were collected and retrospectively iden-
tiﬁed by Vitek2 updated GN cards (Biomerieux, France), as well
as by Api 32 GN system (Biomerieux, France). The antibiotic
sensitivity proﬁle was tested by standard Kirby-Bauer method,
and all strains were analysed by PFGE, to investigate the
epidemiology of the infection. Bactec 9240 system was used to
incubate and to identify positive blood cultures. Bottles with
different lot numbers were used for sampling during the
examined period.
Results: The strain formerly identiﬁed as C. testosteroni, was
proved to be Alcaligenes denitriﬁcans subsp. denitriﬁcans, by all
methods used. Disk susceptibility testing showed that all isolates
were resistant to aminoglycosides and most cephalosporins, but
were susceptible to piperacillin, imipenem, ceftazidime and
trimethoprim-sulfamethoxazole. The PFGE proved identical for
all strains analysed. Regarding the clinical status most patients
showedno clinical signs of septicemia. All of themhad peripheral
venous catheters in place during the day of the reported
bacteraemia. In all cases only one bottle, of the multiple blood
culture sets,waspositiveperpatient.Nonewcases of bacteraemia
due to A. denitriﬁcans were identiﬁed in our hospital since July
2005. Since the study was retrospective, it was not possible to
further investigate the source of the bacteraemia.
Discussion: A. denitriﬁcans is often considered as a colonizer,
although several outbreaks of hospital-acquired infections have
been reported in the literature, due to bacterial contamination of
antiseptic solutions, central venous catheters, etc. Five cases of
pseudo-bacteraemia due to contamination of ESR tubes have
been also reported. In the present report PFGE results showed
that all strains were identical, which is a clue of a true outbreak.
However, the diversity of clinical signs and outcome, the
widespread of the infection and the sudden ending of the
‘epidemic’ make us sceptical as whether we experienced a true
bacteraemia or a pseudo-bacteraemia.
P1353
Infections with hepatitis B and C viruses in
haemodialysed patients
A. Pisula, E. Janczewska-Kazek, A. Piskorowska-Plis,
J.Wieczorek,A. Boron-Kaczmarska (Opole, Chorzow, Szczecin, PL)
Objectives: Infections with Hepatitis B (HBV) and C (HCV)
viruses are common in Poland. Patients treated with hemodi-
alyses (HD) in hospital conditions are the ones most susceptible
to the infection.
Methods: We analysed medical records of 297 patients with
end stage renal failure, treated in the years 2000–2004 in 6
dialysis units which operate 59 hemodialysers in total. The
retrospective analysis was made on the basis of medical
documentation, analysis of medical procedures conducted,
blood treatment and preventive vaccinations.
Results: Number of HBV infected among HD systematically
decreases from 11% in year 2000 to 4.5% in year 2004. Such
signiﬁcant decrease in the number of infections was possible to
achieve thanks to systematically conducted protective vaccina-
tions, implemented in the pre-dialysis period or in the moment
of ﬁrst dialysis. Correctly performed vaccinations resulted in
immunization of 77% HD. About 7.0% of HD required addi-
tional inoculations (anti-HBs titre <10 IU). The HD patients
population susceptible to a possible infection had been limited
to 18.5%. HCV infection pose a decidedly more serious problem.
The number of infected patients hasn’t decreased in the years
2000-2004. HCV was newly diagnosed in 70 HD who may be a
potential source of infection. The analysis of the new infections
indicates a dialysis unit as the place of transmission in 9 of the
cases. The reason for the spread of the infection in one of the
dialysis stations was, most probably, the process of dialysers re-
utilization (4 cases). In the material analysed, a connection
between the duration of dialysis therapy, and the number of
HCV infection in HD was conﬁrmed (6% after 1 year, 45% after
10 years). No time relation between transfusions and the change
in the patient’s serologic status has been found. The use of
erythropoietin (EPO) among HD increases systematically (an
208% increase from year 2000 till 2004) and replaces red blood
cells concentrate (RBC) transfusions.
Conclusion: Transmission of an HBV infection among dialyzed
patient systematically decreases due to effective immunization
of the susceptible population. Number of hemodialysed patients
infected with HCV does not decrease and stays on a high level.
Transmission of HCV among HD is connected with inappro-
priate compliance with sanitary standards. Blood and its
products possess a low risk of HBV/HCV transmission among
HD in Poland.
P1354
Phenotypes and genotypes of slime positive -
methicillin-resistant Staphylococcus epidermidis
clinical isolates
A. Foka, V. Chini, E. Petinaki, F. Kolonitsiou, E.D. Anastassiou,
G. Dimitracopoulos, I. Spiliopoulou (Patras, Larissa, GR)
Objectives: Methicillin-resistant-coagulase negative staphylo-
cocci (MR-CNS) constitute a major cause of hospital infections,
especially in neonatal intensive care units (nICU). Staphylococcus
epidermidis is the predominant species associated with clinically
relevant infections. The role of bioﬁlm formation as a major
factor in CNS infections, especially among patients with inva-
sive procedures, such as implanted prosthetic devices and
intravascular catheters, is well established. The purpose of the
present study was to correlate slime production with the
presence of ica operon and clones among methicillin-resistant
S. epidermidis (MRSE) isolated from different patients hospital-
ized in the nICU of our University Hospital.
Methods: The MIC of oxacillin was determined by the agar
dilution method in Mueller-Hinton supplemented with 2%
NaCl, according to the guidelines of NCCLS. The presence of
mecA gene was investigated by Southern blot hybridization of
ClaI digests with a mecA DNA probe. Susceptibility proﬁles
were performed, by the E-test method against: tobramycin (Tm),
amikacin (Ak), gentamicin (Gm), netilmicin (Net), quinupristin-
dalfopristin (Rp), linezolid (Lin), erythromycin (Em), clindamy-
cin (Cm). The MICs of vancomycin (Va) and teicoplanin (Tp)
were determined by the agar dilution method, according to the
NCCLS guidelines. Slime production was detected by qualitat-
ive and quantitative methods. PCR was performed for the
detection of ica operon, (genes icaA, icaD, icaB, icaC) and the
insertion sequence element IS256. Clonal types were identiﬁed
by PFGE of chromosomal DNA SmaI digests.
Results: All 115 MRSE isolates were mecA positive while 106
(92.2%) produced slime. Ninety two (87%) slime-producing
isolates had all four ica genes tested, whereas the rest possessed
different combinations. Seventy four (70%) slime-positive iso-
lates belonged to the same PFGE type, named z. Four strains
belonged to PFGE type g and the rest 28 (26%) were classiﬁed
into 27 different PFGE types. All PFGE type z isolates exhibited
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the same resistance phenotype to Em, Cm, Ak, Gm, Tm. PFGE
type g isolates showed a common resistance phenotype to Em
and Cm, with the exception of one strain.
Conclusions: One dominant PFGE type z is characterized
among the slime-producing MRSE tested, resistant to Em, Cm,
Ak, Gm, Tm. This multi-resistant slime-producing clone is
spread in the nICU associated with bloodstream and catheter
infections.
Multidrug-resistant Gram-negative organisms: survey and risk
factors
P1355
Antimicrobial resistance of Enterobacteriaceae
isolated from patients in Austrian intensive care
units
C. Jebelean, H. Mittermayer (Linz, AT)
Objective: To investigate the epidemiology of the antimicrobial
resistance of Enterobacteriaceae isolated from intensive care unit
(ICU) patients in 43 Austrian hospitals.
Methods: 571 strains of Enterobacteriaceae (193 E. coli, 150
Klebsiella spp., 109 Enterobacter spp., 50 Proteus spp., 69 strains
of other species) isolated in clinical laboratories from 8 different
regions of Austria between January 2005 through September
2005 were tested for susceptibility to ampicillin/sulbactam (A/
S), piperacillin/tazobactam (P/T), cefazolin (CZ), cefoxitin
(FOX), cefuroxim (CXM), cefotaxim (CTX), ceftazidim (CAZ),
cefepim (FEP), gentamicin (G), ciproﬂoxacin (CI) and imipenem
(IM) using the agar dilution method as recommended by CLSI.
The strains with CAZ or CTX MIC >1 mg/L were further
investigated for the production of ESBL using 3 E-test strips:
TZ/TZL, CT/CTL, PM/PML. For interpretation we used the
breakpoints as recommended by CLSI.
Results: Overall, the rates of susceptibility were: A/S 51%, P/T
86%, CZ 37%, FOX 64%, CXM 65%, CTX 87%, CAZ 86,4%, FEP
95,8%, G 94%, CI 88%, and IM 100%. For A/S and CZ higher
resistance rates were encountered in Salzburg: 62% and 69%;
Carynthia: 58% and 73%; and Vienna: 53% and 66%, respect-
ively, whereas CI resistance was more prevalent in Vienna (22%)
and Upper Austria (13%). The CI resistance was higher in E. coli
17% and Proteus spp. 14%, as compared to Klebsiella spp. and
Enterobacter spp. 11% and 9%, respectively. The rates of
resistance to 3rd gen Cephs and CI were higher in the medical
ICUs as compared to mixed and surgical ICUs. The rates of
ESBLs in E. coli and Klebsiella spp. were higher in surgical ICUs
(7,5%) as compared to medical (5,7%) and mixed ICUs (3%). The
ESBL strains were concentrated in some hospitals were they
reached 33% of E. coli or 25% of Klebsiella spp.
Conclusions: Although the overall antimicrobial resistance rates
were moderate (with the exception of CZ, A/S and CXM), the
emergence of CI resistance in isolates of Enterobacteriaceae (with
rates as high as 43% in some ICUs) and the associationwith potent
ESBLs in some strains is of great concern.
P1356
Risk factors for polymyxin-only susceptible
Pseudomonas aeruginosa bacteraemia
P. Koletsi, P. Kopterides, A. Michalopoulos, Z. Mastora, K.
Rellos, M. Falagas (Athens, GR)
Objectives: To identify risk factors associated with the devel-
opment of polymyxin-only susceptible (POS) P. aeruginosa
bacteraemia.
Methods: Case-control study performed in a tertiary-care hos-
pital in Athens, Greece (01/2002-08/2005).
Results: Our study population consisted of 56 patients with P.
aeruginosa bacteremia. In 16 of these patients (28.6%) the isolate
was susceptible only to polymyxins (POS group) and in 40
(71.4%) the isolate remained sensitive to carbapenemes (non-
POS group). Mortality was 62.5 % and 37.5% for the POS and
non-POS group, respectively (p = 0.09). Bivariable analysis
showed that exposure to carbapenems (p = 0.001), quinolones
(p = 0.043), metronidazole (p = 0.035), and glycopeptides
(p = 0.018) as well as admission to the intensive care unit
(ICU) (p = 0.023), tracheotomy (p = 0.035), steroid treatment
(p = 0.008) and parenteral feeding (p = 0.008) were associated
with isolation of a POS strain among patients with P. aeruginosa
bacteremia. The multivariable analysis showed that only prior
use of carbapenem was an independent risk factor (OR, 9.0; 95%
CI, 2.4–34.3; p = 0.001) for development of POS P. aeruginosa
bacteremia.
Conclusion: The results of this study provide insight into the
rising problem of POS P. aeruginosa bacteremia by showing that
is associated with a high mortality and highlighting that prior
carbapenem use as an independent risk factor for its develop-
ment.
P1357
Exposure to ﬂuoroquinolones is a risk factor for
polymyxin-only susceptible Acinetobacter
baumannii bacteraemia
P. Kopterides, P. Koletsi, P. Morfou, K. Rellos, Z. Mastora,
M. Rizos, M. Falagas (Athens, GR)
Objectives: Previous studies have examined risk factors for
multidrug-resistant (MDR) A. baumannii, including carbapenem-
resistant strains. However, there is an epidemic of infections due
to A. baumannii resistant to all available antibiotics except
polymyxins in several parts of the world. Thus, we aimed to
explore the risk factors associated with bacteremia due to
polymyxin-only susceptible (POS) A. baumannii.
Methods: We conducted a retrospective, cohort study of
patients with A. baumannii bacteremia who were hospitalized
during 01/Jan/2002–31/Aug/2005 at the ‘‘Henry Dunant’’
Hospital, Athens, Greece. To identify risk factors for develop-
ment of POS A. baumannii bacteremia, the distribution of several
variables between patients with bacteremia due to POS A.
baumannii was compared with that of patients with bacteremia
due to A. baumannii susceptible to other antibiotics besides
polymyxins.
Results: Thirty-nine patients with bacteremia due to A. bau-
mannii (35 ICU and 4 ward patients) were studied. Twenty-ﬁve
patients (64%) had POS A. baumannii bacteremia while the rest
(36%) had bacteremia due to A. baumannii susceptible to
polymyxins as well as carbapenems. Mortality was 56% (14/
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25) and 35.7% (5/14) for patients in the two groups, respectively
(P = 0.22). The bivariable analysis showed that prior exposure to
ﬂuoroquinolones (P = 0.01) and antipseudomonal penicillins
(P = 0.004) was associated with isolation of a POS strain among
patients with A. baumannii bacteremia. The multivariable ana-
lysis using a backward logistic regression model showed that
only exposure to ﬂuoroquinolones was associated with devel-
opment of POS A. baumannii bacteremia (OR, 11.6; 95% CI 2.4 –
55.9; P = 0.02).
Conclusion: The appearance of POS Acinetobacter baumannii
infections represents a major threat to hospitalized patients.
Exposure to ﬂuoroquinolones is an independent risk factor for
development of POS A. baumannii bacteremia.
P1358
Multiresistant strains of Escherichia coli isolated
from dogs
M. Totaro, M. Corrente, A.L. Bellacicco, V. Martella, G. Greco,
C. Buonavoglia (Valenzano, IT)
Objectives: To analyse the antimicrobial susceptibility of
Escherichia coli isolates from ill and healthy pups.
Methods: Fifty-one strains of E. coli were isolated from 47 pups
(mean age of 2 months). Thirty-four animals were from kennels,
9 were from private owners and 4 were free-ranging dogs.
Thirty-one isolates were obtained from ill animals while 20
isolates were obtained from faecal samples of healthy dogs. All
the strains were tested for susceptibility to 20 antimicrobial
drugs by the agar diffusion method. The strains resistant to at
least one extended-spectrum cephalosporin and/or augmentin
were also analysed by the double-disk test and by a PCR speciﬁc
for the blaAmpC, blaTEM, blaSHV and blaCTX-M-type genes
that encode for beta-lactamases.
Results: Twenty-four out of 31 E. coli strains (77.3%) isolated
from ill dogs displayed a multiresistant pattern, i.e. they were
resistant to three or more drugs of different classes. In detail,
96.8% of the strains were resistant to sulfamethoxazole, 90.2% to
streptomycin, 67.6% to co-trimoxazole and ciproﬂoxacin, 54.7%
to doxycycline. One strain was resistant to imipenem. Only 2
isolates (6.4%) displayed resistance to a single drug. Seven
strains were found to be resistant to cephalosporins and/or
augmentin and positive to the double-disk test. By PCR, 3 such
isolates were found to possess the blaAmpC, blaTEM and
blaCTX-type genes, while 1 possessed only the blaCTX-type
gene and 1 displayed only the blaAmpC-type gene. None of the
isolate had the blaSHV-type gene. By contrast, multiresistance
was detected only in 1 out of 20 E. coli isolates (5%) derived from
healthy dogs. The rate of resistance observed in such strains was
signiﬁcantly lower than that of the strains isolated from ill dogs
(Fisher exact test, p < 0.001).
Conclusion: Analysis of E. coli strains revealed resistance to
new-generation molecules, that are used commonly in human
therapy, such as ciproﬂoxacin, imipenem and cephalosporins,
although most samples were from pups housed in kennels,
suggesting frequent exposure of animals to humans micro-
organisms. Altogether, the ﬁndings of the present investigation
highlight the need for surveillance of antibiotic resistance in E.
coli strains of animal origin. In particular, the detection of
multiresistant strains in family pets, that live in close contact
with owners, underscores the risks of transmission to humans of
E. coli strains bearing resistance to antimicrobials of new
generation.
P1359
Clonal diversity and distribution of tetracycline
resistance genes among E. coli strains isolated
from aquatic environments
R. Cernat, V. Lazar, M.C. Balotescu (Bucharest, RO)
Introduction: The presence of more than one efﬂux-mediating
tet gene in clinical and environmental E.coli strains is well
documented.
Aim: to delineate the clonal diversity and transmission patterns
and to investigate the occurrence and distribution of tet genes to
antibiotic resistant E.coli strains isolated from aquatic sources.
Methods: 12 E. coli strains from fresh and polluted waters were
studied for (i) antibiotic susceptibility by disc diffusion, double-
disc and inductibility disc diffusion tests, and MICs values, (ii)
plasmid DNA proﬁles, RAPD and Rep-PCR ﬁngerprinting,
PFGE restricted with XbaI and 16S rDNA sequences, and (iii)
screening for the presence of tet genes using multiplex-PCR
(tetA-tetG, tetH, tetJ, tetY, tetZ and tet30). PFGE, RAPD and
Rep-PCR patterns were compared into clonal groups and
variants using UPGMA algorithms. The 16S rDNA amplicons
were directly sequenced and Blast searches against GenBank
and RDPII databases were performed.
Results: All E.coli strains showed multiple antibiotic resistance
phenotype without ESBL or inducible beta-lactamase produc-
tion, with 100% resistance to AM, CM and TC, 80% to
cephalosporins, 60% to aminoglycosides, 20% to quinolones.
Plasmid DNA proﬁles showed variable number of plasmids
ranging from 80 bp to >50 kb. Genomic DNA digested with
XbaI produced an average of 30 fragments ranging between 1.0–
70.0 kb. 4 of epidemiologically related strains were classiﬁed in
two clusters by Rep-PCR and RAPD. Most informative proﬁle
was obtained with PFGE analysis, only 1 cluster with two strains
being identiﬁed; the remaining 10 strains were not related to the
clonal strains. 16S rDNA analysis identiﬁed 1 and 2 phylogenet-
ic clusters grouping strains isolated from fresh and polluted
waters. The aquatic E.coli strains are phylogenetically diverse
from the clinical E.coli strains. Multiplex-PCR screening showed
the prevalence of the tet (A) and tet (B) genes (100% of the
isolates) followed by tet(D) gene (53%).
Conclusion: According with the isolation source, E.coli strains
belonged to 2 genetically diverse populations, with only one
cluster of related strains isolated from the polluted waters, 8
unrelated isolates having possible clonal relatedness. Both
RAPD and PFGE are suitable for molecular typing of environ-
mental E. coli isolates. All isolates carried more than one tet gene
responsible for the active efﬂux-mediated resistance and there-
fore for the multiple antibiotic resistance phenotypes.
P1360
Laboratory identiﬁcation and transmission of
Burkholderia cepacia and Stenotrophomonas
maltophilia in an intensive care unit
W. Pﬁster, W. Barclay, F. Gerlach, E. Straube (Jena, DE)
Objectives: Aim of our study is to assess identiﬁcation and also
transmission of strains of B. cepacia and S. maltophilia isolated
from patients of an interdisciplinary ICU over a 5-year period by
pulsed-ﬁeld gel electrophoresis.
Methods: 32 clinical isolates of B. cepacia and 112 strains of S.
maltophilia were cultivated from 144 patients. Strains were
obtained from BAL of 98 patients (68,1%), from wound materials
of 35 patients (24.3%) and from blood cultures of 11 (7.6%)
patients. Copy strains were excluded. Identiﬁcation of the
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isolates was performed phenotypically by means of the identi-
ﬁcation system api 20 NE (bioMerieux, Marcy l‘Etoile, France).
Genotypical identiﬁcation of the B. cepacia strains was per-
formed by determination of the rec A-gen by PCR followed by
nucleotide sequencing. Antibiotic resistance of the strains was
assessed by determination of MICs using microbouillon dilution
technique (Micronaut S GENARS GN 3, Merlin, Bornheim-
Hersel, Germany). For determination of the genotypes of the B.
cepacia strains pulsed-ﬁeld gel electrophoresis analysis using Spe
restriction enzyme and GenPath group 3 reagents kit (Bio-Rad,
Hercules, CA, USA) and for the DNA macrorestriction analysis
of S. maltophilia XbaI restriction enzyme and GenPath group 6
reagents kit (Bio-Rad, Hercules, CA, USA) were used.
Results: 21.9 % of the B. cepacia strains tested were in vitro
sensitive against ceftazidime (CAZ), 40.6% against ciproﬂoxacin
(CIP) and 53.1% against cotrimoxazole (SXT). The S. maltophilia
isolates had following sensitivity rates: CAZ 37.5%, CIP 22.9%,
SXT 96.5%. All B. cepacia strains had the rec A-gen with identical
nucleotide sequences. PFGE analysis of the B. cepacia strains
showed the same genotype in all patients whereas PFGE
analysis of the S. maltophilia isolates revealed for most of the
patients different genotypes of this species. Only 25 of the 144
patients (17.4%) had the same PFGE type.
Conclusions: Determination of the rec A-gen improves identi-
ﬁcation of B. cepacia in clinical laboratory. Transmission of B.
cepacia from one patient to another in ICU is obviously very
common and has to be avoided. All infections observed in our
ICU were hospital acquired. Infections in hospitals with S.
maltophilia seem to be different. According to our results a
transmission of strains in ICU occurs only in 17.4% of the
patients. This means that most of the patients have already got
their own S. maltophilia strain when coming to the ICU.
P1361
Is Stenotrophomonas maltophilia an emerging
pathogen in German ICUs?
E. Meyer, F. Schwab, P. Gastmeier, H. Ruden, F. Daschner,
D. Jonas (Freiburg, Berlin, Hannover, DE)
Objective: We analysed over a period of 4 years the proportion
of S. maltophilia on all SARI isolates (Surveillance of Antimicro-
bial Use and Antimicrobial Resistance in Intensive Care Units)
and the incidence density of nosocomial infections (NI) caused
by S. maltophilia (data from KISS the German Hospital Infection
Surveillance System).
Methods: The proportion of S. maltophilia on all SARI isolates
(%SM) is deﬁned by dividing the number of S. maltophilia by
the total number of SARI isolates multiplied by 100, the
incidence density of S. maltophilia (SM/1000 pd) by dividing
the number S. maltophilia isolates by the total number of the
patient days multiplied by 1000. The incidence density of NIs
caused by S. maltophilia is deﬁned by dividing the number of
NIs caused by SM by the total number of the patient days
multiplied by 1000.
Results: The data of 34 ICUs continuously participating in SARI
from 2001 to 2004 were analysed. The data cover a total of 51,536
isolates and 576,446 patient days. Pooled mean %SM was 2.4
(median 2.0, range 0.7–6.9) and pooled mean incidence density
of S. maltophilia was 2.2 (median 1.6, range 0.2–7.6). The
incidence density of NIs caused by S. maltophilia ranged between
0–0.467 with a mean at 0.134. Over a period of 4 years no
signiﬁcant change in %SM (17 ICU had an increase, 17 an
decrease) or in SM/1000 pd was observed. Antibiotic consump-
tion was statistically not different in the two groups. Neither
increased the incidence density of NIs caused by S. maltophilia
signiﬁcantly between 2001 and 2004.
Conclusion: S. maltophilia not revealed to be an emerging
pathogens in 34 German ICUs over the last four years.
P1362
Achromobacter xylosoxidans from the airway
secretions of patients with cystic ﬁbrosis
H. Alexandrou-Athanasoulis, S. Doudounakis, A. Sergounioti,
K. Halmouki, A. Pangalis (Athens, GR)
Achromobacter xylosoxidans (Ax) is a potential pathogen, which
has been increasingly recovered from the sputum of patients
with CF last years.
Objectives: The aim of our study was to determine trends in
prevalence of this microorganism in patients with CF and to
evaluate its resistance to the antibiotics. We reviewed retrospec-
tively the clinical, demographic and laboratory data of the 388
patients with CF who have been attended our hospital between
01/2000-11/2005 for at least one year. During this period 6100
sputum or deep throat specimens were cultured. The identiﬁ-
cation was made by the API 20NE, as well as by the Vitek II
automated system (Biomerieux). The antibiotic resistance was
evaluated by the Kirby-Bauer and the Vitek II methods.
Results: 1) Positive for A. xylosoxidans were 53 cultures, corres-
ponding to 19 patients (4.9 %) (12 males and 7 females).2) The
mean age of patients at the 1st isolation of A. xylosoxidans was
6.7 y (SD: 3.9).
3) A. xylosoxidans has been repeatedly isolated from seven of the
patients (36.8%), whereas twelve of these patients (63.2%) had
only one or two positive cultures.
4) A. xylosoxidans was the only microorganism isolated from 16 of
the 53 positive for Ax specimens, while the other yielded two
(26) or three (11) bacterial species. The most frequent co-isolated
microorganism was P. aeruginosa (18 specimen), followed by S.
aureus (4), H. inﬂuenzae (2), and Pseudomonas spp (2). In addition
to Ax, seven cultures yielded P. aeruginosa and S. aureus, two P.
aeruginosa and Candida albicans, one P. aeruginosa and S. aureus
and one Pseudomonas spp and S. aureus
5) All strains were sensitive to piperacillin, piperacillin/tazobac-
tam, whereas sensitivities to other antibiotics tested (%) were:
ticarcillin (76.4), ticarcillin + clavulanic acid (88.2), ceftazidime
(67.1) cefepime (29.4) imipenem (67.1), meropenem (64.7), co-
trimoxazole (47.1) and colistin (76.4) respectively.
Conclusions: 1. A. xylosoxidans has been harboured by 19 (4.9
%) of our patients. 2. The mean annual incidence rate showed no
changes. 3. Piperacillin and piperacillin/tazobactam were the
most effective antibiotic for this species followed by ticarcil-
lin + clavulanic acid.
P1363
Genotypic and phenotypic analysis of
Pseudomonas aeruginosa isolates from sputum of
patients with cystic ﬁbrosis following
antimicrobial treatment
O. Perovic, E. Marais, A. Duse, M. Mer, G. Richards,
O. Perovic (Johannesburg, ZA)
Objectives: The study aimed to determine genotypic and
phenotypic characteristics of P. aeruginosa strains isolated from
sputum specimens before, during and after antibiotic treatment
in cystic ﬁbrosis (CF) patients who were routinely admitted for
14 days of therapy every four months for 1 year.
Methods: Only CF patients permanently colonized with P.
aeruginosa were enrolled in the study. Sputum samples were
collected ‘‘pre’’, ‘‘during’’ and ‘‘post’’ treatment with antimi-
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crobial therapy. Microscopy, culture, quantitative bacterial
count (CFU) and susceptibility testing were performed. All
isolates were evaluated phenotypically as mucoid or nonmucoid
strains. Multiple drug resistance (MDR) was deﬁned as resist-
ance to more than two classes of anti-pseudomonal drugs. P.
aeruginosa isolates were all identiﬁed using API 20 NE. Antibi-
otic susceptibility testing was performed using the disk diffu-
sion method.Macrorestriction analysis using 30U XbaI and
pulsed ﬁeld gel electrophoresis (PFGE) was performed. The
PFGE patterns were compared visually and Tenover criteria
used to assess relatedness.
Results: A total of 163 phenotypically different strains of P.
aeruginosa were identiﬁed from 14 patients. The number of
mucoid strains decreased from 22 at the ﬁrst to 10 at the third
visit and 9 patients showed a more than 2 fold decrease in CFU
(Table 1).Five of 7 patients with MDR isolates demonstrated the
same susceptibility pattern throughout the course of treatment
in all 3 visits.The PFGE patterns of 4 of 13 patients from sputum
from 3 visits were indistinguishable. In another 4 patients, minor
band differences were observed (less than 3 bands) between
isolates over the treatment period, with 1 strain having 5-band
difference. This shows that the strains were in all probably
related, but have started to diverge. No interpatient strain
similarities were found.
Conclusion: Although all the patients were colonized with
genotypically indistinguishable strains of P. aeruginosa, these
demonstrated phenotypic variability in the form of colony
morphology and multi drug resistance. This reﬂects the ability
of organism to survive and adapt to host immune mechanisms.
Antimicrobial treatment decreased the total number of P.
aeruginosa strains but had no effect on MDR isolates. The
diversity of the strains between patients in this study suggests
that transmission amongst patient did not occur and that the
patients obtained their strains from different environments.
P1364
Genodiversity of resistant P. aeruginosa in ICUs
varies in relation to antimicrobial usage and
resistance rates
D. Jonas, E. Meyer, F. Schwab, B. Spitzmu¨ller, F. Daschner,
H. Grundmann (Freiburg, Berlin, DE; Bilthoven, NL)
Objectives: The prevalence of resistant strains in health care
institutions depends on the selection of imported resistance
traits and the rate of spontaneously arising mutants, but can also
be due to expansion by cross-transmission of resistant strains.
To improve our understanding of the underlying dynamics, the
frequency of different genotypes was determined in P. aerugi-
nosa isolates from ICUs and correlated with antimicrobial usage
densities (AD) and resistance rates (RR). The numbers of
indistinguishable genotypes found were considered as an
indirect measure of cross- transmission events.
Methods: From the German SARI surveillance project, 273
ciproﬂoxacin- and 317 imipenem-resistant isolates of P. aerugi-
nosa were obtained from 29 ICUs, together with unit - based
antimicrobial consumption data (AD) and resistance rates (RR).
Additionally, for one month in spring 2003, the participants
collected a cross sectional sample of 146 clinical P. aeruginosa
isolates irrespective of the antimicrobial susceptibility. ICUs
were grouped according to their relative positions above or
below the median RR and AD of all ICUs. All strains were
assigned ICU-based to genotypes by use of AFLP. ICU-speciﬁc
diversity (Div) was expressed as the numbers of different
genotypes per numbers of typed strains per ICU.
Results: In ICUs with high RR and low AD, the genodiversity
of resistant P. aeruginosa - isolates was signiﬁcantly lower (Fisher
P < 0.05) than in those ICUs that featured low RR in the
presence of high AD. No such differences could be shown in the
cross sectional sample of P. aeruginosa isolates irrespective of
their antimicrobial susceptibility. RR correlated with AD. How-
ever, in ICUs with a low diversity of resistant P. aeruginosa -
isolates there was a stronger rise of RR with increasing AD than
in those ICUs with a high diversity.
Conclusions: This study on resistant P. aeruginosa supports the
assumption that a high RR in the presence of low AD results
from more frequent cross-transmission events. A stronger rise of
RR in ICUs with a low genodiversity indicates that RR in ICUs
might be markedly determined by cross-transmission events
beside AD.
P1365
Relationship between prior antibiotic exposure
and multidrug-resistant Pseudomonas aeruginosa
T.P. Lodise, N. Patel, J. Graves, B.M. Lomaestro (Albany, US)
Background: The increasing emergence of multi-drug resistant
Pseudomonas aeruginosa (MDR-PA) infections (infx) is a major
public health concern. Despite the rising rates, MDR-PA risk
factors have not been well deﬁned & quantitative evaluations of
the relationship between prior antibiotic (abx) exposure & MDR-
PA have not been performed in patients (pt).
Objective: To examine the risk factors for MDR-PA & to
quantify the relationship between prior abx exposure & MDR-
PA.
Methods: Study period: 1/02–4/04. Inclusion criteria: (1) ‡
18 yrs, (2) PA respiratory culture (met CDC infx criteria), (3)
non-cystic ﬁbrosis. Demographics, co-morbid conditions, abx
(30 days (d) prior PA) were recorded. Recursive partitioning
(CART) was used to identify the duration of abx exposure for
each antipseudomonal class that was associated with an
increased probability of MDR-PA. MDR was deﬁned as resist-
ance to ‡ 4 anti-pseudomonal abx classes. Logistic regression
was performed to identify the predictor variables that were
independently associated with MDR-PA. Variables that were
associated with MDR-PA in the univariate analysis were
included in the logistic regression analysis at model entry and
a stepwise process was used to identify independent predictors.
Results: During study, 353 pts met criteria. Mean age:
60.6 ± 18.9. Median LOS prior PA: 24 d [0–178]. Mechanical
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ventilation at PA onset: 80.2%. MDR-PA: 34.6%. 30-day mortal-
ity: 8.8%Note for Table: Data are number (%) of pts with MDR-
PA or non-MDR-PA.In logistic regression, prior carbapenem
exposure ‡3 d (OR = 1.9, 95% CI: 1.1–3.4), prior piperacillin/
tazobactam exposure ‡12 d (OR = 1.8, 95% CI: 1.1–3.1) & LOS
prior PA ‡ 33 d (OR = 3.5, 95% CI; 2.2–5.8) were the only
univariate predictor variables independently associated with
MDR-PA.
Conclusion: Prior carbapenem exposure ‡3 d, prior piperacil-
lin/tazobactam ‡12 d, & prolonged prior LOS were the strong-
est predictors of MDR-PA. Further epidemiologic and molecular
studies are needed to ascertain the reasons for higher rates of
MDR-PA associated with certain prior abx.
P1366
Multiresistant Pseudomonas aeruginosa outbreak
caused by multiple sources and strains
C. Petignat, I. Federli, G. Zanetti, A. Wenger, J. Bille, P. Francioli,
D.S. Blanc (Lausanne, CH)
Pseudomonas aeruginosa is an opportunistic pathogen. Multiple
resistances (multi-R) to antibiotics is generally observed after a
prolonged treatment, and their occurrences are generally spor-
adic. In some instances, the spread of the multi-R bacteria is
responsible for outbreak. Between November 2002 and January
2003, we observed an unusual increase (15 cases) of patients
with multi-R P.a. The majority of the patients had a cardiovas-
cular surgical intervention or were hospitalised in the surgical
ICU. All but two underwent a transoesophagal echocardiogra-
phy during the intervention. The analysis of the procedure
showed a potential contamination of the sound during its
rinsing after disinfection. The sink where this rinsing was
performed was found to be contaminated with the same P.a.
strain as that of the patients. Retrospective analysis identiﬁed 4
other patients harbouring the same strains in 2002. Despite a
new disinfection protocol, new cases of ICU patients with multi-
R P.a. continued to be reported. In April 2003, an investigation in
the ICU revealed that the siphons of several sinks were
contaminated with multi-R P.a. A disinfection protocol of the
siphons was set up and isolation precautions were taken for all
patients with multi-R P.a. Despite these measures, new cases
continued to be reported, a total of 39 patients were reported at
the end of 2003. A molecular epidemiological investigation was
undertaken including all ICU patients with P.a. The results
showed that i) 2 strains were responsible for this epidemic, ii)
one strain was found in the sinks of the operative room and the
ICU (suggesting an environmental source) whereas the other
was found only in patients (suggesting patient to patient
transmission), iii) several P.a. isolates (10 patients) showing a
non multi-R phenotype were found to be genetically identical to
the epidemic strains. It was only after isolation precautions were
enforced for all ICU patients with P.a. (multi-R or not) that the
number of cases went back to baseline. This is the ﬁrst report of
a multi-resistant P. aeruginosa outbreak involving two strains
and multiple sources of contamination (transoesophageal
sound, siphons, other patients). The duration of the outbreak
was probably due to the persistence of the epidemic strains in
the environment, and to the lack of isolation of ICU patients
harbouring the epidemic strains which did not showed a multi-
R phenotype.
P1367
Nosocomial Acinetobacter baumannii vs.
Klebsiella pneumoniae bloodstream infections:
risk factors and outcomes
M. Paul, E. Robenstock, A. Fraser, L. Leibovici, S. Perez, S. Pitlik,
I. Ostfeld, Z. Samra, M. Weinberger (Petah Tikva, IL)
Objectives: To assess mortality associated with nosocomial
Acinetobacter baumannii (AB), bloodstream infections (BSIs),
independent of other risk factors for mortality. We compared
risk factors and outcomes for patients with nosocomial AB vs.
nosocomial Klebsiella pneumoniae (KP) BSIs.
Methods: The study was conducted at Rabin Medical Center,
Beilinson campus, a 900-bed primary and tertiary care hospital
in Israel. All patients with nosocomial AB and KP BSIs between
2000–2003 were identiﬁed from an ongoing prospective data-
base. Only ﬁrst episodes were included. Detailed demographic,
microbiologic, antibiotic treatment and other clinical data were
collected retrospectively through patient chart review, using a
standardized questionnaire. Nosocomial BSIs were deﬁned as
those developing more than 48 hours after admission. Mortality
was deﬁned as 30-day all-cause deaths. Variables signiﬁcantly
associated with mortality at the univariate level (p < 0.1) were
entered into a multivariable logistic regression model.
Results: 112 patients with AB and 90 patients with KP nosoco-
mial BSIs were included. AB was signiﬁcantly associated with
poorer performance status; burns; pneumonia, mechanical
ventilation, arterial line and nasogastric tube prior to BSI;
prior treatment with steroids and carbapenems, but not other
antibiotics; pneumonia as source of infection; lower albumin
and higher urea. KP BSIs were associated with urinary tract
infections. Appropriate empirical antibiotic treatment was
administered to 19.6% of patients with AB and 42.2% of patients
with KP BSI (p < 0.001). AB BSIs were associated with a
signiﬁcantly higher percentage of septic shock and respiratory
failure and resulted in longer hospital stay (32 ± 27 days vs.
22 ± 20 days for patients alive). Mortality was 61.6% with AB vs.
38.9% with KP (p < 0.001). Independent risk factors for
mortality on multivariate analysis included AB BSI, diabetes,
septic shock and urea (Table).
Conclusions: AB affects patients with more severe underlying
conditions in hospital, when compared to a common nosocomial
Gram-negative pathogen. However, the mortality associated
with AB BSIs is higher than that of KP BSIs, after correction for
underlying patients’ conditions.
Abstracts
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
P1368
Neurosurgical meningitis due to Acinetobacter
baumannii: comparasion between different
treatments
A. Rodrı´guez-Guardado, A. Blanco, J. Torres, V. Asensi,
V. Pintado, F. Pe´rez, M. Lantero, E. Bustillo, J. Maradona,
J. Carto´n (Oviedo, Madrid, ES)
Background: The treatment of multidrug-resistant Acinetobacter
baumannii meningitis is a serious therapeutic problem. We
describe the outcome of nosocomial neurosurgical meningitis
treated with different therapeutic options.
Methods: 64 patients with nosocomial postsurgical meningitis
due to Acinetobacter baumannii diagnosed between 1990–2004
were retrospectively reviewed.
Results: Mean hospital stay before the infection was 26.5 [19.7]
(limits 7–99 days); main underlying diseases were: intracerebral
hemorrhage (45.3%), head trauma (29.7%) brain neoplasms
(20.3%), and hydrocephalus (4.7%). 49 cases had intraventricular
catheters, 4 had a ventriculoperitoneal shunt and 11 cases had
CSF leakage. The most important treatment showed in table 1.
Two patients dead without treatment. Although no patients
treated with colistin dead and the mortality rate were lower in
intrathecally treated patients (4 patients vs 18 p = 0.095) we
have not observed statistically differences between the treat-
ments. 22 patients dead due to the infection and the rest cure.
The mortality was associated with no removal of CSF devices
(p = 0.007, OR: 4.88 [1.27–19.48]), inadequate treatment
(p = 0.0002, OR: 1.467; [1.102–1.951]), lack of stay in ICU
(p = 0.041; OR: 3 [1.025-8.777]. and delayed in the beginning of
treatment (p = 0.004)
Table 1. Characteristics of antibiotics treatments
Conclusions: Nosocomial Acinetobacter meningitis have a high
related mortality. This is lower in patients with intraventricular
treatment. Colistin is a useful and safe option in the treatment of
this entity.
P1369
Clinical epidemiology of bioﬁlm production in
Acinetobacter baumannii clinical isolates
J. Rodrı´guez-Bano, S. Martı´, S. Soto, J.M. Cisneros, J. Pacho´n,
A. Pascual, L. Martı´nez-Martı´nez, J. Vila on behalf of the GEIH
Objectives: A. baumannii is an important cause of device-
associated nosocomial infections. We investigated the frequency
and epidemiology of bioﬁlm formation among clinical strains of
A. baumannii.
Methods: In vitro bioﬁlm formation was tested in 92 epidem-
iologically unrelated A. baumannii isolated from clinical samples
during November 2000 in 25 Spanish hospitals participating in
the GEIH-Ab 2000 project. Bioﬁlm formation was determined in
an overnight culture, which was diluted 1:100 in LB broth and
incubated without shaking at 37C for 48 hours. The bioﬁlm was
stained with 1% crystal violet and quantiﬁed at 570 nm after
solubilization with ethanol-acetone. The following variables
were collected: age, sex, type and severity of underlying
diseases, duration of hospital stay, invasive procedures, previ-
ous antimicrobials, types of infections and outcome. Univariate
and multivariate analysis using logistic regression were per-
formed.
Results: Among the 92 A. baumannii strains, 56 (61%) formed
bioﬁlm, 33 (36%) did not, and 3 could not be evaluated.
Clinical and epidemiological data were available for 85
patients; 53 of them had a bioﬁlm-forming strain (62%) and
32 (38%) a non-forming one. Bioﬁlm-forming strains were less
frequently epidemic (31% vs. 53%, p = 0.04), imipenem-resist-
ant (25% vs. 47%, p = 0.03), ciproﬂoxacin-resistant (66% vs.
94%, p = 0.004) and isolated from the respiratory tract (25% vs.
52%, p = 0.01), but were more frequently isolated from urine
(33% vs. 14%, p = 0.06) and blood (10% vs. 0, p = 0.07).
Patients with bioﬁlm-forming strains were less frequently in
ICU (26% vs. 53%, p = 0.01) and had more frequently received
aminoglycosides (43% vs. 20%, p = 0.07). There were only 3
pediatric patients, and all of them had bioﬁlm-forming isolates.
Multivariate analysis showed that ICU stay (OR = 0.1, 95% CI:
0.04–0.8), isolation from the respiratory tract (OR = 0.2, 95% CI:
0.05–0.9), and ciproﬂoxacin-resistance (OR = 0.06, 95% CI: 0.00–
0.4) were associated with non-bioﬁlm formation, while previ-
ous aminoglycoside use (OR = 13.1, 95% CI: 2.3–74.9) was
associated with bioﬁlm formation. There were no differences in
mortality or duration of hospitalisation between patients with
infections caused by bioﬁlm forming and non-forming A.
baumannii.
Conclusions: About 60% of unrelated A. baumannii strains were
showed to form bioﬁlm. ICU stay, isolation from the respiratory
tract and ciproﬂoxacin-resistance were associated with bioﬁlm
non-forming A. baumannii strains.
P1370
Dissemination of tetracycline and
chloramphenicol resistance genes in Portuguese
Salmonella isolates carrying class 1 integrons
P. Antunes, J. Machado, L. Peixe (Porto, Lisbon, PT)
Objectives: In this study we evaluated the genetic background
of tetracycline and chloramphenicol resistance in Salmonella
carrying class 1 integrons.
Methods: The minimum inhibitory concentration for 10 anti-
microbial agents was determined by the agar dilution method in
1511 isolates collected from human, food products and envi-
ronment (2002–2004). Characterization of class 1 integrons was
performed by PCR, RFLP (TaqI) and sequencing in the 331
sulfonamide resistant isolates. Screening for tetA, tetB, tetG,
ﬂoR, cmlA and catA genes was searched by multiplex PCR
assays. Conjugation assays and clonality analysis (PFGE-XbaI)
were performed.
Results: 26% (386/1511) of the isolates were multiresistant
(ranging from two to eight antibiotics). Class 1 integrons were
found in 78% (259) of the sulfonamide resistant isolates, with 241
(93%) resistant to tetracycline and 188 (73%) to chloramphenicol.
Resistance to tetracycline was related to tetA (46%), tetB (21%) or
tetG (32%) and to chloramphenicol to ﬂoR (43%), catA (29%) or
cmlA (24%). In contrast to the antimicrobial resistance determi-
nants speciﬁc of the multiresistant DT104 serotype Typhimu-
rium clone (Int1 1000: aadA2 + 1200: blaPSE-1, ﬂoR and tetG),
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class 1 integrons in the remaining isolates (85/182) were
transferred by conjugation, mostly associated to tetracycline
and chloramphenicol resistance genes. Gene cassettes conferring
resistance to aminoglycosides (aadA1, aadA2 and aadA5),
trimethoprim (dfrA1, dfrA12 and dfrA17) and b-lactams
(blaPSE-1 and blaOXA-30) were found. Interestingly, a gene
cassette encoding chloramphenicol resistance (cmlA) was also
detected.
Conclusion: The presence of class 1 integrons is signiﬁcantly
associated with multidrug resistance including to tetracycline
and chloramphenicol, which genes are not usually integrated in
gene cassettes. Our results suggest that co-selection and main-
tenance of MDR in Salmonella might be the result of the use of
several agents in food animals, namely sulfonamides, ﬂorfenicol
and tetracyclines, which could difﬁcult the reduction of antimi-
crobial resistance in this zoonotic bacteria.
P1371
Epidemiological types and integrons in
multidrug-resistant Acinetobacter baumannii
strains from intensive care units in Rome, Italy
S. D’Arezzo, A. Capone, N. Petrosillo, P. Visca on behalf of
Gruppo Romano Acinetobacter baumannii GRAB
Introduction: Acinetobacter baumannii is a major opportunistic
pathogen and a serious clinical challenge in Intensive Care Units
(ICU). Molecular typing is essential for epidemiological tracing
of A. baumannii infection and monitoring of multiple drug
resistance (MDR). Studies on MDR in A. baumannii have
demonstrated the presence of several antibiotic-resistance
genes arrayed into integrons.
Objectives: 1) To investigate the epidemiology of A. baumannii
isolates from ICU patients cared in six local Hospitals; 2) to
evaluate the genetic relatedness between A. baumannii strains by
random ampliﬁed polymorphic DNA (RAPD) analysis; 3) to
characterize the structure of their integrons; 4) to correlate
epidemiological types with integron carriage and MDR patterns.
Methods: Ninety A. baumannii isolates were obtained over a 12-
month period from critically ill patients and the associated ICU
environment in six public Hospitals in the Rome urban area.
Four primers were employed for RAPD ﬁngerprinting. Finger-
prints were considered distinct if they diverged by more one
band. Integrase and blaIMP genes were detected by PCR with
appropriate primer pairs. For the detection of resistance genes in
class-1 integrons, PCR was performed with the primers for the
5’- and 3’-conserved segments (CS). PCR products were se-
quenced to determine integron structure. Restriction fragment
length polymorphism (RFLP) was used to compare integrons
between isolates.
Results: Comparison of A. baumannii RAPD ﬁngerprints
showed six different types, with two main clusters. Most MDR
strains were clustered in types I and II (cluster I: 70/90 isolates;
cluster II: 15/90 isolates). The int1 gene was detected in 90/90 of
the A. baumanni strains. Four integrons were identiﬁed, whose
combination deﬁned cluster I (carrying integrons A and D) and
cluster II (carrying integrons A, B and C). Sequencing of the
variable DNA region interposed between the 5’-CS and the 3’-CS
indicates that most MDR determinants in A. baumanni are
assembled within class-1 integrons. RFLP conﬁrmed the identity
of similar sized integrons between strains belonging to the same
cluster.
Conclusion: RAPD ﬁngerprinting and search for integrons by
PCR provided evidence of clonal distribution of two epidemic
strains circulating for at least one year in the ICUs of six
different Hospitals, and conﬁrmed the high prevalence of class-1
integrons in MDR A. baumannii strains from both clinical and
environmental ICU specimens.
P1372
Ward investigation after hospitalising a case with
pandrug-resistant Acinetobacter baumannii
infection
Y-H. Huang, Y-C. Huang, C-H. Lin, L-H. Su, C-T. Wu
(Kweishan, Taoyuan, TW)
Background: Pandrug-resistant Acinetobacter baumannii
(PDRAB) emerged in Taiwan in early 2000s and spread rapidly
throughout the whole island. This organism was not identiﬁed
in our Children¡|s Hospital (Hospital A) until March 2005 when
a patient with pneumonia was transferred from a respiratory
care hospital (Hospital B). PDRAB was subsequently recovered
from her sputum specimen obtained on admission.
Methods: Being aware of the culture results, we placed the
patent into a single room and implemented contact precaution
immediately. We also conducted an investigation in the related
wards of both hospitals. A total of 212 specimens were obtained
from the 30 hospitalized patients (7 in Hospital A, 23 in Hospital
B), their ward bed related facilities and environmental objects
for the detection of PDRAB. All the AB isolates were analysed
with antibiograms (imipenem, amikacin, gentamicin, ciproﬂ-
oxacin, ceftazidime, cefepime, aztreonam, and piperacillin) and
2 genotyping methods.
Results: Of the 84 specimens obtained from Hospital A, 13
(15%) specimens were positive for AB, among which 6 were
PDRAB. Of the 6 PDRAB isolates, 5 isolates were from the index
case and her related facilities. Of the 128 specimens obtained
from Hospital B, 23 specimens were positive for AB, among
which 5 were PDRAB. The 5 PDRAB isolates were from 3
patients and their related facilities. One patient had 1 PDRAB
isolate each while he stayed in Hospitals A and B, respectively.
Of the 36 AB isolates, there were 9 IRS-PCR patterns, 12 PFGE
patterns and 6 antibiogram patterns identiﬁed. 25 isolates
belonged to a major IRS-PCR type (4 PFGE patterns) and
presented with either pandrug resistance (all 11 PDRAB isolates
clustered in this type) or multi-drug resistance (only susceptible
to imipenem). From a single patient, the isolates were indistin-
guishable in 2 of 3 patients with multiple isolates. Compared to
the isolate from a single patient, the isolates from its related
facilities were indistinguishable in 2, highly related in 3 and
distinct in 2 of 7 pairs of isolates.
Conclusion: A. baumannii is a ubiquitous organism that can be
isolated from the patients and environmental objects. A clone of
AB with multi- or pan-drug resistance was circulating in both
Hospitals.
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Epidemiology of resistance to antibiotics - I
P1373
Increase of resistant Enterobacter isolates and
correlation with antibiotic consumption at the
ward level
P. Haller, S. Tschudin, M. Dangel, M. Simcock, R. Frei,
H. Plagge, A.F. Widmer, M. Battegay, U. Fluckiger, S. Bassetti for
the Multidisciplinary Antimicrobial Group University Hospital Basel,
CH
Objectives: Enterobacter spp. (EB) are frequent causes of serious
nosocomial infections. The incidence of EB resistant to 3rd
generation (gen.) cephalosporins (ceph.) at the University
Hospital Basel increased from 2003 to 2004. We analysed the
relationship between antibiotic consumption and incidence of
resistant EB at the ward level. EB have an inducible AmpC beta-
lactamase. Under selective antibiotic pressure a stably dere-
pressed mutant resistant to 3rd gen. ceph. can be selected. It has
been shown that 3rd gen. ceph. and piperacillin/tazobactam
(pip/taz) can select these resistant mutants. The role of 2nd gen.
ceph. for the selection of resistant EB is controversial.
Methods: All patients with a resistant EB between 1/03 and 12/
04 and the ward, where they were hospitalised at the time of EB
isolation, were identiﬁed. The pharmacy provided antibiotic
consumption data of the different wards (pip/taz, ceph, carb-
apenems, glycopeptids, aminoglycosides, quinolones) in DDD/
100 patient-days for 2003 and 2004. With linear regression
analysis we correlated resistance and antibiotic consumption of
the wards.
Results: From 2000–2003 the incidence of resistant EB
remained stable (0.1 per 1000 patient-days) with a sudden
rise in 2004 to 0.227. In the linear regression analysis only
consumption of 2nd gen. ceph. was signiﬁcantly associated
with incidence of resistant EB (p < 0.0001). The surgical ICU
had the highest incidence of resistant EB (2003: 0.57 and 2004:
3.71) and the highest use of 2nd gen. ceph.: 20.1 DDD in both
years. The ward with the 2nd highest incidence of resistant
EB was the medical ICU with 0.57 in 2003 and 0.73 in 2004.
This ward used only 2.4 DDD of 2nd gen. ceph. in both years,
but had a high antibiotic consumption of 99.1 DDD in 2003
and 85.1 DDD in 2004. The ward with the highest antibiotic
consumption was the bone marrow transplant unit (133.3
DDD in 2004). It had no resistant EB in both years and no
2nd gen. ceph. were used. Overall antibiotic consumption was
not signiﬁcantly correlated with resistant EB.
Conclusion: Use of 2nd gen. ceph. was associated with a higher
incidence of resistant EB. This observation is supported by the
high incidence of resistant EB in the surgical ICU, probably due
to the ample use of 2nd gen. ceph. for perioperative prophylaxis,
which is the only indication for these antibiotics at our
institution. Our study adds more evidence to the hypothesis
that also 2nd gen. ceph. may select derepressed EB mutants.
P1374
Risk factors for carbapenem-resistant
Pseudomonas aeruginosa among patients with
respiratory tract infections
N. Patel, T.P. Lodise (Albany, US)
The prevalence of Carbapenem-resistant Pseudomonas aeruginosa
(CR-PA) infections is increasing in many hospitals and is a major
public health concern. Despite the rising rates, risk factors for
CR-PA have not been well deﬁned & quantitative evaluations of
the relationship between prior antibiotic exposure & CR-PA
have not been performed in patients.
Objective: To examine the risk factors for CR-PA & to quantify
the relationship between prior antibiotic exposure & CR-PA.
Methods: Study period: 1/02–4/04. Inclusion criteria: (1)
‡18 yrs, (2) PA respiratory culture (met CDC infection criteria),
(3) non-cystic ﬁbrosis. Demographics, co-morbid conditions,
prior antibiotic exposure (30 days prior onset PA culture) were
recorded. Recursive partitioning (CART) was used to identify
the duration of abx exposure for each antipseudomonal class
that was associated with an increased probability of CR-PA.
Logistic regression (LR) was performed to identify independent
predictors of CR-PA.
Results: During study, 351 pts met criteria. Mean age:
60.5 ± 18.9. Male: 61.0%. Median LOS prior PA: 24 d [0–178].
Mechanical ventilation at PA onset: 80.2%. CR-PA: 48.1%. 30-
day mortality: 8.3. Of the CR-PA, 84.6% and 71.0% of cultures
were cross-resistant ‡4 classes of anti-pseudomonas antibiotics
compared 10.4% of carbapenem susceptible pseudomonas cul-
tures. In the logistic regression, prior mechanical ventilation for
>9 days (OR = 4.1; 95% CI: 2.4–6.9), prior carbapenem exposure
>2 days (OR = 4.1; 95% CI: 2.1–7.6) and prior ﬂuoroquinolone
exposure >3 days (OR = 2.4; 95% CI: 1.3–4.5) were indepedent
predictors of CR-PA.
Conclusion: The overall prevalence of CR-PA was extremely
high (48.1%) and the overall majority of CR-PA were cross-
resistant to multiple classes of anti-pseudomonal antibiotics.
Mechanical ventilation >9 days, Prior carbapenem exposure >
2 d, and prior ﬂuoroquinolone exposure >3 days were the
strongest predictors of CR-PA. Further epidemiologic and
molecular studies are needed to ascertain the reasons for
higher rates of CR-PA associated with certain prior antibiotic
exposures.
P1375
Risk factors associated with S. pneumoniae
multiple resistance in Belgium over a 10-year
period
J. Van Eldere, R.M. Mera, L.A. Miller, J. Verhaegen,
J.A. Poupard (Leuven, BE; New Orleans, Upper Providence,
Philidelphia, US)
Objectives: Resistance to two or more antibiotics has been
increasing over time in many European countries. Factors
associated with multiple resistance are investigated using 10-
year surveillance data from Belgium.
Methods: Multiple resistance (MR) is deﬁned as non-suscepti-
bility to two or more antibiotic classes (penicillins, macrolides,
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tetracyclines, quinolones and sulfas). Surveillance data consists
of 14,488 S. pneumoniae invasive isolates from 1994–2004,
identiﬁed by postal code as well as clinical and demographic
information. Risk factors associated with MR were analysed
using multivariate logistic regression.
Results: Resistance to two or more antibiotic classes was 14.1%
of all isolates in 1994, increasing to reach a peak of 30.7% in 2000,
decreasing slightly to 28.8% in 2004. In 2004 out of all penicillin
resistant isolates, 80% were erythromycin and 75% were
cotrimoxazole resistant respectively. Similarly, 90.3% of all
tetracycline resistant isolates were macrolide resistant. In a
multivariate analysis, signiﬁcant risk factors were age, source of
the isolate, population density, serotype, location and previous
antibiotic use. Isolates from children less than 5 years old were
1.55 times more likely to be multiply resistant (95% CI 1.3 – 1.7);
ear isolates were 1.54 times more likely to be resistant than blood
isolates (95% CI 1.4 – 1.8); for every 1,000 inhabitants per km2,
there is a 7% increase in resistance (95% CI 1.8% – 12.4%). 7
valent pneumococcal vaccine isolates were 14.3 times more
likely to be MR than non-vaccine related serotypes (95% CI 12.5
– 16.4). Provinces that border France were 1.54 times more likely
to be MR than those located by the Dutch border (95% CI 1.4 –
1.8). Subjects previously treated with antibiotics were 1.3 times
more likely to harbor a multiply resistant strain (95% CI 1.2 – 1.5,
p = 0.01) independent of location, time and other risk factors.
Conclusion: More than two thirds of all non-susceptible isolates
in Belgium are resistant to two or more antibiotic classes. The
proportion of all isolates that are MR has been increasing over
time, while single resistant isolates have declined slightly, even
though the overall trend has been toward a plateau in resistance.
This study conﬁrms the importance of population density even
after adjusting for the effect of population structure, time,
location and other known risk factors.
P1376
Association between antimicrobial resistance and
virulence in Escherichia coli blood and faeces
isolates from humans in Denmark
L. Bagger-Skjøt, D. Sandvang, C.H. Lester, L.J. Porsbo,
D.L. Monnet, N. Frimodt-Møller, A.M.
Hammerum (Copenhagen, Bagsværd, Søborg, DK)
Objectives: The aim of this study was to investigate possible
associations between resistance phenotype and virulence genes
in Escherichia coli isolates obtained from the blood of bacter-
aemic patients and from the faeces of non-hospitalised humans.
Methods: Between January and September 2003, 123 consecu-
tive E. coli blood isolates were collected at the Clinical Micro-
biology Laboratory, Statens Serum Institut. During the same
period, 85 E. coli faeces isolates from non-hospitalised human
volunteers were obtained as part of the Danish Integrated
Antimicrobial Resistance Monitoring and Research Programme
(DANMAP). Susceptibility to 17 antimicrobial agents was
determined by micro-broth dilution using the Sensititre system
(Trek Diagnostics Systems Ltd., East Grinstead, United King-
dom). The presence of the following 9 virulence genes was
assessed by PCR: iutA, fyuA and iroN (siderophores); hlyA and
cnf1 (toxins); sfaS and focG (adhesins); traT, associated with
serum resistance; and malX, a marker for a pathogenicity-
associated island.
Results: The associations between antimicrobial resistance phe-
notype and virulence gene that were signiﬁcant are presented in
the Table. Table. Signiﬁcant associations (P < 0.006, Bonferroni
correction) among antimicrobial resistance phenotypes (S,
susceptible; R, resistant) and presence of virulence factor genes
(VF+)
Conclusion: Clear associations were found between certain
common resistance phenotypes and two virulence genes, i.e.
iutA and traT, both in E. coli isolated from the blood of patients
with bacteraemia and from the faeces of non-hospitalised
humans. It is difﬁcult to explain these associations and further
studies are needed. However, such links between resistance
and virulence are disturbing since the use of antimicrobial
agents may result not only in the selection of resistant isolates,
but also of more virulent ones.
P1377
Antimicrobial resistance surveillance in 2004 in
Korea: further increase of vancomycin-resistant
Enterococcus faecium, expanded-spectrum beta-
lactam-resistant Klebsiella pneumoniae and
imipenem-resistant Pseudomonas aeruginosa and
Acinetobacter spp.
K. Lee, C.H. Rhim, J.H. Cho, W.G. Lee, Y. Uh, H.J. Kim, D. Yong,
Y. Chong for the KONSAR Group (Seoul, Korea)
Objectives: Monitoring temporal trends of antimicrobial resist-
ance can provide useful information for empirical selection of
antimicrobial agents to treat infected patients and for the control
of nosocomial infections. Aim of this study is to determine
resistance trends of important nosocomial pathogens in Korea.
Methods: Antimicrobial susceptibility test data in 2004 were
collected from KONSAR program-participating hospitals. Data
from 37 hospitals were analysed after excluding the hospitals
with unreliable quality control performance. Resistance rates
did not include intermediate category.
Results: Resistance rates in 2004 vs. in 2003 were compared.
The rates were similar in oxacillin-resistant Staphylococcus aureus
(68% vs. 68%) and oxacillin-resistant Streptococcus pneumoniae
(68% vs. 70%). Slight increase of vancomycin-resistant Entero-
coccus faecium (25% vs. 20%) was noted. Klebsiella pneumoniae
showed increased resistance to expanded-spectrum cephalosp-
orin (34% vs. 25%) and cefoxitin (32% vs. 23%). Fluoroquino-
lone-resistance remained similar in Escherichia coli (32% vs. 32%),
Acinetobacter spp. (56% vs. 58%), and Pseudomonas aeruginosa
(38% vs. 40%). Rates of imipenem resistance further increased in
P. aeruginosa (24% vs. 20%) and Acinetobacter spp. (17% vs. 13%).
Amikacin resistance rate was similar in P. aeruginosa (24 vs.
25%), but slightly decreased in Acinetobacter spp. (46% vs. 54 %).
Conclusion: It is a concern that vancomycin-resistant E. faecium,
expanded-spectrum cephalosporin-resistant K. pneumoniae, and
imipenem-resistant P. aeruginosa and Acinetobacter spp. further
increased in 2004 in Korea.
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P1378
Prevalence of antibiotic resistance and antibiotic
resistance genes among Enterococcus faecium
from pigs and poultry in the United Kingdom
V.I. Enne, E. Pleydell, P.M. Bennett (Bristol, Weybridge, UK)
Objectives: To determine the incidences of antibiotic resistance
and expressed and silent resistance genes among Enterococcus
faecium from healthy farm animals, reared on organic and
conventional farms in the UK.
Methods: Faecal samples from broilers, turkeys and pigs reared
on farms using either conventional or organic methods were
collected. One colony displaying E. faecium morphology on
Slanetz and Bartley agar was chosen at random per sample.
Identity of the isolates as E. faecium was conﬁrmed by PCR.
Susceptibility of the isolates to chloramphenicol (CHL), eryth-
romycin (ERY), gentamicin (GEN), quinupristin-dalfopristin
(Q/D), tetracycline (TET) and vancomycin (VAN) was deter-
mined by disc diffusion. Presence of the resistance genes cat,
ermB, tetM, vanA and vatE in resistant and susceptible isolates
was determined by PCR. Unexpressed resistance genes were
investigated by DNA sequencing.
Results: In total 304 E. faecium isolates were obtained. The
prevalence of antibiotic resistance was high, with 87.8% of
isolates resistant to at least one agent. Of these, 11.8% were
multi-resistant (deﬁned as resistance to three or more agents).
Prevalence of resistance was 0.7% to VAN, 7.6% to Q/D, 7.9% to
CHL, 55.9% to ERY, and 83.2% to TET. There was no resistance
to GEN. Resistance was more common among isolates from
conventionally than organically reared animals, with 72.4% of
isolates from organically reared animals being fully sensitive or
resistant to just one agent, while 81.1% of isolates from
conventionally reared animals were resistant to at least two
agents. In terms of gene frequencies both VAN resistant isolates
had vanA, 91.3% of Q/D resistant isolates had vatE, 89.3% of
TET resistant isolates had tetM, 74.1 % of ERY resistant isolates
had ermB and 20.8% of CHL resistant isolates had cat. Four
isolates were PCR positive for ermB but susceptible to ERY.
DNA sequencing showed that in three of these, the sequences of
the ermB gene and its promoter were intact and wild type. In the
fourth isolate, a mutation was found in the ermB promoter.
Conclusion: The incidence of antibiotic resistance among E.
faecium isolated from healthy pigs and poultry is relatively high,
although most isolates are susceptible to frontline therapeutic
agents such as VAN or GEN. The genes investigated in this
study accounted for most of the resistance detected, except for
CHL. Three isolates were found to harbour apparently silenced
ermB genes and warrant further investigation.
P1379
Antibiotic susceptibility of bacteria isolated from
hospitalised patients in Mauritius
M.I. Issack (Quatre-Bornes, MU)
Objectives: Microorganisms that cause nosocomial infections
and their antibiotic susceptibility vary markedly according to
region or hospital, and over time. We conducted a retrospective
survey of bacteria recently isolated from hospitalised patients in
Mauritius.
Methods: Specimens sent for bacteriological investigations
from all government hospitals in Mauritius are processed at
the Central Health Laboratory. Results of all specimens received
in March 2005 were reviewed and analysed. Duplicate isolates
from the same patient were excluded
Results: Information was available on antibiotic suceptibility of
541 gram-negative bacteria, of which the most common were
Klebsiella spp. (98), Pseudomonas aeruginosa (86), E.coli (84),
Proteus spp. (84) and Acinetobacter spp. (76). Most isolates
originated from urine in the case of E.coli and from pus swabs
and tracheal secretions for the other organisms. Percentage
susceptibility of Klebsiella spp. to cefotaxime, ciproﬂoxacin,
gentamicin, amikacin and meropenem was 56%, 63%, 54%,
90% and 100% respectively whereas the corresponding ﬁgures
for E.coli was 83%, 75%, 83%, 86% and 100% respectively.
Susceptibility of Proteus and Acinetobacter spp. were as follows:
50% and 13% respectively to cefotaxime, 46% and 21% to
ciproﬂoxacin, 44% and 17% to gentamicin, 54% and 67% to
amikacin, and 100% and 48% to meropenem. Most Pseudomonas
aeruginosa were susceptible to ceftazidime (74%), piperacillin
(67%), ciproﬂoxacin (57%), amikacin (80%) and meropenem
(90%) but only 47% were sensitive to gentamicin. All Klebsiella
spp. and E.coli, 99% of Pseudomonas aeruginosa and 97% of
Acinetobacter spp. were reported as susceptible to colistin.
Among the 85 Staphylococcus aureus isolates noted, only 5%
were susceptible to penicillin but most were susceptible to
erythromycin (84%), tetracycline (82%) and meticillin (86%).
Half of the MRSA isolates were obtained from specimens from
the Burns Unit. Only one of 12 S.aureus isolates from blood
cultures during the period surveyed was an MRSA. 89% of 53
enterococci were susceptible to ampicillin and no vancomycin-
resistant Enterococcus sp. was isolated.
Conclusion: Resistance to broad-spectrum antibiotics among
Gram-negative bacteria isolated from hospitalised patients in
Mauritius is very common and seriously limits therapeutic
options. On the other hand, resistance among S.aureus and
enterococci are not a major problem, with the exception of MRSA
in the Burns Unit.
P1380
Antimicrobial resistance patterns in 14 neonatal
intensive care units in Bogota, Colombia
2001–2004
G. Buitrago, G.A. Contreras, A.L. Leal, C.A. Alvarez,Grupo para
el Control de la Resistencia Bacteriana de Bogota´ (GREBO)
Objectives: Nosocomial infections are a challenge health prob-
lem and cause signiﬁcant morbidity and mortality, specially in
critical patients and the increase in antimicrobial resistance
during the last years complicates the management of this type of
infections. The objective of this epidemiologic surveillance was
to analyse the bacterial isolates and the antimicrobial suscepti-
bilities in the neonatal intensive care units (NICU) that belong to
GREBO (Grupo para el Control de la Resistencia Bacteriana de
Bogota´-Colombia, South America).
Methods: A descriptive retrospective study was performed.
The data was collected from the microbiology laboratories from
14 high-complexity NICU in Bogota´, Colombia. The data was
obtained from the automated systems (Vitek and MicroScan)
and it was transferred to WHONET 5.3 with the aid of BacLink
software. Quality assurance was performed by the National
Institute of Health (Bogota´, Colombia). Duplicated isolates, more
than one isolate per patient, were identiﬁed and deleted. Results
were scored as susceptible, intermediate or resistant according
to Clinical Laboratory Standards Institute (CLSI) criteria.
Results: 6051 microorganisms were isolated. The most import-
ant microorganisms were: Staphylococcus coagulase negative
(37,91 %), Klebsiella pneumoniae (10,94 %), Escherichia coli (8,61
%), Staphylococcus aureus (8,10 %), Enterococcus faecalis (2,99 %),
Serratia marcescens (2,84 %) and Enterobacter cloacae (2,68 %). The
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microorganisms were obtained from blood (47,09 %), catheter
(11,94 %), urine (8,33 %) and feces (7,93 %). The chart illustrates
the antimicrobial resistance for each microorganisms.
Conclusion: This study shows the great importance of the
cogulase negatives Staphylococcus (CoNS) in the NICU, which
have higher percentage of antimicrobial resistance, in special to
oxacillin and ciproﬂoxacin. On the other hand, the gram-
negative bacillus has compatible proﬁles with Extended Spec-
trum Betalactamase and AmpC and is worrisome specially in K.
pneumoniae. The development of this type of studies in devel-
oping countries, will facilitate to guide the empirical antimicro-
bial treatment in our Institutions and stablish control strategies
of the bacterial resistance.
P1381
Integrating susceptibility data from two
surveillance programmes with unique
methodological techniques: the Antibiogram
Resistance Method Or isolate-based Resistance
monitoring (ARMOR) study
B. Epstein, J. Gums, P. Turner, for the Antibiogram Resistance
Method Or isolate-based Resistance Monitoring (ARMOR) Study
Group
Objectives: The Antimicrobial Resistance Management (ARM)
and Meropenem Yearly Susceptibility Test Information Collec-
tion (MYSTIC) programs are ongoing antibiotic surveillance
studies that operate by different methods. Our aim was to
compare the susceptibility data generated by each program in
order to determine if the two methods produce similar results.
Methods: The ARM Program is a web-based (www.armpro-
gram.com), antibiogram-driven surveillance system, whereas
MYSTIC tracks minimum inhibitory concentrations (MIC) by
analyzing individual bacterial isolates. MYSTIC isolates
undergo antimicrobial susceptibility testing via broth microdi-
lution in a reference laboratory (for US institutions) in accord-
ance with Clinical Laboratory Standards Institute (CLSI)
methods. We compared national susceptibility rates during
1999–2004 from ARM and MYSTIC for Escherichia coli, Klebsiella
pneumoniae, and Pseudomonas aeruginosa. ARM captured data on
572,927 E. coli; 153,171 K. pneumoniae; and 207,454 P. aeruginosa.
The corresponding isolate numbers from MYSTIC (US) were
2,333; 1,267; and 2,254.
Results: For E. coli, susceptibility rates were similar with the
exception of levoﬂoxacin, for which susceptibility was reported
as 92.3% in the ARM Program and 83.0% in MYSTIC. (Table 1)
Results for ciproﬂoxacin were 92.3% and 88.2%, respectively. For
K. pneumoniae, susceptibility rates were comparable. Overall, for
P. aeruginosa, susceptibilities were similar, though differences
were evident for ciproﬂoxacin, cefepime, and gentamicin.
Resistance was higher among isolates submitted to ARM
compared to MYSTIC. Ciproﬂoxacin resistance was 26.6% in
MYSTIC and 36.7% in ARM. Resistance to cefepime was 25.5%
and 16.2%, respectively. Likewise, for gentamicin, resistance
was 29.5% and 14.8%, respectively. Similar patterns were
apparent for other members of the ﬂuoroquinolone, late gen-
eration cephalosporin, and aminoglycoside classes, but the
differences were less marked.
Conclusion: The ARM program, an antibiogram-based surveil-
lance system, and MYSTIC, an isolate-based initiative, produce
nearly identical susceptibility data for K. pneumoniae and E. coli.
For P. aeruginosa, susceptibility tended to be higher for ciproﬂ-
oxacin, cefepime, and gentamicin in MYSTIC. These results
suggest that surveillance of antibiotic activity patterns can be
performed conﬁdently with either method. Subtle changes in
MICs and resistance mechanisms can only be elucidated by
isolate-based surveillance.
P1382
Antimicrobial resistance of major Gram-negative
bacterial pathogens during a 7-year period
A. Slavcovici, M. Lupse, M. Flonta, V. Zanc, D. Tatulescu,
A. Almas, D. Carstina (Cluj-Napoca, RO)
Objective: During studied period consumption of all major
classes of antibiotics increased signiﬁcantly. The aim of our
study is to assess the prevalence of antibiotics resistance for
E. coli, Klebsiella spp., Enterobacter spp. and Pseudomonas aerugi-
nosa between 1998 – May 2005.
Methods: 1464 isolates were collected from ICU, medical and
surgical hospitals in Cluj-Napoca: 736 E. coli, 271 Klebsiella spp.,
194 Enterobacter spp., 263 P. aeruginosa. Bacterial identiﬁcation
and susceptibility testing were carried out following standard
procedures (using API-bioMerieux system, disk diffusion
method) in the Teaching Hospital of Infectious Diseases Cluj-
Napoca. For E. coli and Klebsiella spp. extended-spectrum Beta-
lactamases (ESBLs) production was conﬁrmed by double-disc
test.
Results: Of 736 E. coli isolates tested 13% were resistant to
ceftazidime, 17.4% to ciproﬂoxacine and 7.8% to amikacine. The
presence of ESBLs and multi-drug resistant isolates (MDR) in
E. coli was detected in 8.4% respectively 7.4%. In Klebsiella spp.
the prevalence of resistance was 45% for ceftazidime, 21% for
amikacine, 30% for ciproﬂoxacine, 0.4% for carbapenems and
0.8% for colistin. The presence of ESBLs and MDR was detected
in 28.7% respectively in 23.2% of Klebsiella spp. isolates. During
the studied period the resistance rate increased signiﬁcantly for
ceftazidime (p = 0.0007) in correlation with ESBLs presence. In
Enterobacter spp. the resistance frequency was 41% for ceftazi-
dime, 23% for amikacine and ciproﬂoxacine, 3% for colistin.
MDR strains were identiﬁed in 14.4%. Of 263 P. aeruginosa
isolates, 67% were resistant for ceftazidime, 55% for ciproﬂoxa-
cine, 30% for amikacine, 18% for carbapenems and 3.5% for
colistin. MDR P. aeruginosa was identiﬁed in 26.9%.
Conclusions: Cephalosporins, ciproﬂoxacine and amikacine
resistance is becoming increasingly common in Enterobacteriaceae
and P. aeruginosa. The carbapenems and colistin are now the
only reliable antibiotics against ESBL producing Gram-negative
pathogens and MDR strains. There is necessary to limit the
overuse of antibiotics and implementation of a new antibiotic
policy.
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Serious developments of antimicrobial resistance
in Europe: results from EARSS (European
Antimicrobial Resistance Surveillance System)
N. Bruinsma, M.E.A. de Kraker, G. Kahlmeter, G. Cornaglia,
F. Baquero, J. Monen, H. Grundmann and EARSS participants
Objectives: EARSS collects data from laboratories that serve
over 30% of the European population, and for several countries
the coverage amounts to 100%. This makes EARSS the most
comprehensive public health effort describing and analysing
geographic and secular trends in antimicrobial resistance in
Europe. Recently, the EARSS data, irrespective of the base-line
level of resistance in individual countries, showed increasing
trends of antibiotic resistance across the board. In this study,
resistance trends of indicator pathogens over time will be
presented.
Methods: EARSS collects routinely generated antimicrobial
susceptibility (AST) data for the indicator pathogens: Streptococ-
cus pneumoniae, Staphylococcus aureus, Enterococcus faecalis, En-
terococcus faecium, Escherichia coli and clinically relevant
antibiotics. This data are regularly reported by over 800
laboratories serving 1300 hospitals in 31 European countries.
We looked at resistance trends in Europe from 1999 to 2004. To
determine signiﬁcant trends the Cochrane Armitage test was
used.
Results: MRSA-proportions are mainly increasing in countries
that showed moderate to low prevalences over the past few
years (central and northern European countries). In Scandina-
vian countries and the Netherlands that before long had MRSA
rates well below 1% over the past 3 years a clear increase can be
discerned. This trend must be taken seriously since a low
threshold for loosing control may exist but is not well deﬁned. In
E. coli the increase in ﬂuoroquinolone resistance (FQ) continues
unabated in most European countries; and, when including the
trends for the ESBL expansion, this species treatment options are
becoming slim. Vancomycin-resistance in Enterococcus faecium
(VRE) remains below 10% in most European countries, but
higher levels are reported from Portugal, Italy, Ireland, and
Greece. Signiﬁcant increases are observed for Germany, France,
and Ireland.
Conclusions: Even for countries which successfully maintained
low levels of MRSA for decades, EARSS data show a consis-
tently rising trend, which call for a reappraisal of existing
control strategies The observed increase of VRE can be
explained by the spread of strains belonging to a particularly
hospital adapted clonal lineage, termed complex 17. The
increasing trends of FQ resistance in E. coli is most probably
the result of widely used ﬂuoroquinolones, predictably posing
an increasing challenge to European health care systems for
years to come.
P1384
Stenotrophomonas maltophilia surveillance in a
Greek tertiary care hospital
K. Koraki, P. Karapavlidou, D. Soﬁanou (Thessaloniki, GR)
Objectives: To determine the spectrum of infection and anti-
microbial susceptibility of Stenotrophomonas maltophilia, a signi-
ﬁcant emerging pathogen that primarily affects patients who
have been hospitalized for prolonged periods, have been
subjected to invasive procedures or have received broad-
spectrum antibiotics.
Methods: A total of 95 non-repeat S. maltophilia strains were
isolated in our hospital from January 2002 to December 2004.
Identiﬁcation was done using the Vitek2 automated system
(bioMerieux, France), while susceptibility testing was performed
using the broth dilution method according to NCCLS guidelines.
Results: The most frequent source of isolation were bronchial
secretions (23.1%), followed by wounds (14.7%), sputum
(14.7%), blood (11.6%), intraperitoneal drainage catheters
(10.5%), pus (8.4%), central and periferal venous catheters
(7.4%) and other sources (7.5%). Some of these isolates
probably represent colonization rather than true infection.
Intensive care units (ICUs) accounted for the majority of
isolates (43.1%), followed by surgical clinics (16.8%) and the
children outpatient department (14.7%) where all isolates
derived from cystic ﬁbrosis patients. S. maltophilia was found
most often in bronchial secretions of ICU patients whereas it
was most often isolated from wound swabs in the ward
patients. The organism was isolated from blood more often in
ICU (17.6%) than in ward patients (8.2%). Regarding the
antibiotic susceptibility, 63.6% of isolates were susceptible to
ticarcillin/clavulanate, 62.7% to ciproﬂoxacin and 43.6% to
ceftazidime. Aminoglycosides inhibited less than 40% of
isolates. All isolates were susceptible to trimethoprim/sulfo-
methoxazole while full resistance was reported for imipenem.
A great variety of antibiotic resistance phenotypes were
observed suggesting that there were no epidemic clusters of
infection in the hospital.
Conclusion: S. maltophilia is a signiﬁcant emerging nosocomial
pathogen against which very few compounds showed reason-
able in vitro activity. Resistance surveillance studies are neces-
sary to guide empirical antimicrobial therapy and to assure
effective control measures especially in critical hospital wards.
P1385
Activity of ertapenem and tigecycline against
recent isolates from community-acquired lower
respiratory infections in the UK and Ireland
R. Reynolds, D. Felmingham, BSAC Working Party on Respiratory
Resistance Surveillance
Objective: To monitor the prevalence of resistance in the agents
of community-acquired lower respiratory infection and to assess
the activity of newer antimicrobial agents.
Methods: Community-acquired lower respiratory tract isolates
of Streptococcus pneumoniae, Haemophilus inﬂuenzae and Moraxella
catarrhalis have been collected from 20 centres in the UK and
Ireland between October and April each winter since 1999 and
tested centrally by BSAC agar dilution methodology. Ertapenem
and tigecycline were ﬁrst tested in 2004–05.
Results: 93% of 750 S. pneumoniae were susceptible and 7%
intermediate to penicillin; 9 and 14% were resistant to tetracyc-
line and erythromycin, respectively. Beta-lactamase production
(and corresponding ampicillin resistance), tetracycline resist-
ance and erythromycin resistance was seen in 12, 1 and 4% of
888 H. inﬂuenzae and 93, 0.5 and 0% of 403 M. catarrhalis
respectively; a further 94% of H. inﬂuenzae showed intermediate
susceptibility to erythromycin. Ciproﬂoxacin resistance was
rare, <4% in S. pneumoniae and <1% in H. inﬂuenzae and M.
catarrhalis. Tigecycline MICs were £1 mg/L (mode 0.25 mg/L)
for S. pneumoniae and H. inﬂuenzae, and £0.5 mg/L (mode
0.12 mg/L) for M. catarrhalis. Tigecycline MIC distributions
were unaffected by the presence of penicillin-non-susceptibility,
tetracycline resistance or beta-lactamase production, showing
that the mechanisms involved in these resistances did not
impinge on its activity. 92% of S. pneumoniae were susceptible to
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ertapenem at £0.03 mg/L, and 8% had intermediate suscepti-
bility (0.06 – 1 mg/L). Ertapenem MICs increased from a mode
of 0.004 and maximum 0.12 mg/L for penicillin-susceptible to
mode 0.25 and maximum 0.5 mg/L for penicillin-non-suscept-
ible S. pneumoniae; 7% had intermediate susceptibility to both
agents. All H. inﬂuenzae and M. catarrhalis isolates were
susceptible to ertapenem at £2 mg/L, with maximum MICs of
1 and 0.06 mg/L and modes of 0.03 and 0.015 mg/L respect-
ively. Ertapenem MICs were slightly raised by beta-lactamase
production for M. catarrhalis (mode 0.015 vs. 0.004 mg/L) but
unaffected for H. inﬂuenzae.
Conclusion: The prevalence of resistance among community-
acquired lower respiratory S. pneumoniae, H. inﬂuenzae, and M.
catarrhalis remains relatively low in the UK and Ireland.
Ertapenem and tigecycline showed very good activity against
most or all of these isolates; ertapenem and penicillin suscep-
tibility in S. pneumoniae were closely associated.
P1386
Trends in resistance of bacteraemia isolates in the
UK and Ireland and current activity of
ceftobiprole
R. Reynolds, R. Hope,BSAC Working Party on Bacteraemia
Resistance Surveillance
Objective: To monitor the prevalence of resistance in the agents
of bacteraemia and to assess the activity of newer antimicrobial
agents, including ceftobiprole, a cephalosporin that binds
staphylococcal PBP2’.
Methods: MICs were determined centrally, by BSAC agar
dilution methodology, for bacteraemia isolates collected from
25 laboratories in the UK and Ireland each year since 2001.
Ceftobiprole was included for the ﬁrst time in 2004.
Results: There was little change in the prevalence of methicillin-
resistance in S. aureus (43–48%) or in coagulase-negative staphy-
lococci (62–80%), or vancomycin resistance in E. faecium (21–
23%), whilst penicillin non-susceptibility in S. pneumoniae fell
slightly (3–9%) over the 4 surveillance years. By contrast, there
were sharp rises in the prevalence of ciproﬂoxacin resistance
and ESBL production among Enterobacteriaceae (e.g. 8–18 and 0–
6% respectively in E. coli); imipenem and ertapenem remained
almost universally active against Enterobacteriaceae (<0.5%
resistant in any species in 2004). Ceftobiprole, like daptomycin,
linezolid and tigecycline, retained universal activity against
staphylococci and streptococci. Modal MICs for methicillin-sus-
ceptible and resistant S. aureus were 0.5–1 and 2 mg/L,
respectively, compared with 0.5–2 and 2 mg/l for correspond-
ing groups of coagulase-negative staphylococci and 0.06 and
0.5 mg/l for penicillin-susceptible and non-susceptible S. pneu-
moniae. MICs >4 mg/L were seen for 3/139 E. faecalis, and for
63/80 E. faecium. MICs were from 8 to ‡128 mg/L for 5/9 P.
vulgaris/penneri, 6/6 K. oxytoca hyperproducing K1 enzyme, 14
/58 Enterobacter hyperproducing AmpC, and almost all ESBL-
producers; otherwise MICs for Enterobacteriaceae were mostly
£0.12 mg/L, with values of £0.12 to 4 mg/L for many with
derepressed AmpC. MICs for P. aeruginosawere mostly (98%) 2–
16 mg/L, whilst 29/32 S maltophilia required MICs >4 mg/L
(mode 64 mg/L).
Conclusion: The prevalence of methicillin resistance is high but
stable among staphylococci while ESBL production and ciproﬂ-
oxacin resistance are increasing in Enterobacteriaceae. Ceftobi-
prole had good activity against most organisms from
bacteraemias in 2004, including MRSA, S. pneumoniae, E. faecalis
and most Enterobacteriaceae, but not E. faecium, S. maltophilia nor
ESBL-, K1- or many AmpC-producing Enterobacteriaceae; it may
also have potential against P. aeruginosa.
P1387
Eight years of Belgian MYSTIC surveillance:
19982005
M. Ieven, M. Delmee, P. De Mol, H. Goossens, Y. Glupczynski,
D. Pierard, M. Struelens, J. Verhaegen, G.
Verschraegen (Edegem, Brussels, Lie`ge, Yvoir, Leuven, Ghent, BE)
Objectives: As part of the Meropenem Yearly Susceptibility
Test Information Collection (MYSTIC) surveillance, the activity
of meropenem and six comparators was studied on a total of
11455 isolates from eight teaching hospitals in Belgium, collec-
ted from 1998 to 2005.
Materials and Methods: Centres collected consecutively up to
100 and 150 unduplicated, aerobic, Gram-positives and Gram-
negatives respectively from patients admitted in ICU, neutrope-
nia-, cystic ﬁbrosis centres and general wards. CLSI methods
and E-test were used for susceptibility testing. ESBL and AmpC
production were conﬁrmed by at least a 3 log2 reduction in
ceftazidime MIC in the presence of clavulanate and a ceftazi-
dime MIC more than 8 mg/l not lowered by the presence of
clavulanate respectively.
Results: Carbapenems were active against all Gram-positives:
98–100% susceptibility. Among the Enterobacteriaceae, there was
no signiﬁcant decrease in susceptibility from 1998–2005 for the
antibiotics tested: 96.1–97.1% for imipenem, 99.6–99.4% for
meropenem, 96.7–93.4% for cefepime 83.3–83.9% for ceftazi-
dime, 82.7–84.7% for piptazo, 93.9–94.1% for amikacin and 83.2–
83.3% for ciproﬂoxacin. Resistance among E.aerogenes was
signiﬁcantly higher in Belgian isolates compared to other
European countries, susceptibilities varying from 23–40% for
both ceftazidime and ciproﬂoxacine and 40– 66% for piptazo
between 1998 and 2005. The occurrence of ESBL-producing E.
coli and K. pneumoniae remained stable varying between 2–4%
for E.coli and 6–15% for K. pneumoniae. ESBL-producing E.
aerogenes isolates increased signiﬁcantly. The % of AmpC
producers among Enterobacter spp decreased from 50% in
1998 to 14.0% in 2005, for Serratia spp from 22.9% to 4.1% and for
Proteus spp from 5.3% to 0%. Susceptibilities of ESBL and
AmpC producers to carbapenems varied between 98-
100%.Multidrug resistance in P. aeruginosa (R for ceftazidime,
ciproﬂoxacin and gentamicin) was 9.4% among all isolates
without signiﬁcant trends. Piptazo and meropenem remain the
most active agents against P.aeruginosa susceptibilities for
piptazo between 73.0% in 1998 and 81.9% in 2005, for merope-
nem between 85.1% and 78.1%.
Conclusions: Resistance among E. aerogenes in Belgium is high.
Prevalence of ESBL producers among E.coli and K. pneumoniae
remained stable, prevalence of AmpC producers decreased.
Carbapenems retain their activity against ESBL and AmpC
producers. There is a trend towards decreased carbapenem
susceptibility of P. aeruginosa.
P1388
Resistance of Streptococcus pneumoniae
nasopharyngeal isolates from children in selected
Russian orphanages: 2003 vs. 2004
R.S. Kozlov, O.U. Stetsiouk, J.A. Poupard, L.S.
Stratchounski (Smolensk, RU; Philadelphia, US)
Objectives: Orphanages have been shown to be reservoirs of
resistant strains of Streptococcus pneumoniae (SPN) which could
spread to the community. A special survey was done to monitor
resistance changes of SPN nasopharyngeal isolates from chil-
dren living in orphanages in 2003 and one year later, in 2004.
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Methods: This survey was performed as a part of the pros-
pective study CORPUS in 12 orphanages (##1–12) from 5 cities
(Moscow, Saint-Petersburg, Smolensk, Karachev, Bryansk)
located in European part of Russia. Nasopharyngeal swabs
were collected from 772 children < 7 years in 2003 and from 752
children in 2004 that yielded 399 and 397 SPN isolates
respectively. Susceptibility to penicillin G (PEN), amoxicillin
(AMO), amoxicillin/clavulanate (AMC), cefuroxime (CEF),
cefotaxime (CTX), erythromycin (ERY), clindamycin (CLI),
chloramphenicol (CHL), tetracycline (TET) and co-trimoxazole
(SXT) was performed by CLSI (formerly the NCCLS) broth
dilution methodology.
Results: SPN nasopharyngeal colonization rates were quite
stable during the study period – 51.7% in 2003 and 52.8% – in
2004. There were no increase in SPN non-susceptibility (NS) or
resistance (R) to PEN, AMO and AMC. However our data
revealed a statistically signiﬁcant increase of I and R SPN
isolates to II and III generation cephalosporins (CEF and CTX) –
1.3/39.4 vs 17.9/31.2 and 3.8/2.5 vs 9.3/8.3 in 2003 vs 2004
respectively. It is noteworthy that NS SPN population to CEF
increased due to the higher frequency of I isolates with the
stable rate of R strains, while in the case of CTX NS – it was due
to simultaneous (2.4 fold and 3.3 fold) increase of I and R
isolates, respectively. At the same time no statistically signiﬁcant
changes in ERY, CLI and SXT susceptibility and statistically
signiﬁcant decrease in CHL R rates (15.0 vs 8.1%) were noted.
Conclusions: The results of the survey show stable rates of NS
and R SPN nasopharyngeal isolates from children living in
orphanages to penicillins, macrolides and lincosamides, tetra-
cyclines and co-trimoxazole. Emerging resistance to II-III gen-
eration cephalosporins necessitates further evaluation of these
alarming data to determine responsible risk factors and respect-
ive resistance mechanisms.Decrease of SPN resistance to chlo-
ramphenicol can be a positive example of possibility to diminish
resistance following the restricted use of antimicrobials.
P1389
Geographical and temporal analysis of the
changes in S. pneumoniae multiple resistance to
antibiotics in Belgium over a 10-year period
R.M. Mera, J. Van Eldere, L.A. Miller, J.A. Poupard,
J. Verhaegen (New Orleans, US; Leuven, BE; Upper Providence,
Philadelphia, US)
Objective: The evolution of resistance to two or more antibiotic
classes in Belgium has a strong spatial component since it is
located between countries with very high (France) or very low
(Germany, The Netherlands) levels of antimicrobial resistance.
Changes over time and space in Belgium are studied using a 10-
year surveillance study.
Methods: Surveillance data consists of 14,488 S. pneumoniae
invasive isolates by postal code in the period 1994–2004.
Geospatial data for all postal codes by month is available.
Spatial analysis uses a trend surface model, and temporal
analysis is done with standard time series analysis techniques.
Results: 77% of all postal codes had at least one isolate in the
database. There is a signiﬁcant clustering of MR isolates near the
border with France, which is independent of time. Postal codes
located near the French border region of Hainaut-Namur are
1.95 times more likely to have multiply resistant isolates than
those in the Dutch border region of Antwerp-Limburg (95% CI
1.7 – 2.3). Areas of high multiple resistance tend to cluster
around main roads and rail lines connecting Lille (France) to
Brussels and Liege to the west, Brugge to the north and Chaleroi
to the southwest, independent of population density. Areas of
low MR density cluster around urbanized centers near the
border with The Netherlands, and rural postal codes bordering
Germany and Luxembourg.Time series analysis of monthly MR
prevalence shows that there is a strong seasonal component
with higher resistance in February and lower in August (7%
average difference). There is also a strong statistically signiﬁcant
trend toward increasing prevalence over time that starts in the
areas of West Flanders and Namur provinces, migrates to the
main cities (Brussels, Liege) in the centre of the country and
spreads roughly from the southwest to the northeast. There is a
tendency toward a plateau since the year 2000, with some
convergence in the prevalence rates, at levels of 32% in West
Flanders and 25% in Antwerp in 2004 respectively.
Conclusions: Evolution of MR in Belgium since 1994 has
followed a gradient that started at the postal codes bordering
the French border and has spread through urban and rural
postal codes following main roads to cities in the centre of the
country. MR prevalence peaked in the year 2000, but the
geographical differences have remained.
P1390
Selection and characterization of biocide resistant
Salmonella enterica serovar Typhimurium
M. Webber, M. Woodward, L.J.V. Piddock (Birmingham,
Weybridge, UK)
Objectives: To select biocide tolerant mutants from a panel of S.
Typhimurium and determine whether exposure to biocides
promotes antibiotic cross-resistance.
Methods: The strains used were SL1344 and derivatives lacking
efﬂux genes acrB (L643) and tolC (L108), a laboratory gyrA
(L696) mutant selected on ciproﬂoxacin, a ciproﬂoxacin resistant
ﬁeld isolate (L378), a representative DT104 isolate (L357) and a
cyclohexane tolerant strain (L699). Mutants were selected with
biocides Farm Fluid S, Virkon, AQAS and Superkill. Mutants
were selected after exposure to 1X and 2X the MIC of each agent
in agar and overnight incubation. Mutant colonies were retained
and the susceptibility to a range of antibiotics determined as
well as growth kinetics in both in the presence and absence of
biocide.
Results: Mutants were selected for all biocides. Strains lacking
efﬂux genes were more susceptible to biocides than all other
strains. The MICs of biocide tolerant mutants were similar to
those of parents or one dilution higher. However growth kinetic
analysis revealed the tolerant strains were able to grow better in
the presence of 1X the MIC of the selective biocide when
challenged in mid logarithmic growth phase. Some mutants
were also less susceptible to antibiotics when compared to their
parent strain, notably mutants from L699 (cyclohexane tolerant
strain). These were 8 fold less susceptible to ciproﬂoxacin than
their parent and were inhibited by 4 mg/L, above the recom-
mended breakpoint concentration for ciproﬂoxacin.
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Conclusions: Biocide exposure led to the selection of strains
with increased tolerance to all biocides tested although the MIC
changes were generally small. Biocide selected mutants dem-
onstrated some antibiotic resistance, notably to ciproﬂoxacin
after exposure to superkill. Further work to determine the
mechanisms of resistance in these mutants is underway.
P1391
Polymyxin B resistance in multidrug-resistant
Pseudomonas aeruginosa
J.L. Sampaio, C. Mendes, S.I. Sinto, P.C. Koga, A.C. Arruda,
C. Kiffer (Sao Paulo, BR)
Objectives: To evaluate polymyxin B (POLB) resistance inmulti-
drug resistant (MDR) P. aeruginosa clinical isolates by broth
microdilution (BMD), Etest and agar screening (AS) methods.
Methods: The susceptibilities of 243 P. aeruginosa MDR clinical
isolates previously determined to be resistant to at least three
drugs among ciproﬂoxacin, cefepime, ceftazidime, meropenem
or piperacillin-tazobactam were evaluated. A single isolate per
patient was included. POLB minimal inhibitory concentrations
were determined by BMD according to CLSI and by the Etest.
Isolates were also evaluated in regard to their ability to grow on
Mueller-Hinton agar containing POLB (4 mg/L). Innoculum
was approximately 1.5 x 10e6 CFU; plates were incubated in
ambient air at 35C, observed after 24 h and 48 hours and the
presence of colonies recorded. For BMD and AS assays calcium
and magnesium concentrations were adjusted to 20 mg/L and
10 mg/L, respectively. Antimicrobial concentrations ranges in
BMD were 0.03 mcg/mL to 32 mcg/mL. Results were only
considered if P. aeruginosa ATCC 27853, tested along with each
batch tests, showed adequate results.
Results: Among 243 isolates, 27 (11.1%) showed skipped wells
in BMD panels. All wells with higher drug concentrations where
visible growth was detected after skipped wells were plated and
grew again P. aeruginosa. Among these, 14 isolates with this
feature were randomly assayed by BMD in triplicates, and
skipped wells occurred in 9.7% (7/72) of tests. Bacterial
population recovered from higher concentration wells did not
show a stable POLB resistance phenotype, but presented again
the pattern of skipped wells. In contrast, P. aeruginosa
ATCC27853 tested 16 times did not show skipped wells. POLB
MIC50 and MIC90 by BMD were 0.5 mcg/mL and 2.0 mcg/mL,
respectively (liberal reading). However, if growth after skipped
wells was considered (conservative endpoint), MIC90 would
increase to 4.0 mcg/mL and resistance rate would change from
2.0% to 11.5%. Four isolates with a MIC of 4.0 mcg/mL for
POLB by BMD hadMICs £ 1.5 mcg/mL by Etest. AS with POLB
detected four among ﬁve resistant isolates.
Conclusions: Etest should not be used as a conﬁrmatory test to
determine POLB resistance in MDR P. aeruginosa. AS with 4 mcg
of polymyxin B/mL is not an adequate screening method to
detect resistance in this bacterial population. The adequate
endpoint (liberal or conservative) to be reported for isolates
showing skipped wells is not deﬁned.
P1392
Antibiotic resistance does not impede persistence
of Escherichia coli in the infantile intestinal
microbiota
N. Karami, E. Lindberg, A. Wold, I. Adlerberth,
F.L. Nowrouzian (Go¨teborg, SE)
Objectives: The commensal intestinal microﬂora represent a
large reservoir of bacteria which may carry antibiotic resistance
determinants, but the prevalence of antibiotic resistance among
intestinal commensals and its ecological consequences has been
poorly studied.
Methods: We have determined phenotypic resistance to eleven
antibiotics in 271 E. coli strains obtained from 127 healthy
Swedish infants followed longitudinally over their ﬁrst year of
life with quantitative cultures of the intestinal E. coli ﬂora.
Individual E. coli strains in each child were distinguished by
random ampliﬁed polymorphic DNA (RAPD). The strains were
characterized with respect to virulence factor genes, persistence
in the gut microbiota, and faecal population numbers.
Results: E. coli strains were most commonly resistant to
ampicillin (11%), tetracycline (9%) and trimethoprim (7%).
Only 1% were resistant to 3 antibiotics. Resistant strains
showed equally high population numbers as sensitive strain
and persisted equally well in the microﬂora. Resistant intestinal
E. coli strains often had p-ﬁmbrial gene than sensitive E. coli
strains (p = 0.009).
Conclusion: Antibiotic-resistant strains of E. coli seem to be as
ﬁt for competition in the large intestinal microbiota as suscept-
ible strains. Carriage of certain virulence genes may contribute
to their colonizing success.
P1393
Evaluation of daptomycin and other anti-
staphylococcal antibiotics against clinical strains
of community- and hospital-derived MRSA
M. Rybak, M. Amjad, C. Cheung, K. Lau, G. Kaatz (Detroit, US)
Objectives: Isolation of Methicillin-Resistant Staphylococcus
aureus (MRSA) has increased dramatically. The increase in
reports of community-associated MRSA (CAMRSA) will likely
contribute to further complications associated with MRSA
infections. We evaluated the antimicrobial activity of daptomy-
cin (D), clindamycin (C), linezoid (L), erythromycin (E), doxy-
cycline (Dx), vancomycin (V), teicoplanin (T), trimethoprim/
sulfamethoxazole (TS) levoﬂoxacin (Lv) gentamicin (G), and
quinupristin/dalfopristin (QD), against 563 well characterized
MRSA clinical isolates.
Methods: CAMRSA and healthcare-associated MRSA
(HAMRSA) meeting clinical and SCCmec type deﬁnitions
were evaluated. Multiplex PCR was used to determine
SCCmec type, presence of Panton-Valentine Leukocidin (PVL)
and accessory gene regulator (agr) type. The presence of
inducible MLSB resistance was determined by disk diffusion.
MIC and MBC values were determined using microdilution
techniques. MIC determinations (n = 20) also were carried out
in the presence of 50% serum for D and T to determine the
impact of protein on susceptibility.
Results: 332 and 231 MRSA isolates met clinical and SCCmec
typing deﬁnitions for CAMRSA and HAMRSA, respectively.
CAMRSA were 100%l SCCmec type IV, 85% agr type I, 83%
PVL,, and 5% iMLSB ; 99.9% of HAMRSA were SCCmec type II,
79% agr type II, 15% PVL, and 50% iMLSB. Of interest, 92 of the
231 HAMRSA were found to be SCCmec type IV 61% agr type I,
58% PVL and 26% iMLSB. Against CAMRSA, MIC50/MIC90 for
D:0.25/1, C:0.125/0.5, L:2/4, E:32/256, Dx:0.25/4, V:1/2, T:0.5/
1, TS:0.125/0.25, Lv:0.25/4, G:0.5/2, QD:0.25/0.5 Against
HAMRSA MIC50/MIC90 for D: 0.25/1, C: 64/64, L:2/4, E:
128/256, Dx: 0.5/4, V: 1/2, T: 0.5/2, TS: 0.125/1, Lv: 16/64, G:
0.5/1, QD: 0.25/1. Against HAMRSA (SCCmec type IV),
MIC50/MIC90 D: 0.5/1,0, C:0.25/64, L:2/4, E: 64/128, Dx: 0.5/
8, V:1/2, T: 0.5/1, TS:0.25/4, Lv:0.5/16,G:0.5/1, QD:0.25/0.5.
MIC tests performed in 50% serum for D and T were 2-4 fold
higher. MBC values followed MIC trends and were increased 1-
4 fold for most antimicrobials.
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Conclusions: Against CAMRSA and HAMRSA, MIC and MBC
values were lowest for D, TS, V, T G and QD followed by Dx and
L. Susceptibility to all antimicrobials tested was higher among
CAMRSA compared to HAMRSA. Notably, HAMRSA SCCmec
type IV had higher rates of iMLSB resistance and higher MIC90
values for C, TS and Lv. compared to CAMRSA.
P1394
Susceptibility of recent European Gram-positive
bacteria to daptomycin
C. Soussy, J. Bille, R. Canto´n, A. MacGowan, C.E. Nord, G.
Schito, H. Seifert, M. Struelens, J. Verhoef, I. Morrissey (Creteil,
FR; Lausanne, CH; Madrid, ES; Bristol, UK; Stockholm, SE; Genoa,
IT; Cologne, DE; Brussels, BE; Utrecht, NL; London, UK)
Objectives: Daptomycin (DAP) is a new cyclic lipopeptide
antibiotic active against Gram-positive bacteria (GPB) and is
licensed in the USA for the treatment of complicated skin and
skin-structure infections. As marketing approval is being sought
for Europe this study sought to determine DAP susceptibility for
GPB from Europe
Methods: Staphylococcus aureus (SA), coagulase-negative staphy-
lococci (CNS), Enterococcus faecalis & E. faecium (E), beta-
haemolytic streptococci (BHS), ‘viridans’ streptococci (VS) and
Corynebacterium spp. (COR) were collected from 81 laboratories
in Austria, Belgium, France, Germany, Ireland, Italy, Nether-
lands, Portugal, Spain, Sweden, Switzerland and UK between
October 2004 and March 2005 and CLSI broth microdilution
MIC determined. CLSI breakpoints were used, except for
teicoplanin against BHS & VS. SA CLSI breakpoints were used
for COR.
Results: Susceptibility data for the collection (2867 isolates) are
shown in the table [MR, methicillin-resistant; MS, methicillin-
susceptible; VR, vancomycin-resistant; VS, vancomycin-suscept-
ible; CTX, ceftriaxone; CLI, clindamycin; ERY, erythromycin;
GEN, gentamicin; LEV, levoﬂoxacin; LZD, linezolid; SYN,
quinupristin-dalfopristin; EI, teicoplanin; VAN, vancomycin].
Only 8 isolates were found to be DAP non-susceptible: 1 MSSA,
1 MRCNS & 6 VS all with a DAP MIC of 2 mg/L (1 dilution
higher than the susceptible breakpoint for these bacteria).
Conclusion: DAP was very active against contemporary GPB in
Europe including MRSA and VRE. Overall, 99.8% of staphylo-
cocci (n = 1320) and 100% of enterococci (n = 679) were suscept-
ible to DAP independent of resistance to other drugs.
Daptomycin should (subject to marketing authorisation) provide
an excellent alternative therapeutic option for the treatment of
infections caused by Gram-positive bacteria.
P1395
Exposure of Staphylococcus aureus isolates to
daptomycin (DA) alone or DA plus vancomycin
(VA) leads to a diminished macrophage
inﬂammatory response (compared with VA
alone)
B. English, E. Maryniw, A. Talati, E. Meals (Memphis, US)
Objectives: Treatment of Staphylococcus aureus (SA) infections
with cell-wall active antibiotics such as vancomycin (VA) may
lead to rapid bacterial lysis and trigger a pronounced host
inﬂammatory response. Daptomycin (DA) is a cyclic lipopeptide
antibiotic that exhibits bactericidal activity against SA but does
not trigger rapid bacterial lysis. We hypothesized that exposure
of SA isolates to DA or DA plus VA (compared with VA alone)
would lead to a blunted macrophage inﬂammatory response
with reduced accumulation of inducible nitric oxide synthase
(iNOS) protein and decreased secretion of tumor necrosis factor
(TNF).
Methods: Six bacterial strains were studied: two community-
acquired (CA)- MRSA strains, two hospital-associated (HA)-
MRSA strains, and two methicillin-susceptible (MSSA) strains.
RAW 264.7 murine macrophages were stimulated with live
bacteria (106 or 107 cfu/mL) and either DA 20 mcg/mL, VA
20 mcg/mL, or DA + VA.For studies of iNOS accumulation,
cells were also exposed to recombinant murine interferon-
gamma 10–25 U/mL. After incubation for 18 hrs, cell lysates
were prepared and analysed for iNOS protein content by
immunoblotting, and cell supernatants were collected and
assayed for TNF concentrations by ELISA.
Results: VA-treated SA isolates stimulated large amounts of
iNOS protein accumulation and TNF secretion by RAW 264.7
cells. Compared with VA, exposure of each of the six SA strains
to DA led to marked reductions in iNOS protein accumulation
(by densitometry, mean reduction was 51%, n = 19). Similarly,
exposure of each of the six SA strains to DA (vs. VA) led to
signiﬁcantly lower TNF secretion (mean reduction 45%, n = 28).
Finally, exposure of the SA isolates to combinations of DA plus
VA (vs. VA alone) also resulted in substantially less macrophage
iNOS protein accumulation (mean reduction 53%, n = 6) and
TNF secretion (mean reduction 55%, n = 27).
Conclusion: Exposure of each of the six SA isolates to DA alone
or DA plus VA resulted in substantially reduced macrophage
iNOS accumulation and TNF secretion in response to these
bacteria. These ﬁndings suggest that treatment of SA infections
with DA (instead of or with VA) could result in a less intense
host inﬂammatory response.
P1396
Further increase of ﬂuoroquinolone resistance
among Escherichia coli isolates in a Central
European area
M. Kresken, D. Hafner on behalf of the Working Group for
Antimicrobial Resistance of the Paul-Ehrlich-Society for
Chemotherapy
Objectives: Since 1984 when the ﬁrst ﬂuoroquinolone (FQ) was
introduced in Central Europe the consumption of the FQ has
markedly increased. To evaluate the inﬂuence of the increasing
consumption on the prevalence of resistance to FQ in clinical
isolates of Escherichia coli we reviewed the susceptibility data
from four collaborative studies conducted between 1995 and
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2004 by the Working Group for Antimicrobial Resistance of the
Paul-Ehrlich-Society for Chemotherapy.
Methods: Isolates collected in 26 to 32 laboratories that partici-
pated in surveillance studies conducted in 1995, 1998, 2001 and
2004were included. Every year each laboratory collected up to 30
consecutive, clinically signiﬁcant isolates. MICs of isolates were
determined by the broth microdilution method according to the
standard of the German DIN. Ciproﬂoxacin was tested as
reference FQ.
Results: A total of 2,930 isolates (1995, n = 783; 1998, n = 783;
2001, n = 619; 2004, n = 745) were tested. Resistance to FQ
steadily increased during the study period from 5.2% in 1995 to
21.6% in 2004. FQ resistance was more prevalent in isolates from
patients >60 years than in those from patients <21 years or
patients aged 21–60 years. In isolates from patients >60 years,
resistance to FQ jumped from 7.2% in 1995 to 27.7% in 2004. The
level of resistance in patients aged 21–60 years raised from 4.2%
to 18.5%, whereas it remained below 5% in patients <21 years.
Of the 163 FQ-resistant isolates collected in the 2004 survey,
91.4%, 82.2% and 31.9% were cross resistant to ampicillin, co-
trimoxazole, and gentamicin, respectively. FQ-resistant isolates
also exhibited reduced susceptibility to third-generation ce-
phalosporins. Susceptibility rates of FQ-resistant isolates for
cefepime, ceftazidime, and ceftriaxone (85.3%, 82.2%, and 82.2%)
were signiﬁcantly lower than those for CIP-susceptible isolates
(99.3, 99.3%, 98.3%) (P < 0.001). In contrast, ertapenem and
meropenem retained in vitro activity against all FQ-resistant
isolates.
Conclusion: Resistance to FQ has steadily increased among
Escherichia coli isolates recovered from patients in hospitals
located in Germany, Austria, and Switzerland. We strongly
recommend a judicious use of FQ in order to combat the spread
of FQ resistance in Escherichia coli.
P1397
Risk factors for invasive infection with
ﬂuoroquinolone-resistant S. pneumoniae and
failure of oral outpatient ﬂuoroquinolone therapy
K. Green, A. McGeer, D.E. Low, for the Toronto Invasive
Bacterial Diseases Network TIBDN
Background: There is increasing concern about the emergence
of ﬂuoroquinolone (FQ) resistance in S. pneumoniae. We looked
at FQ resistance rates and risk factors in patients with invasive
pneumococcal disease (IPD) in Toronto, Canada.
Methods: From 01/00–12/04, TIBDN performed population-
based surveillance for IPD in persons living in Toronto/Peel
Region, Can. (pop 4M). IPD was deﬁned as illness associated
with isolation of SPN from a sterile site. Patients (pts) exposed to
ﬂuoroquinolones were classiﬁed as: treated with FQ for current
infection before presenting with IPD (failure out-pt Rx) or
received FQ for another infection in the previous 3 months (FQ
prior 3 mos). Failures were deﬁned as bacteremia while on or
within 2 days of ﬁnishing oral FQ therapy.
Results: 1773/1879 (94%) case isolates were available for sus-
ceptibility testing; 28 (1.5%) hadciproﬂoxacin MIC ‡ 4 (CipR),
21(1.2%) had levoﬂoxacin MIC ‡ 8 (LevR) and 5 (0.3%) had
moxiﬂoxacin MIC ‡ 4 (MoxR). 145 pts received FQ prior to
presentationwith IPD; 28 (1.5%) pts failed their out-patient FQRx
for current infection while 117 (6.2%) had received a FQ for a
different infection in the prior 3 months. Of the 21 LevR isolates
identiﬁed, 6(28.4%) were in pts failing FQ Rx, 8 (38%) were in
residents of nursing homes and 4 (19%)were nosocomial isolates.
Of the 5 pts with MoxR isolates, 2 were failing Ciproﬂoxacin out-
pt Rx, 2 had received a FQ for another infection in the prior
3 months and 1 isolate was from a nursing home resident with no
FQexposure. FQ resistance in these patient groups is shown in the
Table below.
Conclusion: Patients who have been receiving a FQ for therapy
and present to hospital with pneumonia or sepsis should be
treated with a different class of antibiotics. FQ resistance in IPD
in Toronto occurs almost exclusively in patients with recent
direct exposure to ﬂuoroquinolones, or recent exposure to a
healthcare institution. In patients with none of these risk factors,
all isolates were susceptible to moxiﬂoxacin.
P1398
Mechanisms of resistance to quinolones in
Shigella spp. causing traveller’s diarrhoea
L. Mensa, E. Mendez-Arancibia, M. Navia, F. Marco, J. Vila,
J. Gasco´n, J. Ruiz (Barcelona, ES)
Objectives: To determine the molecular mechanisms of resist-
ance to quinolones in a series of Shigella spp. causing traveller’s
diarrhoea (TD), attending to their geographical origin.
Methods: The study includes all isolates of Shigella spp. recov-
ered as a cause of TD during the period 1995–2004: 97 S. ﬂexneri,
113 S. sonnei, 6 S. dysenteriae, 3 S. boydii and 7 Shigella spp. To
analyse the evolution of the resistance, two sub-periods were
considered (1995–2000 [125 strains] and 2001–2004 [101 strains].
Antimicrobial susceptibility to nalidixic acid (NAL) and ciproﬂ-
oxacin (CIP) was established by the Kirby-Bauer method. Muta-
tions in the gyrA and parC genes were detected by PCR and
sequencing.
Results: From 229 Shigella spp. recovered, 12 isolates (5.2%)
presented resistance or decreased susceptibility to quinolones.
The resistant isolates were: S. sonnei (58%), S. ﬂexneri (33%) and S.
dysenteriae (8%). Four resistant isolates were recovered in the ﬁrst
period (3.3% of resistance) while 8 were recovered in the second
one (7.9%of resistance).All strainswithquinoloneresistancewere
isolated from trevellers returning from India (75%) or Western
Africa (25%).
Conclusions: An increase in the number of resistant strains
isolated is observed in the last years mainly due to Shigella
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strains isolated from patients to India. The most frequently
found mechanism of resistance to quinolones are mutations in
the gyrA gene.
P1399
Emergence of high-level ﬂuoroquinolone-
resistance in clinical isolates of group
G. streptococci
G. Brigante, F. Luzzaro, A. Bettaccini, G. Lombardi, B. Pini,
G. Sokeng, A. Toniolo (Varese, IT)
Objectives: High-level resistance to ﬂuoroquinolones (FQ) is an
emerging problem in streptococci, including S. pneumoniae, S.
pyogenes, and S. agalactiae. Group G streptococci (GGS) are
involved in a wide spectrum of infections, including bacteremia,
osteomyelitis, pharyngitis, skin and soft tissue infections. GGS
are usually susceptible to most antibiotics, although resistance to
macrolides and tetracycline (but not FQ) was reported. The
purpose of the study was to evaluate susceptibility to different
drugs (including FQ) in clinical isolates of GGS obtained over a
ﬁve-year period.
Methods: Consecutive nonreplicate GGS isolates collected from
March 2000 to March 2005 were investigated. Serotyping was
obtained by a latex agglutination method (Strepto slide, Diesse,
Siena, IT). Susceptibility to antibiotics (penicillin, erythromycin,
clindamycin, tetracycline, ciproﬂoxacin, levoﬂoxacin, and mox-
iﬂoxacin) was determined by both Etest (AB Biodisk, Solna,
Sweden) and microdilution methods.
Results: GGS were obtained from 202 patients, 82.2% of whom
were non-hospitalized. Most frequently, isolates were obtained
from skin or soft tissue infections. GGS were consistently
susceptible to penicillin. Resistance to other drugs was as
follows: erythromycin (6.9%), clindamycin (4.9%), and tetracyc-
line (22.3%). Notably, 32/202 isolates (16.3%) showed high-level
resistance (MIC, >32 mg/l) to ciproﬂoxacin, levoﬂoxacin, and
moxiﬂoxacin. The ﬁrst strain showing high-level resistance to
FQ was recovered in March 2002; since then, every year we
noticed an increasing number of patients affected with infec-
tions due to these pathogens.
Conclusion: High-level resistance to FQ is now emerging in
GGS. As described in other species, this phenomenon could be
due to mutations in target genes. Our results suggest that
clinical microbiology laboratories should include FQ in their
susceptibility testing of streptococci, in order to detect the
presence of this particular resistance trait.
P1400
Comparative analysis of levoﬂoxacin and
ciproﬂoxacin activity against Gram-negative
pathogens collected in ﬁve European countries
grouped by site of infection, from GLOBAL
Surveillance Study - 2005
M. Jones, D. Draghi, D. Sahm, C. Thornsberry (Plaisir, FR;
Herndon, US)
Objectives: Fluoroquinolones used empirically or targeted,
provide an important therapeutic option in treating infections
caused by gram-negative (GN) pathogens. This includes infec-
tions of the urinary tract, bloodstream, and respiratory tract. The
GLOBAL Surveillance 2005 determined antimicrobial resistance
trends among GN pathogens derived from different infection
sites in ﬁve European (EU) countries. Data from this study
provides a benchmark of activity that may serve as a guide for
future treatment regimens.
Methods: 1,493 non-repeat GN pathogens were isolated from
the following specimens: urinary tract (UT), blood (BL), and
lower respiratory (LRT) at hospital laboratories in ﬁve EU
countries (United Kingdom [Uk], France [Fr], Germany [Ger],
Italy [It], and Spain [Sp]). Isolates were centrally tested by CLSI
broth microdilution (M7-A6, 2003) against levoﬂoxacin (LEV)
and relevant clinical comparator agents for each site of infection.
MICs were interpreted using the CLSI published interpretive
criteria (M100-S15, 2005).
Results: Escherichia coli (EC) was the most prevalent organism
isolated from UT, BL, and LRT sources. Among BL and UT
isolates, LEV had superior activity compared with ciproﬂoxacin
(CIP) based on resistance (R) rates. The %R rates for LEV and
CIP were as follows, respectively: 25.4 and 29.9 for BL, 20.6 and
23.4 for UT, and 44.2 among both for LRT. Among Klebsiella spp.
the %R rates for LEV and CIP were as follows, respectively: 7.5
and 14.9 for LRT, 6.2 and 10.7 for UT, and 11.7 among both for
BL. Pseudomonas aeruginosa (PA) %R rates among BL were 22.0
for both LEV and CIP, among UT 41.3 for LEV and CIP, and
among LRT 28.0 for LEV and 26.8 for CIP. Among Proteus spp.
the %R rates for LEV and CIP were as follows, respectively: 8.7
and 13.0 for BL, 10.8 and 10.7 for LRT, and 6.3 and 8.4 for UT.
The LEV %R ranged from 8.2 in Fr to 55.6 in Uk for EC; 3.6 in
Ger to 21.2 in Uk for KL; 0 in Uk to 12.6% in It for PR; and 10 in
Sp to 44.6 in It for PA.
Conclusions: Overall LEV showed slightly better in vitro
activity than CIP against GN organisms tested, irrespective of
the specimen source. Resistance rates varied signiﬁcantly by
country. Data derived from the longitudinal GLOBAL Surveil-
lance initiative provides a useful tool to track and monitor
antimicrobial resistance trends through time.
P1401
European surveillance study on the in vitro
susceptibility of clinical bacterial isolates to
telavancin
W. Jansen, A. Verel, A. Fleer, J. Verhoef, D. Milatovic (Utrecht,
NL)
Objective: To test the in vitro activity of telavancin, a novel
semi-synthetic glycopeptide, against a total of 620 clinically
relevant Gram-positive pathogens isolated from 25 European
hospitals.
Methods: MICs were determined by broth microdilution
according to NCCLS.
Results: Telavancin was highly active against Staphylococcus
aureus and coagulase negative staphylococci (MIC50/90 0.25/
0.25 mg/L for both), with no difference in activity being
observed for methicillin-susceptible and methicillin-resistant
strains. It was the most active agent against Staphylococcus aureus
being twice as active as daptomycin, 4-times more active than
vancomycin and 8-times more active than teicoplanin and
linezolid. Against Enterococcus faecalis and Enterococcus faecium
telavancin showed high potency, the MIC50/90 values being
0.25/0.5 mg/L and 0.12/2 mg/L, respectively. The activity of
telavancin was 4–8 times higher against vancomycin susceptible
enterococci compared with VRE (0.25/0.5 mg/L versus 1/4 mg/
L). Against VRE daptomycin, telavancin and linezolid were the
most potent agents tested (MIC50/90 1/2 mg/L, 1/4 mg/L and
2/2 mg/L, respectively). Telavancin exhibited excellent activity
against both, penicillin susceptible and non-susceptible Strepto-
coccus pneumoniae, all strains being inhibited by 0.06 mg/L.
Compared with vancomycin, telavancin was 8-times more active
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against beta-hemolytic streptococci and 16-times more active
against viridans streptococci (MIC90 0.06 versus 0.5 mg/L and
1 mg/L, respectively).
Conclusion: Telavancin has excellent activity against gram-
positive cocci including methicillin-resistant staphylococci,
penicillin-resistant pneumococci and vancomycin-resistant en-
terococci. It holds promise of becoming an important therapeu-
tic option for infections caused by gram-positive bacteria,
especially in view of the increasing resistance problems of
certain species against other classes of antibiotics.
P1402
Molecular epidemiology of invasive high-level
gentamicin resistance Enterococcus faecium
isolates in Denmark
C.H. Lester, D. Sandvang, H.C. Schønheyder, J.O. Jarløv, D.S.
Hansen, T.G. Jensen, N. Frimodt-Møller, A.M.
Hammerum (Copenhagen, Bagsværd, Aalborg, Hillerød, Odense,
DK)
Objectives: Enterococcal infections are often treated with a
combination of an aminoglycoside and a cell-wall-active agent
such as penicillin or a glycopeptide. In Denmark vancomycin
resistant enterococci still have a very low prevalence, whereas
high-level resistance to gentamicin (MIC > 500 mg/l) seems to
be more common. In the other Nordic countries high-level
gentamicin resistance (HLGR) is most frequently detected in
Enterococcus faecalis. In Denmark more than half of the high-level
gentamicin isolates are Enterococcus faecium. In the present study
the high-level gentamicin resistance was encoded by aac (6’)-Ie-
aph (2’’)-Ia in all isolates. The aim of our study was to
investigate the molecular epidemiology of these aac (6’)-Ie-aph
(2’’)-Ia E. faecium isolates obtained from 5 clinical de-partments
in Denmark.
Methods: A total of 62 invasive (mainly blood) HLGR E. faecium
isolates were consecutively collected between January 2004 and
December 2004. The strains were collected at four Danish
Departments of Clinical Microbiology (Aalborg, Odense, Herlev,
and Hillerød) and sent to the National Center for Antimicrobials
and Infection Control at SSI. Only one isolate from each patient
was included in this study. All isolates were typed by PFGE
using SmaI as restriction enzyme. The PFGE patterns were then
compared using BioNumerics 3.0 (Applied Maths, Kor-trijk,
Belgium). The PFGE patterns were designated indistinguishable
if the pat-terns consisted of the same number of bands and the
corresponding bands were of the same size. Only PFGE-proﬁles
with indistinguishable PFGE-proﬁles were de-ﬁned as the same
PFGE-type.
Results: The 62 HLGR E. faecium isolates had 53 different PFGE-
types. Despite the many PFGE-types clones did occur; ﬁve of the
isolates from one of the Danish Departments of Clinical
Microbiology belonged to PFGE-type 41. Five other clones
consisted of two isolates each.
Conclusion: Spread of HLGR in E. faecium isolates in Denmark
seems to be due both to horizontal spread (probably by




CTX-M extended spectrum beta-lactamases in
community-acquired infections caused by
Escherichia coli in the North West of Spain,
Pontevedra, Galicia
P. A´lvarez, M. A´lvarez, C. Garcı´a-Riestra, V. Pulian,
M. Herna´ndez, M. Garcı´a (Pontevedra, Vigo, Santiago de
Compostela, ES)
Objectives: The aim of this study was to know the prevalence
and type of CTX-M Beta-lactamases in community acquired E.
coli infections in a population of 221.612 habitants in Pontevedra,
Spain.
Methods: From April to December 2002, all non duplicate E. coli
isolates were collected from patients with a suspected commu-
nity acquired infection according to the criteria of the CDC.
Identiﬁcation and susceptibility testing was performed using
WIDER system (Fco. Soria Melguizo, Spain). Any strain with a
MIC ‡ 1 to cefotaxime (CT) and/or ceftazidime (TZ) were
screened for the presence of an extended spectrum beta-
lactamase (ESBL) by the double synergy disk test and the
ESBL-detecting E-test strip (AB Biodisk, Solna, Sweden). The
identiﬁcation of blaCTX-M genes was performed by PCR with
speciﬁc primers.
Results: A total of 2.119 community acquired infections caused
by E. coli were documented. Forty four E. coli strains with
MICs ‡ 1 to CT and/or TZ were identiﬁed, 24 isolates were
suspicious of being ESBL producers according to the used
criteria, 21/24 (87.5%) were positive for CTX-M-14 like-beta
lactamases. In one strain the coexistence of CTX-M-14 and CTX-
M-2 like-beta lactamases was identiﬁed. The remainder 2 strains
(8.3%) were negative for blaCTX-M genes. The urinary tract
infection was the most common source where the strains were
isolated representing the 90%.
Conclusion: CTX-M-beta lactamases were the most frequent
ESBL identiﬁed in community acquired infections caused by E.
coli. Being CTX-M-14 like-beta-lactamases the most frequent
CTX-M subtype identiﬁed. An isolate producing both CTX-M-14
and CTX-M-2 like-beta lactamases was identiﬁed. Nevertheless
the low prevalence of ESBL-CTX-M E. coli producers in our area
1.04% (22/2.119), continuous surveillance would be desirable in
order to control this important emerging problem. On the other
hand, the antimicrobial prescription of oral extended spectrum
cephalosporins by clinicians could be inappropriate in some
patients in the community setting.
P1404
Five-year evaluation of clonal dissemination and
expansion of VIM-1 producing
Enterobacteriaceae in Greece: a report from the
SENTRY Antimicrobial Surveillance Program
(2001–2005)
L. Deshpande, N. Legakis, R. Jones, H. Sader (North Liberty, US)
Objective: VIM-1 producing Enterobacteriaceae (ENT) emerged
in 2000 and has become endemic in Greece. The objective of this
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study was to characterize VIM-1 genotypes and to evaluate
clonal relationships among VIM-1 producing ENT strains
isolated in Greece during the course of the SENTRY Program.
Methods: All isolates received as part of the SENTRY Program
were susceptibility tested by reference CLSI methods against
>25 antimicrobials. ENT isolates (except Proteus mirabilis and
indole-positive Proteae) with MIC ‡ 2 mg/L for imipenem (IMI)
and meropenem (MER) were screened for metallo-beta-lacta-
mase (MBL) by disk approximation test followed by PCR. ENT
isolates from Greece with positive MBL screen test results were
further evaluated. MBL gene and its genetic context were
revealed by PCR and sequencing techniques. The isolates were
also epidemiologically typed by PFGE.
Results: In the 2001–2005 period 16 K. pneumoniae (KPN) and 2
E. aerogenes (EAE) isolates from a medical center in Greece were
found to produce VIM-1. Multiple distinct clonal outbreaks of
VIM-1 producing ENT were identiﬁed during this period.
Susceptibility and molecular typing results are summarized in
the table.
Conclusions: blaVIM-1 emerged and rapidly became endemic
among ENT in Greece. The high mobility of blaVIM-1 was
demonstrated by the ﬁnding of: i) different PFGE patterns
among VIM-1 producing KPN; ii) variable sizes of the integron
amplicons; and iii) the emergence of VIM-1 in EAE. Our results
also demonstrated that blaVIM-1 is disseminating horizontally
as well as vertically within the medical center. These ﬁndings
represent a critical problem for the healthcare facility as
carbapenems remain the last antimicrobial resort for treatment
of infections caused by multi-drug resistant Gram-negative
bacilli. In addition, this is the ﬁrst report of EAE producing VIM-
1.
P1405
VIM-1 producing Enterobacter cloacae strains
from Madrid, Spain: report from the SENTRY
Antimicrobial Surveillance Program 2005
L. Deshpande, H. Sader, M. Tato, F. Baquero, R. Jones,
R. Canton (North Liberty, US)
Objective: To characterize Enterobacteriaceae (ENT) strains with
reduced susceptibility (S) to carbapenems (CARB) isolated in
Madrid, Spain.
Methods: As part of the SENTRY Program bacterial isolates are
S tested by reference CLSI methods against >25 antimicrobial
agents. ENT isolates (except Proteus mirabilis and indole + Pro-
teae) exhibiting MIC results at >=2 mg/L to imipenem (IMI) and
meropenem (MER) were screened for metallo-beta-lactamases
(MBL) and Bush-Jacoby-Medeiros group 2f carbapenemases by
disk approximation (DA) and PCR. PCR amplicons were
sequenced for epidemiological purposes as well as to reveal
genetic context of resistance genes. Isolates were also typed by
PFGE.
Results: Two E. cloacae (ECL) strains (2700A and 726C) showed
elevated CARB MIC values as well as resistance to all beta-
lactams, except aztreonam (AZT) in strain 726C (Table 1). The
strains were isolated in March 2005 (12 days apart) from
bloodstream and respiratory tract infections of patients hospit-
alized in two distinct hospital units. The strains showed distinct
antibiograms and PFGE patterns (Table 1). Both strains showed
positive DA test results and PCR screens positive for blaVIM
with a Class 1 integron of approximately 2.5 kb. Sequencing of
integron from the index strain (726C) revealed blaVIM-1 along
with aacA4 and aadA1 genes.
Conclusions: This is the ﬁrst report of VIM-1-producing ECL
from Spain. VIM-1 has been recently reported in ENT (K.
pneumoniae and E. coli) from Barcelona, Spain. The ﬁnding of
blaVIM-1 in two clonally unrelated strains emphasizes the
mobility of these genes. Thus, MBL may be emerging as a
signiﬁcant, geographically diverse resistance mechanism among
ENT in Spain. It is imperative to screen ENT isolates with
modestly elevated (not resistant) MIC values of either IMI or
MER for carbapapenamse production and to control the spread
of this resistance mechanism in ENT isolates causing nosocomial
infections
P1406
Occurrence and prevalence of CTX-M type beta-
lactamases in Gram-negative bacteria from
tertiary care hospital, North India
M. Shahid, V.M. Ensor, P.M. Hawkey (Aligarh, IN; Birmingham,
UK)
Objectives: CTX-M beta-lactamases are increasingly reported
worldwide. Although the ESBL phenotype has been reported
from India, no further molecular surveys have been published
with the exception of the ﬁrst report of CTX-M-15 type. This
study was designed to identify the presence, species distribu-
tion, and sub-types of CTX-M genes in a large tertiary hospital
between 2003–2005.
Methods: Gram-negative bacteria from various clinical samples
submitted to the department of Microbiology, J.N. Medical
College & Hospital Aligarh, India, for routine culture and
susceptibility testing were studied. 130 non-duplicate isolates
resistant to a third generation cephalosporin were randomly
selected. These were subjected to a Multiplex PCR designed to
identify all geno-groups of a blaCTX-M. Further identiﬁcation of
the speciﬁc CTX-M types was done by Reverse Line Hybridiza-
tion (RLH).
Results: A total of 130 bacterial isolates from 130 non-repeat
clinical samples (Urine = 108, Bronchoalveolar lavage
(BAL) = 16 and Pus = 6) were included in the study. Urinary
isolates were Escherichia coli (n = 91), Klebsiella pneumoniae
(n = 9), Acinetobacter (n = 6), Klebsiella oxytoca (n = 1) and Cit-
robacter spp. (n = 1). The isolates from BAL were E.coli (n = 11)
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and K. pneumoniae (n = 5) and from pus were E. coli (n = 2) and
K. pneumoniae (n = 4). Eighty-two (63.1%) of the 130 isolates
were found to be CTX-M Group-1 positive by PCR. RLH
identiﬁed all of them as CTX-M-15 type beta-lactamase produc-
ers.
Conclusion: CTX-M Group-1 beta-lactamases are the only CTX-
M type in our area, and only CTX-M-15 was found. It is
surprising that no other CTX-M subtypes are present in this
survey population in contrast with other countries. This is the
ﬁrst systematic survey report from India detecting CTX-M-15
type beta-lactamases.
P1407
Characterization of class 1 integrons carrying the
genes for VIM- and IMP-type metallo-beta-
lactamases in Pseudomonas aeruginosa strains
from Russia
O. Shevchenko, M. Edelstein, V. Kretchikov, L. Stratchounski
(Smolensk, RU)
Objectives: To investigate the genetic context of metallo-beta-
lactamase (MBL) coding genes in Russian strains of P. aerugi-
nosa.
Methods: The six strains studied were isolated respectively in 6
hospitals of 3 cities of Russia as part of the RESORT national
surveillance study in 2002–2004. Based on results of our recent
study (O. Shevchenko, et al., 45th ICCAC, P. C2-105), ﬁve of
them were found to produce VIM-2 beta-lactamase and were
assigned to 3 distinct clonal groups. One unrelated isolate
produced a single (E59K) mutation variant of IMP-1. A PCR
with primers facing outward from the intI1 and blaVIM or
blaIMP genes was used to conﬁrm the location of MBL genes in
class I integrons. The entire cassette arrays were then ampliﬁed
using the primers matching conserved sequences at the 5’ (intI1)
and 3’ (qacEdelta1) ends of integrons, separated by gel electro-
phoresis and sequenced using the nested intI1-, qacEdelta1- and
cassette-speciﬁc primers.
Results: All the MBL genes were associated with class I
integrons. Sequence analysis demonstrated that the blaVIM-2
gene cassettes were all identical to that reported from In58 in
France (GenBank acc. no. AF263520), however the structure of
the blaVIM-2-carrying integrons was different. Two out of 3
isolates representing the same clone broadly disseminated in
Russia contained the cassette array: aacA7, blaVIM-2, dhfr,
aacC-A5, whose sequence was 100% identical to that of the
recently described outbreak strain from the USA (GenBank acc.
no. AY943084). The genetic content of the blaVIM-2-carrying
integron from the third clonally related isolate was distinct:
aadB, blaVIM-2, and aacA4 gene cassettes. The integron of one
of the remaining unrelated strains contained only two gene
cassettes: blaVIM-2 and aadA1, and that of another one carried
blaVIM-2 and aadB cassettes separated by the unknown frag-
ment of 315 bp that includes a 150-bp sequence 90% homologous
to the orfE-like gene (GenBank acc. no. AY139595). The genetic
environment of the novel blaIMP gene was also unique. There
was an aadB gene cassette located upstream of blaIMP, and
downstream of it there was a 305-bp unknown sequence
followed by cmlA and blaOXA gene cassettes.
Conclusion: The results of our study demonstrate an increasing
complexity and diversity of class I integrons carrying MBL
genes in P. aeruginosa.
P1408
Prevalence of AmpC over-expression in
bloodstream isolates of Pseudomonas aeruginosa
V.H. Tam, A.N. Schilling, M.T. LaRocco, L.O. Gentry, K. Lolans,
J.P. Quinn, D.A. Melnick, K.W. Garey (Houston, Chicago,
Wilmington, US)
Objectives: The prevalence of AmpC over-expression in Pseu-
domonas aeruginosa (PA) as a mechanism of beta-lactam resist-
ance was reported to be 6% in France previously (De Champs,
AAC 2000). However, its prevalence is not well established in
the U.S. We examined the contribution of AmpC over-expres-
sion towards beta-lactam resistance in clinical isolates of PA
obtained in our hospital.
Methods: All bloodstream PA isolates obtained in 2003 were
screened for ceftazidime (CAZ) resistance with and without
the presence of clavulanic acid (4 lg/mL). AmpC stable
derepression was ascertained phenotypically by a spectropho-
tometric assay (with and without prior induction by imipe-
nem) using nitroceﬁn as the substrate, and subsequently
conﬁrmed by real-time quantitative PCR of the ampC gene.
The presence of AmpC was conﬁrmed by isoelectric focusing
(with cloxacillin inhibition). The clonal relatedness of the
AmpC over-expressed mutants was assessed using PFGE. In
addition, the ampC and ampR genetic sequences were
determined by PCR. For comparison, 2 standard wild type
(PAO1 and ATCC 27853) and 3 multi-drug susceptible PA
isolates were used as controls.
Results: 76 non-repeat bloodstream PA isolates were available.
Stable derepression of ampC [a single beta-lactamase inhibited
by cloxacillin (pI = 8.7)] was conﬁrmed in 14 isolates (preval-
ence rate = 18.4%), and consisted of 7 distinct clones. The most
prevalent point mutations in ampC were found to be G27D,
V205L, and G391A, respectively.
Conclusion: In contrast to the previous study, AmpC over-
expression is a signiﬁcant mechanism of beta-lactam resistance
in PA. Understanding the prevalence and mechanism of beta-
lactam resistance in PA may guide the choice of empiric therapy
for nosocomial infections in our hospital.
P1409
Characterization of ESBL producing Salmonellae
isolated in Hungary in 2000 – 2004
N. No´gra´dy, A´. To´th, J. Pa´szti, M. Fu¨zi (Budapest, HU)
In case of Salmonella infections caused by multiple resistant
strains, for infants, elderly or immuno-compromised patients
extended-spectrum cephalosporins (ESCs) are recommended for
treatment. Consequently, since the 1990s outbreaks and cases of
infections caused by Salmonella resistant to ESCs have been
increasingly reported. The aim of the study was to screen the
Salmonella isolates received by the ‘Johan Be´la’ National Centre
for Epidemiology, Hungary, during 2000–2004, for isolates
producing extended-spectrum-beta-lactamase (ESBL) and to
characterise the strains by molecular methods. An initial
screening for cefotaxime resistant (CtxR) strains was performed
by disk diffusion method. The ESBL phenotype of the CtxR
strains was conﬁrmed by double disk approximation test and
ESBL Etest. The strains were investigated by PCR using
conserved primer sets speciﬁc for blaTEM, blaSHV and
blaCTX-M genes and also for class 1 integron. The PCR products
were sequenced. The transferability of the identiﬁed ESBL genes
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was tested by conjugational experiments; the clonal relationship
of the strains was tested by PFGE. Eight S. Typhimurium and one
S. Enteritidis have been found to show cefotaxime resistance and
produce ESBL. Five S. Typhimurium strains harboured CTX-M-5
gene, which was transferred by an approx. 6.7 kb plasmid to the
transconjugants. Two S. Typhimurium strains had CTX-M-15 and
TEM-1 genes, both of which were transferred via an approx.
140 kb plasmid. These two strains plus one CTX-M-5 positive
strain produced one or both of the 1.45 kb (aadB-catB3) and 2.05
kb (oxa1-aadA1) integrons. In a single S. Typhimurium strain
SHV-5 and TEM-1 genes were identiﬁed which were not
transferable. This strain was integron negative. The CTX-M
positive strains belonged to the same genetic cluster; the SHV-5
positive strain represented a distinct cluster. The S. Enteritidis
strain possessed an SHV-5 gene alone, which was located on
and transferred by an approx. 90 kb plasmid, together with an
approx. 3.2 kb integron (aacC4-aacC1-ORFX-ORFX’-
aadA1a).ESBL producing of the Hungarian Salmonella strains
appears to link mainly to plasmid-mediated CTX-M type genes.
Emergence of the CTX-M-5, CTX-M-15 and SHV-5 genes in S.
Typhimurium, as well as appearance of an ESBL producing S.
Enteritidis in Hungary is reported for the ﬁrst time.
Acknowledgement: Noe´mi No´gra´dy is holder of the Bolyai
Ja´nos stipend of the Hungarian Academy of Sciences.
P1410
Phenotypic and genotypic identiﬁcation of
metallo-beta-lactamases in Pseudomonas
aeruginosa in a university hospital, Ankara,
Turkey
A. Cakar, B. Sener, G. Hascelik (Ankara, TR)
Objectives: Pseudomonas aeruginosa(Pa) is a leading cause of
nosocomial infections and is resistant to many antibiotics. Since
carbapenemresistancedue tometallo-beta-lactamases(MBL) is an
increasing problem all around theworld, identiﬁcation ofMBL in
clinicalmicrobiology laboratory is very important. The aim of this
study is to identify MBL enzyme in clinical Pa isolates, by
phenotypic and genotypic methods and also evaluate the per-
formance of phenotypic tests in identiﬁcation of the MBL.
Methods: Seventy-ﬁve clinical Pa isolates resistant to ceftazi-
dime and/or imipenem were included in this study. Antibiotic
susceptibilities were investigated by agar dilution method. For
phenotypic identiﬁcation of MBL, double disk synergy test, E-
test, combined disk synergy test and Modiﬁed Hodge test were
performed. Imipenem hydrolysis was screened in the crude
extracts of the isolates. In order to conﬁrm the results of the
phenotypic tests, PCR analysis were performed with the speciﬁc
primers for the conserved regions of blaVIM and blaIMP genes.
Results: Among the Pa isolates tested 50 (75%) of them were
found as multiple drug resistant. According to the PCR analysis
eight (10.6%) isolates were found blaVIM positive. Double disk
synergy test identiﬁed three (37.5%) PCR positive isolates. Five
(62.5%) isolates were positive with E-test, two (20%) of them
were positive with Modiﬁed Hodge test and seven (87.5%) of the
eight PCR positive isolates were also positive with combined
disk synergy test. Four of the PCR positive isolates proved to be
positive also with the hydrolysis test.
Conclusion: The results of this study revealed that MBL are
prevalent among beta-lactam resistant Pa isolates in our hospi-
tal. Phenotypic tests alone are not always sufﬁcient to detect
MBL, since MBL genes are not always expressed. When PCR
analysis based on the presence of MBL genes was taken as the
gold standard, among the phenotypic tests the most reliable one
seemed to be the combined disk synergy test.
P1411
Prevalence of CTX-M producing bacteria in
Ireland
D. Morris, M. McManus, C. Slater, V. Buckley, L.E. Fenelon,
G. Corbett-Feeney, M. Cormican (Galway, Dublin, IE)
Objectives: Extended Spectrum Beta Lactamase (ESBL) produ-
cing bacteria are a problem in hospitalized patients and are
increasingly associated with community-acquired infection. The
CTX-M class of beta-lactamases have emerged as a serious
problem with a sharp increase in the occurrence of urinary tract
infection (UTI) associated with CTX-M-15 producing E. coli
noted in the U.K during 2003/2004. Dissemination within the
UK of CTX-M-15 producing E. coli ‘‘strain A’’ has been reported.
This aim of this study is to determine to what extent the strain A
reported in the UK, or other CTX-M/ESBL positive Enterobac-
teriaceae are present in Ireland.
Methods: Threehundredand thirty two suspectESBLproducing
Enterobacteriaceae were provided by 24 laboratories throughout
Ireland.Isolates were collected from hospitalized and primary
care patients between 1997 and 2005.Susceptibility testing to
cefpodoxime, cefotaxime, ceftazidime and cefoxitin was per-
formed and interpreted in accordance with Clinical Laboratory
Standards Institute (CLSI) disk diffusion methods. Suspect ESBL
producers were assessed using three ESBL Etest strips (AB
Biodisk, Solna, Sweden): ceftazidime/ceftazidimeplus clavulanic
acid (TZ/TZL); cefotaxime/cefotaxime plus clavulanic acid (CT/
CTL); and cefepime/cefepime plus clavulanic acid (PM/PML).
Conﬁrmed ESBL producers and appropriate controls were exam-
ined for blaCTX-M,blaSHV, andblaTEMbyPCRwith sequencing
of selected amplicons. Pulsed ﬁeld gel electrophoresis (PFGE)
using XbaI was performed.
Results: Three hundred and ten isolates (93%) were identiﬁed
as suspect ESBL producers and 156 (47%) were conﬁrmed ESBL
positive. The blaCTX-M gene was detected in 92 isolates (68
CTX-M group-1, 23 CTX-M group-9, and 1 to be identiﬁed), the
blaSHV gene in 58 and blaTEM gene in 84. DNA sequencing
conﬁrmed blaCTX-M-15 in 3 of the CTX-M group-1 isolates and
blaCTX-M-14 in 1 of the group-9 isolates. One isolate harboring
blaCTX-M-15 was indistinguishable from strain A from the UK.
Conclusions: CTX-M producing Enterobacteriaceae have been
present in Ireland since at least 2000 and were widely dissem-
inated in Ireland before their presence was ﬁrst conﬁrmed in
2005.The clonal group designated strain in the UK is also
present in Ireland.
P1412
Widespread dissemination of blaOXA-51-like
among carbapenem-resistant Acinetobacter spp.
isolates in Brazil
D.E. Xavier, A.C. Gales, A.S. Pereira, A.C.C. Pignatari,
M. Castanheira (Sao Paulo, BR)
Objective: blaOXA-51 and variants have been recently des-
cribed among carbapenem-resistant Acinetobacter spp. isolates
from Argentina. In current study we evaluated the presence of
blaOXA-51-like among carbapenem-resistant Acinetobacter spp.
isolated from seven Brazilian hospitals.
Methods: A total of 30 non-duplicated imipenem-resistant
Acinetobacter spp. clinical isolates were collected during the
2000–2001 period from seven distinct hospitals located in six
Brazilian cities. The isolates were susceptibility tested by CLSI/
NCCLS broth microdilution method against 12 antimicrobial
agents. The genetic relationship among the isolates was deter-
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mined by RAPD. Gel ComparTMÆ generated dendograms for
interpretation of RAPD results. The detection of blaOXA-51-like
was performed by PCR with primers designed to align with the
blaOXA-51 family. DNA sequencing of one amplicon was
performed in both strands. Restriction digestion of the remain-
ing ampliﬁcation products conﬁrmed the presence of blaOXA-
51-like.
Results: All isolates showed high levels of resistance against
most beta-lactam agents, including penicillins in combination
with serine-beta lactamase inhibitors, broad-spectrum cephalo-
sporins, imipenem, meropenem and aztreonam. The isolates
were also resistant to aminoglycosides (amikacin and gentam-
icin) and ﬂuoroquinolones (ciproﬂoxacin and gatiﬂoxacin). The
restriction proﬁle of the PCR products showed that blaOXA-51-
like was detected in 29 of 30 (96.6%) Acinetobacter spp. isolates
studied. A great genomic variety was found among the
Acinetobacter spp. isolates collected from different institutions
but a predominant clone was observed in one of the hospitals.
Conclusions: Although recent reports have suggested that the
OXA-type enzymes naturally occur among Acinetobacter isolates,
speciﬁc OXA-encoding genes are only disseminated in partic-
ular regions. In the current study, the presence of blaOXA-51-
like was widely detected among Acinetobacter spp. isolates
collected from Brazilian hospitals located in Southern and
Southeastern regions, which are closer to Argentina.The pres-
ence of OXA-51-like producing isolates might be one of
contributing factors to justify the elevated carbapenem resist-
ance rates found among Acinetobacter spp. isolated in Brazil.
P1413
Genetic analysis of metallo-beta-lactamase
producing Klebsiella pneumoniae and
Pseudomonas aeruginosa isolates in the intensive
care unit of a university general hospital in
Greece
E. Koratzanis, I. Galani, M. Souli, Z. Chryssouli,
H. Giamarellou (Chaidari, GR)
Objective: During a study for the evolution and horizontal
transfer of metallo-B-lactamase(MBL) genes from commensal to
pathogenic gram-negative bacteria in patients of an intensive
care unit of a tertiary care university hospital, we analysed the
integrons carrying the MBL gene in K. pneumoniae and P.
aeruginosa isolates.
Methods: Isolates from surveillance cultures as well as isolates
considered pathogenic from the same patient that exhibited a
positive EDTA-imipenem disk synergy test were studied.
Susceptibility testing was performed by the disk diffusion
technique and MICs were determined by the broth microdilu-
tion method according to NCCLS guidelines. EDTA-disc syn-
ergy test, was used to screen for MBL production. PCR and
PCR-RFLP analysis and Southern hybridization were used to
identify and analyse the blaVIM-containing integrons.
Results: All isolates exhibited reduced susceptibility or resist-
ance to imipenem (0.5–>8 lg/ml) and a positive EDTA-synergy
test. Strains were resistant to ceftazidime, ceftriaxone and
cefotaxime. Class I integrons associated with VIM-type MBL
genes were found in all strains. Preliminary PCR-based experi-
ments and RFLP analysis revealed the presence of 5 different
integrons (1500–5500 bp) carrying blaVIM-1 in K. pneumoniae
isolates. The predominant type is that of 1500 bp probably
corresponding to an integron containing only blaVIM-1 gene
cassette. A new integron containing blaVIM-1 and aac (6´)-IIc
that has been characterized by our group in an Enterobacter
cloacae clinical isolate was also found in a K. pneumoniae isolate.
Interestingly, the same patient was also colonized by a Citrob-
acter freundii carrying the same integron. PCR and Southern
hybridization revealed the presence of 2 integrons (both >2 kb)
carrying blaVIM-2 in all of the P. aeruginosa isolates. The size
and RFLP analysis revealed no similarities between the integ-
rons of P. aeruginosa and those of K. pneumoniae.
Conclusions: MBLs of the VIM-type represent an emerging
threat in Greek hospitals. All isolates of our study harboured
blaVIM-1 (K. pneumoniae) or blaVIM-2 (P. aeruginosa), in class I
integrons. We observed: 1) the diversity of blaVIM-1 containing
integrons in different K. pneumoniae isolates of the same patient
and the integration of the same class I integrons in K. pneumoniae
nosocomial isolates of different patients and 2) no similarities of
VIM-containing integrons from P. aeruginosa and K. pneumoniae
isolates even those isolated from the same patient.
P1414
Detection of extended-spectrum beta-lactamases
in E. coli and Klebsiella spp. by isoelectric
focusing and PCR
L. Oksuz, N. Gurler (Istanbul, TR)
Objectives: The aim of this study was the detection of beta
lactamases types in extended spectrum beta lactamases produ-
cing E. coli and Klebsiella spp strains. The study strains consisted
of 12 E. coli and 32 Klebsiella spp (28 K. pneumoniae and 4 K.
oxytoca) isolated from various specimens of patients hospitalized
in different units (Intensive Care, Hematology, Oncology,
Neonatology, Transplantation and Pediatric Surgery Units) of
the Istanbul Medical Faculty between July 2002–March 2004.
Methods: Antimicrobial susceptibility tests were performed by
disc diffusion according to the CLSI guidelines. MICs of
cefotaxime and ceftazidime were determined by the agar
dilution method and by the E-test ESBL. Isoelectring focusing
was performed by the method of Matthew et al (J Gen Microbiol,
1976). Polimerase chain reaction was performed using primers
speciﬁc for the bla TEM, blaSHV and blaCTX-M genes. Conju-
gation was carried out by broth mating. A rifampicin-resistant
E.coli strain (J62-2) was used as the recipient. Plasmid extraction
was performed by the alkaline lysis method.
Results: Resistance to imipenem or meropenem was not detec-
ted. Amikacin was the second most effective antibiotic against
all strains, after carbapenems. All isolates demonstrated an
ESBL phenotype using the double-disc synergy test. MIC50 and
MIC90 for cefotaxime were found 16 lg/ml and 64 lg/ml in
Klebsiella spp and E.coli strains, respectively. IEF results indica-
ted that all isolates produced 1–4 beta lactamases. Isoelectric
points of the isolates were between 5.4–9.0. Among K. pneumo-
niae and E.coli strains, rates of TEM, SHV, CTX-M beta
lactamases were found 64.3%, 92.9%, 67.9%; 66.7%, 25%,
83.3%, respectively. The proﬁles generated with ERIC-2 PCR
primer contained several bands, ranging in size from 170 to
1500 bp. Ten, three and six groups were separated for K.
pneumoniae, K. oxytoca and E. coli, respectively. Thirty-one of the
isolates (70.45%) were able to transfer their resistance to
recipient E. coli strains by conjugation. Twenty of the trans-
konjugants (64.5%) were found to carry only one plasmid (>48a).
Eleven strains (35.5%) harbored more than one plasmid, with
sizes ranging from 10 to 100 kb.
Conclusions: In conclusion, we found that CTX-M was more
common than TEM and SHV beta lactamases in E. coli strains
isolated from patients hospitalized in Istanbul Medical Faculty,
however SHV was the most common beta lactamase in K.
pneumoniae. The present work was supported by the Research
Fund of Istanbul University. Project no T223/06032003.
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P1415
Molecular characterization of Enterobacteriaceae
producing CTX-M-1-like ESBL (CTX-M-1, -3, -15,
and -32) in Madrid, Spain (2000–2004)
A. Novais, R. Canto´n, R. Moreira, F. Baquero, T.M. Coque
(Madrid, ES)
Objectives: CTX-M enzymes are the most widespread class A
extended spectrum beta-lactamases (ESBL), CTX-M-9-like and
CTX-M-10 being the most commonly found in Spain. However,
CTX-M-1-like variants have been recently detected. The aim of
the study was to characterize the genetic diversity of these ESBL
from our institution.
Methods: 20 E. coli CTX-M-1-like producing isolates from 14
patients were studied. ESBL characterization was performed by
IEF, PCR and sequencing. Antibiotic susceptibility was deter-
mined by standard methods. Clonal relatedness was established
by PFGE and E. coli phylogenetic groups determined by a
multiplex PCR assay. Transfer of bla was carried out by broth
and ﬁlter matings. Plasmid analysis was accomplished by the
method of Barton, RFLP and characterization of the incompa-
tibility group by the PCR assay based on replicon typing
described by Carattoli et al. Presence of ISEcP1, IS26 and IS903
and their association with blaCTX-M genes were searched by
PCR.
Results: Isolates were recovered from outpatients (45%) and
from patients at medical (25%), ICU (25%) and surgical wards
(5%). Nine CTX-M-1, 5 CTX-M-15, 5 CTX-M-32 and 1 CTX-M-3
producing isolates corresponding to 12 PFGE types (3 CTX-M-1,
3 CTX-M-15, 5 CTX-M-32 and 1 CTX-M-3) were studied. Most
belong to phylogenetic group D (58,3%) followed by groups B1
(16,7%), A (16,7%) and B2 (8,3%). Resistance to quinolones,
sulfonamides, and aminoglicosides was commonly observed
(64%, 45% and 55%, respectively). Transfer of bla genes was
achieved in most cases (83%). Plasmids containing blaCTX-M-
15, blaCTX-M-1 and blaCTX-M-3 were diverse and assigned to
incompatibility groups FIB, F and A/C. Plasmids carrying
blaCTX-M-32 were related and belong to incompatibility group
N. ISEcP1 was located upstream of all blaCTX-M studied
although a copy of IS5 interrupting ISEcp1 was identiﬁed in all
CTXM-32 and 1/3 CTX-M-1 strains. Most isolates (10/12) were
positive for IS26.IS903 was only detected among isolates
containing blaCTX-M-15 and blaCTX-M-3.
Conclusions: The high clonal and plasmid diversity found
among CTX-M-15 and CTX-M-1 isolates reﬂects a wide spread
of these ESBL also in Spain. Dissemination of CTX-M-32 is
linked to genetically related plasmids in our area. Association of
ISEcP1, IS26 and IS903 to different bla genes and plasmids
contributes to the spread, maintenance and ampliﬁcation of a
variety of resistance genes and elements in both community and
nosocomial environments.
P1416
Repeated occurrence of extended-spectrum beta-
lactamase CTX-M-9 in Salmonella enterica,
serotype Virchow, isolated in Spain from 2002 to
2005
S. Herrera, R. Ramiro, R. Gonzalez-Sanz, S. Valdezate, R. Diez,
A. Aladuen˜a, M.A. Echeita (Majadahonda. Madrid, ES)
Members of a new group of extended-spectrum beta-lactamases
(ESBLs), the CTX-M type, derived from chromosomal class A
beta-lactamases, have been identiﬁed in the past 10 years. They
have been detected in a variety of species of the family
Enterobacteriaceae in very distant regions and, although one
speciﬁc enzyme could be detected in different regions, it seems
that there are predominant enzymes in each region. In a one-
year long study our group detected the presence of CTX-M-9
enzyme strongly associated to Salmonella enterica, serotype
Virchow, phage-type 19.
Objectives: i) to survey the Salmonella enterica, serotype Vir-
chow, phage type 19 strains submitted to the Spanish Reference
Laboratory for Salmonella and Shigella (SRLSS) from 2002 to
2005 in order to determinate the rate of beta-lactam resistances.
ii) to identify the ESBLs responsible for the resistances and iii) to
further characterize the strains harboring the ESBLs to establish
the genetic relationship among them.
Material and methods: The antimicrobial susceptibility for the
S. Virchow isolates was determined by the disk diffusion method
using Mueller–Hinton agar medium. ESBLs phenotype was
detected by the double disk synergy test (DDST). A PCR and
later sequencing of the obtained fragments were performed for
the molecular ESBLs characterization. The genetic relationship
among the strains was determined by PFGE.
Results and discussion: We found an association between S.
Virchow, phage-type 19 and a resistance proﬁle that affected not
only to beta-lactams but also to other antimicrobial drugs.
Regarding to the beta-lactams, the resistance found in most of
the strains is due to the combined presence of TEM-1E and CTX-
M-9 enzymes. Although different, some of the serotype Virchow
PFGE ﬁngerprints were highly related (similarity, 90%) which
may indicate clonal spread of this resistance rather than
horizontal transfer. Although the SRLSS is focus on the study
of Salmonella isolated from human origin, some of the received
strains had a non-human origin. It is interesting that S. Virchow,
phage-type 19 is highly distributed in Spain but just in the
human case.
Conclusion: We could be facing the spread of a clone of a
multirresistant Salmonella enterica, serotype Virchow, phage-
type 19 harboring a CTX-M-9 beta-lactamase distributed in most
of the Spanish provinces.
P1417
High clonal and plasmid diversity of CTX-M-14
and SHV-12 producing isolates in the community
(Madrid, Spain)
A. Valverde, T.M. Coque, A. Novais, J.C. Gala´n, F. Baquero,
R. Canto´n (Madrid, ES)
Objectives: Class A extended spectrum beta-lactamases produ-
cing Enterobacteriaceae have been increasingly recovered, being
CTX-M-14 and SHV-12 the most common enzymes detected.
The aim of this work is to study the epidemiological features
and genetic diversity of these enzymes recovered in our
institution since ﬁrst description.Methods: We studied CTX-M-
14 (76 isolates/67 patients) and SHV-12 (44 isolates/43 patients)
producing isolates from 1999 to 2005. Clonal relatedness was
established by XbaI- PFGE. Phylogenetic groups among E. coli
isolates were identiﬁed by a multiplex PCR assay. Transfer of
bla genes was searched by broth and ﬁlter mating. Plasmid
characterization was accomplished by S1 nuclease and RFLP.
Presence of ISEcp1, IS903, IS26 and association with blaCTX-M-
14 or blaSHV-12 was elucidated by PCR.
Results: CTX-M-14 and SHV-12 were mainly recovered from
the community setting (50%–70%, respectively) corresponding
to outpatients, healthy volunteers and environmental samples.
In the hospital, they were isolated from patients at medical (20/
32%), surgery (5/11%) and ICU (2.5/ 7%) wards. Resistance to
quinolones was higher among CTX-M-14-isolates than SHV-12
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(23/4.5%) but resistance to sulphonamide was more common
among SHV-12 strains (75/54%). blaCTX-M-14 was mainly
associated to E. coli (96%) while blaSHV-12 was linked to both E.
coli (68%) and K. pneumoniae (31%). E. coli isolates belong to
phylogenetic groups D (36.9%), A (36.9%) and B1 (24.3%).
Among CTX-M-14 producing isolates, a high clonal diversity
(index diversity (D) = 0.7) was detected. Transfer of blaCTX-M-
14 was achieved in most cases, involving different plasmids
(48.5 – 330 kb). This gene was mainly linked to ISECp1 and
occasionally to IS903. High clonal diversity among SHV-12- E.
coli was also observed (D = 0.7) while most K. pneumoniae
isolates belong to a single PFGE type (5 PFGE types/14 isolates)
recovered from 2001 to 2003. Most isolates were able to transfer
blaSHV-12 gene, located in plasmids ranging from 48–145kb.
Presence of IS26 was detected in most of SHV-12-isolates.
Conclusions: Strains containing blaCTX-M-14 and blaSHV-12
are mainly associated to the community. The high clonal and
plasmid diversity among E. coli isolates indicates a wide
dissemination of these particular genes outside the hospital
and suggests that this species plays a relevant role in the spread
and maintenance of resistance genes linked to ISEcp1 or IS26
both in community and nosocomial settings.
P1418
Dissemination of acquired metallo-beta-
lactamases in Gram-negative pathogens: ﬁrst
Italian countrywide survey
L. Pagani, F. Luzzaro, C. Mugnaioli, M. Spalla, F. De Luca,
M. Perilli, G. Babini, G. Gesu, G. Amicosante, A. Toniolo,
G.M. Rossolini (Pavia, Varese, Siena, L’Aquila, IT; Erembodegem,
BE; Milan, IT)
Objectives: The emergence of acquired metallo-beta-lactamases
(MBLs) in gram-negative pathogens (Pseudomonas aeruginosa,
Acinetobacter spp. and Enterobaceriaceae) is a worrisome phe-
nomenon since MBLs can confer resistance to carbapenems and
most other beta-lactams. MBL producers have now been
reported worldwide. In Italy, both IMP- and VIM-type enzymes
have been detected, mostly in P. aeruginosa but also in other
gram-negatives. In this work we report the results of the ﬁrst
Italian nationwide survey on the prevalence of acquired MBLs
in P. aeruginosa and other gram-negative nonfermenters
(GNNFs), and in Enterobacteriaceae.
Methods: During a 4 month period (Sept.–Dec. 2004), consecu-
tive nonreplicate isolates showing reduced susceptibility to
imipenem (using ad hoc breakpoints, depending on species)
were selected from 14 clinical microbiology laboratories distri-
buted across Italy. Identiﬁcation and susceptibility testing were
carried out with the Phoenix ID/AST System (Becton Dickin-
son). MBL genes were screened by colony-blot hybridization
and identiﬁed by sequencing.
Results: Of 2721 GNNFs and 12 245 Enterobacteriaceae nonrep-
licates isolated at the participating laboratories during the study
period, 319 and 117, respectively, were selected for further
investigation. Overall, 30 isolates were positive for acquired
MBL genes including 27 P. aeruginosa (1.3% of total and 10% of
carbapenem-resistant P. aeruginosa isolates, respectively), 1
Pseudomonas putida, 1 Acinetobacter baumannii, and 1 Enterobacter
cloacae. MBL producers were detected in 10 of 14 sites. In 24
isolates the enzyme was of the VIM type, while in the remaining
6 it was of the IMP type.
Conclusions: P. aeruginosa producing acquired MBLs are
broadly distributed in Italy, although their overall prevalence
remains relatively low. In other gram-negative species acquired
MBLs remain quite uncommon. Enzymes of the VIM type
appear to be more common than those of the IMP type. A
ﬁnancial contribution from Becton Dickinson Europe is acknow-
ledged.
P1419
Phenotypic and molecular detection of metallo-
beta-lactamases in imipenem-resistant
Pseudomonas aeruginosa in a hospital centre,
Coimbra, Portugal
A. Pena, A.F. Alves, R.M. Leita˜o, O.M. Cardoso (Coimbra, PT)
Objectives: Pseudomonas aeruginosa (PA) is one of the leading
causes of nosocomial infections. Clinical isolates harbouring the
metallo-beta-lactamases (MBLs) IMP and VIM have been
increasingly reported worldwide, and VIM has been reported
especially in Mediterranean Europe. Recently, another two
MBLs have been described: SPM-1 in Brazil and GIM in
Germany. The aim of this study was to determine the occurrence
of these enzymes in Portuguese clinical isolates of PA imipenem
(IP) resistant.
Methods: During two years (April 2003 to April 2005) 773
clinical isolates of PA were collected in Centro Hospitalar of
Coimbra and were identiﬁed by MicroScan WalkAway (Da-
debehering) system. The susceptibilities were determined with
this system that uses the following antibiotics: Piperacillin (PIP),
Piperacillin plus Tazobactam (TZP), Aztreonam (AZT), Ceftaz-
idime (CAZ), Imipenem (IP), Meropenem (MP), Gentamicin
(GN), Tobramicin (NN), Amicacin (AMK), and Ciproﬂoxacin
(CIP). Interpretation was done according recommendations of
NCCLS. In order to determine the occurrence of MBLs, 136
isolates IP resistant were studied. Screening was made with
double disk synergy test. PCR using conditions and primers
speciﬁcs for blaVIM, blaIMP, blaSPM and blaGIM previously
described. The amplicons obtained were sequenced to identify
the MBLs genes.
Results: Among the 773 isolates of Pa collected 136 (17.6 %)
were IP resistant. The susceptibilities to other antibiotics of the
IP resistant isolates were: MP 20.3%, CAZ 56.7%, AZT 37.3%,
AMK 73.1%, and CIP 53%. Double disk synergy test was
positive in 40 (29.4%) isolates. By PCR, 24 isolates (60%)
demonstrated the presence of blaVIM. The others MBLs tested
were negative. Sequencing demonstrated the presence of VIM-2
in these isolates. Among these strains that harboured VIM-2,
AZT inhibited 79.2%, followed by CAZ 66.7% and AMK 54.0%.
Conclusions: Twenty-four (17.6%) of the IP resistant isolates
exhibited a MBL VIM-2, and were isolated from nosocomial
infections. The emergence of MBL producing bacilli that are
resistant to carbapenems, aminoglycosides, and ﬂuoroquinolo-
nes is becoming a severe therapeutic problem, indicating the
need of alternative antimicrobial therapies, and search of
inhibitors of this kind of enzymes. A regular screening/
monitoring system should be set up to prevent the wider
spread of this resistance determinant.
P1420
Prevalence and molecular characterisation of
beta-lactamases in Gram-negative rods isolated
from oral ﬂora
V. Toussaint, C. Voha, I. Madinier, T. Fosse (Nice, FR)
Objectives: Beta-lactam resistance in most gram-negative
anaerobic bacteria is mediated by the production of class A
extended-spectrum beta-lactamases. In the case of oral cavity
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infections, a variable prevalence of CfxA-like beta-lactamase
was described in Prevotella spp. strains. The aim of this study
was to determine the prevalence of beta-lactamase producing
Gram negative rods isolated from oral ﬂora and to identify by
PCR beta-lactamase genes according to species.
Methods: Over a period of 24 months 142 gingival samples
were collected from 71 adult patients from dental department
(Teaching University Hospital of Nice, France). Anaerobic or
microaerophilic Gram negative rods presumptively resistant to
beta-lactams were screened by culture on supplemented blood
agar dishes with amoxicillin antibiotic disks. Beta-lactamase
production was determined by the nitroceﬁn disk test. Antibi-
otic susceptibility was determined by Etest MICs. Beta-lacta-
mase genes were determined by PCR (CblA-CepA, CfxA, Fus-1,
TEM) and cfxA probe.
Results: Overall a very high prevalence (85%) of beta-lactamase
producing strains was found. A total of 224 strains were
identiﬁed (>3/patient). Most of the resistance was due to CfxA
beta-lactamase. Main CfxA producing species were P. buccae (58
strains), P.intermedia (43), P. denticola (25), P.oralis (16) and
Capnocytophaga sp. (9). A group of Prevotella sp. (25) cfxA
negative producing a new extended-spectrum beta-lactamases
was found. Fusobacterium nucleatum beta-lactamase positive
strains were PCR Fus-1 positive (oxacillinase). TEM type beta-
lactamase was only found in two Hamophilus sp. strains but not
in Prevotella or Capnocytophaga strains.
Conclusions: With a sensitive culture screening method a very
high prevalence of cfxA producing ß-lactamase was found in
oral ﬂora. A new extended-spectrum beta-lactamases was found
in Prevotella sp. and deserves further studies. This high
prevalence was probably due to extensive horizontal transfer
of mobile genetic element among oral ﬂora.
Non-molecular diagnostics of MRSA
P1421
Implementation of BBL CHROMagar orientation
for routine urine cultures in a high-volume
clinical laboratory
S. Whittier, P. Della-Latta (New York, US)
The Clinical Microbiology Service of Columbia University
Medical Center receives over 200 urine specimens per day for
routine culture. Our current practice utilizes a bi-plate consist-
ing of 5% sheep blood agar and MacConkey agar (Becton
Dickinson, Sparks, MD). The purpose of this investigation was
to determine the feasibility of replacing our existing bi-plate
with the BBL CHROMagar Orientation agar, which was
designed to detect and identify two of the most commonly
isolated urinary tract pathogens, E. coli and Enterococcus species.
We prospectively planted 1350 urine specimens on both the bi-
plate and CHROMagar plate. Of these, 662 (49%) samples were
determined to be positive by both methods, 634 (47%) were
negative by both and there were 54 (4%) discordant sets of
culture results. Of the 662 culture positive samples, 351 (26% of
total specimens) grew clinically signiﬁcant urinary tract patho-
gens. The remaining 311 (23% of total specimens) were either
mixed (>3 organisms) or grew insigniﬁcant quantities
(<10,000 CFU) of bacterial pathogens. Forty-two of the 54
discordant results were samples in which the bi-plate was
positive for <10,000 CFU of nonpathogenic bacterial isolates
while the CHROMagar plate demonstrated no growth. These
discordant results were considered to be insigniﬁcant. The
remaining 12 discordants were reported as >100,000 CFU mixed
urogenital ﬂora, however examination of the CHROMagar plate
clearly demonstrated a predominance of Enterococcus species.
This bi-plate ‘‘misses’’ were considered to be signiﬁcant due to
the implications of missing a potential uropathogen, particularly
a VRE isolate. Identiﬁcations and susceptibilities were per-
formed on the Vitek 2 system (bioMerieux, Durham, NC) from
colonies isolated on the bi-plate as well as the CHROMagar
plate. Results were consistent, independent of the media.
Overall, the CHROMagar plate performed extremely well in
our laboratory. The potential for cost-savings can be realized
through the use of rapid identiﬁcation and increased capacity to
recognize mixed cultures, thus obviating unnecessary subcul-
tures.
P1422
Evaluation of chromogenic Biome´rieux MRSA ID
medium for direct detection of methicillin-
resistant Staphylococcus aureus from surveillance
cultures and from clinical samples
C. Sa´nchez-Carrillo, E. Cercenado, M. Marı´n, J. Jensen,
M. Guembe, M. Rivera, E. Bouza (Madrid, ES)
Objectives: Rapid detection of methicillin-resistant Staphylococ-
cus aureus (MRSA) from surveillance cultures and from clinical
samples is crucial in order to control the spread of MRSA. We
evaluate a new selective and differential chromogenic medium,
MRSA ID medium (Biome´rieux, Marcy L’Etoile. France) which
enables recovery and concomitant identiﬁcation of MRSA
strains directly from nasal swab specimens and from other
clinical samples.
Methods: From May to June 2005, all samples received in our
laboratory requesting MRSA search were studied. A total of 530
clinical samples were inoculated to MRSA ID and mannitol-salt
agar (MSA, Tec-Laim. Spain): 452 surveillance nasal swab
specimens obtained from the anterior nares and 78 other
samples (57 wounds, 21 bronchial aspirates). Green colonies
on MRSA ID and mannitol-positive on MSA at 24 hours and
48 hours were identiﬁed by the MicroScan system (Dade
Behring) using Pos Combo 2SA panels and by detection of the
mecA and femA genes by PCR.
Results: A total of 202 S. aureus isolates were recovered; of these
67 (33%) were oxacillin susceptible (MSSA) and 134 (66%) were
oxacillin resistant (MRSA). On MRSA ID, 132/134, or 98.5% of
MRSA were recovered, whereas recovery on MSA was 82.8%
(111/134) (p < 0.0001). The overall sensitivity, speciﬁcity,
positive predictive value and negative predictive value of
MRSA ID were: 98.5%, 98.2%, 94.9%, and 99.4%, respectively;
whereas, the corresponding values for MSA were: 82.8%, 99.7%,
99.1%, and 94.5%. Seven false positive readings on MRSA ID
were detected (one nasal swab and 6 other samples) and
corresponded to Enterobacter cloacae (3 isolates), MSSA (1),
methicillin-resistant coagulase-negative Staphylococci (1), Can-
dida spp. (1), and Bacillus spp. (1). Fifty-eight MRSA isolates (43%)
were detected on MRSA ID at 24 hours; 42% at 48 hours, and in
the remaining 15% of MRSA, readings were only performed at
48 hours. On MSA followed by conventional methods for the
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ﬁnal identiﬁcation of MRSA, identiﬁcation was delayed to
72 hours in 14% of cases, and to more than 72 hours in 86%.
Conclusions: In this study, MRSA ID was superior to conven-
tional methods for recovery of MRSA from nasal swabs and
from other clinical samples, and shortened the detection time of
MRSA to 24 or 48 hours. The enhanced recovery of MRSA using
this medium and the identiﬁcation of most MRSA isolates at
24 hours without additional susceptibility testing will beneﬁt
the patients and decrease costs associated to infections caused
by MRSA.
P1423
Comparative evaluation of the chromogenic
MRSA ID media with standard procedure for
screening of methicillin-resistant Staphylococcus
aureus carriers and detection of high-level
resistance to mupirocin by disk diffusion
I. Mansoor, J. Brouillard, S. Cannoot, C. Ducastel (Baudour, Ath,
BE)
Objectives: The procedure for screening patients with methi-
cillin-resistant Staphylococcus aureus (MRSA) is very laborious. It
includes the use of agar plates and selective enrichment broth
(SEB). Results are available to clinicians only after 48–96 hours,
thus delaying isolation measures needed for preventing nosoco-
mial transmission of MRSA. In this study we evaluated the yield
of direct plating specimens on MRSA ID without SEB.
Moreover high-level resistance to mupirocin was determined
by disk diffusion (200 lg) and MICs.
Methods: A total of 523 specimens were cultured: 487 nasal and
36 wounds swabs. To overcome inoculation bias, a random table
was used. Direct plating on MRSA IDwith a disk of mupirocin
(200 lg) was compared with our procedure which includes a
Columbia ANC blood agar (COL) and a NaCl 7.5% SEB. Plates
were read after 24/48 hours and broths sub cultured on COL
after 24 hours. All colonies resembling S. aureus on the COL and
green colonies on MRSA ID plates were identiﬁed with the
Slidex Staph Plus (SSP) latex. Oxacillin susceptibility was done
with an oxacillin (6 lg/ml) agar screen method (OAS). Mup-
irocin inhibition zone diameters (IZD) were recorded for MRSA
strains isolated from clinical samples and from 14 well-charac-
terized mupA strains. Mupirocin MICs were done with E-test
strips for MRSA strains with IZD <20 mm.
Results: A total of 39 (7%) MRSA were isolated by a combina-
tion of all methods. The overall sensitivities for primary plating
were 77(87%) for COL and 90(100%) for MRSA ID after
24(48 h) of incubation time respectively. The SEB in combination
with COL gave a yield of 92%. The speciﬁcities for the MRSA
ID plates after 24 (48 h) incubation were 99.8(98.3%). No
methicillin susceptible Staphylococcus aureus was isolated on the
MRSA ID while 65(12%) with our routine procedures. The
number of SSP and OSA tests done were 281(54%), 149(28%) for
routine procedure and 48(9%), 39(7%) for direct plating on
MRSA ID  respectively (p < 0.05). The mupirocin IZD range
from 6 to 50 mm and 6 to 14 mm for clinical and mupA strains
respectively. Mupirocin MICs for strains (19) tested were
> 1024 lg/ml.
Conclusions: The use of MRSA ID with 24 hours of incuba-
tion time is as sensitive as standard procedure for MRSA
screening. Green colonies appearing after 48 hours should be
further identiﬁed and susceptibility testing done. High dose
mupirocin disks could be a good alternative to E-test for
detecting high-level resistance to mupirocin.
P1424
Direct identiﬁcation and methicillin
susceptibility of Staphylococcus aureus from
blood-culture bottles using the Vitek 2 system
C. Flo´rez, E. Lo´pez-Oviedo, C. Martı´n, J. Cabezas, D. Morilla,
E. Martı´n-Mazuelos (Seville, ES)
Objectives: To asses the ability of The Vitek System in order to
rapid identiﬁcation of S. aureus and detection of methicillin
resistance from blood-culture bottles.
Methods: Only blood cultures bottles showing Gram-positive
cocci in clusters on direct Grams stain in more than one set of
blood cultures were processed. The direct method was done
using a suspension made by differential centrifugation of
positive blood culture broth for inoculation of the Vitek ID-
GPC, ID-GP and AST-536 cards (bio-Merieux). Standard iden-
tiﬁcation was done using an inoculummade from and overnight
culture on solid media and coagulase production (Staphaurex,
Remel). The detection of methicillin resistance was evaluated
with the oxacillin disk diffusion and PBP-2a latex test (Oxoid).
Results: A total of 51 consecutive S. aureus isolates from blood
cultures were evaluated. The direct method resulted in 11.8%
misidentiﬁcations or non-identiﬁcations. Methicillin resistance
was detected in 6 isolates (11.8%) by direct method and the PBP-
2a test and in 7 by disk diffusion.
Conclusions: The direct Vitek method could correctly report
identiﬁcation and susceptibility patterns within 8 hours in 88.2%
of bacteraemic episodes with S. aureus. All direct results should
be considered only preliminary reports and they should be
contrasted with cultures and standard methods in order to
detect mixed cultures or errors the identiﬁcation or susceptibil-
ity.
P1425
Evaluation of BBL CHROMagar MRSA medium
to detect methicillin-resistant Staphylococcus
aureus
B.M.W. Diederen, M. van Leest, I. van Duijn, P. Willemse,
P.H.J. van Keulen, J.A.J.W. Kluytmans (Tilburg, Breda, NL)
Objectives: All over the world, methicillin-resistant Staphylo-
coccus aureus (MRSA) is an important and increasing problem.
Optimal treatment and prevention is largely dependent on
laboratory detection of this pathogen. The purpose of this study
is to evaluate the in vitro sensitivity and speciﬁcity of a recently
developed medium called BBL CHROMagar MRSA (BD Diag-
nostics, Le Pont de Claix, France).
Methods: A well-deﬁned collection of S. aureus (251 methicillin
susceptible (MSSA) and 270 MRSA) was used. The isolates were
stored at )70C until they were tested. The MRSA isolates were
collected in The Netherlands and all had a unique typing
pattern. BBL CHROMagar MRSA was supplied as prepoured
culture plates by BD Diagnostics (Le Pont de Claix, France). The
isolates were inoculated on Columbia agar-plates with 5% sheep
blood and incubated for 24 hours at 35C. From the resulting
cultures a suspension of 0.5 MacFarland was made and
subsequently 10 ll was streaked on a BBL CHROMagar
MRSA plate using a sterile loop. The results were read after 24
and 48 hours of incubation at 35C. Growth of colonies showing
green coloration was considered to be positive (indicating
MRSA). Results for the detection of MRSA were compared to
the performance of a conventional mannitol salt agar plate with
an added concentration of 4 lg/ml oxacillin (MSA). Discordant
results were conﬁrmed by molecular tests (e.g. mecA-gene PCR).
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Results: In the current evaluation, 29 MRSA strains gave
discordant results and on these isolates a PCR for the mecA
gene was performed. A total of 27 (93%) of the MRSA strains
had a negative result of the mecA PCR. These strains were
removed from the analysis. The results obtained with BBL
CHROMagar MRSA are shown in table 1. The sensitivity of BBL
CHROMagar MRSA was 99.2% (241/243) after 24 hours and
99.6% (242/243) after 48 hours (p = 1.0). The speciﬁcity was
100% (251/251) after 24 hours and 99.2% (249/251) after
48 hours (p = 0.5). The sensitivity and speciﬁcity of MSA was
statistically signiﬁcant lower at both time intervals.
Conclusion: In conclusion, BBL CHROMagar MRSA is highly
sensitive and speciﬁc to differentiate between MSSA and MRSA.
Since the performance of BBL CHROMagar MRSA is already
optimal after 24 hours of incubation, results can be obtained
within a day.
P1426
Evaluation of MRSASelect medium to detect
methicillin-resistant Staphylococcus aureus
B.M.W. Diederen, M. van Leest, I. van Duijn, P. Willemse,
P.H.J. van Keulen, J.A.J.W. Kluytmans (Tilburg, Breda, NL)
Objectives: All over the world, methicillin-resistant Staphylo-
coccus aureus (MRSA) is an important and increasing problem.
Optimal treatment and prevention is largely dependent on
laboratory detection of this pathogen. The purpose of this study
was to evaluate the in vitro sensitivity and speciﬁcity of a
recently developed medium called MRSASelect (BioRad,
Marnes-la-Coquette, France).
Methods: A well-deﬁned collection of S. aureus (249 methicillin
susceptible (MSSA) and 271 MRSA) was used. The isolates were
stored at )70C until they were tested. The MRSA isolates were
collected in The Netherlands and all had a unique typing
pattern. MRSASelect was supplied as prepoured culture plates
by BioRad (Marnes-la-Coquette, France). The isolates were
inoculated on Columbia agar-plates with 5% sheep blood and
incubated for 24 hours at 35C. From the resulting cultures a
suspension of 0.5 MacFarland was made and subsequently 10 ll
was streaked on an MRSASelect plate with a sterile loop using a
three-streak dilution method. The results were read after 24 and
48 hours of incubation at 35C. Growth of colonies showing any
pink coloration was considered to be positive (indicating
MRSA). Results for the detection of MRSA were compared to
the performance of a conventional mannitol salt agar plate with
an added concentration of 4 lg/ml oxacillin (MSA). Discordant
results were conﬁrmed by molecular tests (e.g. mecA-gene PCR).
Results: In the current evaluation, 30 MRSA strains gave
discordant results and on these isolates a PCR for the mecA
gene was performed. A total of 28 (93%) of the MRSA strains
had a negative result of the mecA PCR. These strains were
removed from the analysis. The results obtained with MRSA-
Select are shown in table 1. The sensitivity of MRSASelect was
99.1% (241/243) after 24 hours and 100% (243/243) after
48 hours (p = 0.5). The speciﬁcity was 95.6% (238/249) after
24 hours and 94.8% (236/249) after 48 hours (p = 0.8). The
sensitivity of MSA was statistically signiﬁcant lower at both time
intervals (91.4% and 96.3% respectively). The speciﬁcity of MSA
was higher at 24 hours (96.8%), but not statistically signiﬁcant.
After 48 hours, the speciﬁcity of MSA was statistically signiﬁ-
cant lower (62.7%).
Conclusion: In conclusion, MRSASelect is highly sensitive and
speciﬁc to differentiate between MSSA and MRSA. Since the
performance of MRSASelect did not differ signiﬁcantly between
24 hours or 48 hours of incubation, optimal results can be
obtained within a day.
P1427
Detection of nasal carriage of Staphylococcus
aureus and methicillin-resistant Staphylococcus
aureus in general population with a new
chromogenic medium: MRSA ID agar
P. Ciragil, M. Gul, M. Aral, S. Alkis (Kahramanmaras, TR)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA),
known as a nosocomial pathogen, has been isolated from
community-acquired infections since 1980’s. We assessed a new
chromogenic medium MRSA ID agar (bioMe´rieux, France) for
the prevalence of and risk factors for community associated
MRSA and Staphylococcus aureus (S. aureus) nasal carriage in
general population.
Methods: A total of 429 apparently healthy subjects who
accompanied the patients from the community were evaluated
for the prevalence of nasal S. aureus colonization and to identify
risk factors (i.e., hospitalization, antibiotic therapy or underlying
chronic disease) associated with S. aureus and MRSA coloniza-
tion. Cultures of nares were performed and inoculated on
Columbia with 5% sheep blood agar (CBA) and a new
chromogenic medium: MRSA ID agar. Methicillin resistance of
colonies isolated from CBA were evaluated by using mini API,
ATB STAPH 5 (bioMe´rieux, France).
Results: Out of 429 samples, a total of 101 (23.5%) samples
were positive for nasal S. aureus colonization. After 24 hours
of incubation 13 (3%) of the samples were identiﬁed as MRSA
with green colonies on MRSA ID agar. However, CBA was
achieved to identify 12 (2.8%) MRSA isolates by combination
of tests, including tube coagulase test and ATB STAPH 5 in
48 hours.
Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
Conclusion: There was an excellent agreement between the two
media CBA and MRSA ID agar according to kappa test (Table).
So, MRSA ID agar may be used instead of CBA for identiﬁcation
of MRSA strains, because identiﬁcation of MRSA strains with
MRSA ID agar are faster than CBA. Although no signiﬁcant risk
factors were observed among MSSA carriers and MRSA carriers
(p > 0.05), further surveillance studies should be carried out in
our region.
P1428
Evaluation of Bio-Rad MRSA-Select for the
detection of methicillin-resistant Staphylococcus
aureus
L. Louie, D. Soares, H. Gardner, H. Meaney, M. Vearncombe,
A. Simor (Toronto, Ontario, CA)
Objectives: The prompt detection of MRSA is important for
implementation of infection control measures and patient
management. Newer chromogenic media for the detection of
MRSA show promise for the rapid isolation of MRSA. We
evaluated the use of MRSA-Select (Select) compared to mannitol
salt agar with 8 lg/ml cefoxitin (MSFOX) for the detection of
MRSA from clinical samples submitted for MRSA screening and
surveillance.
Methods: A total of 6199 specimens from 1883 patients were
tested, consisting of nares swabs (n = 2483), perianal/rectal
swabs (2312), catheter exit sites (647), skin/soft tissue (632),
sputum (58), and urine (67). Specimens were planted onto Select
and MSFOXmedia, incubated in ambient air at 35C, and read at
24 and 48 hours; the media were read independently by two
technologists. Suspicious colonies (pink from Select; yellow from
MSFOX) were worked up independently from both media for
MRSA using standard methods, including a commercial latex
agglutination test to detect PBP2a.
Results: A total of 181 MRSA were isolated. Select detected a
total of 177/181 (98%) MRSA compared with 164/181 (91%)
with MSFOX (p = 0.006). Of the 177 MRSA detected by Select,
169 (96%) grew after overnight incubation while only 132/164
(81%) were detected on MSFOX after overnight incubation
(p < 0.0001). There were a total of 178 specimens planted on
Select that yielded pink colonies after overnight incubation. All
but one of these was conﬁrmed as MRSA (177/178, 99.4%). The
number of specimens with suspicious growth at 24 and 48 hours
requiring further investigation and ultimately determined not to
be MRSA was more often found with MSFOX (1302/6199, 21%)
than with Select (468/6199, 8%) (P < 0.001).
Conclusion: Our results showed that MRSA-Select was super-
ior to MSFOX for the detection of MRSA from clinical screening
specimens, allowing greater yield, more rapid and easier
detection after overnight incubation, and was less likely to
support the growth of non-MRSA isolates.
P1429
Rapid detection of methicillin-sensitive and
resistant Staphylococcus aureus direct from blood
cultures
J. Montgomery, J. Bywater, B. Mayall (Melbourne, AU)
Objectives: Rapid detection of S. aureus (STAU) bacteraemia
including those resistant to methicillin (MRSA) signiﬁcantly
improves outcomes in these infections, and may reduce empiric
vancomycin use. Blood cultures with a Gram stain resembling
Staphylococci had modiﬁed latex agglutination (MLA) testing if
direct tube coagulase test (DTC) was positive on the day of
detection (Becton Dickinson, USA). The aim was to determine
the accuracy of DTC and MLA test directly from blood culture
broth (BCB).
Methods: For the DTC: 0.1 ml of mixed BCB was added to
0.5 ml rabbit plasma, incubated at 36C and read at 2, 4 and
24 hours. Incubation of bottles was continued at 36oC until DTC
became positive. If positive, a modiﬁcation of the PBP2a-Latex
Test (Oxoid Ltd., England) was performed. A 10 ml aliquot of
the BCB was centrifuged using a gel separator, the deposit
washed twice in saline, and re-suspended in extraction reagent.
The test was then performed as instructed by the manufacturer.
mecA gene PCR was used as the reference.
Results: DTC were performed on 571 bottles with Gram-
positive cocci resembling Staphylococci. Of those positive, 87%
(186) were detected within four hours. There were 124 STAU
and 91 MRSA. One false positive and one false negative were
detected. Sensitivity (SN) and Positive Predictive Value (PPV)
were 99.5%; speciﬁcity (SP) and Negative predictive values
(NPV) were 99.7%. MLA was performed on 212 DTC positive
bottles from 176 patients. Of these, 124 were mecA negative from
107 patients, and 88 mecA positive from 69 patients tested. Five
false positive and ﬁve false positive MLA tests occurred. SN and
PPV were 95% and SP and NPV were 96%. All false negatives
occurred early in the study and may have been due to
insufﬁcient growth so extended incubation is important.
Adequate washing of the bacterial pellet and adherence to the
method is important to avoid false positive results.
Conclusion: The DTC and MLA test, performed as part of the
routine processing of any blood culture with a Gram stain
resembling Staphylococci, gives accurate phenotypic detection of
MRSA at least twelve hours earlier than routine subculture. It
has signiﬁcant impact on the laboratory turnaround time and
clinical relevance of results.
P1430
Optimisation of screening for methicillin-
resistant Staphylococcus aureus by using the
chromogenic medium MRSA ID
M.J. Bruins, M.J. Egbers, G.J.H.M. Ruijs, M.J.H.M. Wolfhagen
(Zwolle, NL)
Objectives: In hospitals in the Netherlands, a strict search and
destroy policy to prevent the spread of methicillin-resistant
Staphylococcus aureus (MRSA) has so far kept the incidence of
MRSA under 1%. To shorten patient isolation periods and
control hospital and laboratory costs, screening methods need to
be rapid, highly sensitive, speciﬁc and inexpensive. We pro-
spectively analysed whether using the new chromogenic
medium MRSA ID (bioMe´rieux, Marcy l’Etoile, France) instead
of the currently used CHROMagar S. aureus (CHROMagar,
Paris, France) improved our MRSA screening protocol with
respect to turnaround time and workload.
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Methods: Swabs submitted for MRSA screening were inocula-
ted into a mannitol broth containing 2.5% NaCl. After 18–
24 hours at 35C broths were sub-cultured onto MRSA ID (MID)
and CHROMagar S. aureus (CSA), which were incubated at
35C. MID was read after 24 and 48 hours, CSA after 48 hours
because in our experience 24 hours yielded insufﬁcient growth
and colony pigmentation. Green colonies on MID and mauve
colonies on CSA were tested for DNase production and screened
for methicillin resistance on Columbia sheep blood agar con-
taining 6 mg/l oxacillin and with a methicillin strip on Mueller
Hinton agar. Suspected MRSA isolates were conﬁrmed by Vitek
2 followed by PCR for mecA and sa442 genes.
Results: In total 449 cultures from 190 individuals were ana-
lysed. After 24 hours green colonies were found on MID in 43
cultures, of which 29 were positive for MRSA. After 48 hours,
another 35 cultures on MID were suspect but MRSA negative. Of
the 29 MRSA positives, 26 were found on CSA. Sensitivities and
speciﬁcities of the media were 100% and 97% for MID after
24 hours, 100% and 88% for MID after 48 hours, and 90% and
55% for CSA after 48 hours respectively.
Conclusions: In this study, MID was found to be a 100%
sensitive, easy to interpret medium with the highest speciﬁcity
after 24 hours incubation. On the less selective CSA, three
MRSA isolates were not found because of overgrowing (mauve)
colonies of methicillin-sensitive Staphylococcus aureus and other
ﬂora. Changing to MID shortens the turnaround time of our
MRSA screening protocol by 24 hours and its high speciﬁcity
limits conﬁrmative testing considerably, thus resulting in a
decrease of cost.
P1431
Comparison of four commercial media for the
detection of MRSA carriage from nasal and
perineal specimens
L. Stoakes, R. Reyes, J. Daniel, G. Lennox, M. John, R. Lannigan,
Z. Hussain (London/Ontario, CA)
Objective: The objective of this study was to compare four
commercially prepared media for the rapid detection of MRSA
on nasal and perineal specimens. The media included were
Mannitol Salt Agar w/ 6 mg/l Oxacillin (MSA-OXA, Oxoid,
Ottawa, Canada) Mannitol Salt Agar w/ Cefoxitin (2 mg/l,
MSA-CFOX, Oxoid) and two chromogenic media CHROMagar
MRSA (CMRSA, BD Diagnostic, MD, USA) and a new selective
medium MRSASelect (MSRAS, Bio-Rad, Marnes-la-Coquette,
France).
Method: Routine nasal and perineal swabs for MRSA were
collected and plated on MSA-OXA, MSA-CFOX, CMRSA and
MSRAS. Each medium was inoculated using 50 ml of a 400 ml
prepared test suspension. Plates were incubated aerobically at
35C. All media types were read after 18 and 48 hours
incubation, with the exception of MRSAS, which were read at
18 to 24 hours. MRSA colonies were pink on the chromogenic
media and yellow on mannitol salt media. Suspected colonies
were conﬁrmed by multiplex PCR for the presence of mecA with
nuc and/or femB genes.
Results: A total of 2125 (1243 nasal and 882 perineal) consecu-
tive swabs were tested. Of these, 111 specimens were positive
for MRSA. Results are tabulated below according to specimen
type and media incubation time: Overall, the sensitivity and
speciﬁcity for MSA-OXA, MSA-CFOX, CMRSA and MRSAS are
80.2%/79%, 99.1%/84.8%, 82.9%/99.1% and 97.3%/99.8%
respectively.
Conclusion: MSA-CFOX and MRSAS were equally sensitive in
the detection of MRSA; however, MRSAS was more speciﬁc and
allowed faster conﬁrmation of MRSA, and earlier reporting of
results. Pink colonies can be regarded as MRSA without
additional testing or can be conﬁrmed by simple tests such as
gram smear, and/or coagulase test.
Antibiotic susceptibility testing: management, speciﬁc organisms
and resistant traits
P1432
External quality assessment for antimicrobial
susceptibility testing with ESBL-producing
Enterobacteriaceae
C. Walton, D. Brown (London, Cambridge, UK)
Objectives: To assess the results from clinical diagnostic labor-
atories taking part in the United Kingdom National Quality
Assessment Service antimicrobial susceptibility scheme with
specimens containing extended b-lactamase (ESBL) producing
strains of the Enterobacteriaceae.
Methods: EQA of antimicrobial susceptibility testing in 775
European laboratories was performed on a Klebsiella pneumoniae
(SHV-5 and SHV-2) and four Escherichia coli (one CTX-M-14, one
TEM-5, one TEM-10 and one TEM-26). Results were also
analysed for four ESBL-negative E. coli and one Citrobacter koseri.
Results: The overall performance for all strain/antimicrobial
combinations was good. On average 96% of the reports received
were correct. However, detection of ESBL-mediated resistance
to b-lactam agents by participants varied with the b-lactam
tested and the ESBL present. Resistance to ceftazidime, cefotax-
ime and cefuroxime respectively was reported by 75, 97 and 99%
participants with the CTX-M-14 E coli; 93, 87 and 93% with the
TEM-26 E. coli; 99, 86 and 89% with the TEM-10 E. coli; 96, 91 and
97% with the TEM-5 E. coli; and 95, 92 and 93%with the SHV-2 +
SHV-5 K. pneumoniae. Between 32 and 83% laboratories did
additional tests for ESBLs with ESBL-positive strains, the
percentage increasing with time, and 88–97% correctly reported
ESBL detection. 30% of laboratories reported additional tests for
ESBL production on ESBL-negative organisms. There was no
signiﬁcant difference in reliability of detection of resistance by
laboratories using BSAC, SRGA or CLSI methods.
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Conclusions: These data provide an insight into the ability of
European laboratories to detect ESBL-mediated resistance to b-
lactam agents in Enterobacteriaceae. In general for ESBL-producers
resistance was more likely to be reported to ceftazidime than to
cefotaxime, except for CTX-M-producers. False reporting of
resistance to ceftazidime and cefotaxime was rare, but was more
likely with cefuroxime. The number of laboratories performing
additional tests for ESBL detection increased over time and there
was little difference in reliability of standardized methods in
detecting resistance or ESBL production.
P1433
Analysis of the comparative workﬂow and
accuracy of two automated identiﬁcation and
susceptibility testing systems
Y. Gil, M.G. Garcı´a, B. Barreda, J.L. Go´mez-Garce´s (Madrid, ES)
Objectives: The aim of this study was to perform a comparative
study of the performance and productivity of two automated
identiﬁcation and susceptibility testing systems.
Methods: A total of 306 routine clinical isolates derived from
urine specimens were tested: 279 Gram-negative bacilli (276
Enterobacteriaceae and 3 non-fermenting bacilli) and 27 Gram-
positive cocci (17 Enterococcus spp., 5 Streptococcus spp., and 5
Staphylococcus spp.). All these isolates were processed by using
both the WIDER (W), (F. Soria Melguizo Spain) and the VITEK 2
Compact (V2C), (bioMerieux France), according to manufacturer
instructions.
Performance: Identiﬁcation and susceptibility testing was per-
formed on both systems.
Productivity: Chronometric measurements were made in three
batches, each with 5 E. coli isolates.
Results: Of the 279 Gram-negative bacilli tested, 277 (99.3%) and
274 (98.2%) were correctly identiﬁed by the V2C and W systems,
respectively. Excluding for this analysis the E. coli isolates
(n = 221), we obtained 98.3% (57/58) and 93.1% (54/58) of correct
identiﬁcations by the V2C and the W systems, respectively.
Performance: For Gram-positive cocci, we obtained a 100% of
correct identiﬁcation results by both methods. For AST, the
overall category agreement was 99.0% and 98.4% by the V2C
and the W systems, respectively. The minor error rates, major
error rates, and very major error rates for all bacterial isolates
tested were 0.9, 0.1, and 0.1 and 1.2, 0.2, and 0.2 for V2C and W,
respectively.
Productivity: The mean time to prepare one isolate using V2C
was 2.0 min and for W was 2.5 min. The mean time to results for
all bacterial groups was 319 minutes for V2C and 1080 minutes
for W.
Conclusion: Both systems give good identiﬁcation results for all
isolates. V2C showed better identiﬁcation performance for
Enterobacteriaceae, especially when E. coli isolates were excluded.
For AST, both systems showed equivalent and optimal results in
terms of category agreement. The V2C system required less
manual manipulation time and less time than the W system to
yield results.
P1434
A rapid DNA-based assay to detect
M. tuberculosis resistance
S. Nikolaou, S. Anagnostou, A. Raftopoulou, F. Kontos,
S. Karabela, S. Kanavaki (Athens, GR)
Objectives: The aim of our study was to evaluate the new Hain
Lifescience Geno Type MTBDR test (Hain Lifescience GmvH,
Nehren, Germany) for the detection of isoniazide (INH) and
rifampicin (RIF) resistance of M. tuberculosis isolates.
Material and Methods: Our study included 93 MTB strains
both resistant to INH, or RIF, or both and 50 strains susceptible
to these drugs, which were collected from Greek patients and
investigated by the Genotype assay. Our method is a nucleic
acid based assay for multiplexed analysis of the rpoB-gene
associated with resistance to RIF and the katG-gene position 315
associated with high-level resistance to INH. The test procedure
starts from cultured MTB bacteria and the time to result is about
ﬁve hours. DNA is ampliﬁed with the technique of PCR and the
amplicons are hybridized in a ‘reverse hybridization’ strip
format. All discrepant genotypes were conﬁrmed either by DNA
sequencing of the rpoB gene fragment, or for the katG 315 with
sequencing and ‘mass-PCR’.
Results: The 50 susceptible phenotypes were in full concor-
dance to the Genotype result. RIF’s resistance had a 91.6%
concordance with culture (46/48) and INH high-level resistance
had a 96.5% concordance with culture. From the 77 specimens
showing resistant cultural phenotype, 20 exhibited only low-
level resistance and showed no mutation in the katG region.
Conclusions: The Genotype MTBDR assay could be an appro-
priate addition to conventional drug resistance methods, to
shorten time to result from weeks to one day. All strains tested
by the Genotype assay showed highly concordant results
compared to the phenotypic characterization.
P1435
Use of 2, 3, 5- triphenyl tetrazolium chloride for
detection of drug resistance in Mycobacterium
tuberculosis
J. Ghanaat, K. Ghazvini, T. Rashed, P. Farnia,
A. Mohammadzadeh, M. Behdani (Mashhad, IR)
Objectives: Drug-resistant TB increases morbidity and the risk
of mortality, as well as the costs associated with its management,
thus poses a great health risk. Classical methods of detection of
drug resistance in M. tuberculosis are expensive and time
consuming, while the newer methods are not easily applicable
in low-income countries.
Methods: In this study, we have evaluated the possibility of
using colorimetric assay by mean of TTC (2, 3, 5- triphenyl
tetrazolium chloride) to detect antibiotic susceptibility of Myco-
bacterium tuberculosis strains as a rapid and less expensive
method. For this study 24 isolates of MTB were obtained from
Iranian National Research Institute of Tuberculosis & Lung
Disease (NRITLD). 12 isolates were resistant to RIF and INH and
12 isolates were susceptible to RIF and INH. The test was
performed with a critical concentration of 0.2 lg/ml for INH
and 2.0 lg/ml for RIF in 7H9GC broth with 1.25 mg of TTC.
Each strain was incubated in these tubes and inspected daily for
colour change up to 14 days.
Results: The sensitivity and speciﬁcity of this tested method
were 100% and 92% for both INH and RIF, respectively. So,
there was excellent agreement between colorimetric method
using TTC and proportion method (kappa values, 0.93 for INH
and RIF; p < 0.001). In this study the results were available in
average of 4.9 days.
Conclusion: Considering rapidity, use of low technology and
low cost, this assay that use tetrazolium-type compounds have
the potential of becoming the methods of choice for drug
susceptibility testing of M. tuberculosis isolates for most of the
countries where tuberculosis is a major problem.
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P1436
Direct E-test on lower respiratory tract samples:
improving antimicrobial use in ventilator-
associated pneumonia
E. Bouza, M.V. Torres, C. Radice, E. Cercenado, P. Mun˜oz,
R. de Diego, C. Sanchez (Madrid, ES)
Introduction: Rapid microbiological assessment of Ventilator-
Associated Pneumonia (VAP) can reduce morbidity and mor-
tality. Conventional isolation, identiﬁcation and susceptibility of
bacteria can take no less than 48–72 hours for a ﬁnal report.
Direct E-Test on Lower Respiratory Tract Samples (eT-LRT)
samples correlates well with conventional antimicrobial suscep-
tibility tests (Cercenado E, et al. ABSTRACT 42nd ICAAC).
Objective: We prospectively assessed the impact of providing
direct eT-LRT to clinicians in our institution in patients with
clinical suspicion of VAP.
Methods: From December 2003 to June 2005, patients with
suspicion of VAP and a positive direct Gram stain on LRT
samples were randomised in two groups (2:1) for two different
laboratory routines. Routine A included a direct eT-LRT
antibiogram performed with 6 antibiotic strips (oxacillin, ci-
proﬂoxacin, amikacin, cefepime, imipenem and piperacillin-
tazobactam). Results of this ‘‘preliminary’’ eT-LRT were sent to
the attending physician a mean of 1.4 days afterwards with no
further intervention followed by the traditional routine report.
Routine B included only traditional routine identiﬁcation and
antibiogram when susceptibility test results were available. We
measured the impact of Routine A and B in the management of
antimicrobial agents and in the clinical evolution of both groups.
Results: Overall, 231 patients with conﬁrmed VAP were inclu-
ded in the study (157 routine A and 74 routine B). Both
populations had similar basal epidemiological and clinical
characteristics. The comparison between Routine A and Routine
B was as follows: days of fever (4.5 ± 5 vs. 8 ± 6; P < 0.01);
DDDs of antibiotics (31 ± 24 vs. 43 ± 33; P < 0.01) days of
antimicrobial therapy (15 ± 9 vs. 19 ± 10; P: 0.03); percentage
of DDDs considered adequate (91% vs. 65%, P < 0.01); propor-
tion of days on adequate therapy (95% vs. 74%, P < 0.01); C.
difﬁcile-associated diarrhoea (1.9% vs. 10.8%; P < 0.01); plain
expenses on antimicrobials per episode (666 vs. 982; P = 0.01).
Days on ventilation (18 vs. 19 ns) and ICU stay (24 vs. 27 ns).
Conclusions: A rapid susceptibility test performed directly on
LRT secretions by 6 e-test strips signiﬁcantly improves the
accuracy of antimicrobial therapy of patients with VAP and
reduces the rates of adverse effects.
P1437
Piperacillin-sulbactam: determination of zone
diameter interpretive criteria using the new DIN
recommendations
H. Grimm, W. Heizmann, H. Kruepe, A. Rodloff (Weingarten,
Berlin, Fulda, Leipzig, DE)
Objectives: To obtain updated interpretative criteria for the
agar diffusion test with piperacillin-sulbactam (PIS) using the
new DIN-recommendations for susceptibility testing of b-lacta-
mase inhibitor-protected penicillin. A 4 mg/l instead of an
8 mg/l ﬁxed sulbactam-concentration is recommended in the
newest supplement of DIN 58940.
Methods: 530 strains of various species of the enterobacteriaceae,
preferable with reduced susceptibility or resistance against
piperacillin were included in the study. The MICs of piperacillin
alone as well as piperacillin with sulbactam (4 mg/l ﬁxed
concentration) were determined by means of micro dilution
technique as recommended in DIN 58940. In addition the agar
diffusion test was performed with disks loaded with 30 mcg of
piperacillin and 15 mcg of sulbactam according to DIN 58940.
Inhibition zone breakpoints were calculated by regression
analysis using the Excel software.
Results: On the basis of MIC breakpoints according to DIN
58940, 52.5% of the strains were susceptible, 14.1% intermediate
and 33.4% resistant to piperacillin. The respective ﬁgures for PIS
were 74.3%, 12.3% and 13.4%. The regression analysis showed
x = )0.40y + 20.95 and y = )2.03x + 47.70. Because of the mod-
erate correlation (r = )0.90) between zone and MIC, the average
equation from both regression equations shall be applied
resulting in the following interpretation of PIS-inhibition
zones: resistant up to 18 mm, intermediate 19–25 mm and
susceptible more than 25 mm.
Conclusion: The calculated new PIS-inhibition zone breakpoints
are 4–5 mm larger in comparison to the ﬁgures given in the DIN
58940 so far. This correction is necessary to avoid false suscept-
ible results in susceptibility testing of piperacillin-sulbactam.
P1438
The culture and antibiotic sensitivity testing of
pathogenic microorganisms on a highly porous
ceramic
C. Ingham, P. Wever, P. Schneeberger (Den Bosch, NL)
Objective: To develop a fast and widely applicable, culture-
based antibiotic sensitivity testing (AST) assay based around the
growth and in situ imaging of micro-organisms on a porous
ceramic support.
Methods: Sterile Anopore strips (an inert nanoporous ceramic
derived from aluminium oxide, see ﬁgure) were placed upon
appropriate agar plates (generally Mueller-Hinton or Sabouraud
media) containing deﬁned concentrations of test antibiotics. The
strips were inoculated with the bacteria or fungi to be tested and
were incubated in a CO2 incubator at 37C (for 40 minutes to a
period of several hours). Subsequent staining of cells on the
Anopore surface was with ﬂuorescent dyes (Fun-1 for fungi,
Syto 9 for bacteria: Invitrogen) through the pores from beneath.
Stained microcolonies were imaged directly using an Olympus
BX41 epiﬂuorescence microscope. Image capture used an 8-bit
Kappa CCD camera and TIFF ﬁles were converted to a binary
image and then quantiﬁed using ImageJ software (http://
rsb.info.nih.gov/ij/). Comparisons were made between the
Vitek 2 and E –Test methods and this approach for 24 clinical
isolates of the Enterobacteriaceae. Fungal pathogens, including
Candida albicans, were also tested.
Results: Growth of Enterobacter aerogenes could be detected on
anopore within 25 minutes and the earliest effects of the
trimethoprim were noticed after 40 minutes (Figure: Scanning
electron micrograph of a dividing Enterobacter aerogenes cell
cultured on Anopore). AST testing against trimethoprim was
performed with 2–3 hours culture and gave MIC values that
were comparable with the Vitek 2 and E-Test methods. By the
Anopore method, 5/5 trimethoprim-resistant and 19/19 trim-
ethoprim-sensitive strains were assigned correctly. Additionally,
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AST testing of Candida was demonstrated with detection of
sensitivity with 90 minutes culture and MIC values could be
derived with 3 hours culture.
Conclusions: Microcolony imaging appears to be a rapid and
effective approach to AST testing. Performing these tests on a
porous ceramic facilitates staining and imaging in situ and has
allowed rapid assessment of whether an antibiotic was inhib-
itory to growth.
P1439
Susceptibility pattern and toxigenicity of
Clostidium difﬁcile strains isolated from patients
with diarrhoea in a tertiary hospital in Athens
M. Orfanidou, H. Kafkoula-Alevizou, P. Karabogia-Karaﬁllidis,
E. Kontekaki, M. Theodoropoulos, A. Strouza,
H. Malamou-Lada (Athens, GR)
Objective: To report the susceptibility pattern and toxigenicity
of Clostridium difﬁcile strains (C. d.), isolated from hospitalized
patients suffering from C. difﬁcile associated diarrhoea (CDAD),
in a tertiary hospital in Athens, Greece, during 3 years period
(03/02–03/05).
Methods: During the study period 1482 stool samples were
examined for C. d. using cycloserin cefoxitin fructose agar with
5% egg yolk (CCFA) and cycloserin cefoxitin blood agar (BD).
The strains were identiﬁed by rapid ANA II (Remel, Lenexa)
and latex test (Culturette, BD). Toxin A was detected from C. d.
strains by an ELISA (Vidas, bioMerieux) and a chromatographic
assay (ColorPac, BD). Both toxins A&B were detected by an EIA
(Premier Toxins A&B, Meridian) and a chromatographic assay
(Immunocard Toxins A&B, Meridian). Antibiotic susceptibility
testing was performed by E-test (AB Biodisk, Solna) and b-
lactamase production by a chromogenic test (Lioﬁlchem).
Results: C. d. strains were isolated in 104/1482 (7%) stool
specimens. Toxin A was detected in 90/104 (86.5%) strains, toxin
B in 9/104 (8.7%) and A-B- in 5/104 (4.8%) strains. The
resistance rate of the isolated C.d. strains to penicillin was 69%
(MICs 1– > 32 lg/ml), clindamycin 52% (MICs 6– > 256 lg/
ml), tetracycline 31% (MICs 8–64 lg/ml), while no resistance
was observed to metronidazole (MICs £ 0.38 lg/ml), vancomy-
cin (MICs £ 1 lg/ml) and piperacillin/tazobactam (MICs £ 16 lg/
ml). Only one strain, which produced toxin B, was found
resistant to both meropenem and ertapenem (MICs 24 lg/ml
and > 32 lg/ml respectively). The MIC’s range of moxiﬂoxacin
and erythromycin for 34 C. d. strains was found to be 0.25–
> 32 lg/ml and 0.125– > 256 lg/ml and their resistance rate
was 23% and 62% respectively. All strains that produced toxin B
were found resistant to penicillin, clindamycin and erythromy-
cin (MICs 1.5– > 32 lg/ml, > 256 lg/ml, 12– > 256 lg/ml
respectively) and most of them 6/9 were found resistant to
tetracycline (MIC 6–64 lg/ml). None of the strains produced b-
lactamase.
Conclusions: (a) The most common toxin detected remains
toxin A but there is an up going presence of toxin B, (b) There is
a high resistance rate to penicillin, clindamycin, erythromycin,
tetracycline and moxiﬂoxacin, while there is still no resistance to
metronidazole and vancomycin, and (c) The resistant mechan-
ism to penicillin does not seem to be the production of b-
lactamase.
P1440
Comparison of dalbavancin MIC values tested
against Gram-positive organisms using E-test (AB
BIODISK) and reference dilution methods
T. Fritsche, H. Sader, R. Jones, B. Goldstein (North Liberty, US)
Objective: To evaluate the comparative accuracy of the E-test
(AB BIODISK, Solna, Sweden) method to determine dalbavancin
(DAL) MIC results using the CLSI agar and broth micro dilution
methods as the reference standards. A total of 100 organisms
were tested, all Gram-positive species susceptible (S) to DAL.
Methods: DAL and control vancomycin (VAN) E-test strips
were utilized, applying manufacturer technical and interpretive
recommendations. CLSI agar dilution (AD) and broth micro
dilution (BMD) methods were used as the reference method
results and all control tests (15 replicates) were within published
MIC ranges (M100–S15, 2005). 100 strains were processed as
follows: 35 S. aureus (SA, 15 MRSA), 20 coagulase-negative
staphylococci (CoNS) of 6 species (10 methicillin-resistant), 10
Enterococcus spp., 10 S. pneumoniae (SPN), 15 b-haemolytic
streptococci (BHS, representing 5 groups), 10 viridans group
streptococci and 3 QC strains. DAL was tested by BMD with
0.002% polysorbate 80 by CLSI methods.
Results: All E-test and CLSI reference QC results were within
established limits as follows (E-test results only): SA ATCC
29213 (0.032–0.047 mg/l), E. faecalis ATCC 29212 (0.094–
0.125 mg/l) and SPN ATCC 49619 (0.016–0.023 mg/l). DAL E-
test versus reference BMD (table) demonstrated 66% identical
results and 98% ± one log 2 dilution, but versus AD the E-test
MICs were generally 2-fold lower with 88 and 98% ± 2-fold and
± 4-fold from reference MIC values, respectively. Only BHS
showed an E-test modal MIC one log 2 dilutions greater than the
BMD MIC. The VAN E-test results compared to BMD (72%
identical; 100% ± one log 2 dilution) and to AD (72% identical;
99% ± one log 2 dilution) MICs also showed excellent correla-
tion. (See Table)
Conclusion: DAL E-tests provide an excellent and accurate
alternative MIC method as demonstrated by these results. E-test
could be applied with diagnostic conﬁdence when used with
concurrent QC determinations.
P1441
Evaluation of daptomycin 5, 10 and 15 mcg disks
on IsoSensitest and Mueller Hinton agar against
Staphylococcus aureus
L. Koeth, R. Smyth, G. Kahlmeter (Westlake, US; Vaxjo, SE)
Objectives: This study was performed in order to determine if
the use of 5, 10 or 15 mcg daptomycin disks on either
IsoSensitest agar or Mueller Hinton agar is a reliable disk
diffusion methodology for detection of susceptible and non-
susceptible S. aureus.
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Methods: Four daptomycin/calcium disks at concentrations of
5/50, 10/50, 15/10 and 15/50 mcg were tested on 2 lots of
IsoSensitest agar (ISA1 and ISA2) using semi-conﬂuent growth
according to BSAC and SRGAmethods. Three daptomycin disks
(2 manufacturers) at concentrations of 5, 10 and 15 mcg were
tested on 2 lots of Mueller Hinton agar (MHA1 and MHA2). All
disks were tested against 39 stock strains (including a challenge
set consisting of 15 strains with daptomycin MIC = 2, 12 = 4 and
1 = 8 mcg/ml) and 49 clinical strains of S. aureus. The QC strain,
S. aureus ATCC 25923 was tested on each day of testing.
Results: A non-susceptible breakpoint (NS BP) was chosen
based on analysis of susceptible and non-susceptible zone sizes
for each of the disk methodologies. All 12 strains with dapto-
mycin MICs of 4 mcg/ml were reliably detected by all disks.
The number of clinical (susceptible) strains that were categor-
ized as non-susceptible and the number of stock strains with
MICs of 2 mcg/ml (n = 15) that were categorized as susceptible
are shown in the table.
Conclusions: Daptomycin 10 or 15 mcg disks on MHA and for
ISA a combination disc with daptomycin/calcium at 15/10 were
best methods for discriminating between non-susceptible strains
with MICs of 2 or more and susceptible strains of MICs of 1 or
less. BD daptomycin disks on MHA were less likely to result in
categorization of susceptible strains as non-susceptible com-
pared to Mast disks, although Mast disks were slightly better at
detection of non-susceptible strains compared to BD disks.
Further assessment utilizing multiple test sites and media
batches is necessary for method validation.
P1442
Evaluation of effect of low concentrations of
calcium in daptomycin 30 mcg disks on
IsoSensitest agar against Staphylococcus
L. Koeth, R. Smyth, G. Kahlmeter (Westlake, US; Vaxjo, SE)
Objectives: As a result of lack of detection of some daptomcyin
non-susceptible S. aureus using the daptomycin 30 mcg disk on
Mueller Hinton agar, disk diffusion testing for daptomycin is
currently not recommended by CLSI. Levels of ionised calcium
in Mueller Hinton agar have been variable between manufac-
turers and batches, ranging from 17–64 mg/l. In contrast,
calcium levels in IsoSensitest agar have been more consistent
and at lower levels of approximately 10 mg/l. This study was
performed as an initial screen to evaluate daptomycin 30 mcg
disks containing calcium between 0 and 20 mg on IsoSensitest
agar as a potential disk method.
Methods: Daptomycin 30 mcg disks containing 5, 10, 15 and
20 mg of calcium were utilized against a challenge set of S.
aureus with elevated daptomycin MICs and against a set of
recently isolated daptomycin susceptible S. aureus. The QC
strains, S. aureusATCC 25923 and E. faecalis 29212 were tested on
each day of testing.
Results: Zone diameter ranges for each of the disks are shown
in the table.
Conclusions: The daptomycin 30 mcg disk with 5, 10, 15 or
20 mcg of calcium when used with IsoSensitest agar could
potentially detect all strains with MICs of ‡ 4 mcg/ml. The
20 mcg calcium disk was the best disk for detection of non-
susceptible strains with MICs = 2 mcg/ml. However, the
10 mcg calcium disk was superior at categorization of suscept-
ible strains with MICs of 1. The introduction of a buffer zone
could resolve some discrepancies observed at MICs of 1 and/or
2 mcg/ml. Additional testing of lower daptomycin concentra-
tion disks with similar levels of calcium may provide further
separation of zones between susceptible and non-susceptible
strains.
P1443
Evaluation of Cefoxitin Disk for detection of
methicillin-resistant Staphylococcus aureus
M. Rahbar, S. Moulanaee, P. Islami, R. Atifeh, K. Pirayesh
(Tehran, IR)
Objectives: Methicillin resistant Staphylococcus aureus (MRSA)
is a major cause of nosocomial and community acquired
infections. Detection of MRSA in laboratories is very important
for treatment and appropriate infection control. The aim of this
study was to evaluate of cefoxitin disk diffusion method for
detection of MRSA.
Methods: A total of 175 clinical isolates of S. aureus isolated
from clinical specimens were studied. The isolates were iden-
tiﬁed by conventional laboratory methods. E-test MIC, cefoxitin,
oxacillin disk diffusion methods and MAST ID Methicillin Strips
were used for detection of MRSA. All disk diffusion methods
performed as recommend by NCCL and manufactures guide-
lines.
Results: By using E-test MIC 53 (33.7%) of strains of S. aureus
were resistant to methicillin. Disk diffusion method by using
oxacillin disk showed 52 strains resistant to methicillin. In this
method 8 strains had intermediate resistance to methicillin. In
Cefoxitin disk diffusion method 52 strains were resistant to
methicillin. This method had a good correlation with E-test MIC
method. MAST ID Methicillin Strips showed 47 resistant to
methicillin. Sensitivity and speciﬁcity for both cefoxitin and
oxacillin disk diffusion methods were 98%and 100% respect-
ively, however cefoxitin was better than oxacillin for detection of
intermediate resistant strains of S. aureus. Sensitivity and
speciﬁcity for MAST ID Methicillin Strips was 91%and 100%
respectively.
Conclusion: Our study reveals that using cefoxitin is a god
alternative method for oxacillin disk diffusion method for
detection of MRSA. This method is reliable for identiﬁcation of
intermediate resistant strains of S. aureus.
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P1444
Estimating methicillin resistance in
Staphylococcus hospital strains: a comparison
between Kirby-Bauer disc diffusion antibiogram
and PBP2a detection with latex
A. Ksanthos, V. Kafarakis, E. Christoforaki, A. Vittoraki,
D. Drygiannakis (Rethymnon, Crete, GR)
Objectives: (i) To evaluate methicillin resistance of several
Staphylococcus hospital strains performing both PBP2a detection
test with latex and Kirby-Bauer (K-B) disk diffusion antibio-
gram.(ii) To compare the results of the two methods.
Materials & methods: We examined 136 Staph. strains (46 Staph.
aureus, 90 coagulase negative Staphylococcus-CNS) isolated in
cultures of several materials (blood, catheters etc) from patients
of our hospital. All the above strains were checked over the
possibility of: (i) methicillin resistance, using the K-B disk
diffusion antibiogram (according to NCCLS guidelines) (ii)
PBP2a production, using the kit slidex MRSA Detection
(Biomerieux), containing monoclonal antibody against PBP2a
protein.
Results: According to the K-B method, methicillin resistance
was detected in 8 of 46 Staph. aureus strains–for all of them, latex
test was (+). From the rest of the strains, 36 were susceptible and
2 moderately susceptible to methicillin, while all of them were (-
) to the latex. We also examined 90 CNS strains, out of which 59
proved to be methicillin resistant, according to the K-B, while to
latex 45 were tested (+). The remaining 31 strains were sensitive
to methicillin – 29 of them were (-) when tested with latex, while
2 strains were tested (+).
Discussion: (1). Regarding the Staph. aureus strains, the results
of the two performed methods were in complete agreement.
Thus, by using the latex test, a reliable preliminary estimation
about the resistance of a Staph. aureus strain can be obtained
within the ﬁrst 24 hours, an information of major clinical
interest, mainly in severe infections (e.g. bacteraemia). (2). As
far as the CNS strains are concerned, we observed certain
differences between the two methods, since there was a 24%
(14/59) percentage among the methicillin resistant (according to
K-B) strains, which gave a (-) latex test. In these cases,
determination of Oxacillin MIC (through E-test) is highly
recommended. Moreover, 6.5% (2/31) of the CNS strains with
phenotypic sensitivity to methicillin, were tested (+) to latex.
These bacteria may be carriers of mecA gene and, therefore, if K-
B is the only method performed, a false negative result is
considerably possible. (3). As a result, a preliminary examina-
tion of all Staph strains using the PBP2a detection latex test
(before an antibiogram performance) can be proved invaluable
since, in case of a positive result, it can lead to an immediate
brieﬁng of the attending physicians.
P1445
Detection of methicillin resistance in
Staphylococcus aureus clinical isolates by
phenotypic methods and PCR ampliﬁcation of
mecA gene
M.A. El-Sweify, M.F. Ahmed Fahmy Ali, A.A. Heiba,
G.I. Gebreel (Ismailiya, EG)
The unique resistance of MRSA to all b-lactam antibiotics is
primarily due to the acquisition of mecA gene, coding for PBP2a.
The diagnostic methods that rely on phenotypic features of
MRSA differ in reliability and sensitivity. Preferring a particular
MRSA diagnostic method that suits a given laboratory requires
continuous assessment and evaluation of already available
techniques. In the Suez Canal faculty of medicine microbiology
dept., this work aimed to explore the most appropriate and
applicable diagnostic assay by examining the available and
popular methods. Sixty S. aureus clinical isolates were ﬁrst tested
for the presence of mecA gene by PCR and subsequent
visualization on agarose gel, since this is the "gold standard"
method for MRSA detection. All mecA-positive (36) and mecA-
negative (24) isolates were further tested by agar disk diffusion
using oxacillin 1 lg and cefoxitin 30 lg disks; agar dilution
method to determine oxacillin MIC; MRSA-Screen latex agglu-
tination test that detects PBP2a (Denka Seiken Co., Japan).
Results showed that MRSA-latex was 100% concordant to the
PCR assay. It was rapid, simple, and reliable. Agar disk
diffusion showed sensitivity of 100% for cefoxitin and 83.3%
for oxacillin, while speciﬁcity was 95.8% and 87.5%, respect-
ively. The ranges for inhibition zone diameter for MRSA and
MSSA were more distinct when cefoxitin was used, than with
oxacillin disk. MIC assay by agar dilutions method showed
91.7% sensitivity and 95.8% speciﬁcity. Isolates showing MIC
between 2 and 4 lg/ml required retesting using closer serial
dilutions of oxacillin. In conclusion, MRSA screen latex test was
most appropriate as regards to cost, simplicity, timesaving, and
reliability than all other phenotypic methods, with accuracy that
almost matched PCR-assay accuracy. The latex test is therefore
qualiﬁed to rely on as a single routine test for MRSA identiﬁ-
cation
P1446
Evaluation of diagnostic methods for detecting
methicillin-resistant Staphylococcus aureus
strains in clinical microbiology laboratories in
Finland
A. Virolainen, A. Nissinen, A-M. Kerttula, J. Vuopio-Varkila and
the Finnish Study Group for Antimicrobial Resistance
Objectives: The aim of this study was to evaluate diagnostic
methods including cefoxitin disk vs. oxacillin disk tests to detect
methillicillin-resistant S. aureus (MRSA) in all clinical microbio-
logy laboratories in Finland.
Methods: All 26 Finnish clinical microbiology laboratories were
sent 20 isolates of Staphylococcus aureus strains previously
characterized at the Hospital Bacteria Laboratory in National
Public Health Institute. The study strains included high- and
low-level methicillin-resistant MRSA strains, borderline oxacil-
lin-resistant S. aureus strains (BORSA), and methicillin-sensitive
S. aureus strains. The laboratories were asked to test oxacillin
susceptibility of the strains according to their own routine
methods and also by using cefoxitin 30 lg disks, which were
provided to them along with the test strains.
Results: All of the 26 laboratories used oxacillin 1 lg disk
diffusion test with conﬂuent inoculum as the principal screening
method for detecting MRSA. Four major variations of the testing
conditions were used: Six laboratories preferred Mueller-Hinton
agar (MH) without salt, incubation at 35–36C for 18 to 24 hours
as the CLSI standard suggests, six used MH with added NaCl
(2–4%) at the same temperature, six used MHwith NaCl at 30C,
and ﬁve used Iso-Sensitest agar (IS) at 35–36C. The remaining
three laboratories had a different approach each. For the
cefoxitin disk diffusion-screening test for prediction of mecA-
mediated resistance, 12 of the 26 laboratories used MH without
salt, incubation at 35–36C for 18 to 24 hours, and 13 used IS at
35–36C. One laboratory preferred MH and incubation at 30C.
The mecA-mediated resistance was best detected by decreased
susceptibility to oxacillin when using MH with extra NaCl,
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incubation at 30C for either 18 or 24 hours sensitivity 100%,
speciﬁcity 78%. Compared to oxacillin testing, screening by
cefoxitin was less sensitive but more speciﬁc, giving an accurate
result with one BORSA strain but missing one low-level MRSA
isolate.
Conclusion: Amongst the four major oxacillin testing condi-
tions and cefoxitin screening, MH with extra salt and incubation
at 30C over night was the most sensitive alternative for
detection of MRSA.
P1447
Efﬁcacy of practised screening methods for
selection of cephalosporin-resistant
Enterobacteriaceae
R. Hope, N.A.C. Potz, M. Warner, D.M. Livermore (London, UK)
Objective: Enterobacteriaceae with extended-spectrum b-lacta-
mases (ESBL) are now widespread in the UK, and simple
phenotypic tests are required to identify them in diagnostic
laboratories. The simplest is to screen with cefpodoxime and to
do clavulanate synergy tests on isolates found resistant, but
many laboratories screen with further cephalosporins in the
initial screen. We investigated the screening methods used by 16
hospitals in Southeast England.
Method: Sixteen laboratories in the South-East of England
submitted a total of 1195 consecutive Enterobacteriaceae isolates
that they found to be resistant by their routine methods to any or
all of cefpodoxime, ceftazidime and cefotaxime. These isolates
were then tested centrally by the BSAC’s agar dilution method
using various cephalosporin/clavulanate combinations with
multiplex PCR for blaCTX-M and blaAmpC alleles.
Results: Screening methods used were; cefpodoxime discs
alone (1 site); cefpodoxime, cefotaxime and ceftazidime by
discs (9 sites) or agar dilution (1 site); Phoenix (2 sites) Vitek 1 (1
site) and Vitek 2 (2 sites). Eight percent of isolates submitted
based on disc tests proved fully cephalosporin sensitive,
compared with 3% sent based on tests with automated systems
(Phoenix, Vitek 1 and 2) and none of those sent based on agar
dilution test. Among isolates submitted only on the basis of
resistances to cefpodoxime 256/372 (69%) proved either cepha-
losporin susceptible or to have only borderline resistance with
no clear mechanism demonstrable; this proportion fell to 18/122
(15%) for those submitted on the basis of resistance to cefotax-
ime, 28/160 (18%) for ceftazidime and 26/496 (5%) for those
with both cefotaxime and ceftazidime resistance. The inference
of ESBL production by Vitek 2 had the best agreement with
reference results.
Conclusion: Many isolates found resistant only to cefpodoxime
at the source sites proved not to have ESBLs or AmpC; screening
with cefotaxime and ceftazidime allowed better speciﬁcity for
identiﬁcation of general mechanism based resistance, as did the
automated systems; nevertheless cefpodoxime remains a useful
single primary screen before conﬁrmatory testing.
P1448
Accurate and rapid antibiotic susceptibility
testing of Haemophilus inﬂuenzae by ﬂow
cytometry
M. O’Donoghue, W.L. Pong, M.V. Boost (Hong Kong, HK)
Objectives: Haemophilus inﬂuenzae continues to cause signiﬁcant
levels of morbidity and mortality and is responsible for serious
infections such as pneumonia and meningitis. Susceptibility
testing was not required for this organism in the past as it was
generally considered sensitive to certain antimicrobials. With
the increasing development of resistance in recent years,
previously employed empirical therapy is no longer adequate.
The fastidious nature of this organism limits the options for
susceptibility test methods and requires a minimum of 24 hours
turn around time. This study aimed to develop a rapid
antimicrobial susceptibility test method (AST) using a ﬂow
cytometer (FCM) and to compare the results with standard
methods.
Methods: Effects of a range of concentrations of ampicillin and
tetracycline on a H. inﬂuenzae control strain (ATCC 49247) were
determined by FCM (Coulter EPICS Elite ESP ﬂow cytometer)
using the ﬂuorescent probes DiBAC4 (3) and Propidium iodide
(PI). A further 30 clinical isolates of H. inﬂuenzae obtained from
several district hospitals in Hong Kong were then tested by FCM
method to determine their susceptibilities to ampicillin and
tetracycline and the results were compared to the Standard
Broth Dilution method (SBD). Results obtained were categorized
as sensitive, intermediate or resistant using a previously
published formula.
Results: Treatment with antibiotics resulted in a reproducible
and easily detectable change in ﬂuorescence. The degree of
change correlated well with sensitivity or resistance as deter-
mined by standard methods. There was no difference of
categorization of 29 strains tested. The remaining strain being
categorized as intermediately resistant by FCM and sensitive by
SBD i.e. a minor error.
Discussion: Reliable results were obtained within 3 hours
allowing the test to be completed within one working day,
which may have a considerable clinical impact. The reduction of
time for issuing of AST results would enable physicians to
choose more appropriate, narrower spectrum and less costly
antimicrobial therapy at the initiation of therapy. As reliable
results were obtained for both static (tetracycline) and cidal
(ampicillin) antibiotics suggesting the method can be extended
to other antibiotics. As most hospitals already have a FCM for
haematology purposes, it would not be necessary to purchase an
additional machine.
P1449
Detection of Helicobacter pylori and
clarithromycin resistance by real-time PCR in
children
Y. Akyo¨n, S. Tuncer, H. Demir, M. Misirlioglu, Y. Usta (Ankara,
TR)
Objective: Our aim was to detect both Clarithromycin resist-
ance and Helicobacter pylori from the biopsy sample, and to show
the Clarithromycin resistance rate in children.
Methods: Four hundred and forty biopsy samples obtained
from children who had dyspeptic complaints were included in
the study. The age range was 2–19. Two hundred and forty
seven were female, 193 were male. Chromosomal DNA was
extracted by Cetryl-trimethyl- ammonium bromide (CTAB)
method using Wilson’s miniprep protocol. Real-time PCR
assay on LightCycler (Roche Diagnostics, Germany) instrument
was used for the detection of clarithromycin resistance associ-
ated point mutations in the 23S rRNA gene by using primers,
probes and reaction conditions described by Chisholm SA et al
(1). After ampliﬁcation of 96-bp region clarithromycin resistance
related mutations of A2143C, A2143G/A2144G were analysed
by melting curve analysis on LightCycler Software version 3.5.3.
Melting peaks of 82–86C showed the detection of H. pylori in
the sample. Probe melting peaks of positive samples has been
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analysed by the same method and sensitive strains, A2143C, and
A2143G/A2144G gave peaks around 65C, 60C and 55C,
respectively.
Results: Of the 440-biopsy samples 46 (10.5%) of them were
negative forH. pylori. From the 394H. pylori positive patients 122
(31%) of them had clarithromycin resistance.
Conclusion: The rate of clarithromycin resistance was found to
be signiﬁcantly high, in this study. H. pylori prevalence is 70–
80% in Turkey, but cure rate is about 60%. Our ﬁnding explains
the reason of the low cure rate. Clarithromycin is one of the ﬁrst
choice drugs for H. pylori treatment. Therefore in countries,
which have similar H. pylori prevalence, clarithromycin resist-
ance rate should be known and if possible H. pylori antibiotic
susceptibility testing, should be performed before treatment.
P1450
Comparison of E-test, disc-diffusion and Phoenix
for antibiotic susceptibility assessment of
Stenotrophomonas maltophilia strains
M. Mentasti, P. Morelli, G. Manno (Genoa, IT)
Stenotrophomonas maltophilia (Sm) is an emerging pathogen in
immunocompromised patients (pts) and frequently isolated
from airway samples of cystic ﬁbrosis (cf) pts. Often multire-
sistant, Sm is intrinsically resistant to carbapenems and virtually
resistant to all b-lactams, but at present only CLSI breakpoints
for levoﬂoxacin (L), minocycline (M) and trimethoprim/sulfa-
metoxazole (TS) are available. Agar dilution is the method
recommended by CLSI to determine Sm antibiotic susceptibility
pattern and E-Test (AB BioDisk) is described as a reliable
alternative method.
Objectives: This work is aimed to assess the reliability of disc-
diffusion with semi-automatic analysis by BioMIC Vision (Giles
Scientiﬁc Inc.) and automated Phoenix System (BD) in Sm
antibiotic susceptibility pattern determination, compared to E-
Test results.
Methods: 70 non-repetitive Sm strains (38 from cf pts, 23 from
nosocomial pts and 9 from nosocomial environment) identiﬁed
by API Z0NE and conﬁrmed by species-speciﬁc ampliﬁcation of
23S rRNA gene (Whitby PW, 2000), were tested by E-test and
disc-diffusion on Mueller Hinton Agar (24 hours at 35C) for L,
M, TS, ceftazidime (C), gentamicin (G) and ticarcillin/clavula-
nate (TC), and tested by Phoenix with NMIC/ID-4 card
containing C, G, L and TS. Sm ATCC 13637 and Escherichia coli
ATCC 25922 were used as quality control strains. Discrepancies
were classiﬁed as Very Major Error (VME), Major Error (ME)
and minor Error (mE) as described in NCCLS M23-A2 (2000).
Results: MIN resulted active on all strains tested by E-test,
followed by TS, L, TC, G and C. No discrepancy was detected
between results of disc-diffusion with BioMIC Vision reading
and E-Test for M and TS; for C, G and L 21 total mEs were
detected, while for TC there were 6 VMEs. Phoenix generated 1
VME for L and 43 total MEs for C, G, L and TS.
Conclusions: Mwas more active than TS considered Sm drug of
choice, which showed 2 resistant strains (1 from cf pts and 1 from
non-cf pts). Disc-diffusion resulted a reliable method to test C, G,
L, M and TS on Sm strains and BioMIC Vision an accurate system
to asses disc-diffusion results for these antibiotics. Although
Phoenix generatedonly 1VME, it reportedmanymore resistances
(MEs) than E-test, consequently reducing therapeutical choices;
moreover, it didn’t testMandTC,which are very effective against
these isolates. In our experience, Phoenix System seems not
suitable to determine antimicrobial susceptibility of Sm isolates.
P1451
Prospective evaluation of imipenem/EDTA
combined disk and E-test for detection of MBL
producing Pseudomonas aeruginosa
L. Berge`s, A. Deplano, H. Rodriguez-Villalobos, A. Mazzariol,
M.J. Struelens (Anderlecht, BE; Verona, IT)
Objective: Nosocomial infection with multi-resistant P. aerugi-
nosa is a growing problem worldwide. The recent emergence of
metallo-b-lactamases (MBL) carried by integrons in this organ-
ism raises the issue of detecting this mechanism in multi-
resistant strains. The aim of this study was to analyse the
accuracy of imipenem-EDTA combined disk (MBL-CD) as part
of the routine disk diffusion susceptibility test and imipenem-
EDTA double E-test (MBL-E-test) for routine detection of MBL-
producing P. aeruginosa clinical isolates.
Methods: From May 2004 to February 2005, all clinical P.
aeruginosa isolates were prospectively screened for MBL pro-
duction using a MBL-CD (ROSCO) test. The test is positive if the
diameter of MBL-CD inhibition zone is > 6 mm wider than the
IMI disk inhibition zone. All meropenem (MEM) and imipenem
(IMI) resistant strains were tested by MBL-E-test (AB-Biodisk).
This test is positive for a ratio MIC IMI/ MIC IMI-EDTA ‡ 8.
PCR for bla VIM and bla IMP gene detection and measure of
hydrolysis of IMI with UV spectrophotometry were used as
reference tests.
Results: Among 587 P. aeruginosa isolates during the study
period, 42 (7%) were resistant to both IMI and MEM. MBL-CD
was positive in 26 (62%) of these strains, 23 (55%) were MBL-E-
test positive, 19 (45%) had VIM or IMP gene by PCR (16 VIM
genes, 3 IMP genes) and 1 strain lacking VIM and IMP gene
expressed carbapenemase activity conﬁrmed by spectrophotom-
etry. All carbapenem-resistant isolates with negative MBL-CD
screening were conﬁrmed as E-test and PCR negative. The
sensitivity, speciﬁcity, positive and negative predicted values for
MBL-CD was 100%, 73%, 77% and 100% respectively. MBL-E-
test showed a better speciﬁcity (86%) and predictive positive
value (87%) than MBL-CD.
Conclusion: In our setting MBL-CD test appeared to be an easy
and sensitive tool for rapid screening of MBL producing P.
aeruginosa isolates. MBL-E-test could be considered for conﬁr-
mation of MBL production although PCR appeared necessary to
provide conﬁrmation and characterize the enzyme type.
P1452
Phenotypic detection of metallo-b-lactamases and
extended-spectrum b-lactamases among
Gram-negative bacterial clinical isolates
N. Fam, M. Diab, H. Gomaa, I. El-Defrawy (Giza, EG)
Objectives: Detection of metallo-b-lactamases (MBLs) and
extended spectrum-b-lactamases (ESBLs) Gram negative bacilli
(GNB) is crucial for the optimal treatment of patients and to
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control spread of resistance. However, NCCLS documents do
not contain a method for detection of MBL producing isolates.
Lack of sufﬁcient reports from Egypt indicated the need for this
study to determine the proportion of MBL producers among
GNB isolated from clinical multi-drug resistant pathogens. We
also attempted to assess the efﬁciency of several phenotypic
tests for the rapid and convenient detection of MBLs between
Pseudomonas and Acinetobacter spp. The efﬁciency of testing
ceftazidime (CAZ) resistant versus imipenem (IMP) resistant
pathogens was also compared.
Methods: A total of 70 CAZ intermediate/resistant GNB were
identiﬁed and tested for antibiotic sensitivity by Vitek 2
Automated System (BioMerieux). Screening for ESBLs was
performed by Oxoid combined test (CDO2) and conﬁrmed by
Vitek 2. The phenotypic detection of MBL production among
Pseudomonas and Acinetobacter isolates was performed by modi-
ﬁed Hodge test, EDTA-disk synergy test (DST), IMP-EDTA
combined disk test (CDT) and E-test MBL strips. Negative
control strain (P. aeruginosa ATCC 27853) was included in the
tests.
Results: Of the 70 GNB pathogens, 25(35.7%) were ESBL
producers mainly E. coli and Klebsiella spp., while 8 (11.4%) P.
aeruginosa isolates were IMP resistant. Their MIC was 16 lg/ml
as conﬁrmed by E-test. None of the Acinetobacters showed
resistance to IMP. Isolates were considered as MBL producers
when three of the phenotypic tests were positive. Both DST and
CDT (7/8) were superior to Hodge and E-tests (4/8) for
detection of MBL production. One IMP resistant isolate was
negative by all tests suggesting non-MBL production. None of
the IMP resistant isolates was an ESBL producer.
Conclusion: The majority of our IMP resistant P. aeruginosa
isolates seemed to be MBL producers. Genetic conﬁrmation and
analysis of MBL producers is mandatory for positive isolates
screened by phenotypic tests. Between the latter DST and CDT
proved to be more rapid and convenient tests for their detection
in the clinical laboratory. Testing IMP resistant rather than CAZ
resistant isolates could reduce screening work for MBL detec-
tion.
P1453
Reliability of carbapenem resistance in
Pseudomonas spp. detected by automated systems
O. Karatuna, G. Soyletir (Istanbul, TR)
Objective: Ever since automated antimicrobial test systems
took their places in microbiology laboratories, effort has been
made to improve their accuracy. Even though antimicrobial
susceptibility testing became much easier with automated
systems, they are still far away from standard methods when
it comes to accuracy of the test results. Micro organisms like
Pseudomonas show multidrug resistance and accurate results for
their last resort antibiotics such as carbapenems became of vital
importance. In the literature false-resistant results have already
been documented for carbapenems in Pseudomonas, which
falsely limits therapy options.
Materials and Methods: In this study all Pseudomonas spp. (n:
133) isolated in our hospital between May and November 2005
have been evaluated for their carbapenem resistance. Identiﬁ-
cation and antimicrobial susceptibility testing were performed
with Vitek2 system using Vitek2 GN and Vitek2 AST-GN09
cards (bioMe´rieux). No further tests were performed for isolates
(n: 77), which were susceptible for carbapenems, imipenem and
meropenem since our aim was to detect false resistance. For the
remaining isolates (n: 36), which were, imipenem and/or
meropenem resistant, both imipenem and meropenem MIC
values have been established using E-test strips (AB BIODISK)
even when one of the carbapenems was susceptible according to
Vitek2.
Results: Agreement and minor error rates between two meth-
ods for carbapenem susceptibility testing (n: 72) were 63.9% and
29.1%, respectively. We also observed discrepant results causing
very major error rate of 4.2% in strains, which were intermediate
or resistant to one of the drugs but susceptible to the other
(Figure).
Conclusion: Our results exhibiting error rates out of acceptable
ranges proved once again that laboratories, which use an
automated system should consider using at least a second
method to validate intermediate or resistant results for carb-
apenem group antibiotics when tested against Pseudomonas
species. More importantly, ﬁnding an unacceptable rate of very
major error even in a limited number of the tested strains
strongly indicates that any result, either susceptible or resistant,
obtained from an automated system should not be relied on.
P1454
Detection of extended spectrum b-lactamases in
Enterobacteriaceae strains using four different
methods in a Tunisian paediatric hospital
N.E. Jlili, H. Smaoui, S. Rejiba, A. Kechrid (Tunis, TN)
Objectives: The reliability of four phenotypic methods to detect
extended-spectrum b-lactamases (ESBLs) was investigated in
the present study.
Methods: A total of 55 non-duplicate clinical isolates of third
generation cephalosporin-resistant Enterobacteriaceae species sus-
pected of ESBL production were collected from January to
September 2003. Medium and disc charge are used according to
the CA-SFM guidelines. The isolates were screened for ESBL
production by: (i) double-disk synergy test (DDST), (ii) modi-
fying double-disk test (MDDT), performed with discs used in
the DDST in addition to cefepime, aztreonam and piperacillin-
tazobactam association, (iii) E-test ESBL (AB BIODISK) detection
system, based on the reduction in the ceftazidime or cefotaxime
MIC in the presence of clavulanic acid, and (iv) Cica- b test I/
MBL (Kanto Chemical Co.Inc.) using the chromogenic cepha-
losporin HMRZ-86, which reacts ESBL directly and changing the
colour rapidly.
Results: Among 55 strains (39 Klebsiella pneumoniae, 4 Escherichia
coli, 6 Enterbater cloacae and 5 Enterobacter aerogenes) studied, the
classic DDST based clavulanate synergy classiﬁed only 36
(56.4%) ESBL positive, while, the MDDT detected the presence
of ESBL in 47 (85.4%). Negative synergy affected all the species
with DDST, whereas negative synergy spared the totality of K.
pneumoniae with MDDT. Results of the E-test ESBL conﬁrmed
the ESBL production in 44 (80%) among the 47 ESBL producers
screened by MDDT. The results of the E-test were indeterminate
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for the other eleven clinical isolates. The chromogenic test gave
the highest ESBL detection rates with 52 (94.5%) strains.
According to the study, the sensitivity and speciﬁcity of the
HMRZ-86 for detecting ESBLs seemed to be the better. The
combination of all ESBL detection methods showed agreement
for 35 ESBL positive (32 K. pneumoniae, 3 E. aerogenes) and 3 ESBL
negative clinical isolates, that belong to third bacterial group. At
least, one method yielded a discordant result for each of the
remaining 17 isolates.
Conclusion: Excepted the DDST, all the other methods con-
ferred good rates to detect ESBL production. Chromogenic test
seems to be potential and suitable tool to ESBL screening and it
must be valuable in clinical laboratory.
P1455
The reliability of in vitro susceptibility tests for
multi-resistant Pseudomonas aeruginosa isolates
B. Sener, S. Ak, G. Hascelik (Ankara, TR)
Objectives: Therapeutic approaches dealing with antibiotic-
resistant Pseudomonas aeruginosa (Pa) infections depend on the
results of in-vitro susceptibility testing. However, in vitro test
results always are not successfully applied to in vivo conditions.
This study was conducted to test the agreement between disk
diffusion (DD), agar dilution (AD) and bactericidal testing
which is considered to resemble more the in vivo conditions, for
cystic ﬁbrosis (CF) and non-CF Pa isolates.
Methods: Thirtynine CF and 40 non-CF Pa isolates were tested
for susceptibility against aztreonam (AZ), ceftazidime (CAZ),
cefepime (CEF), ciproﬂoxacin (C), amikacin (A), tobramycin 4
(T4), tobramycin 200 (T200) mg/ml and meropenem (M) by DD
and AD, and the results were evaluated according to CLSI
breakpoints. The bactericidal activities were determined in
microtiter plates by using single antibiotic concentrations
based on estimates of the average peak levels in serum after
single dose IV administration.
Results: DD and AD methods exhibited overall 83.5% inter-
method agreement, discrepant results being more detected in CF
(11/39) than non-CF (2/30) isolates (p < 0.05). % susceptibility
according to bactericidal activity was less than the susceptibility
rates obtained by AD and DD especially for b-lactam agents
tested for CF Pa isolates.
Conclusion: Although AD and DD have acceptable agreement
with each other, a signiﬁcant discordance was observed when
the results were evaluated according to bactericidal activity for
CF Pa isolates. This discrepancy can be attributed to the
presence of mucoid and slow growing variants for CF strains.
Since bactericidal testing seems to mimic the in vivo conditions
more than the other two tests, for the choice of effective
antibiotic therapy especially for CF Pa infections, single bacte-
ricidal sensitivity testing can be taken into consideration. To
asses whether the use of bactericidal testing improves the results
obtained by accordingly directed antibiotic therapy for Pa
infections, controlled clinical trials should be performed.
P1456
Performance of cefoxitin in phenotypic
susceptibility testing of cMRSA, ST80, and
hMRSA, ST45
C. Cuny, W. Witte (Wernigerode, DE)
Objective: cMRSA of MLST ST80 which are widely dissemin-
ated in Europe and hMRSA of MLST ST45 exhibit a pronounced
heteroresistance phenotype for oxacillin (MIC’s 1–2 mg/l). Here
we report about the performance of cefoxitin in microbroth
dilution and in disk diffusion test.
Methods: Microbroth MIC according to CLSI standard 2005 for
oxacillin and cefoxitin; disk diffusion test for oxacillin and for
cefoxitin according to CLSI and to SRGA; screening tests by use
of oxacillin-salt-agar (CLSI), tube test with oxacillin-sulbactam-
salt (Cuny et al., Eur. J. Clin. Microbiol. Infect. Dis. 20 (2001) 683–
6), and chromagar MRSA.
Results: For 63 isolates of MRSA (mecA positive) from inde-
pendent cases of infections and belonging to lineages ST80
(n = 37) and ST45 (n = 30) low micro broth MIC’s 1–2 mg/l for
oxacillin but growth on oxacillin-salt-agar (incubation up to
48 hours essential), in oxacillin tube test and on chromagar
MRSA was recorded. MIC’s (mg/l) of cefoxitin were 2 (n = 2), 4
(n = 23), 8 (n = 30), and 16 (n = 8). In disk diffusion test with
cefoxitin according to CLSI 35 from 63 isolates were classiﬁed as
susceptible whereas performance according to SRGA correctly
identiﬁed them as resistant.
Conclusion: Reliable detection of MRSA of ST80 and ST45
needs screening tests in parallel to micro broth MIC and disk
diffusion test for oxacillin. For cefoxitin the MIC breakpoint
should be 4 mg/l and above as resistant. For disk diffusion the
interpretative criteria of SRGA should be used.
P1457
Phenotypic characterization of heterogeneous
methicillin-susceptible Staphylococcus aureus
correlates to patient outcome
V. Huang, M. Perri, D. Vager, M. Zervos (Atlanta, Detroit, US)
Objective: Thus far there has never been a case report of
heterogeneous methicillin-susceptible S. aureus (hMSSA). We
described a case of a 45-year-old African American female
who presents with MSSA bacteraemia; cultures were taken
from the peripherally inserted central catheter (PICC) line of
the left arm. She was admitted for an infected PICC line.
Patient was bacteraemic on vancomycin for 34 days, secon-
dary to endocarditis with no abscess to drain. The patient
was allergic to penicillin. She was given 1 dose of linezolid
upon admission. Patient was sent for a new PICC line to
complete her vancomycin therapy. In addition, blood cultures
times 2 was ordered as well as a computed tomography (CT)
scans of the abdomen and pelvis to ﬁnd any sources of
hidden infection. The CT scan is negative, however, patient
cultures were positive for MSSA with vancomycin MIC of 2.0
by Vitek. Due to patient allergy and positive blood culture
after 34 days of therapy, we sought to investigate this
particular isolate.
Methods: Strains utilized were hMSSA (FS 33732) and ATCC
29213 as a control. MICs were performed according to CLSI.
Subpopulation proﬁles were performed on MHA plates con-
taining various concentrations (0.25–32 lg/ml) of vancomycin
(V) according to Pfetz et al procedure. Macro E-test was
performed on BHI plate with a 2.0 McFarland as well as micro
E-test on MHA plate with a 0.5 McFarland.
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Results: FS 33732 and ATCC 29213 MICs were 2.0 and 1.0
respectively. Macro and micro E-test exhibited no colonies of
subpopulation growth with MICs of 4.0 and 3.0. Population
analysis for FS 33732 revealed various densities across 0.25–
1.0 lg/ml, see graph in Figure 1 at 24 hours and Figure 2 at
48 hours.
Conclusions: We demonstrated FS 33732 to have characteristics
of hMSSA. Discovery of hMSSA is of importance because it may
provide further insight into treatment failures in those patients
with penicillin allergy who require to be on vancomycin. Patient
was sent to the intensive care unit (ICU) for desensitization of
penicillin for her allergy. Patient tolerated well and nafcillin was
initiated promptly to be completed for 8 weeks course.
P1458
Decreased susceptibility to glycopeptides in
methicillin-resistant Staphylococcus aureus:
a 20-year study in a large French teaching
hospital, 1983–2002
J. Robert, R. Bismuth, V. Jarlier (Paris, FR)
Objective: To assess the evolution of glycopeptides’ suscepti-
bility in methicillin-resistant Staphylococcus aureus (MRSA)
strains isolated in a large French teaching hospital from 1983
to 2002.
Method: Determination of glycopeptides’ MICs by using the E-
test method in Mueller-Hinton agar on a sample of randomly
selected MRSA strains.
Results: A total of 1445 MRSA were tested, and one vancomycin-
intermediateMRSA (VISA) and 31 teicoplanin-intermediateMRSA
(TISA) strainsweredetected.Theﬁrst strainsweredetected in 1985,
and all strains were gentamicin-resistant (GR). None of the
gentamicin-susceptible strains has a glycopeptide MIC> 3 mg/L.
In addition, there was a signiﬁcant increase in glycopeptides’ MIC
geometric means over the years, and this increase was higher for
teicoplanin than for vancomycin.
Conclusion: The higher increase in teicoplanin MICs and the
good correlation between both glycopeptides’ MICs, suggests
systematic determination of teicoplanin MIC to screen for
abnormal glycopeptide susceptibility between GR-MRSA.
P1459
Trends in resistance to some antibiotics in
selected bacterial species-S. aureus,
S. pneumoniae, E. faecalis, E. faecium-causing
invasive infections in the Czech Republic in
2000–2004
B. Mackova (Prague, CZ)
Objectives: Invasive infections caused by Staphylococcus aureus,
Streptococcus pneumoniae, Enterococcus faecium and Enterococcus
faecalis can be serious due to widespread resistance to different
antibiotics. Serious problem for some hospitals are MRSA
(methicillin-resistant Staphylococcus aureus), PNSP (penicillin
non-susceptible Streptococcus pneumoniae) and VRE (vancomy-
cin-resistant Enterococci). The incidence of MRSA, PNSP and
VRE infections in the Czech Republic varies widely with the
regions and population groups.
Methods: Since 2000 the Czech Republic has been taking part in
the European Antimicrobial Resistance Surveillance System
(EARSS). EARSS monitored the incidence of seven pathogens
in invasive isolates from blood and cerebrospinal ﬂuid. Four of
the causative agents under surveillance are Staphylococcus
aureus, Streptococcus pneumoniae, Enterococcus faecium and Entero-
coccus faecalis. The incidence of MRSA, PNSP and VRE has been
currently monitored from 92 hospitals of the Czech Republic.
Data on patients, hospitals and phenotypes of antibiotic resist-
ance in the bacterial strains isolated have been recorded. Basic
statistical methods are used for epidemiological analysis.
Results: Between years 2000–2004, 5684 S. aureus strains and
781 S. pneumoniaewere analysed. Between years 2001–2004, 1997
E. faecalis strains and 346 E. faecium strains were analysed. Out of
these strains 6.5% were MRSA (increase from 3.8% in 2000 to
8.6% in 2004), 5.2% were PNSP (resistance oscillated around
5%), 0.6% were vancomycin-resistant E. faecalis (resistance
oscillated around 0.5%) and 3.8% were vancomycin-resistant
E. faecium (resistance oscillated around 3.6%). The incidence of
resistant bacteria varied with types of hospitals, hospital wards,
age groups and time. Thanks to collaboration of 48 laboratories,
highly valid data covering 88% of the Czech population have
been available.
Conclusion: Surveillance of MRSA, PNSP and VRE strains as a
basis for active antibiotic policy has become of increasing
concern to both health care providers in hospitals and commu-
nity general practitioners. The incidence of MRSA infections in
last years in the Czech Republic shows increasing trend. The
incidence of PNSP and VRE infections have invariable trend.
Very interesting is local distribution of resistant strains. The
development of the incidence of infections caused by monitored
agents in their spread will be the subject of further study.
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